

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

AVENTIS PHARMACEUTICALS INC. and	)	<b>REDACTED</b>
SANOFI-AVENTIS US LLC,	)	<b>PUBLIC VERSION</b>
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 06-286-GMS
	)	
BARR LABORATORIES, INC.,	)	
	)	
Defendant.	)	

**FINAL PRETRIAL ORDER**

ASHBY & GEDDES  
Steven J. Balick (#2114)  
John G. Day (#2403)  
Tiffany Geyer Lydon (#3950)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
[sbalick@ashby-geddes.com](mailto:sbalick@ashby-geddes.com)  
[jday@ashby-geddes.com](mailto:jday@ashby-geddes.com)  
[tlydon@ashby-geddes.com](mailto:tlydon@ashby-geddes.com)

*Attorneys for Plaintiffs*

YOUNG CONAWAY STARGATT &  
TAYLOR, LLP  
Josy W. Ingersoll (#1088)  
Karen L. Pascale (#2903)  
Karen E. Keller (#4489)  
The Brandywine Building  
1000 West Street, 17th Floor  
Wilmington, DE 19801  
(302) 571-6600  
[jingersoll@ycst.com](mailto:jingersoll@ycst.com)  
[kpascale@ycst.com](mailto:kpascale@ycst.com)  
[kkeller@ycst.com](mailto:kkeller@ycst.com)

*Attorneys for Defendant*

Dated: April 7, 2008

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

AVENTIS PHARMACEUTICALS INC. and )  
SANOFI-AVENTIS US LLC, )  
 )  
Plaintiffs, )  
 )  
v. )  
 )  
BARR LABORATORIES, INC., )  
 )  
Defendant. )

C.A. No. 06-286-GMS

**REDACTED**  
**PUBLIC VERSION**

**FINAL PRETRIAL ORDER**

This matter having come before the court at a pretrial conference held pursuant to Fed. R. Civ. P. ("Rule") 16, and Steven J. Balick, John G. Day, and Tiffany Geyer Lydon, Ashby & Geddes, 500 Delaware Avenue, 8<sup>th</sup> Floor, Wilmington, Delaware, 19801, 302-654-1888, Paul H. Berghoff, Joshua R. Rich, and Jeremy E. Noe, McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Chicago, Illinois 60606, 312-913-0001 having appeared as counsel for plaintiffs and Josy W. Ingersoll, Karen L. Pascale and Karen E. Keller, Young Conaway Stargatt & Taylor, LLP, The Brandywine Building, 1000 West Street, 17<sup>th</sup> Floor, Wilmington, Delaware, 19801, 302-571-6600 and James F. Hurst, Taras A. Gracey, Maureen L. Rurka, and Julia M. Johnson, Winston & Strawn, LLP, 35 West Wacker Drive, Chicago, Illinois, 60601, 312-558-5600 having appeared as counsel for defendant, the following actions were taken:

- (1) This is an action for patent infringement and the jurisdiction of the court is involved under 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202. Jurisdiction is not disputed as to Plaintiff Aventis Pharmaceuticals Inc.'s patent infringement claims

and Defendant Barr Laboratories Inc.'s counterclaims. Barr disputes Article III subject matter jurisdiction as to Plaintiff Sanofi-Aventis US LLC's patent infringement claims on the ground that Sanofi-Aventis is not the patentee as required under 35 U.S.C. § 281.

(2) The following stipulations and statements were submitted and are attached to and made a part of this Order.

- (a) A comprehensive statement of all uncontested facts, which will become a part of the evidentiary record in this case, attached hereto as Appendix A;
- (b) An agreed statement by the parties of the contested issues of fact and law, attached hereto as Appendix B; Plaintiffs' statement of contested issues of fact and law not agreed to, attached hereto as Appendix C; and Defendant's statement of contested issues of fact and law not agreed to, attached hereto as Appendix D;
- (c) Except for rebuttal exhibits, schedules of all exhibits expected to be offered into evidence and all demonstrative evidence and experiments to be offered during trial are set forth as follows:
  - (1) Exhibits offered by Plaintiffs received in evidence, attached as Schedule (c)(1);
  - (2) Exhibits offered by Plaintiffs and objected to by Defendant, attached as Schedule (c)(2);
  - (3) Exhibits offered by Defendant received in evidence, attached as Schedule (c)(3);

- (4) Exhibits offered by Defendant and objected to by Plaintiffs, attached as Schedule (c)(4);
- (d) A list of the potential witnesses to be called by Plaintiffs, attached as Appendix E; and a list of the potential witnesses to be called by Defendant, attached as Appendix F; the parties having agreed to reserve until trial the right to object to certain uses of the witnesses identified in Appendices E and F;
- (e) Statements setting forth the qualifications of each of Plaintiffs' expert witnesses, attached as Appendix G; Statements setting forth the qualifications of each of Defendant's expert witnesses, attached as Appendix H;
- (f) List of all depositions, or portions thereof, to be read into evidence on behalf of Plaintiffs, attached as Appendix I; list of all depositions, or portions thereof, to be read into evidence on behalf of Defendant, attached as Appendix J;
- (g) Not applicable in this case;
- (h) Not applicable in this case;
- (i) Not applicable in this case;
- (j) Plaintiffs' proposed *Findings of Fact and Conclusions of Law* are being filed separately by Plaintiffs under seal, duplicate hard copies to be delivered to the Court; and Defendant's proposed *Findings of Fact and Conclusions of Law* are being filed separately under seal, duplicate hard copies to be delivered to the Court.



(k) Pursuant to this Court's Order dated June 30, 2006, prior to the Scheduling Conference held on July 18, 2006 in this case, the parties, after discussion, determined that this matter could not be resolved by settlement at that juncture. Pursuant to Court Order dated August 21, 2006, the parties engaged in a settlement conference with Magistrate Judge Thyng on October 16, 2006 during which, after discussion, the parties indicated to Magistrate Judge Thyng that this matter could not be resolved by settlement at that juncture. Pursuant to Court Order dated October 19, 2006, the parties engaged in a follow-up settlement conference with Magistrate Judge Thyng on May 10, 2007 during which, after discussion, the parties indicated to Magistrate Judge Thyng that the possibility of settlement in this litigation was remote and that further negotiations were unlikely to be productive.

(l) The parties have completed all fact and expert discovery.

(m) motions *in limine*: The parties have filed the following motions *in limine*:

By Plaintiffs:

(1) Plaintiffs' First Motion *in Limine* (Concerning the Supplemental Expert Report of Barry A. Siegel, M.D.)

(2) Plaintiffs' Second Motion *in Limine* (Concerning the Expert Report of Dr. Ian S. Mackay)

(3) Plaintiffs' Third Motion *in Limine* (Concerning the Responsive Expert Report of Dr. Ian S. Mackay)

By Defendant:

(1) Barr Laboratories, Inc.'s Motion *in Limine* to Exclude Any Documents Related to Barr's ANDA to Show Proof of Copying

The parties have agreed to forego Reply Briefs in support of motions *in limine*, *i.e.*, briefing for motions *in limine* shall comprise only an Opening Brief and an Answering Brief. The parties will deliver to the Court an original and two (2) hard copies of each brief, excluding appendices, declarations, affidavits and exhibits.

(3) Trial of this case is expected to take four (4) days.

(4) [Indicate the type of trial by placing an X in the appropriate box]

Jury ☐ Non-jury ☒

(5) Not applicable for this case.

(6) This Order will control the course of the trial and may not be amended except by consent of the parties and the court, or by order of the court to prevent manifest injustice.

(7) Possibility of settlement of this case was considered by the parties.

---

Chief Judge

Date: \_\_\_\_\_

ASHBY & GEDDES

*/s/ Tiffany Geyer Lydon*

---

Steven J. Balick (#2114)  
John G. Day (#2403)  
Tiffany Geyer Lydon (#3950)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
sbalick@ashby-geddes.com  
jday@ashby-geddes.com  
tlydon@ashby-geddes.com

*Attorneys for Plaintiffs*

YOUNG CONAWAY STARGATT &  
TAYLOR, LLP

*/s/ Karen L. Pascale*

---

Josy W. Ingersoll (#1088)  
Karen L. Pascale (#2903)  
Karen E. Keller (#4489)  
The Brandywine Building  
1000 West Street, 17th Floor  
Wilmington, DE 19801  
(302) 571-6600  
jingersoll@ycst.com  
kpascale@ycst.com  
kkeller@ycst.com

*Attorneys for Defendant*

## **APPENDIX A**

### **PARTIES' STATEMENT OF UNCONTESTED FACTS**

#### **The Parties**

1. Plaintiff Aventis Pharmaceuticals Inc. ("Aventis"), a subsidiary of Sanofi-Aventis SA, is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business at 55 Corporate Drive, Bridgewater, New Jersey 08807.

2. Plaintiff Sanofi-Aventis US LLC ("Sanofi-Aventis"), a subsidiary of Sanofi-Aventis SA, is a limited liability company organized and existing under the laws of the State of Delaware, with its principal place of business at 55 Corporate Drive, Bridgewater, New Jersey 08807.

3. Defendant Barr Laboratories, Inc. ("Barr") is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business at 223 Quaker Road, Pomona, New York 10970.

#### **Allergic Rhinitis**

4. Allergic rhinitis is the consequence of an exaggerated reaction by the body's immune system as a response to foreign substances (antigens) in the nasal cavity.

5. Seasonal and perennial allergic rhinitis are associated with sneezing, nasal drainage, itching and congestion.

6. Seasonal allergic rhinitis, sometimes known as hay fever, results from foreign substances (antigens) found in pollen from trees, grasses, and weeds and occurs during certain times of the year.

7. Perennial allergic rhinitis may occur year-round and results from antigens such as animal dander, mold spores, and dust mites that are present in the environment

independent of the time of year. Perennial allergic rhinitis can coexist with seasonal exacerbations of the symptoms.

**The Patents**

8. U.S. Application Number 08/678,465, from which United States Patent No. 5,976,573 (“the ‘573 patent”) issued, was filed on July 3, 1996. The ‘573 patent issued on November 2, 1999, to Soo-II Kim. The USPTO shows that the ‘573 patent was assigned to Rôrer Pharmaceutical Products Inc. (“RPR”), a predecessor-in-interest to Aventis. The USPTO shows that by assignment, through a chain of predecessors-in-interest, Aventis is the present owner of the ‘573 patent.

9. The ‘573 patent is set to expire on July 3, 2016.

10. U.S. Application Number 09/315,454, from which United States Patent No. 6,143,329 (“the ‘329 patent”) issued, was filed on May 20, 1999. The ‘329 patent issued on November 7, 2000, to Soo-II Kim. The USPTO shows that the ‘329 patent was assigned to RPR. The USPTO shows that by assignment, through a chain of predecessors-in-interest, Aventis is the present owner of the ‘329 patent.

11. The ‘329 patent claims priority to the parent application of the ‘573 patent, which was filed on July 3, 1996.

12. The ‘329 patent is set to expire on July 3, 2016.

13. Other than the claim of priority set forth in col. 1, lines 4-10 of the ‘329 patent, the ‘573 patent and the ‘329 patent share a common specification that is substantively the same for both patents.

14. Aventis is the manufacturer of Nasacort® AQ.

15. Sanofi-Aventis is the owner of NDA 20-468.

**Asserted Claims**

16. Plaintiffs are asserting claims 5, 6, 7, 8, 21, 22, 23, 24, 26, 27, 28, 34, and 35 of the '573 patent against Barr in this case.

17. Plaintiffs are asserting claims 13, 14, 15, 16, 23, 24, 25, and 26 of the '329 patent against Barr in this case.

**NDA 20-468**

18. NDA 20-468 was approved on May 20, 1996.

19. The FDA's Orange Book lists the '573 patent and the '329 patent in connection with NDA 20-468.

**ANDA 78-104**

20.

**REDACTED**

21. By letter dated March 20, 2006, and received March 23, 2006, Barr notified Plaintiffs of the filing of ANDA 78-104 with the Paragraph IV certification.

**Barr's ANDA product**

22.

**REDACTED**

23.

24.

**REDACTED**

**REDACTED**



**REDACTED**

**REDACTED**

;

;

**REDACTED**

**REDACTED**

**REDACTED**

**Prior Art**

**A. Prior Art Products**

89. Some formulation of each of the products sold using the trademarks Beconase AQ<sup>®</sup>, Vancenase AQ<sup>®</sup>, Flonase<sup>®</sup>, Nasalide<sup>®</sup> and Nasacort<sup>®</sup> Nasal Inhaler was introduced in the United States more than one year before July 3, 1996.

90. Limited information for each of the products sold using the trademarks Beconase AQ<sup>®</sup>, Vancenase AQ<sup>®</sup>, Nasalide<sup>®</sup> and Nasacort<sup>®</sup> Nasal Inhaler is included in the 1995 Physician's Desk Reference ("95 PDR").

91. Limited information for a product sold using the trademark Flonase<sup>®</sup> is included in the 1995 Physician's Desk Reference Supplement A ("95 PDR Supplement A").

92. The '95 PDR and '95 PDR Supplement A were publicly available and publicly accessible more than one year before July 3, 1996.

93. The '95 PDR qualifies as a printed publication under 35 U.S.C. § 102(b).
94. The '95 PDR Supplement A qualifies as a printed publication under 35 U.S.C. § 102(b).
95. The active ingredient in Flonase<sup>®</sup> is fluticasone propionate.
96. The active ingredient in Beconase AQ<sup>®</sup> and Vancenase AQ<sup>®</sup> was beclomethasone dipropionate.
97. The active ingredient in Nasalide<sup>®</sup> is flunisolide.
98. The active ingredient in Nasacort<sup>®</sup> Nasal Inhaler was triamcinolone acetonide.
99. Fluticasone propionate, beclomethasone dipropionate, flunisolide and triamcinolone acetonide are glucocorticosteroids.
100. Vancenase AQ<sup>®</sup> has been discontinued.
101. As of July 3, 1995, each of Flonase<sup>®</sup>, Beconase AQ<sup>®</sup> and Vancenase AQ<sup>®</sup> was an aqueous pharmaceutical composition.
102. Each of Flonase<sup>®</sup> and Beconase AQ<sup>®</sup> is an aqueous pharmaceutical composition.
103. As of July 3, 1995, each of Flonase<sup>®</sup>, Beconase AQ<sup>®</sup>, Vancenase AQ<sup>®</sup> and Nasalide was capable of being sprayed into the nasal cavity of an individual.
104. Each of Flonase<sup>®</sup> and Beconase AQ<sup>®</sup> is capable of being sprayed into the nasal cavity of an individual.
105. As of July 3, 1995, each of Beconase AQ<sup>®</sup>, Vancenase AQ<sup>®</sup>, Flonase<sup>®</sup> and Nasalide<sup>®</sup> was propellant-free.
106. Each of Flonase<sup>®</sup> and Beconase AQ<sup>®</sup> is propellant-free.

**REDACTED**

**REDACTED**



**REDACTED**

129. The entry for Nasalide<sup>®</sup> in the 1994 PDR indicates that Nasalide<sup>®</sup> contained edetate disodium.

130. The entry for Nasalide<sup>®</sup> in the 1995 PDR indicates that Nasalide<sup>®</sup> contained edetate disodium.

131. The entry for Nasalide<sup>®</sup> in the 1994 PDR indicates that Nasalide<sup>®</sup> contained benzalkonium chloride.

132. The entry for Nasalide<sup>®</sup> in the 1995 PDR indicates that Nasalide<sup>®</sup> contained benzalkonium chloride.

**REDACTED**

**REDACTED**

137. As of July 3, 1995, the Flonase<sup>®</sup> entry in the 1995 PDR Supplement A indicated that Flonase<sup>®</sup> had a recommended starting dosage in adults of two sprays, 50 mcg of fluticasone propionate each, in each nostril once a day for a total daily dose of 200 mcg.

138. Flonase<sup>®</sup> is marketed for the once-daily treatment of seasonal and perennial allergic rhinitis at a starting dosage in adults of two sprays, 50 mcg of fluticasone propionate each, in each nostril once a day for a total daily dose of 200 mcg.

139. As of July 3, 1995, Nasacort<sup>®</sup> Nasal Inhaler was marketed for a once-daily treatment of seasonal and perennial allergic rhinitis at a starting dosage in adults of two sprays, 55 mcg of triamcinolone acetonide per spray, in each nostril once a day for a total daily dose of 220 mcg.

140. As of July 3, 1995, Beconase AQ and Vancenase AQ were marketed to treat seasonal and perennial allergic rhinitis.

141. Beconase AQ<sup>®</sup> is marketed to treat seasonal and perennial allergic rhinitis.

142. As of July 3, 1995, Nasalide was marketed to treat seasonal and perennial allergic rhinitis.

143. As of July 3, 1995, each product sold using the trademarks Beconase AQ<sup>®</sup>, Vancenase AQ<sup>®</sup>, Flonase<sup>®</sup>, Nasalide<sup>®</sup> and Nasacort<sup>®</sup> Nasal Inhaler was an article of manufacture.

144. As of July 3, 1995, each product sold using the trademarks Beconase AQ<sup>®</sup>, Vancenase AQ<sup>®</sup>, Flonase<sup>®</sup>, Nasacort<sup>®</sup> Nasal Inhaler and Nasalide<sup>®</sup> used a vessel to contain the composition.

145. As of July 3, 1995, each of Beconase AQ<sup>®</sup>, Vancenase AQ<sup>®</sup>, Flonase<sup>®</sup>, Nasalide<sup>®</sup>, and Nasacort<sup>®</sup> Nasal Inhaler used a vessel that contains greater than two full doses of the composition.

**REDACTED**

148. The documents bearing bates numbers SP00001 through SP02097, produced by third party Schering Corp. and/or Schering-Plough Corp., include true and correct copies of portions of New Drug Application Nos. 19-589 and 20-469 for Vancenase AQ<sup>®</sup>, filed with the U.S. Food and Drug Administration.

149. The documents bearing bates numbers SP00001 through SP02097, produced by third party Schering Corp. and/or Schering-Plough Corp., were kept in the course of the regularly conducted activity of Schering and were made by the regularly conducted activity of Schering as a regular practice.

150. The document bearing bates number SP01613, produced by third party Schering Corp., sets forth the formulation for Vancenase AQ<sup>®</sup> as approved by the FDA on or about December 23, 1987.

151. The documents bearing bates numbers GLAXA1001 through GLAXA1083, produced by third party GlaxoSmithKline Corp., include true and correct copies of portions of New Drug Application No. 19-389 for Beconase AQ<sup>®</sup>.

152. The documents bearing bates numbers GLAXA1001 through GLAXA1083, produced by third party GlaxoSmithKline Corp., were kept in the course of the regularly conducted activity of GlaxoSmithKline and were made by the regularly conducted activity of GlaxoSmithKline as a regular practice.

**REDACTED**

154. The document bearing bates number GLAXA1078, produced by third party GlaxoSmithKline Corp., sets forth the formulation for Beconase AQ<sup>®</sup> as approved by the FDA on or about July 27, 1987.

155. The documents bearing bates numbers GLAXA1001 through GLAXA1083, produced by third party GlaxoSmithKline Corp., include true and correct copies of portions of New Drug Application No. 20-121 for Flonase<sup>®</sup>.

156. The document bearing bates number GLAXA1079, produced by third party GlaxoSmithKline Corp., sets forth the formulation for Flonase<sup>®</sup> as approved by the FDA on or about October 19, 1994.

**REDACTED**

158. The prescribing information for Vancenase® AQ does not contain the word “thixotropic.”

159. The package insert for Vancenase® AQ does not contain the word “thixotropic.”

160. Schering Corp. and/or Schering Plough Corp. was the manufacturer of Vancenase® AQ.

**REDACTED**

162. GlaxoSmithKline is the manufacturer of Beconase® AQ and Flonase®.

163. The prescribing information for Beconase® AQ does not contain the word “thixotropic.”

164. The package insert for Beconase® AQ does not contain the word “thixotropic.”

165. The prescribing information for Flonase® does not contain the word “thixotropic.”

166. The package insert for Flonase® does not contain the word “thixotropic.”

**REDACTED**

**B. Settipane and Kobayashi References**

168. *Settipane, et al., Triamcinolone Acetonide Aqueous Nasal Spray in Patients with Seasonal Ragweed Allergic Rhinitis: A Placebo-Controlled, Double-Blind Study*, Clinical Therapeutics 17:252-263 (1995) (“Settipane”) was publicly available and accessible prior to July 3, 1995.

169. *Kobayashi, et al., Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Patients with Perennial Allergic Rhinitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study*, *Clinical Therapeutics* 17:503-513 (1995) (“Kobayashi”) was publicly available and accessible prior to July 3, 1995.

170. The Settipane, et al. article does not contain the phrases “propellant-free,” “pH of about 4.5 to about 7.5,” “a mixture of microcrystalline cellulose and carboxymethylcellulose sodium,” “polysorbate 80,” “disodium ethylenediamine tetraacetate,” “benzalkonium chloride,” and “dextrose.”

171. The Settipane et al. article does not contain the phrase “Nasacort AQ.”

172. The Kobayashi, et al. article does not contain the phrases “propellant-free,” “pH of about 4.5 to about 7.5,” “a mixture of microcrystalline cellulose and carboxymethylcellulose sodium,” “polysorbate 80,” “disodium ethylenediamine tetraacetate,” “benzalkonium chloride,” and “dextrose.”

173. The Kobayashi et al. article does not contain the phrase “Nasacort AQ.”

**C. Avicel®**

174. The documents bearing bates numbers FMC000001 through FMC000652 are true and correct copies of documents produced by FMC Corporation.

175. The documents bearing bates numbers FMC000001 through FMC000652 were kept and maintained in the course of the regularly conducted activity of FMC.

176. Avicel® RC-591 was commercially available prior to July 3, 1995.

177. Avicel® CL-611 was commercially available prior to July 3, 1995.

**D. U.S. Patent No. 4,767,612**

178. U.S. patent No. 4,767,612 (“the ‘612 patent”) was publicly available and publicly accessible more than one year before July 3, 1996.

179. The '612 patent qualifies as prior art to the '573 and '329 patents under 35 U.S.C. § 102(b).

180. No composition discussed in U.S. Patent No. 4,767,612 ("the '612 patent") is described therein as being a thixotropic aqueous pharmaceutical composition.

181. The '612 patent does not describe a thixotropic aqueous nasal spray that is propellant-free.

182. The '612 patent does not state that a nasal spray has a pH of about 4.5 to 7.5.

183. The '612 patent does not describe a thixotropic aqueous nasal spray that is propellant-free.

184. The '612 patent does not describe a thixotropic aqueous nasal spray that includes a mixture of microcrystalline cellulose and carboxymethylcellulose sodium, Polysorbate 80, disodium ethylenediamine tetraacetate, benzalkonium chloride, dextrose, and purified water.

**E. Physicians' Desk Reference**

185. The 1995 Physicians' Desk Reference Supplement A was published on a different date from the 1995 Physicians' Desk Reference.

186. The 1995 Physicians' Desk Reference is a compendium of official, FDA-approved prescription drug labeling.

187. In the entries for Beconase AQ, the '94 PDR and '95 PDR state:  
"Beconase AQ Nasal Spray is a metered-dose, manual pump spray unit containing a microcrystalline suspension of beclomethasone dipropionate, monohydrate equivalent to 0.042% w/w beclomethasone dipropionate, calculated on the dried basis, in an aqueous

medium containing microcrystalline cellulose, carboxymethyl cellulose sodium, dextrose, benzalkonium chloride, polysorbate 80, and 0.25% v/w phenylethyl alcohol.”

188. In the entries for Beconase AQ, the ‘94 PDR and ‘95 PDR state that Beconase AQ® is “for intranasal use only.”

189. In the entries for Vancenase AQ, the ‘94 PDR and ‘95 PDR state: “Vancenase AQ Nasal Spray is a metered-dose, manual pump spray unit containing a microcrystalline suspension of beclomethasone dipropionate, monohydrate equivalent to 0.042% w/w beclomethasone dipropionate calculated on the dried basis in an aqueous medium containing microcrystalline cellulose and carboxymethyl cellulose sodium, dextrose, benzalkonium chloride, polysorbate 80, and 0.25% v/w phenylethyl alcohol; hydrochloric acid may be added to adjust pH.”

190. In the entries for Vancenase AQ, the ‘94 PDR and ‘95 PDR state that Vancenase AQ® is “for intranasal use only.”

191. With respect to Nasalide®, the ‘94 PDR and ‘95 PDR entries state: “Each 25 mL spray bottle contains flunisolide 6.25 mg (0.25 mg/mL) in a solution of propylene glycol, polyethylene glycol 3350, citric acid, sodium citrate, butylated hydroxyanisole, edetate disodium, benzalkonium chloride, and purified water, with NaOH and/or HCl added to adjust the pH to approximately 5.3.”

192. With respect to Nasalide®, the ‘94 PDR and ‘95 PDR entries further state that Nasalide® is “for nasal use only.”

193. In the entry for Flonase, the ‘95 PDR Supplement A states: “Flonase Nasal Spray (0.05% w/w) is an aqueous suspension of microfine fluticasone propionate



for topical administration to the nasal mucosa by means of a metering, atomizing spray pump.”

194. In the entry for Flonase, the ‘95 PDR Supplement A also states that Flonase™ is “for intranasal use only.”

195. No single aqueous nasal spray disclosed the ‘95 PDR is described therein as being a thixotropic aqueous pharmaceutical composition which (i) is capable of being sprayed into the nasal cavity of an individual, (ii) is propellant-free, (iii) has a pH of about 4.5 to 7.5, and (iv) includes triamcinolone acetonide.

196. No single aqueous nasal spray disclosed the ‘95 PDR is described therein as being a thixotropic aqueous pharmaceutical composition which (i) is capable of being sprayed into the nasal cavity of an individual, (ii) is propellant-free, (iii) has a pH of about 4.5 to 7.5, and (iv) includes (a) a mixture of microcrystalline cellulose and carboxymethylcellulose sodium; (b) polysorbate 80; (c) disodium ethylenediamine tetraacetate; (d) benzalkonium chloride; (e) dextrose; and (f) purified water.

197. No single aqueous nasal spray disclosed the ‘95 PDR is described therein as being a thixotropic aqueous pharmaceutical composition which (i) is capable of being sprayed into the nasal cavity of an individual, (ii) is propellant-free, (iii) has a pH of about 4.5 to 7.5, and (iv) includes (a) triamcinolone acetonide; (b) a mixture of microcrystalline cellulose and carboxymethylcellulose sodium; (c) polysorbate 80; (d) disodium ethylenediamine tetraacetate; (e) benzalkonium chloride; (f) dextrose; and (g) purified water.

198. No single aqueous nasal spray disclosed the ‘96 PDR is described therein as being a thixotropic aqueous pharmaceutical composition which (i) is capable of being

sprayed into the nasal cavity of an individual, (ii) is propellant-free, (iii) has a pH of about 4.5 to 7.5, and (iv) includes triamcinolone acetonide.

199. No single aqueous nasal spray disclosed the '96 PDR is described therein as being a thixotropic aqueous pharmaceutical composition which (i) is capable of being sprayed into the nasal cavity of an individual, (ii) is propellant-free, (iii) has a pH of about 4.5 to 7.5, and (iv) includes (a) a mixture of microcrystalline cellulose and carboxymethylcellulose sodium; (b) polysorbate 80; (c) disodium ethylenediamine tetraacetate; (d) benzalkonium chloride; (e) dextrose; and (f) purified water.

**F. PCT Application Nos. WO 92/14473, WO 94/05330 and WO 92/04365**

200. PCT Application Nos. WO 92/14473 ("the '473 application"), WO 94/05330 ("the '330 application") and WO 92/04365 ("the '365 application") were publicly available and publicly accessible more than one year before July 3, 1996.

201. The '473 application, the '330 application and the '365 application qualify as printed publications under 35 U.S.C. § 102(b).

202. None of the pharmaceutical compositions disclosed in the '473 application is described therein as including a chelating agent.

203. The '473 application does not contain the words "mucociliary clearance."

204. The '365 application does not contain the phrase "time dependent viscosity recovery."

205. The '365 application does not contain the phrase "mucociliary clearance."

206. The '365 application does not contain the words "once daily dosing."

207. The '330 application does not refer to once-daily dosing of any pharmaceutical composition disclosed therein.

**PTO Examination**

208. Settipane, *et al.*, *Triamcinolone Acetonide Aqueous Nasal Spray in Patients with Seasonal Ragweed Allergic Rhinitis: A Placebo-Controlled, Double-Blind Study*, *Clinical Therapeutics* 17:252-263, 253 (1995), was before the PTO examiner when examining the applications from which the '573 and '329 patents issued.

209. Kobayashi, *et al.*, *Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Patients with Perennial Allergic Rhinitis: A Multicenter, Randomized, Double- Blind, Placebo-Controlled Study*, *Clinical Therapeutics* 17:503-513, 504 (1995), was before the PTO examiner when examining the applications from which the '573 and '329 patents issued.

210. The PTO Examiner's conclusion in favor of patentability was made in part based on his belief that the claimed composition comprised "unique thixotropic properties, with specific viscosity traits (sheared and/or unsheared), and further comprising triamcinolone acetonide as medicant."

**Clinical Trials**

**REDACTED**

**REDACTED**

**REDACTED**

**FDA**

224. The 1999 Guidance on “Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action” contains recommendations.

225. The 2003 Guidance on “Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action” contains recommendations.

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

AVENTIS PHARMACEUTICALS INC. and	)	
SANOFI-AVENTIS US LLC,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 06-286-GMS
	)	
BARR LABORATORIES, INC.,	)	
	)	
Defendant.	)	

**APPENDIX B**

**AGREED STATEMENT OF CONTESTED ISSUES OF FACT AND LAW**

**I. Plaintiffs' Claim of Infringement**

**A. U.S. Patent No. 5,976,573 (the "'573 Patent")**

1. Whether Barr's submission of Abbreviated New Drug Application ("ANDA") No. 78-104 infringes claims 5, 6, 7, 8, 21, 22, 23, 24, 26, 27, 28, 34 and 35 of the '573 patent under 35 U.S.C. § 271(e)(2).

**B. U.S. Patent No. 6,143,329 (the "'329 Patent")**

1. Whether Barr's submission of ANDA No. 78-104 infringes claims 13, 14, 15, 16, 23, 24, 25 and 26 of the '329 patent under 35 U.S.C. § 271(e)(2).

**II. Defendant's Claims of Invalidity**

**A. 35 U.S.C. § 102(b)**

1. Whether the phase III clinical trials for which results were reported in Settipane et al. (1995) Clinical Therapeutics 17:252-63 and Kobayashi et al. (1995) Clinical Therapeutics 17:503-13 were an experimental use or a public use.

B. 35 U.S.C. § 103: Whether the asserted claims of the '573 and '329 patents are invalid as obvious

1. What is the scope and content of the prior art?
2. What was the level of ordinary skill in the art at the time of invention?
3. What are the differences between the prior art and the claimed invention?
4. Whether there are secondary considerations of nonobviousness
  - a. Whether Nasacort AQ was “commercially successful” within the meaning of the patent law.
  - b. Whether there was a long felt need for the claimed invention
  - c. Whether the claimed invention was copied.
  - d. Whether the claimed invention exhibits unexpected results.
  - e. Whether there is evidence of failure of others.

C. 35 U.S.C. § 112

1. Whether the specifications of the '573 and '329 patents enable a person of ordinary skill in the art to make a nasal spray formulation that deposits on all of the regions of the nasal cavity, including specifically the frontal sinuses, recited in the asserted claims.
2. Whether the specification of the '573 and '329 patents enables a person of ordinary skill in the art to make a nasal spray formulation that, following administration, is retained on all of the regions of the nasal cavity, including specifically the frontal sinus, for at least about one hour.

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

AVENTIS PHARMACEUTICALS INC. and	)	
SANOFI-AVENTIS US LLC,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 06-286-GMS
	)	
BARR LABORATORIES, INC.,	)	
	)	
Defendant.	)	

**APPENDIX C**

**PLAINTIFFS' STATEMENT OF CONTESTED ISSUES OF FACT AND LAW**

The following is Plaintiffs Aventis Pharmaceuticals Inc. and Sanofi-Aventis US LLC's Statement of Contested Issues of Fact and Law as of April 7, 2008. Plaintiffs reserve the right to submit revisions to this statement after receiving the Court's rulings on the parties respective motions *in limine*.

**I. CONTESTED ISSUES OF LAW AND FACT ON JURISDICTION**

A. Whether Barr's challenge to Plaintiff Sanofi-Aventis US LLC's patent infringement claims is on the basis of failure to state a claim, rather than lack of subject matter jurisdiction.

B. Whether Barr waived any challenge to Plaintiff Sanofi-Aventis US LLC's patent infringement claims by failing to timely challenge them under Rule 12(b)(6) of the Federal Rules of Civil Procedure.

C. Whether Barr has failed to provide a sufficient basis on which the Court could find that Plaintiff Sanofi-Aventis US LLC's patent infringement claims are barred.



## **II. CONTESTED ISSUES OF LAW AND FACT ON INFRINGEMENT**

### **A. U.S. Patent No. 5,976,573 (the “573 Patent”)**

1. Whether Barr infringed claims 5, 6, 7, and 8 of the ‘573 patent under 35 U.S.C. § 271(e)(2) by filing an ANDA, for the purpose of marketing a drug before the expiration of the patent, for a drug product that meets each and every limitation of these claims.

a.

b.

c.

**REDACTED**

d.

e.

f.

**REDACTED**

2. Whether Barr infringed claims 21, 22, 23, 24, 26, 27, and 28 of the '573 patent under 35 U.S.C. § 271(e)(2) by filing an ANDA for a drug with instructions for physicians and patients for using the drug product that meets each and every limitation of these claims.

a.

b.

c.

**REDACTED**

d.

e.

f.

g.

**REDACTED**

h.

3. Whether Barr infringed claim 34 of the '573 patent under 35 U.S.C. § 271(e)(2) by filing an ANDA for a drug with instructions for physicians and patients for using the drug product that meets each and every limitation of these claims.

a. Whether, for claim 34 of the '573 patent, the term "thixotropic" means: (i) the viscosity of the composition in unsheared form is relatively high, with the composition being in a gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (iii) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucociliary forces which are present in the nasal cavity.

b.

**REDACTED**

c. **REDACTED**

d.

4. Whether Barr infringed claim 35 of the '573 patent under 35 U.S.C. § 271(e)(2) by filing an ANDA for a drug with instructions for physicians and patients for using the drug product that meets each and every limitation of these claims.

a. Whether, for claim 35 of the '573 patent, the term "thixotropic" means: (i) the viscosity of the composition in unsheared form is about 400 to about 1000 centipoises and (ii) the viscosity of the composition when shaken is about 50 to about 200 centipoises.

b.

**REDACTED**

c.

d.

**REDACTED**

e.

B. U.S. Patent No. 6,143,329 (the “‘329 Patent”)

1. Whether Barr infringed claim 13 of the ‘329 patent under 35 U.S.C. § 271(e)(2) by filing an ANDA, for the purpose of marketing a drug before the expiration of the patent, for a drug that meets each and every limitation of these claims.

a. Whether, for claim 13 of the '329 patent, the term "thixotropic" means: (i) the viscosity of the composition in unsheared form is relatively high, with the composition being in a gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (iii) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucociliary forces which are present in the nasal cavity.

b.

**REDACTED**

c.

**REDACTED**

2. Whether Barr infringed claims 14, 15, 16, 23, and 24 of the '329 patent under 35 U.S.C. § 271(e)(2) by filing an ANDA for a drug with instructions for physicians and patients for using the drug product that meets each and every limitation of these claims.

a. Whether, for claims 14, 15, 16, 23, and 24 of the '329 patent, the term "thixotropic" means: (i) the viscosity of the composition in unsheared form is relatively high, with the composition being in a gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (iii) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucociliary forces which are present in the nasal cavity.

b.

**REDACTED**

c.

3. Whether Barr infringed claim 25 of the '329 patent under 35 U.S.C. § 271(e)(2) by filing an ANDA for a drug with instructions for physicians and patients for using the drug Product that meets each and every limitation of these claims.

a. Whether, for claim 25 of the '329 patent, the term "thixotropic" means: (i) the viscosity of the composition in unsheared form is relatively high, with the composition being in a gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (iii) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucociliary forces which are present in the nasal cavity.

b.

c.

**REDACTED**

d.

4. Whether Barr infringed claim 26 of the '329 patent under 35 U.S.C. § 271(e)(2) by filing an ANDA for a drug with instructions for physicians and patients for using the drug product that meets each and every limitation of these claims.

a. Whether, for claim 26 of the '329 patent, the term "thixotropic" means: (i) the viscosity of the composition in unsheared form is about 400 to about 800 centipoise; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition is about 50 to about 200 centipoise.

b.

c.

**REDACTED**

d.

e.

#### **IV. CONTESTED ISSUES OF LAW AND FACT ON VALIDITY**

##### **A. 35 U.S.C. § 102(b)**

1. Whether Rhône-Poulenc Rorer's Phase 3 clinical trials on an aqueous triamcinolone acetonide nasal spray, seeking to determine whether that spray was safe and



effective in humans, were not an invalidating public use of the aqueous triamcinolone acetonide nasal spray.

a. Whether Barr has failed to provide clear and convincing evidence that Rhône-Poulenc Rorer's Phase 3 clinical trials were a public use of the patented invention.

b. If Barr has provided clear and convincing evidence that Rhône-Poulenc Rorer's Phase 3 clinical trials were a public use, whether that public use is negated by it being an experimental use of the patented invention.

i.

ii.

iii.

iv.

v.

**REDACTED**

vi.

vii.

viii.

ix.

x.

xi.

**REDACTED**

xii.

xiii.

B. 35 U.S.C. § 103

1. What is the scope and content of the prior art?

2. What are the differences between the prior art and the claimed invention?

a. Whether the invention described and claimed in the '573 and the '329 patents demonstrates surprising potency.

b. Whether the invention described and claimed in the '573 and the '329 patents has fewer harmful side effects than prior art aqueous inhaled nasal steroids.

c. Whether it would have been surprising that a difference in viscosity of potentially as small as 200 cp between the low end of the range for unsheared and the high end of the range for sheared, as required by some of the claims of the '573 and '329 patents, would provide a product that exhibits long-term stability at rest and desirable sprayability characteristics in sheared form.

3. What is the level of ordinary skill in the art?

a. Whether the person having ordinary skill in the art at the time of invention for the '573 and the '329 patents would have been a team of persons, one member of which would have experience in formulation of aqueous pharmaceutical compositions and one member of which would have been trained medically in the treatment of rhinitis and the use of intranasal steroids.

b. Whether a person of ordinary skill in the art would be required to have experience with the Brookfield LVT Viscometer identified as the device for testing viscosity in the specifications of the '573 and '329 patents.

4. Whether there is objective evidence of nonobviousness.

a. Whether Nasacort AQ was "commercially successful" within the meaning of the patent law.

i. Whether there was a nexus between any commercial success of Nasacort AQ and the benefits of the patented invention.

b. Whether there was a long-felt but unmet need for an aqueous nasal spray that resolved a persistent problem of patient compliance and dissatisfaction with INS-based nasal sprays.

c. Whether there was a long-felt need for an aqueous nasal spray that had the combination of properties of being odorless, resisting clearance to the throat and/or mouth, having uniform dosing through a pre-compression pump, and being safe and effective for adults and children via once-daily dosing administration.

d. Whether others tried but failed to create an aqueous INS nasal spray for the treatment of rhinitis that was odorless, resisted clearance to the throat and/or mouth, and was safe and effective for adults and children via once-daily dosing administration.

e. Whether others tried but failed to create an aqueous triamcinolone acetonide INS nasal spray for the treatment of rhinitis that was odorless, resisted clearance to the throat and/or mouth, and was safe and effective for adults and children via once-daily dosing administration.

f.

**REDACTED**

g. Whether a composition within the scope of the claims of the '573 and '329 patents provides unexpected benefits not present in prior art products.

C. 35 U.S.C. § 112

1. Whether the specifications of the '573 and '329 patents enable a person of ordinary skill in the art to make a nasal spray formulation that deposits on all of the regions of the nasal cavity recited in the asserted claims, including specifically the frontal sinus.

2. Whether the specification of the '573 and '329 patents enables a person of ordinary skill in the art to make a nasal spray formulation that, following administration, is retained on all of the regions of the nasal cavity recited in the asserted claims for at least about one hour.

**APPENDIX D**

**Barr Laboratories' Statement of Contested Issues of Fact and Law**

**I. Infringement (As stated in Appendix B, with the following additions).**

A. Whether Plaintiffs have proved by a preponderance of the evidence that Barr's ANDA product meets every limitation of the asserted patent claims.

B.

C. **REDACTED**

D.

**II. Invalidity (As stated in Appendix B with the following additions).**

A. Obviousness

1. Level of ordinary skill:

- a) Whether the level of ordinary skill in the art is a pharmaceutical formulator of nasal dosage forms.
- b) Whether the level of ordinary skill in the art must include a person trained medically in the treatment of allergic rhinitis.
- c) Whether the level of ordinary skill in the art must include a person with an understanding of and experience with thixotropic aqueous compositions and viscosity testing using a Brookfield LVT viscometer.

2. Prior art disclosures:

- a) Whether the use of EDTA in the claimed invention is obvious to a person of ordinary skill in the art.
- b) Whether a thixotropic aqueous nasal spray composition with a shear viscosity of about 50 to about 200 centipoise would be obvious to a person of ordinary skill in the art.

- c) Whether it would be obvious to substitute triamcinolone acetonide into a prior art nasal spray formulation.

4. Secondary Considerations (As stated in Appendix B):

B. Enablement (As stated in Appendix B).

C. Public Use. (As stated in Appendix B, with the following additions)

1.

**REDACTED**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

AVENTIS PHARMACEUTICALS INC. and )		
SANOFI-AVENTIS US LLC, )		
	)	
Plaintiffs, )		
	)	
v. )		C.A. No. 06-286-GMS
	)	
BARR LABORATORIES, INC., )		
	)	
Defendant. )		

**SCHEDULE C(1)**

**PLAINTIFF'S LIST OF TRIAL EXHIBITS WITHOUT OBJECTIONS**

PTX	Description	Bates No.
1	Certified copy of U.S. Patent No. 5,976,573	
2	Certified copy of file history for U.S. Patent No. 5,976,573	
3	Certified copy of U.S. Patent No. 6,143,329	
4	Certified copy of file history U.S. Patent No. 6,143,329	
5	Triamcinolone Acetonide Nasal Spray Presentation.	PERR00010630 - PERR00010657
6	<b>REDACTED</b>	PERR00010825 - PERR00010832
7		PERR00010730
8		PERR00011624
9		PERR00011625
10		PERR00010846 - PERR00010849
11		PERR00000781
14	Table regarding Triamcinolone Acetonide NS.	PERR00003212
15	Part of an ANDA regarding Triamcinolone Acetonide Nasal Spray, 0.055 mg/spray, Chemistry, Manufacturing and Controls: Drug Substance.	BARR-TAA-000101 - BARR-TAA-000192
18	Part of an ANDA regarding Triamcinolone Acetonide Nasal Spray, 0.055 mg/spray, Chemistry, Manufacturing and Controls: Drug Product. Specifications and Methods for Drug Product Inactive Ingredients.	BARR-TAA-000232 - BARR-TAA-000404
21	<b>REDACTED</b>	PERR00011465 - PERR00011468
22		PERR00001097 - PERR00001100

PTX	Description	Bates No.
28	<b>REDACTED</b>	PERR00014668 - PERR00014678
30		BARR-TAA-016898 - BARR-TAA-016899
32		PERR00014679 - PERR00014680
36	Certificate of analysis for Triamcinolone Acetonide Nasal Spray.	PERR00008368
38	<b>REDACTED</b>	PERR00012273
39		PERR00000749 - PERR00000760
48	Barr ANDA Components and Composition Statements; ANDA for Triamcinolone Acetonide Nasal Spray regarding qualitative and quantitative list of components.	BARR-TAA-000226 - BARR-TAA-000231
49	ANDA for Triamcinolone Acetonide Nasal Spray regarding specifications and methods for drug product inactive ingredients.	BARR-TAA-000232 - BARR-TAA-000234
50	ANDA for Triamcinolone Acetonide Nasal Spray regarding method of manufacturing and packaging.	BARR-TAA-000412 - BARR-TAA-000418
51	ANDA for Triamcinolone Acetonide Nasal Spray regarding in process controls and tests.	BARR-TAA-000845 - BARR-TAA-000866
52	ANDA for Triamcinolone Acetonide Nasal Spray regarding packaging materials controls: container / closure system. Summary of packaging system.	BARR-TAA-001309 - BARR-TAA-001311
53	ANDA for Triamcinolone Acetonide Nasal Spray regarding packaging materials controls: container / closure system. Components Specification and Test Data.	BARR-TAA-001369 - BARR-TAA-001400
59	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use for product Triamcinolone Acetonide.	BARR-TAA-049965 - BARR-TAA-050059
60	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use for product Triamcinolone Acetonide.	BARR-TAA-050060 - BARR-TAA-050197
61	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use for product Triamcinolone Acetonide.	BARR-TAA-050543 - BARR-TAA-050554
62	Guidance for Industry. Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action.	BARR-TAA-017829 - BARR-TAA-017865
74	<b>REDACTED</b>	PERR00004289 - PERR00004302
75		PERR00000786 - PERR00000789
76		PERR00003449 - PERR00003450
77		PERR00010833 - PERR00010835
78		PERR00010836 - PERR00010845
79	Alliance and Integration Management Plan Agis/Triamcinolone Acetonide	BARR-TAA-032016 - BARR-TAA-032028



PTX	Description	Bates No.
94	ANDA for Triamcinolone Acetonide Nasal Spray regarding Chemistry, Manufacturing and Controls for Drug Substance.	BARR-TAA-012143 - BARR-TAA-012709
95	<b>REDACTED</b>	BARR-TAA-050198 - BARR-TAA-050432
97	Letter regarding information on NDA 20468/S002.	BARR-TAA-022418 - BARR-TAA-022419
102	<b>REDACTED</b>	BARR-TAA-014028 - BARR-TAA-014030
103	Bulk Product Monograph regarding Triamcinolone Acetonide Nasal Spray.	BARR-TAA-000819 - BARR-TAA-000844
107	Analytical responses regarding Triamcinolone Acetonide Nasal Spray.	BARR-TAA-017674 - BARR-TAA-017679
108	Pharmaceutical R&D formulations for Q&Q approval.	BARR-TAA-017671
110	Controlled correspondence regarding Triamcinolone Acetonide Nasal Spray, 0.055 mg/spray. Request for Guidance Regarding a Proposed Quantitative Composition.	BARR-TAA-017177 - BARR-TAA-017178
114	Controlled correspondence 04-053 regarding Triamcinolone Acetonide Nasal Spray, 0.055 mg/spray. Request for Guidance Regarding a Proposed Quantitative Composition.	BARR-TAA-013973 - BARR-TAA-013974
115	Email regarding nasal sprays and FDA reponse.	BARR-TAA-017176
116	Letter regarding ANDA Triamcinolone Acetonide Nasal Spray, 0.055 mg/spray.	BARR-TAA-000001 - BARR-TAA-000002
118	Facsimile regarding ANDA #78-104.	BARR-TAA-018376 - BARR-TAA-018378
119	Electronic Labeling Amendment for ANDA 78-104, Triamcinolone Acetonide Nasal Spray 0.055 mg/spray.	PERR00005078 - PERR00005079
121	Facsimile regarding Barr's abbreviated new drug application 78-104 submitted pursuant to Section 505(j) of the Federal Food, Drug and Cosmetic Act for Triamcinolone Acetonide Nasal Spray 0.055 mg/spray.	BARR-TAA-018354 - BARR-TAA-018356
136	Email regarding Triamcinolone Acetonide Nasal Spray.	BARR-TAA-018681 - BARR-TAA-018682
137	<b>REDACTED</b>	BARR-TAA-050651 - BARR-TAA-050653
138	Email regarding nasal sprays	BARR-TAA-050650
139		BARR-TAA-050654
140		BARR-TAA-050649
141	<b>REDACTED</b>	BARR-TAA-016665 - BARR-TAA-016666
143	Email regarding external projects update	BARR-TAA-034029 - BARR-TAA-034032
144	Email regarding external project update	BARR-TAA-034033 - BARR-TAA-034036
145	<b>REDACTED</b>	BARR-TAA-034070 - BARR-TAA-034073
149	Email regarding nasal sprays.	BARR-TAA-050556 - BARR-TAA-050557

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>
150	Email regarding nasal sprays.	BARR-TAA-050555
154	Letter regarding attached submission for IND #39,306.	NAQ0217808 - NAQ0217854
158	Berridge et al., The Journal of Nuclear Medicine, Vol. 39, No. 11, November 1998, pp. 1972 - 1977, entitled Biodistribution and Kinetics of Nasal Carbon-11-Triamcinolone Acetonide.	NAQ0473310 - NAQ0473315
159	Presentation entitled Biodistribution and Kinetics of Nasal 11C Triamcinolone Acetonide (TAA AQ).	NAQ0734944 - NAQ0734956
162	Letter regarding additional research study of Nasacort AQ at University Hospitals of Cleveland.	NAQ0311828 - NAQ0311829
163	<b>REDACTED</b>	NAQ0275644 - NAQ0275645
164	Interoffice correspondence regarding Nasacort project team meeting.	NAQ0140643 - NAQ0140650
165	Flovent v. Nasacort AQ, 2002 study and Flonase v. Nasacort AQ, 2002 study.	NAQ0920071 - NAQ0920093
166	Final Report of PET Study of the Biodistribution and Kinetics of Nasacort AQ and Flonase [AV-PET-0001].	NAQ0372549 - NAQ0372595
167	Nasacort AQ v. Flonase study, 2002.	NAQ0915185 - NAQ0915186
168	Nasal Delivery and Kinetics of Fluticasone Propionate Using Positron Tomography (PET).	NAQ0485918 - NAQ0485919
169	Presentation entitled How Can Equivalence of Inhaled Drugs Be Demonstrated?	NAQ0485949 - NAQ00485983
170	Presentation entitled How Can Equivalence of Inhaled Drugs Be Demonstrated?	NAQ0485920 - NAQ0485948
171	Presentation entitled Movie Loops of 2001-2002 Nasacort-Flonase Study	NAQ0486017 - NAQ0486024
173	Letter regarding Nasacort - NCST studies.	NAQ0272955
174	TAA-AQ Study/Publication Grid	NAQ0521302 - NAQ0521305
179	Brandon E. Simpson Curriculum Vitae	NAQ0121160 - NAQ0121164
180	Letter regarding submission for new studies in accordance with Protocol No. RG 5029Y-304 and RG 5029Y-305.	NAQ0319690 - NAQ0319691
181	Clinical Study Medication Form for Protocol No. RG5029Y-101	NAQ0129062
182	Letter regarding RG 5029Y-102.	NAQ0185425
183	Interoffice correspondence regarding Nasacort project team activity report, June 6, 1995.	NAQ0246328 - NAQ0246331
184	NDA #20-468, Form FDA 356h, Item 8	NAQ0135986 - NAQ0136154
185	Settipane et al., Clinical Therapeutics, Vol. 17, No. 2, 1995, pp. 252 - 263, entitled Triamcinolone Acetonide Aqueous Nasal Spray in Patients with Seasonal Ragweed Allergic Rhinitis: A Placebo-Controlled, Double-Blind Study.	BARR-TAA-012838 - BARR-TAA-012850

PTX	Description	Bates No.
186	Orgel, et al., The Journal of Allergy and Clinical Immunology, Vol. 77, No. 6, June, 1986, entitled Clinical, rhinomanometric, and cytologic evaluation of seasonal allergic rhinitis treated with beclomethasone dipropionate as aqueous nasal spray or pressurized aerosol.	BARR-TAA-050626 - BARR-TAA-050634
189	Kobayashi et al., Clinical Therapeutics, Vol. 17, No. 3, 1995, pp. 503 - 513, entitled Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Patients with Perennial Allergic Rhinitis: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study.	BARR-TAA-012793 - BARR-TAA-012805
190	<b>REDACTED</b>	NAQ0282344 - NAQ0282345
191	Confidential Disclosure Agreement between Roger H. Kobayashi, M.D. and Rhone Poulenc Rorer Pharmaceutical, Inc.	NAQ0305357 - NAQ0305359
192	Rhone Poulenc Rorer Central Research Comprehensive Medical Report for RG 5029Y.	NAQ0034059 - NAQ0034409
193	Interoffice correspondence regarding RG 5029Y-305 Protocol Approval.	NAQ0248227
194	Monitor's Site Visit Log regarding RG 5029Y-305.	NAQ0251709
195	Monitoring Report regarding RG5029Y-305.	NAQ0251704
196	Declaration of Brandon Simpson Under 37 CFR section 1.132	BARR-TAA-012851 - BARR-TAA-012855
197	<b>REDACTED</b>	NAQ0277307 - NAQ0277308
198	<b>REDACTED</b>	NAQ0277288 - NAQ0277294
199	Interoffice correspondence regarding RG5029Y-305 Unblinding.	NAQ0257628 - NAQ0257629
200	Koepke et al., Allergy and Asthma Proc., 1997, pp. 33 - 37, entitled Long Term Safety and Efficacy of Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Perennial Allergic Rhinitis.	NAQ0252570 - NAQ0252575
202	Investigational New Drug Application, Form FDA 1571, Item 2, 4, & 5, RG 5029Y, Nasacort AQ (triamcinolone acetonide)	NAQ0244608 - NAQ0244667
206	Case report regarding Rhone Poulenc Rorer Central Research for RG 5029Y-309, A Placebo Controlled Double Blind Study of the Safety and Efficacy of RG 5029Y Aqueous Nasal Spray in Adult Patients with Ragweed Allergic Rhinitis.	NAQ0056182 - NAQ0056243
212	Comparative PET studies for Nasacort.	NAQ0515025 - NAQ0515026
230	Meltzer et al., Otolaryngology Head and Neck Surgery, February 2005, pp. 197 - 207, entitled Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitis.	NAQ0490680 - NAQ0490690
231	Interoffice Memorandum regarding Nasacort Project Team Activity Report, May 13, 1994.	NAQ0299256 - NAQ0299265
232	Interoffice Memorandum regarding October 13, 1994 Event.	SL001107
233	Interoffice Memorandum Project Activity Report for Nasacort Aqueous Nasal Spray.	NAQ0299243 - NAQ0299252
238	Letter regarding Original New Drug Application #20-468, Nasacort AQ (triamcinolone acetonide) Nasal Spray.	NAQ0019648 - NAQ0019650
239	Application To Market A New Drug For Human Use Or An Antibiotic Drug For Human Use relating to Nasacort AQ Nasal Spray.	NAQ0019651 - NAQ0019652

PTX	Description	Bates No.
243	Interoffice Correspondence regarding Nasacort AQ Project Plan.	NAQ0163205 - NAQ0163210
245	Interoffice Correspondence regarding Triamcinolone Acetonide (TAA) Project Team Meeting April 6, 1993.	NAQ0140892 - NAQ0140901
246	Interoffice Correspondence regarding Aqueous Nasacort Dose Selection.	NAQ0123140
248	Interoffice Correspondence regarding Nasacort AQ Study Summaries, FDA Format (Dr. Love).	NAQ0175031
249	Interoffice Correspondence regarding Triamcinolone Acetonide (Nasacort AQ) Project Team Meeting November 15, 1993.	NAQ0140925 - NAQ0140929
251	Letter with attached IND 39,306, RG 5029Y, Nasacort AQ, Serial No. 016, Protocol Amendment, New Protocol, New Investigators.	NAQ0320117 - NAQ0320225
253	Interoffice Correspondence regarding Nasacort Approvals.	NAQ0140136 - NAQ0140141
256	Rhone-Poulenc Rorer Interoffice Correspondence regarding Nasacort Aqueous (AQ): Development Plan	NAQ 0163124
257	Interoffice Memorandum regarding Nasacort AQ	NAQ0123147
260	<b>REDACTED</b>	NAQ0123149
261	Triamcinolone Acetonide Aqueous Nasal Spray Product and Process Information Summary (PPIS) Volume I of IV	NAQ0009427 - NAQ0009714
262	Handbook of Pharmaceutical Excipients	BARR-TAA-012773 - BARR-TAA-012792
263	Interoffice Memorandum regarding Nasacort AQ	NAQ0123161
264	<b>REDACTED</b>	NAQ0163285
266	Triamcinolone Acetonide Aqueous Nasal Spray Product and Process Information Summary (PPIS) Volume III of IV	NAQ0010026 - NAQ0010219
269	Memo regarding Triamcinolone Acetonide Aqueous Nasal Spray Formulation Development Report	NAQ0010944 - NAQ0010958
273	Triamcinolone Acetonide Aqueous Nasal Spray Product and Process Information Summary (PPIS) Volume IV of IV	NAQ0010220 - NAQ0010685
275	Memo regarding Patient Instructions for Use	NAQ0277225 - NAQ0277226
276	Interoffice Memo regarding Nasacort AQ	NAQ0123165 - NAQ0123166
277	Anita Quinn Lab Notebook No. 3438	NAQ0018943 - NAQ0019070
278	Anita Quinn Lab Notebook No. 3667	NAQ0015445 - NAQ0015580
279	Anita Quinn Lab Notebook No. 4156	NAQ0017136 - NAQ0017180
280	Timothy Lavery Lab Notebook No. 4196	NAQ0017803 - NAQ0017935
285	Nasacort AQ: Rheological Evaluation	NAQ0011044
286	Letter regarding response to FDA request for additional information for NDA #20-468	NAQ0396270 - NAQ0396281
290	Letter regarding NDA 20-468 and Amendment to Annual Report dated July 22, 2003	NAQ0173954 - NAQ0173966

PTX	Description	Bates No.
296	Aventis Report of the Investigation study of RPR107971 level/Particle size in investigational batches of Nasacort AQ	NAQ0064774 - NAQ0064783
297	Nasacort 1996 Brand Plan	NAQ0480621 - NAQ0480953
298	Sanofi-Aventis presentation entitled US Planning Udate - 2006 Tactical Brand Planning Process T3 2005 Update & 2006 Budget	NAQ0488512 - NAQ- 488537
303	Product information regarding Nasacort Nasal Inhaler and Nasacort AQ Nasal Spray	NAQ0250093
307	<b>REDACTED</b>	NAQ0250206
311	Nasacort advertisement entitled Patients prefer once daily Nasacort AQ Nasal Spray	NAQ0340750 - NAQ0340752
312	NDA Application No. 20468 entitled Nasacort AQ Nasal Spray (Triamcinolone Acetonide).	NAQ0409867 - NAQ0409950
313	Aventis product information regarding Nasacort AQ.	NAQ0475910 - NAQ0475933
314	Facsimile regarding NDA Application No. 20-468 entitled Nasacort AQ (triamcinolone acetonide) Nasal Spray.	NAQ0410531 - NAQ0410533
315	Document entitled Nasacort and Nasacort AQ Combined P&L.	NAQ0318628
317	Rhone Poulenc Rorer Interoffice Correspondence regarding Nasacort Support Activities.	NAQ0477532 - NAQ0477537
320	Document regarding Nasacort Sales for 2005 Brand Plan - 10 Year P&L, Nasacort Income Statement for total year 2005 in MUSD, and Business Plan 2002 - 2006.	NAQ0933408 - NAQ0933420
322	Presentation entitled Nasacort AQ: Sales Force Study Executive Summary, October - January, 2005.	NAQ0525171 - NAQ0525201
323	Presentation entitled 2006 Nasacort Call Plan.	NAQ0907509 - NAQ0907523
327	Business Plan for Nasacort Aerosol and Nasacort AQ.	NAQ0478907 - NAQ0478924
329	Presentation entitled Nasacort AQ, MF3 2004 Proposed Sales Forecast.	NAQ0524583 - NAQ0524589
330	Presentation entitled Nasacort Double Play.	NAQ0275722 - NAQ0275739
333	Sanofi Aventis US Pharmaceuticals 2006 January Net Sales.	NAQ0908516 - NAQ0908525
336	<b>REDACTED</b>	NAQ0617347
339	Barr Laboratories Inc.'s Notice of Deposition.	
342	Timothy Lavery's Lab Notebook No. 4309	NAQ0015929 - NAQ0016048
343	Timothy Lavery's Lab Notebook No. 4415	NAQ0016259 - NAQ0016392
345	Interoffice Memorandum regarding Nasacort AQ answers to Tim's questions.	NAQ0123154
346	Suponea to Marc S. Berridge.	
347	<b>REDACTED</b>	NAQ0217840 - NAQ0217849

PTX	Description	Bates No.
348	<b>REDACTED</b>	NAQ0210932 - NAQ0210935
349	Poster presented at the International Society for Aerosol Medicine	NAQ0486010
350	<b>REDACTED</b>	NAQ0486011 - NAQ0486016
351	PET Study of the Biodistribution and Kinetics of Nasacort AQ and Flonase [AV-PET-001] Final Report.	BERRIDGE000007 - BERRIDGE000053
354	Michael A. Kaliner, M.D. Curriculum Vitae	
359	Robert Y. Lochhead, Ph.D. Curriculum Vitae	
360	Order Construing the Terms of U.S. Patent Nos. 5,976,573 and 6,143,329	
361	Joint Claim Construction Chart	
362	Package Insert for Proposed Barr Product (Barr Package Insert)	BARR-TAA-000045 - BARR-TAA-000062
363	A Brookfield Publication included with the Brookfield LVT Viscometer: "Brookfield Dial Reading Viscometer with Electric Drive Operating Instructions, Manual No. M/00151-B0704" ("Brookfield Operating Instructions")	NAQ0956550 - NAQ0956578
364	A Brookfield Publication included with the Brookfield LVT Viscometer: "More Solutions to Sticky Problems. A Guide to Getting More From Your Brookfield Viscometer" ("Brookfield Guide")	NAQ0956523 - NAQ0956549
365	<b>REDACTED</b>	BARR-TAA-050570 - BARR-TAA-050576
369	Eli O. Meltzer, MD Curriculum Vitae	
370	Claim Charts	
371	Nasacort AQ NDA Chemistry, Manufacturing and Controls Summary	NAQ0019699 - NAQ0019705
372	Title: Drug Product - Method of Manufacturing and Packaging	NAQ0020004 - NAQ0020019
373	Nasacort AQ Nasal Spray Information for the Patient, IN-6361B Rev. 10/97	NAQ0474037 - NAQ0474041
374	Nasacort AQ Package Insert	NAQ0482241
377	Robert K. Prud'Homme Curriculum Vitae	
378	October 30, 2007 letter from Steven J. Balick to Chief Judge Gregory M. Sleet	
379	Draft Container Label for Proposed Barr Product	BARR-TAA-000027
380	FMC letter dated November 13, 1998 and accompanying attachment (FMC Letter)	SL001319 - SL001325
381	H.A. Barnes et al., An Introduction to Rheology (Elsevier 1989)	A450 - A454
383	FMC - Avicel RC/CL Microcrystalline Cellulose and Carboxymethylcellulose Sodium, NF	FMC000217; FMC 000389; FMC000652
384	Kim-Chheng Ly Laboratory Notebook 8247 ("Kim Chheng Ly Notebook")	NAQ0014696 - NAQ0014707
385	Nasacort AQ NDA, Drug Substance Specifications ("TAA Specifications")	NAQ0019798 - NAQ0019801
386	Comparative Study of Micronized and Unmicronized Triamcinolone Acetonide Bulk Drug Substance as Supplied by Upjohn Co. ("TAA Bulk Study")	NAQ0060568 - NAQ0060577



PTX	Description	Bates No.
388	Kobayashi, et al., Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Patients with Perennial Allergic Rhinitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, 17 Clinical Therapeutics 503- 513 (1995)	NAQ0271080 - NAQ0271090
389	Beconase AQ Prescribing Information	GSK000027 - GSK000037
390	Flonase Prescribing Information	GSK000005 - GSK000017
393	Gerson, et al., Patient Preference and Sensory Comparisons of Nasal Spray Allergy Medications, 14 Journal of Sensory Studies 491-496 (1999)	NAQ0476110 - NAQ0476117
395	Nasacort Nasal Inhaler Prescribing Information	NAQ0450545
397	<b>REDACTED</b>	NAQ0308857 - NAQ0308864
402	FDA Enforcement Report, June 26, 2002	NAQ0639360
404	Nasacort AQ Prescribing Information	NAQ0250357
409	Bachert & El-Akkad, Patient Preferences and Sensory Comparisons of Three Intranasal Corticosteroids for the Treatment of Allergic Rhinitis, 89 Annals of Allergy, Asthma & Immunology 292 - 297 (2002)	NAQ0476683 - NAQ0476690
412	Patient Information for Nasonex, <a href="http://www.nasonex.com/nasx/application?namespace=main&amp;event=content_display&amp;event_input=isitright">http://www.nasonex.com/nasx/application?namespace=main&amp;event=content_display&amp;event_input=isitright</a>	NAQ0957683-4
413	Patient Information for Veramyst Nasal Spray, <a href="http://us.gsk.com/products/assets/us_veramyst_pil.pdf">http://us.gsk.com/products/assets/us_veramyst_pil.pdf</a>	NAQ0957565-69; NAQ0957570-89, NAQ0957505-509
414	Flonase Prescribing Information <a href="http://us.gsk.com/products/assets/us_flonase.pdf">http://us.gsk.com/products/assets/us_flonase.pdf</a>	NAQ0957670-82
419	Barr Laboratories, Inc.'s Third Supplemental Objections and Responses to Plaintiffs' Interrogatory Nos. 5 & 6	
422	Rhone Poulenc Rorer Central Research Comprehensive Medical Report for Protocol No. RG 5029Y-305	NAQ0034059 - NAQ0034408
423	Rhone Poulenc Rorer Central Research Comprehensive Medical Report for Protocol No. RG 5029Y-305LT	NAQ0186202 - NAQ0186524
424	Investigator Manual, Rhone Poulenc Rorer Protocol RG 5029Y-305	NAQ0282454 - NAQ0282493
425	A Study of the Safety and Efficacy of RG 5029Y Aqueous Nasal Spray in Patients with Perennial Allergic Rhinitis	NAQ0302926 - NAQ0302979
426	Patient Information and Consent Form for RG 5029Y-305	NAQ0251446 - NAQ0251453
427	RG 5029Y-305 Patient Informed Consent	NAQ0282765 - NAQ0282771
428	Patient Information and Consent Form	NAQ0282346 - NAQ0282353
437	Rhone-Poulenc Rorer Central Research Comprehensive Medical Report for Protocol No. RG 5029Y-309	NAQ0056070 - NAQ0056139
438	A Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of RG 5029Y Aqueous Nasal Spray in Adult Patients with Ragweed Allergic Rhinitis	NAQ0056142 - NAQ0056180

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>
439	A Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of RG 5029Y Aqueous Nasal Spray in Adult Patients with Ragweed Allergic Rhinitis, Protocol No. RG 5029Y-309	NAQ0055835 - NAQ0055879
440	Case Report Form, Rhone-Poulenc Rorer Central Research for Protocol No. RG 5029Y-309	NAQ0056182 - NAQ0056243
441	Letter of Agreement for Micheal Lawrence, M.D. for Clinical Study RG 5029Y-309	NAQ0201297 - NAQ0201299
443	Eli Meltzer, et al, "Triamcinolone Acetonide and Fluticasone Propionate Aqueous Nasal Sprays Significantly Improve Nasal Airflow in Patients with Seasonal Allergic Rhinitis" Allergy & Asthma Proc (Jan/Feb 2004) Vol 25, No. 1	NAQ0957655-60
450	Brookfield Model DV-I Operating Instructions M85-150-D and Miscellaneous Documents	BARR-KLING-000016 - BAR-KLING-000028
451	Letter Regarding FOIA Request	BARR-TAA-0022418 - BARR-TAA-0022419
452	Nasacort AQ Composition in Response to FOIA Request	BARR-TAA-022832 - BARR-TAA-022841
453	Beconase AQ Composition	GLAXA1078
454	Marketing Letter Regarding Discontinuation of Vancenase AQ	NAQ0340757
455	Flonase Composition	GLAXA1079
456	Flonase Prescribing Information	BARR-TAA-016539 - BARR-TAA-016542
457	FMC Literature	FMC000429 - FMC000439
458	Tinkler Lab Notebook No. 4517	NAQ0070478-599 at NAQ0070574, NAQ0070584
460	Nasacort AQ FDA Approval Letter	NAQ0271320 - NAQ0271321
461	Nasacort AQ Composition	NAQ0019704
462	Nasacort AQ Prescribing Information	NAQ0250357
463	FOIA Response	PERR00014813
464	FOIA Request	PERR0014814
465	Pharmaceutical Development Report	PERR00008552 - PERR0008570
466	Interim Report	PERR00010833 - PERR00010835
467	Report	PERR00010836 - PERR00010845
468	Pharmaceutical Report	PERR00010850 - PERR00010864
469	Interim Report	PERR00011672 - PERR00011674
471	573 Patent References cited	SL001042
472	Record of Telephone Conference with Examiner	SL001118 - SL001119
473	Information Disclosure Statement	SL001156 - SL001158
474	Form PTO-1449	SL001377 - SL001378
475	USPTO Document	SL001356 - SL001359



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>
476	Vancenase AQ and Vancenase AQ DS Composition	SP01613
478	1996 Physicians' Desk Reference and Supplements	
479	United States Patent No. 4,767,612	NAQ0452650--52
480	International Publication No. WO 92/14473	NAQ0452632-42
481	International Publication No.: WO 92/04365	BARR-TAA-012748-12766
482	International Publication No.: WO 94/05330	BARR-TAA-012727-47
483	1990-95 Avicel Product Brochures	
485	A.K. Pennington et al., The Influence of Solution Viscosity on Nasal Spray Deposition and Clearance, 43 International Journal of Pharmaceutics 221-24 (1988)	BARR-TAA-050622-25
486	H. Alice Orgel et al., Clinical, Rhinomanometric, and Cytologic Evaluation of Seasonal Allergic Rhinitis Treated with Beclomethasone Dipropionate as Aqueous Nasal Spray or Pressurized Aerosol, 77 Journal of Allergy and Clinical Immunology 858-64 (1986)	BARR-TAA-050628-34
493	FDA Orange Book, <a href="http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=019589&amp;TABLE1=OB_Disc">http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=019589&amp;TABLE1=OB_Disc</a>	
497	International Journal of Pharmaceutics Vol 43/3 (1988) - relating to clearance of HPMC solutions from nasal cavity	BARR-TAA-050625
508	Avicel RC/CL - Product Information from FMC	FMC000216 - FMC000221
509	Avicel - Problem Solver and Reference Manual - FMC Corp.	FMC000271 - FMC000428
510	Avicel RC-591 - Pharmaceutical Emulsions and Suspensions - Product Information	FMC000446 - FMC000463
511	Application Bulletin Avicel RC-591 - FMC Corp	FMC000563 - FMC000570
513	Donald O. Beers Curriculum Vitae	
514	The Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 201 et seq. (the "FFDCA")	
516	21 C.F.R. 10.115	
520	Curriculum Vitae and Bibliography of Marc S. Berridge	
521	Claim Charts	
522	Rhinitis and Asthma: Similarities and Differences, edited by Niels Mygind, Ulf Pipkorn, Ronald Dahl, Munksgaard Press (1990), page 25	NAQ0957700-715
523	Nasal Mucociliary Function in Humans, Resp. Def. Mech. 5(1) 427-449 (1978)	NAQ0957716-727
526	1993 PET Study "Harris" Report (Nasacort CFC)	NAQ0182411 - NAQ0182415
527	1996 PET Study Report	NAQ0253415 - NAQ0253437
528	1996 PET Study Report	NAQ0277365 - NAQ0277393
529	1996 PET Study Report	NAQ0449411 - NAQ0449436
557	AventisCA2004.ppt	NAQ0846074
558	AventisCA.ppt	NAQ0846075
559	AventisNasacortFlonase01-02Data.pdf	NAQ0846076

PTX	Description	Bates No.
560	MarcOttowa2.ppt	NAQ0846077
561	MarcOttowa.ppt	NAQ0915052-77
562	FlonaseNasacort2002MinorRegionAverageUptakes.xls	NAQ0915185-186
563	IndividualRawDataFlonaseNasacort2002.xls	NAQ0920071-75
564	Nascrtpg1.jpg	NAQ0920076
565	nasdata.xls	NAQ0920077-79
566	RawData02FlonaseNasacort.xls	NAQ0920080-81
567	RawData98FlonaseNasacort.xls	NAQ0920082-92
568	Si-142.jpg	NAQ0920093
569	ISAMNASA.ppt	NAQ0933407
572	Final PET Report for RG5029Y Pet Study	NAQ0486031 - NAQ0486036, NAQ0449411- NAQ0449436
573	Abstract; Nasal Delivery and Kinetics of Fluticasone Propionate Using Positron Tomography (PET)	NAQ0485918
574	PET Study of the Biodistribution and Kinetics of Nasacort AQ ® and Flonase ® [AV-PET-0001] Final Report	NAQ0372549- NAQ0372595
576	Curricula Vitae of Dr. Gregory K. Bell	
577	Nasacort Net Sales 2000-2003 USA and PR	NAQ0957685
578	Total Nasacort	NAQ0957686
579	Total Nasacort-M previous submission	NAQ0957687
580	Plaintiff's Third Supplemental Response to Interrogatory Nos. 7 and 13 of Barr Laboratories, Inc's Interrogatories (redacted version)	NAQ0957491-495
591	2001 Situation Analysis, Business Information and Planning - Nasacort AQ	NAQ0274308-595 at 590
592	U.S. Anti-Allergic Therapies Market	NAQ0623047-203 at 133, 138
593	Urgent: Voluntary Product Withdrawal, Nasacort ® Nasal Inhaler, July 7, 2003, "Dear Doctor" letter	NAQ0250206
594	Hoovers, Inc. (2008); Sanofi company record: Products/Operations; retrieved January 4, 2008, <a href="http://premium.hoovers.com">http://premium.hoovers.com</a>	NAQ0957440-441
604	It's Covered - Formulary Status 2004 (Nasacort AQ, Rhinocort Aqua, Flonase, Nasonex)	NAQ0483294
606	Nasacort AQ 2007-2009 Strategic Brand Plan, August 2006	NAQ890198-207 at 210
608	1997 Business Plan, Nasacort Aerosol and Nasacort AQ	NAQ0478903-924 at 906- 907
611	Nasacort AQ/HFA Nov 16, 2006 Executive Summary	NAQ0833999-4040 at 4018
613	Plaintiffs Response to Barr Laboratories, Inc's First Set of Interrogatories	
614	Barr Laboratories, Inc's Answer, Affirmative Defenses and Counterclaims	
615	Barr Laboratories, Inc's Second Set of Rule 33 Interrogatories to Plaintiffs	
616	Plaintiff's Response to Barr Laboratories Inc's Second Set of Interrogatories	
617	Complaint & Exhibits	
618	mb_NAQ det dol 00-0907.xls	NAQ0957694
619	mb_NAQ det dol 92-99.xls	NAQ0957695
620	mb_NAQ det 92-99.xls	NAQ0957693
621	mb_NAQ det 00-0907.xls	NAQ0957692

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>
622	mlb_NAQ_dtc_dol_95-0707.xls	NAQ0957696
623	mlb_NAQ_pmea_dol_93-0907.xls	NAQ0957699
624	mlb_NAQ_epromo_dol_0602-0907.xls	NAQ0957697
625	mlb_NAQ_journal_dol_99-0907.xls	NAQ0957698
626	28420_dollars_trx_nrx_1992-current.xls	NAQ0957071-142; NAQ0957689
627	28420_EU_and_Sam_EU_1992-sept_2007.xls	NAQ0957143-228; NAQ0957690
628	28420_NRx_TRx_EU_1992-oct2007.xls	NAQ0957229-316; NAQ0957691; NAQ0957229.1-9.4
629	Nasacort P and L 2000-2007.xls	NAQ0957685-7
636	Drug Details - Beconase	NAQ0957442
637	Drug Details - Flonase	NAQ0957443
638	Drug Details - Nasacort AQ	NAQ0957444
639	Drug Details - Nasarel	NAQ0957445
640	Drug Details - Nasaonex	NAQ0957446
641	Drug Details - Rhinocort	NAQ0957447
642	Drug Details - Nasacort	NAQ0957496
643	Drug Details - Dexacort	NAQ0957497
644	Drug Details - Vancenase	NAQ0957688
648	Certified translation of Document written in Hebrew and English regarding Triamcinolone Acetonide (Nasacort AQ Nasal Spray).	PERR00012125 - PERR00012126
649	Certified translation of Lab notebook 93 relating to triamcinolone acetamide project.	PERR00013819 - PERR00013956
650	Certified translation of Lab notebook 334 relating to triamcinolone acetamide.	PERR00013957 - PERR00013976
651	Perrigo Lab Notebook	PERR00014431 - PERR00014463
652	Perrigo Lab Notebook	PERR00014528 - PERR00014573
653	Perrigo Lab Notebook	PERR00015111 - PERR00015120
656	Datalogger sheets for samples sent to Lochhead	NAQ0957035-036
659	Nasal Distribution of Inhaled Drugs Determined by Positron Tomography	NAQ0933407_00000001
660	Comparison between Generic Drug and Reference Listed Drug	BARR-TAA-000020 - BARR-TAA-000062
665	Nasacort Clinical Documentation Volume 4.27	NAQ0434477 - NAQ0434628
668	Sheth Correspondence, Patient Preferences and Sensory Comparisons of Three Intranasal Corticosteroids for the Treatment of Allergic Rhinitis	NAQ0623839
669	Bachert Response: Patient Preferences and Sensory Comparisons of Three Intranasal Corticosteroids for the Treatment of Allergic Rhinitis	NAQ0731726 - NAQ0731728

PTX	Description	Bates No.
670	Aventis Pharmaceuticals Products Inc. Medical Affairs Final Study Report, RG-5029Y, Evaluation of a Newly Developed Preference Questionnaire for Intranasal Corticosteroids in Patients with Allergic Rhinitis Treated with Nasacort AQ Nasal Spray 220 mcg and Nasonex Nasal Spray 200 mcg - A Pilot Study	NAQ0728557 - NAQ0728644
671	Barr's Supplemental Objections and Responses to Plaintiffs' First Set of Requests for Admission	
672	Joint Submission Regarding Claim Terms at Issue	
673	Barr's Second Supplemental Objections and Responses to Sanofi-Aventis's Interrogatory Nos. 5 & 6; Certificate and Notice of Service; Notice of Electronic Filing	
674	October 31, 2007 Transcript from the Markman Hearing	
675	Letter to Judge Sleet re narrowing issues at claim construction hearing	
676	Letter to Judge Sleet re narrowing the claim construction issues to be addressed at the 10/31/07 Markman hearing	
677	Joint Appendix of Intrinsic and Extrinsic Evidence Relied Upon in Claim Construction Briefing	
678	Barr's Supplemental Objections and Responses to Aventis's Interrogatory Nos. 5 & 6	
681	Barr's Amended Objections and Responses to Aventis's Second Set of Requests for Admission	
682	Barr's Objections and Responses to Second Set of Requests for Admission	
683	Barr's Objections and Responses to Plaintiffs' First Set of Requests for Admission	
684	Barr's Objections and Responses to Plaintiffs' First Set of Requests for Admission	
685	Barr's Objections and Responses to Aventis's Third Set of Requests for the Production of Documents and Things	
686	Barr's Objections and Responses to Aventis's Second Set of Interrogatories (No. 9)	
687	Barr's Objections and Responses to Aventis's Second Set of Requests for Production of Documents and Things (Nos. 92-95); with Notice	
688	Barr's Supplemental Objections and Responses to Aventis's First Set of Interrogatories	
689	Barr's Objections and Responses to Aventis's First Set of Interrogatories	
690	Barr's Objection and Responses to Aventis's First Set of Requests for the Production of Documents and Things	
691	Barr's Initial Disclosures Pursuant to Rule 26(a)(1)	
692	Aventis' Reply to Barr's Counterclaims	
715	Nasacort P&L - Total Nasacort 2000-2007	NAQ0485885
716	Certified translation of Perrigo Lab Notebook	PERR00013819 - PERR00013976
717	Certified translation of Perrigo Lab Notebook	PERR00014431 - PERR00014463
718	Certified translation of Perrigo Lab Notebook	PERR00014528 - PERR00014573
719	Certified translation of Perrigo Lab Notebook	PERR00015111 - PERR00015120

PTX	Description	Bates No.
722	Lab notebook witnessed and understood by Natalie Grabarnick.	PERR00014316 - PERR00014344
723	Lab notebook performed by Natalie Grabarnick.	PERR00014464 - PERR00014509
724	Lab notebook witnessed and understood by Natalie Grabarnick. File name Nba71.	PERR00012653 - PERR00012773
725	Document written in Hebrew and English regarding Triamcinolone Acetonide (Nasacort AQ Nasal Spray).	PERR00012125 - PERR00012126
726	<b>REDACTED</b>	PERR00013819 - PERR00013956
727	Lab notebook 334 relating to triamcinolone acetonide.	PERR00013957 - PERR00013976
728	Executed Manufacturing Batch Records found in Drug Product Portion of Abbreviated New Drug Application No. 78-104	BARR-TAA-000524 - BARR-TAA-000656
729	Finished Product Monograph found in Drug Product Portion of Abbreviated New Drug Application No. 78-104	BARR-TAA-000870 - BARR-TAA-000926
730	Certificates of Analysis found in Drug Product Portion of Abbreviated New Drug Application No. 78-104	BARR-TAA-000951 - BARR-TAA-000962
731	Report: Triamcinolone Acetonide Nasal Spray Characterization Studies found in Drug Product Portion of Abbreviated New Drug Application No. 78-104	BARR-TAA-001208 - BARR-TAA-001248
732	Studies found in Patent and Exclusivity Statement portion of Abbreviated New Drug Application No. 78-104	BARR-TAA-012118 - BARR-TAA-012120
733	Defendant Barr Laboratories, Inc.'s Answering Claim Construction Brief	
734	Aventis Answering Brief on Claim Construction	
735	Barr's Opening Claim Construction Brief and Certificate of Service	
736	Aventis Opening Claim Construction Brief and Certificate of Service	
739	Drettner, The paranasal sinuses, The Nose: Upper Airway Physiology and the Atmospheric Environment, ch. 6, pp. 145-162 (Proctor, D. & Anderson, I.B. eds. 1982)	BARR-TAA-050785 - BARR-TAA-050804
740	Avicel RC/CL Microcrystalline Cellulose and Marine Colloids Carrageenan for Sunscreen Product Formulas	FMC000255 - FMC000257
741	Barr External Project Report	BARR-TAA-034030 - BARR-TAA-034032
743	Agis Packaging Comparison	BARR-TAA-018770 - BARR-TAA-018782
744	Agis Packaging Comparison	PERR00009747 - PERR00009783
748	RawData98FlonaseNasacort.xls.pdf; 1998 Raw Data for each volunteer	Berridge000055
749	nasdata.xls; 1998 summary data - no indication of which worksheet is which	Berridge000054
750	IndividualRawDataFlonaseNasacort2002.xls; 2002 Raw Data for each volunteer	Berridge000056
751	21 C.F.R. 314.94	
752	21 C.F.R. 312.21	
753	21 C.F.R. 314.430	
756	Nasacort Patient Information	BARR-TAA-037623 - BARR-TAA-37633
757	ANDA for Triamcinolone Acetonide Nasal Spray regarding packaging materials controls: container / closure system. Summary of packaging system.	BARR-TAA-001309 - BARR-TAA-001312
761	reference to MacKenzie skin blanching test in article by Gross	NAQ0275492

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>
766	Document demonstrating Nasacort AQ is a commercial embodiment of the patents in suit	NAQ0275126
767	Document demonstrating Nasacort AQ is a commercial embodiment of the patents in suit	NAQ0451649
768	Document demonstrating Nasacort AQ is a commercial embodiment of the patents in suit	NAQ0476109
771	Document demonstrating Nasacort AQ competition	NAQ0537741- NAQ0537780
773	Document demonstrating Nasacort AQ competition	NAQ0833814
777	Document Demonstrating Nasacort annual sales	NAQ0617308
778	Document Demonstrating Nasacort annual sales	NAQ0617593- NAQ0617715
779	Document Demonstrating Nasacort annual sales	NAQ0853959- NAQ0853961
780	Document Demonstrating Nasacort annual sales	NAQ0871358
781	Document Demonstrating Nasacort annual sales	NAQ0886634
782	Document Demonstrating Nasacort annual sales	NAQ0886553
783	Document Demonstrating Nasacort annual sales	NAQ0905623
784	Document Demonstrating Nasacort annual sales	NAQ0911288
785	Document Demonstrating Nasacort annual sales	NAQ0919991
786	Document demonstrating Nasacort AQ market share	NAQ0478043
788	Document demonstrating Nasacort AQ market share	NAQ0530947
790	Document demonstrating Nasacort AQ market share	NAQ0538726- NAQ0538803
796	Document demonstrating Nasacort AQ market share	NAQ0855458- NAQ0855462
797	Document demonstrating Total INS market growth	NAQ0912224
800	Document demonstrating supply interruptions of Nasacort AQ	NAQ0274065
801	Document demonstrating supply interruptions of Nasacort AQ	NAQ0274182
802	Document demonstrating supply interruptions of Nasacort AQ	NAQ0274255
803	Document demonstrating supply interruptions of Nasacort AQ	NAQ0274258
804	Document demonstrating supply interruptions of Nasacort AQ	NAQ0274277
805	Document demonstrating supply interruptions of Nasacort AQ	NAQ0274278
806	Document demonstrating supply interruptions of Nasacort AQ	NAQ0545993
807	Document demonstrating supply interruptions of Nasacort AQ	NAQ0708876
808	Document demonstrating supply interruptions of Nasacort AQ	NAQ0871411
814	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0540532- NAQ0540543
815	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0542458- NAQ0542463
816	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0546548
817	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0546814
818	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0550699- NAQ0550710
820	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0849876- NAQ0849877
821	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0891646



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>
826	Document demonstrating detailing efforts of competitors	NAQ0681960- NAQ0681970
827	Document demonstrating detailing efforts of competitors	NAQ0856108- NAQ0856110
829	Document demonstrating detailing efforts of competitors	NAQ0890219
833	Document demonstrating detailing efforts of competitors	NAQ0901436
835	Document demonstrating detailing efforts of competitors	NAQ0914777
836	Document demonstrating level of expenditures on Nasacort AQ	NAQ0274595
838	Document demonstrating level of expenditures on Nasacort AQ	NAQ0478924
839	Document demonstrating level of expenditures on Nasacort AQ	NAQ0485285
848	Document demonstrating level of expenditures on Nasacort AQ	NAQ0546236
850	Document demonstrating level of expenditures on Nasacort AQ	NAQ0605744
851	Document demonstrating level of expenditures on Nasacort AQ	NAQ0607676- NAQ0607680
852	Document demonstrating level of expenditures on Nasacort AQ	NAQ0713739- NAQ0713740
853	Document demonstrating level of expenditures on Nasacort AQ	NAQ0734195
858	Document demonstrating level of expenditures on Nasacort AQ	NAQ0850562- NAQ0850564
866	Document demonstrating level of expenditures on Nasacort AQ	NAQ0871511
867	Document demonstrating level of expenditures on Nasacort AQ	NAQ0874238
871	Document demonstrating level of expenditures on Nasacort AQ	NAQ0890750
876	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0250294
877	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0250516
878	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0295271
879	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0298228
880	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0298351
881	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0298346
882	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0298347
883	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0485712
884	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0525216
885	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0526451
886	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0544400- NAQ0544674
887	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0607681- NAQ0607682
888	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0637907- NAQ0638037
889	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0667833- NAQ0667834
890	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0667846- NAQ0667847
891	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0673022- NAQ0673044
892	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0673527
893	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0675692
894	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0834395
895	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0835523

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>
896	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0845936
897	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0847627
898	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0857719
899	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0861234
900	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0871374
901	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0879332- NAQ0879338
902	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0880266- NAQ0880276
903	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0880292- NAQ0880321
904	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0880374- NAQ0880384
905	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0881640
906	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0884053
907	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0887115
908	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0890799- NAQ0890811
909	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0891576
910	Document demonstrating MCO tier coverage of Nasacort AQ and competitors	NAQ0892015
911	Document demonstrating Nasacort marketing focused on claimed attributes	NAQ0340750- NAQ0340752
912	Document demonstrating Nasacort marketing focused on claimed attributes	NAQ0475910- NAQ0475932
913	Document demonstrating Nasacort AQ is patient preferred	NAQ0476111-17
914	Document demonstrating Nasacort AQ is patient preferred	NAQ0476683- NAQ0476689
915	Document demonstrating Nasacort AQ is patient preferred	NAQ0548848- NAQ0548855
917	Document demonstrating that Patient compliance a persistent problem	NAQ0298361
918	Document demonstrating that Patient compliance a persistent problem	NAQ0452208- NAQ0452216
919	Document demonstrating that Patient compliance a persistent problem	NAQ0470785
920	Document demonstrating that Patient compliance a persistent problem	NAQ0471232- NAQ0471234
921	Document demonstrating that Patient compliance a persistent problem	NAQ0474753
924	Document demonstrating that Patient compliance a persistent problem	NAQ0528403
925	Document demonstrating that Patient compliance a persistent problem	NAQ0540286- NAQ0540292
926	Document demonstrating that Patient compliance a persistent problem	NAQ0563553
927	Document demonstrating that Patient compliance a persistent problem	NAQ0648483- NAQ0648503
928	Document demonstrating that Patient compliance a persistent problem	NAQ0731857
929	Document demonstrating that Patient compliance a persistent problem	NAQ0733294- NAQ0733328
931	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0273296-8



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>
933	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0273349
935	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0275349
936	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0452190- NAQ0452195
938	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0474723- NAQ0474769
942	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0493516
949	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0540345
955	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0738949-52
958	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0813572- NAQ0813592
960	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	SP00309-SP00310
961	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	SP01059-SP01060
962	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	SP01175-SP01177
964	Document demonstrating that other products sought preferred attributes	NAQ0474876- NAQ0474881
965	Document demonstrating that other products sought preferred attributes	NAQ0474882- NAQ0474885
968	Document demonstrating that other products sought preferred attributes	NAQ0621652
994	Document demonstrating Neither Beconase AQ nor Vancenase AQ were once-daily administration at time of invention.	NAQ0956318- NAQ0956319
995	Document demonstrating Neither Beconase AQ nor Vancenase AQ were once-daily administration at time of invention.	NAQ0956322- NAQ0956324
996	Document demonstrating Neither Beconase AQ nor Vancenase AQ were once-daily administration at time of invention.	NAQ0956331- NAQ0956332
997	Document demonstrating Beconase and Vancenase used ingredient that retarded growth in adolescents	NAQ0955007- NAQ0955012
998	Document demonstrating Beconase and Vancenase used ingredient that retarded growth in adolescents	NAQ0955034- NAQ0955040
999	Document demonstrating Beconase and Vancenase used ingredient that retarded growth in adolescents	NAQ0955041
1000	Document demonstrating Beconase and vancenase use Phenylethyl alcohol	NAQ0956325- NAQ0956327
1001	<b>REDACTED</b>	GLAXA1078- GLAXA1079
1002	July 5, 2007 Declaration of Christopher M. Simonson	
1003	<b>REDACTED</b>	SP 00441
1004	June 27, 2007 Declaration of Mary Jane Nehring	
1005	Document demonstrating that patients rated Nasacort AQ as having better taste and odor than Beconase AQ.	NAQ0476323- NAQ0476326

PTX	Description	Bates No.
1006	Document demonstrating that patients rated Nasacort AQ as having better taste and odor than Beconase AQ.	NAQ0623839
1007	Document demonstrating that patients rated Nasacort AQ as having better taste and odor than Beconase AQ.	NAQ0955006
1017	<b>REDACTED</b>	PERR00005078- PERR00005079
1022		PERR00015116
1023		PERR00014812
1028	Document demonstrating that other competitive products copied some of the aspects of the asserted claims	NAQ0956480- NAQ0956522
1029	Document demonstrating that other competitive products copied some of the aspects of the asserted claims	NAQ0453804- NAQ0453816
1030	Document demonstrating that other competitive products copied some of the aspects of the asserted claims	NAQ0453889- NAQ0453949
1031	Document demonstrating that other competitive products copied some of the aspects of the asserted claims	NAQ0454368- NAQ0454403
1032	Document demonstrating that other competitive products copied some of the aspects of the asserted claims	NAQ0845886
1033	Document demonstrating that other competitive products copied some of the aspects of the asserted claims	NAQ0860117
1034	Document demonstrating that other competitive products copied some of the aspects of the asserted claims	NAQ0900020
1036	Document demonstrating that Nasacort AQ is clinically equivalent to Flonase, despite Flonase active being nine times more potent than Nasacort AQ active	NAQ0471737- NAQ0471744
1037	Document demonstrating that patients rated Nasacort AQ as having better taste and odor than Beconase AQ.	NAQ0145235- NAQ0145458
1038	Document demonstrating that patients rated Nasacort AQ as having better taste and odor than Beconase AQ.	NAQ0294348- NAQ0294351
1039	Document demonstrating that patients rated Nasacort AQ as having better taste and odor than Beconase AQ.	NAQ0481500- NAQ0481506
1044	Document demonstrating that Nasacort AQ is a stable suspension	SL001319-25
1045	Document demonstrating that Nasacort AQ is a stable suspension	NAQ0397241- NAQ0397294
1049	Assignment of Assignors Interest	NAQ0452859
1050	Assignment of Assignors Interest	NAQ0453008
1051	Confirmatory Assignment	NAQ0452841- NAQ0452842
1052	Change of Name	NAQ0452491- NAQ0452492
1053	Merger	NAQ0452591- NAQ0452593
1054	PTO Patent Assignment Record for Patent No. 5,976,573	NAQ0958009- NAQ0958010
1055	PTO Patent Assignment Record for Patent No. 6,143,329	NAQ0958011

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

AVENTIS PHARMACEUTICALS INC. and  
 SANOFI-AVENTIS US LLC,

Plaintiffs,

v.

C.A. No. 06-286-GMS

BARR LABORATORIES, INC.,

Defendant.

**SCHEDULE C(2)**

**PLAINTIFF'S LIST OF TRIAL EXHIBITS WITH OBJECTIONS**

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
12	<b>REDACTED</b>	PERR00004481	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
13		PERR00004490	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
16		BARR-TAA-017938 - BARR-TAA-017966	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
17	Table regarding Triamcinolone Acetonide NS.	PERR00004491	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
19		BARR-TAA-049957 - BARR-TAA-049960	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
20	<b>REDACTED</b>	BARR-TAA-049961 - BARR-TAA-049964	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
23		PERR00003283 - PERR00003283	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
24	E-mail regarding flow chart of TAA nasal spray and formulation.	PERR00002562 - PERR00002564	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
25	E-mail regarding development plans.	PERR00003241 - PERR00003244	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
26	<b>REDACTED</b>	PERR00000831 - PERR00000832	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
27		BARR-TAA-017810 - BARR-TAA-017811	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
29	<b>REDACTED</b>	PERR00002424 - PERR00002425	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
31	E-mail regarding attached TAA FDA Presentation.	PERR00001239 - PERR00001250	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
33	E-mail regarding Triamcinolone Acetonide.	PERR00005947	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
34	E-mail regarding Triamcinolone Acetonide micro.	PERR00001511 - PERR00001514	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
35	<b>REDACTED</b>	PERR00003451	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
37		PERR00002565 - PERR00002567	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
40	Email regarding nasal spray(s) presentation of May 20th.	PERR00008053 - PERR00008054	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
41	Email regarding nasal spray(s) presentation of May 20th.	PERR00008050 - PERR00008052	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
42	Email regarding nasal sprays.	PERR00003294 - PERR00003295	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
43	<b>REDACTED</b>	PERR00008047	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
44	Email regarding nasal sprays.	PERR00008043	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
45	Email regarding NS revised timeline.	PERR00002574	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
46	Email regarding pump sprayer.	PERR00003275 - PERR00003276	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
47	Email regarding triamcinolone acetonide nasal spray suspension.	PERR00003024 - PERR00003027	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
54	ANDA for Triamcinolone Acetonide Nasal Spray regarding bioavailability / bioequivalence general information. Formulation data and in vitro comparative study.	BARR-TAA-001644 - BARR-TAA-001671	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
55	ANDA for Triamcinolone Acetonide Nasal Spray regarding bioavailability / bioequivalence general information. In vitro bioequivalence studies.	BARR-TAA-001672 - BARR-TAA-001706	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
56	Final clinical study report. A study to evaluate the relative bioavailability of two triamcinolone 55 mcg/actuation nasal spray formulations in healthy adult subjects. Study No. 10416911.	BARR-TAA-002603 - BARR-TAA-002640	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
57	Clinical Study Report for Triamcinolone Acetonide Nasal Spray, Protocol CPL-404.	BARR-TAA-005245 - BARR-TAA-5348	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
58	ANDA for Triamcinolone Acetonide Nasal Spray regarding specifications / analytical methods for the drug product.	BARR-TAA-012602 - BARR-TAA-012654	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
63	Consolidated response to multiple citizen petitions submitted to the Food and Drug Administration concerning review and approval standards for abbreviated new drug applications for fluticasone propionate nasal spray suspension products.	BARR-TAA-018011 - BARR-TAA-018034	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
64	Letter regarding rheological properties of nasal spray products.	PERR000008140 - PERR000008147	FRE 402/403/802+E 207	Response to FRE 402: Document related to issues of infringement and validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6); Response to +E207: Plaintiffs cannot respond to this objection because it is not a proper objection.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
65	<b>REDACTED</b>	PERR00003299	FRE 402/403/802	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
66	Email regarding nasal sprays.	PERR00003296	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
67	Email regarding nasal sprays.	PERR00002562 - PERR00002564	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
68	<b>REDACTED</b>	PERR00003206	FRE 402/403/802	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
69		PERR00003211 - PERR00003212	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
70		PERR00003203 - PERR00003205	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
71	REDACTED	PERR00002424 - PERR00002425	FRE 402/403/802	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
72	REDACTED	PERR00007826	FRE 402/403/802	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
73	Perrigo R&D and RA for US Market - Status Report.	PERR00005966 - PERR00005979	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
80	Barr Project Management Meeting: R&D Projects.	BARR-TAA-048848 - BARR-TAA-048850	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
81	CD Weekly Report Active Projects.	BARR-TAA-046125 - BARR-TAA-046134	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
82	<b>REDACTED</b>	BARR-TAA-047520 - BARR-TAA-047522	FRE 402/403	Response to FRE 402: Document related to issues of infringement; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
83	Appointment regarding nasal spray prep meeting.	BARR-TAA-046436	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
84		BARR-TAA-033962 - BARR-TAA-033963	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
85	<b>REDACTED</b>	BARR-TAA-016647	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
86		BARR-TAA-017552	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
87		PERR00000829 - PERR00000830	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
88		BARR-TAA-016898 - BARR-TAA-016899	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
89	<b>REDACTED</b>	BARR-TAA-016873	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
90		BARR-TAA-016884	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
91		BARR-TAA-017130	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
92		BARR-TAA-018814 - BARR-TAA-018816	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
93		PERR00004618	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
96		BARR-TAA-050433 - BARR-TAA-050542	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
98	Item 13 Patent Information for Supplemental New Drug Application #20-468.	BARR-TAA-022423 - BARR-TAA-022425	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
99	Letter requesting a copy of the disclosable approval information for Nasacort AQ manufactured by Rhone Poulenc.	BARR-TAA-022535	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
100	Environmental Assessment FOI Version Nasacort AQ.	BARR-TAA-022832 - BARR-TAA-022860	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
104	<b>REDACTED</b>	BARR-TAA-016872	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
105		BARR-TAA-017718 - BARR-TAA-017720	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
106		BARR-TAA-017672 - BARR-TAA-017673	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
109	Letter of Authorization for Valois Drug Master File No. 17623	BARR-TAA-020786	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
111	Food and Drug Administration, HHS Regulation Section 314.94 Content and format of an abbreviated application.		FRE 402/403	Response to FRE 402: Document related to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
112	<b>REDACTED</b>	BARR-TAA-018048 - BARR-TAA-018055	FRE 402/403	Response to FRE 402: Document related to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
117	Letter in receipt of Barr's abbreviated new drug application submitted pursuant to Section 505(j) of the Federal Food, Drug and Cosmetic Act.	BARR-TAA-012710 - BARR-TAA-012713	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
120	Minor Amendment for Barr's ANDA 78-104 for Triamcinolone Acetonide Nasal Suspension.	BARR-TAA-018358 - BARR-TAA-018362	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
122	<b>REDACTED</b>	BARR-TAA-045712 - BARR-TAA-045719	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
123	<b>REDACTED</b>	BARR-TAA-050609 - BARR-TAA-050610	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
124	Bioequivalency Information Request for Barr's ANDA 78-104.	BARR-TAA-050636 - BARR-TAA-050638	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
125	<b>REDACTED</b>	BARR-TAA-050639 - BARR-TAA-050642	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
126		PERR00005407	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
127	Reference Drug Pharmacy Tracking and Accountability Report for Nasacort AQ Nasal Spray.	BARR-TAA-022374 - BARR-TAA-022375	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
128	Email regarding the attached Pilot PK Protocol.	BARR-TAA-030824 - BARR-TAA-30839	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
129	Email regarding results and caveats, TAA pilot PK.	BARR-TAA-030593 - BARR-TAA-030608	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
130	Email regarding clinical n.	BARR-TAA-017664 - BARR-TAA-017666	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
131	Email regarding TAA In Vitro Program.	BARR-TAA-016771	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
132	<b>REDACTED</b>	BARR-TAA-036281 - BARR-TAA-036292	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
133	Email regarding statistical analysis template for TAA.	BARR-TAA-031233 - BARR-TAA-031253	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
134	<b>REDACTED</b>	BARR-TAA-038041 - BARR-TAA-038051	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
135	Email regarding TAA Spray Pattern Results.	BARR-TAA-013304	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
142	<b>REDACTED</b>	BARR-TAA-017718 - BARR-TAA-017720	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
146	Email regarding Triamcinolone Acetonide Nasal Spray Package.	BARR-TAA-050562 - BARR-TAA-050598	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
147	Email regarding IMS Data.	BARR-TAA-050599 - BARR-TAA-050608	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
148	Handwritten document regarding nasal spray.	BARR-TAA-050558 - BARR-TAA-050561	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
151	Email regarding pump sprayer.	PERR00003275 - PERR00003276	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
152	<b>REDACTED</b>	BARR-TAA-032994 - BARR-TAA-033002	FRE 402/403	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
153	Email regarding patent information.	PERR00008016 - PERR00008026	FRE 402/403/802	Response to FRE 402: Document related to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6).
156	Final P.E.T. Report for RG 5029Y Pet Study.	NAQ0486025 - NAQ0486052	FRE 402/403/802	Response to FRE 402: Document related to issues of infringement and validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6).
161	Abstract, Annals of Allergy, Asthma & Immunology, January, 1997, Volume 78, Number 1, pp. 96.		FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
234	PDR, 49 Edition, 1995, Supplement A, regarding New Product Listings Excerpt for Flonase.	BARR-TAA-049953 - BARR-TAA-049956	FRE 106	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit.
235	PDR Excerpt relating to Beconase, Nasalide and Vancenase.	BARR-TAA-012829 - BARR-TAA-012837	FRE 106	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit.
270	Soo-II Kim Lab Notebook No. 2770	NAQ0014511 - NAQ0014597	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
281	<b>REDACTED</b>	NAQ0013762 - NAQ0013763	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
283	Email regarding Thixotropy	NAQ0011223	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
287	Email regarding Nasacort thixotropic effect	NAQ0011376 - NAQ0011377	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
288	Email regarding Beclomethasone AQ Nasal Spray	NAQ0012518 - NAQ0012519	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
289	Email regarding Nasacort AQ preservative system	NAQ0011787 - NAQ0011788	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
297	Nasacort 1996 Brand Plan	NAQ0480621 - NAQ0480953	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
299	Presentation entitled 2002 - 2011 Momentum Case Nasacort AQ/US	NAQ0545991 - NAQ0546065	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
301	Memorandum regarding rationale to support use of "CHOICE" positioning - POV	NAQ0629388 - NAQ0629390	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
302	Email regarding Nasacort AQ AED Clinical Study	NAQ0487664 - NAQ0487667	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
306	Email regarding important information about Nasacort	NAQ0250089 - NAQ0250090	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
316	Presentation entitled Nasacort AQ 2006 Brand Tactical Plan.	NAQ0485677 - NAQ0485704	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
318	RPR Marketing Research regarding 1999 Allergy Situation Analysis	NAQ0478542 - NAQ0478748	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
319	Aventis 2001 Situation Analysis, Business Information and	NAQ0274308 - NAQ0274595	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
	Planning.			
321	Email regarding CSO activities.	NAQ0681928 - NAQ0681929	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
325	Presentation entitled Nasacort AQ Situation Analysis.	NAQ0908419 - NAQ0908515	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
326	Presentation entitled Nasacort Family, Respiratory National Managers Meeting.	NAQ0488598 - NAQ0488623	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
328	Email with attached Allegra-D & Nasacort Scenario Analysis.	NAQ0673546 - NAQ0674054	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
331	Presentation regarding HFA Potential, Overview of Prescribers, Physician Perspective, Patient Overview and Managed Care Reaction.	NAQ0849440 - NAQ0849500	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
334	Sanofi Aventis US Pharmaceuticals 2006 January Net Sales.	NAQ0908516 - NAQ0908525	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
337	Email regarding Allegra and Nasacort AQ Weeklies for Week ended March 31, 2006, Week 13	NAQ0672057 - NAQ0672059	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
338	Email regarding AQ.	NAQ0672666 - NAQ0672668	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
352	Presentation entitled A PET Study to Probe Formulation Equivalency	NAQ08460077	Note: Should be NAQ0846077.	
353	Expert Report of Michael A. Kaliner		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
355	Opening Expert Report of Robert Y. Lochhead		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
356	How and Why the Nose Runs, J. Allergy & Clin. Immunology		FRE 402/403/802/805	Response to FRE 402: Document related to issues of validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
357	Human Nasal Host Defense and Sinusitis, J. Allergy & Clinical Immunol.		FRE 402/403/802/805	Response to FRE 402: Document related to issues of validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
358	Mediators of Allergic Rhinitis, J. Allergy & Clin Immunology		FRE 402/403/802/805	Response to FRE 402: Document related to issues of validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
366	<b>REDACTED</b>		FRE 901/1003	Response FRE 901/1003: An authenticated and legible copy of the document will be provided.
367	Robert Lochhead Lab Notebook pages 1 -7 and 10		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
375	Skoner, et al., Detection of Growth Suppression in Children During Treatment with Intranasal Beclomethasone Dipropionate	NAQ0955013-33, NAQ0957623-43	FRE 402/403/802/805	Response to FRE 402: Document related to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
376	Opening Expert Report of Robert K. Prud'Homme		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
382	A.N. Beris et al, J. Fluid Mech. (1985), Vol. 168, pp. 219 - 244, Creeping motion of a sphere through a Bingham plastic		FRE 402/403/802/805/901/1003	Response to FRE 402: Document relevant to issues of validity and infringement; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801; Response FRE 901/1003: Defendant has not identified the basis of the objection. An authenticated and legible copy of the document will be used.
387	Rebuttal Expert Report of Eli O. Meltzer		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
391	Gary Gross, M.D. et al., Comparative Efficacy, Safety, and Effect on Quality of Life of Triamcinolone Acetonide and Fluticasone Propionate Aqueous Nasal Sprays in Patients with Fall Seasonal Allergic Rhinitis, 89 Annals of Allergy, Asthma & Immunology (July 2002)	NAQ0481233 - NAQ0481240	FRE 402/403/802/805	Response to FRE 402: Document is relevant to issues of infringement, validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
392	Fishken, David. Patient Preference and Sensory Comparison of Nasacort AQ, Beconase AQ, and Flonase, 78 Annals of Allergy, Asthma & Immunology 154:P206 (1997)	NAQ0452866	FRE 402/403/802/805	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
394	Bunnag, et al., Patient Preference and Sensory Perception of Three Intranasal Corticosteroids for Allergic Rhinitis, 23 Clinical Drug Investigations 39-44 (2003)	NAQ0957510 - NAQ0957515	FRE 402/403/802/805	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
396	Package Insert for Tri-Nasal, 2002 Physicians Desk Reference		FRE 802/901/1003	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6); Response FRE 901/1003: A complete copy of the PDR will be provided for this exhibit.
398	Tri-Nasal Prescribing Information	NAQ0731657 - NAQ0731658	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
399	FDA Recalls and Court Actions: Tri-Nasal, The Pink Sheet, September 25, 2000, Vol. 62, Issue 39	NAQ0596404	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
400	Nasacort AQ 2003 Situation Analysis	NAQ0524866 - NAQ0524947	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
401	Muro Pharmaceutical Inc. Drug Recall	NAQ0517613	FRE 402/403	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
403	<b>REDACTED</b>	NAQ0558589 - NAQ0558590	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
405	LaForce et al., Comparison of Once-Daily Triamcinolone Acetonide Aqueous Nasal Spray and Twice-Daily Beconase AQ for the Treatment of Seasonal Allergic Rhinitis, 97 Journal of Allergy & Clinical Immunology 443:1002 (1996)	NAQ0452865	FRE 402/403/802/805	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
406	Waddell et al., Intranasal Steroid Sprays in the Treatment of Rhinitis: Is One Better than Another?, 117 Journal of Laryngology & Otology 843-845 (2003)	NAQ0957645 - NAQ0957647	FRE 402/403/802/80 5	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
407	Durham, The Ideal Nasal Corticosteroid: Balancing Efficacy, Safety & Patient Preference, 2 Clinical & Experimental Allergy Reviews (2002)	NAQ0957649 - NAQ0957654	FRE 402/403/802/80 5	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
408	Lumry et al., A Comparison of Once-Daily Triamcinolone Acetonide Aqueous and Twice-Daily Beclomethasone Dipropionate Aqueous Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis, 24 Allergy & Asthma Proceedings 203-210	NAQ0957661 - NAQ0957668	FRE 402/403/802/80 5	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
410	Meltzer et al., P247 Abstract, A Patient Preference Evaluation Study Comparing the Sensory Attributes of Fluticasone Furoate Nasal Spray with Fluticasone Propionate Nasal Spray, 100 Annals of Allergy, Asthma & Immunology A89 (2008)	NAQ0957498	FRE 402/403/802/80 5	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
411	Package Insert for Nasonex, 1998 Physicians Desk Reference		FRE 901/1003	Response to FRE 901/1003: A complete copy of the PDR will be provided for this exhibit.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
415	Dr. Kaliner's Rebuttal Expert Report		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
416	Dr. Donovan's Opening Expert Report		FRE 802	Response to FRE 802: Document will not be offered into evidence.
417	Dr. Needham's Opening Expert Report		FRE 802	Response to FRE 802: Document will not be offered into evidence.
420	Tamara Elias et al., Why Products Fail in Phase III, In Vivo The Business & Medicine Report (Apr. 2006)	NAQ0957556-64	FRE 402/403/802/805	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
421	Company News; Shares of Fisons Tumble as Company Halts Asthma Drug, N.Y. Times, April 7, 1993, <a href="http://query.nytimes.com/gst/fullpage.html?res+9F0CE6DB13EF934A35757C0A965958260">http://query.nytimes.com/gst/fullpage.html?res+9F0CE6DB13EF934A35757C0A965958260</a>	NAQ0957555	FRE 402/403	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
429	Patient Information and Consent Form	NAQ0251551 - NAQ0251558	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
430	Patient Information and Consent Form	NAQ0251642 - NAQ0251649	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
431	RG 5029Y-305 Patient Informed Consent	NAQ0282605 - NA10282611	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
432	Confidential Disclosure Agreement between Jerald W. Koepke, M.D. and Rhone-Poulenc Rorer Pharmaceutical Inc.	NAQ0305363 - NAQ0305365	FRE 402/403	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
433	Confidential Disclosure Agreement between James P. Rosen, M.D. and Rhone-Poulenc Rorer Pharmaceutical Inc.	NAQ0305360 - NAQ0305362	FRE 402/403	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
434	Confidential Disclosure Agreement between Wilfred N. Beaucher, M.D. and Rhone-Poulenc Rorer Pharmaceutical Inc.	NAQ0305367 - NAQ0305369	FRE 402/403	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
435	Confidential Disclosure Agreement between Allan Luskin, M.D. and Rhone-Poulenc Rorer Pharmaceutical Inc.	NAQ0305370 - NA10305372	FRE 402/403	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
436	Confidential Disclosure Agreement between Topeka Allergy & Asthma Clinic and Rhone-Poulenc Rorer Pharmaceutical Inc.	NAQ0305373 - NAQ0305375	FRE 402/403	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
442	Confidential Disclosure Agreement between John Winder, M.D. and Rhone-Poulenc Rorer Pharmaceutical Inc.	NAQ0457347 - NAQ0457350	FRE 402/403	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
444	G.H. Philipps, Structure-activity relationships of topically active steroids: the selection of fluticasone propionate, Respiratory Medicine (1990) 84 Supplement A, 19-23	NAQ0955203 - NAQ0955207	FRE 402/403/802/805	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
445	Dr. Lochhead's Rebuttal Report		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
446	Dr. Klingenberg's Opening Expert Report		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
447	Klingenberg Lab Notes	BARR-KLING-000001 to BARR-KLING-000012	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
448	Lochhead Lab Notebook pages 8 & 9		FRE 802/901/1003	Response to FRE 802: Document is relevant to issues of infringement; Response to FRE 901: Document was authenticated during deposition of Dr. Lochhead; Response to FRE 1003: Best available copy.
449	Amira Zeevi Deposition, pages 1-2, 66, and 78-80		FRE 802/805	Response to FRE 402: Document is relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.
477	1995 Physicians' Desk Reference and Supplements	NAQ0957552-4	FRE 106	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit.
484	Appendix 1: Lochhead Lab Notebook		FRE 802/805/901/1003	Response to FRE 802: Document is relevant to issues of infringement; Response to FRE 802/805: Document does not fall within scope of FRE 801; Response to FRE 901: Document was authenticated during deposition of Dr. Lochhead; Response to FRE 1003: Best available copy.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
487	R.M.E. Richards & R.H. Cavill, Electron Microscope Study of Effect of Benzalkonium Chloride and Edetate Disodium on Cell Envelope of <i>Pseudomonas aeruginosa</i> , 65 Journal of Pharmaceutical Sciences 76-80 (1976)	NAQ0114532 - NAQ0114534	FRE 901/1003	Response FRE 901/1003: Defendant has not provided a basis for this objection. An authenticated and legible copy of the document will be provided.
488	Mengping Zhou and Maureen Donovan, Intranasal Mucociliary Clearance of Putative Bioadhesive Polymer Gels, 135 International Journal of Pharmaceutics, 115-125 (1996)		FRE 402/403/802/805/901/1003	Response to FRE 402: Document is relevant to issues of validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
489	Ankur J. Shah and Maureen D. Donovan, Rheological Characterization of Neutral and Anionic Polysaccharides with Reduced Mucociliary Transport Rates, AAPS PharmSciTech 2007; 8 (2), Article 32; published April 20, 2007		FRE 402/403/802/805/901/1003	Response to FRE 402: Document is relevant to issues of validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
490	A.S. Harris et al., Effect of Viscosity on Particle Size, Deposition, and Clearance of Nasal Delivery Systems Containing Desmopressin, Journal of Pharmaceutical Sciences, Vol. 77, No. 5, pages 405-408 (1988)	BARR-TAA-050708-050713	FRE 402/403/802/805/901/1003	Response to FRE 402: Document is relevant to issues of validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
491	Yang Guo et al., The Effect of Formulation Variables and Breathing Patterns on the Site of Nasal Deposition in an Anatomically Correct Model, Pharmaceutical Research, Vol 22, No. 11, November 2005, pages 1871-1878		FRE 402/403/802/805/901/1003	Response to FRE 402: Document is relevant to issues of validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
492	ScienceGear.com 2007 Catalog, <a href="http://www.sciencegear.com/catalogs/Catalog2007/SGCatalog_Feb2007_beakers.pdf">http://www.sciencegear.com/catalogs/Catalog2007/SGCatalog_Feb2007_beakers.pdf</a>		FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement and validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable
494	Company News; Shares of Fisons Tumble as Company Halts Asthma Drug, N.Y. Times, April 7, 1993, <a href="http://query.nytimes.com/gst/fullpage.html?res=9FOCE6DB13EF934A35757C0A965958260">http://query.nytimes.com/gst/fullpage.html?res=9FOCE6DB13E</a>	NAQ0957555	FRE 402/403/802/805	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; ; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
495	Keyur Shah, Thomas E. Needham et al., Nasal Spray Deposition: An Evaluation of Nasal Spray & Clearance in Healthy Human Volunteers Using Gamma Scintigraphy, Drug Delivery Technology Vol. 15, No. 1 (Jan. 2005) available at <a href="http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=311">http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=311</a>		FRE 402/403/802/805/901/1003	Response to FRE 402: Document is relevant to issues of infringement, validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
496	Robert L. Davidson, Handbook of Water-Soluble Gums and Resins, section 3-7 (McGraw-Hill) (1980)		FRE 402/403	Response to FRE 402: Document is relevant to issues of validity and infringement; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
499	Dr. Prud'homme's Rebuttal Report		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
504	U.S. Patent No. 2,978,446		FRE 402/403/1002	Response to FRE 402: Document is relevant to issues of validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 1002: If the Court rules that the copy of the U.S. Patent identified is not sufficient, a certified copy of the patent will be obtained from the U.S. Patent Office to replace this exhibit.
505	U.S. Patent No. 3,141,875		FRE 402/403/1002	Response to FRE 402: Document is relevant to issues of validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 1002: If the Court rules that the copy of the U.S. Patent identified is not sufficient, a certified copy of the patent will be obtained from the U.S. Patent Office to replace this exhibit.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
506	U.S. Patent No. 3,539,365		FRE 402/403/1002	Response to FRE 402: Document is relevant to issues of validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 1002: If the Court rules that the copy of the U.S. Patent identified is not sufficient, a certified copy of the patent will be obtained from the U.S. Patent Office to replace this exhibit.
507	U.S. Patent No. 5,725,886		FRE 402/403/1002	Response to FRE 402: Document is relevant to issues of validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 1002: If the Court rules that the copy of the U.S. Patent identified is not sufficient, a certified copy of the patent will be obtained from the U.S. Patent Office to replace this exhibit.
512	Expert Report of Donald O. Beers		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
515	Guidance For Industry - Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), June 1999, Draft Guidance		FRE 901/1003	Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
517	Guidance For Industry - Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), April 2003, Draft Guidance		FRE 901/1003	Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
518	February 22, 2006 letter from Randall W. Lutter, Ph.D., Acting Associate Commissioner for Policy and Planning, Food and Drug Administration, to Frederick H. Branding, C. Elaine Jones, Ph.D., William M. Zoffer and Charles J. Raubichek		FRE 402/403/802/805/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
519	Expert Report of Marc S. Berridge		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
525	Opening Expert Report of Dr. Eli Meltzer		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
530	Comparison Video1998NAQGreenFVRed.mpg	NAQ0453738	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
531	GammaCorrections.pdf	NAQ0485984-NAQ0485990	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
532	ImagingInDrugDevelopmentDD R2003_59_2.pdf	NAQ08485991 - NAQ08486009	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
533	cole010702.mpg	NAQ0846050	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
534	cole010802.mpg	NAQ0846051	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
535	ComparisonVideo1998NAQGreenFVRed.mpg	NAQ0846052	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
536	Head_ROI_PETDemo.avi	NAQ0846053	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
537	kalt110601.mpg	NAQ0846054	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
538	kalt112001.mpg	NAQ0846055	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
539	meht122201.mpg	NAQ0846056	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
540	meht1229901.mpg	NAQ0846057	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
541	moln010702.mpg	NAQ0846058	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
542	moln010802.mpg	NAQ0846059	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
543	nasdaq.mpg	NAQ0846060	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
544	s3_cmp.mpg	NAQ0846061	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
545	s3_cmpnew.mpg	NAQ0846062	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
546	Subj1Comp.avi	NAQ0846063	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
547	Subj2Comp.avi	NAQ0846064	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
548	Subj3Comp.avi	NAQ0846065	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
549	Subj4Comp.avi	NAQ0846066	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
550	Subj5Comp.avi	NAQ0846067	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
551	Subj6Comp.avi	NAQ0846068	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
552	SubjComp.txt	NAQ0846069	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
553	welk012902.mpg	NAQ0846070	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
554	welk122201.mpg	NAQ0846071	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
555	yeag110610.mpg	NAQ0846072	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
556	yeag112001.mpg	NAQ0846073	FRE 402/403	Response to FRE 402: Document relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
570	Claim Charts for Infringement		FRE 402/403/802	Response to FRE 402: Document is relevant to issues of infringement; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801
571	Rebuttal Report of Dr. Marc S. Berridge		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
575	Expert Report of Dr. Gregory K. Bell		FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
582	Rebuttal report of Eli O Meltzer (redacted version)	NAQ0957590-NAQ0957616	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
585	Schedule 3.1		FRE 402/403/802	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within scope of FRE 801
586	Schedule 4.1		FRE 402/403/802	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within scope of FRE 801

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
587	Momentum Case 2002-2011	NAQ0914693-880 at 699, 702, 703, 782	FRE 402/403/802	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Reponse to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
588	"Collegium Pharmaceutical Provides Update on Development of its Nasal Inhaled Steroid for Allergic Rhinitis" Health & Medicine Week, Aug 27, 2007	NAQ0957382	FRE 402/403/802/805	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Reponse to FRE 802/805: Document does not fall within the scope of FRE 801.
589	"Study data from P.H. Ratner et al provide new insights into allergies" Health & Medicine Week, Oct 1, 2007	NAQ0957383	FRE 402/403/802/805	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Reponse to FRE 802/805: Document does not fall within the scope of FRE 801.
590	<a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/</a>		FRE 901/1003	Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
595	Deposition of Ceci Zak, July 17, 2007, pp83-84, 59, and accompanying exhibits		FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
596	Nasacort AQ - INS Market Overview, September 29, 2006	NAQ0884088-118 at 93, 95	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
597	Schedule 1.1		FRE 402/403/802	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Reponse to FRE 802: Document does not fall within the scope of FRE 801.
598	Nasacort AQ Tactical Brand Plan for 2003, August 14, 2002	NAQ0546213-342 at 215, 272	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801, alternatively, document falls within the scope of FRE 803(6).
599	Momentum Case, 2002-2011, Nasacort AQ/US	NAQ0545991-6065 at 5993	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801 alternatively, document falls within the scope of FRE 803(6).
600	Nasacort AQ Brand Plan, May 10, 2002 (2003-2007)	NAQ0914560-683 at 599, 646	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801 alternatively, document falls within the scope of FRE 803(6).
601	Illinois Formulary Status 2004 (Nasacort AQ, Flonase, Nasones and Rhinocort Aqua)	NAQ0483033	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
602	Illinois Formulary Status 2004 (Nasacort AQ, Flonase, Nasones and Rhinocort Aqua)	NAQ0483033	FRE 402	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness.
603	Illinois Formulary Status 2005 (Nasacort AQ, Flonase, Nasones and Rhinocort Aqua)	NAQ0483132	FRE 402	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness.
605	Nasacort Situation Analysis February 28, 2006	NAQ0908419-515 at 493	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801 alternatively, document falls within the scope of FRE 803(6).
607	Schedule 2.6		FRE 402/403/802	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Reponse to FRE 802: Document does not fall within the scope of FRE 801.



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
609	1999 Allergy Situation Analysis	NAQ0478542-748 at 678	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801 alternatively, document falls within the scope of FRE 803(6).
610	Nasacort Family - Respiratory National Managers Meeting, January 12, 2005	NAQ0488598-623 at 607	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801 alternatively, document falls within the scope of FRE 803(6).
612	Kissan, Joseph and Murali K. Mantrala, "Prescription Drug Promotion: The Role and Value of Physicians' Samples Under Competition", p.7, <a href="http://www.business.ku.edu/home/kjoseph/research/PrescriptionDrugPromotionMarch2003.pdf">http://www.business.ku.edu/home/kjoseph/research/PrescriptionDrugPromotionMarch2003.pdf</a>	NAQ0957448-490	FRE 402/403/802/805	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
630	Direct to Consumer Advertising for Prescription Drugs" ACP Online, 9 Oct 1998 p 4; <a href="http://www.ACPonline.org/hpp/pospaper/dtcads.htm">http://www.ACPonline.org/hpp/pospaper/dtcads.htm</a>	NAQ0957384-94	FRE 402/403	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
631	John P Juergens, "The FDA and Community Pharmacy: Today and Tomorrow" Drug Topics, 3 Aug 1992, p.88	NAQ0957411-421	FRE 402/403/802/805	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
632	Guidance for Industry: Industry Supported Scientific and Educational Activities" Federal Register 62(232) 3 Dec 1997	NAQ0957403-410	FRE 402/403	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
633	Testimony of Janet Woodcock, Director of the FDA's Center for Drug Evaluation and Research, before the Senate Special Committee on Aging, 22 July 2003	NAQ0957395-402; NAQ0957425-439	FRE 402/403/802/805	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
634	"Division of Drug Marketing, Advertising and Communications." <a href="http://www.fda.gov/cder/ddmac">http://www.fda.gov/cder/ddmac</a>	NAQ0957422-424	FRE 402/403	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
635	Opening Report of R.K. Prud'homme (redacted version)	NAQ0957516-522	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
645	Red Book 1997-2007		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
646	Expert Report of Marc S. Berridge (redacted version)	NAQ0957523-551	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801.
647	Certified translation of E-mail regarding Triamcinolone Acetonide Nasacort Nasal Inhaler.	PERR00012039 - PERR00012040	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
654	Current Reviews of Rhinitis, Second Edition, M. Kaliner Editor in Chief; © 2006	NAQ0956579-780	FRE 402/403/802/805	Response to FRE 402: Document is relevant issues of infringement, validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
				the scope of FRE 801.
655	Current Review of Allergic Diseases, M. Kaliner Editor, © 2000	NAQ0956781-7034	FRE 402/403/802/805	Response to FRE 402: Document is relevant issues of infringement, validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
657	Eccleston papers		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant issues of infringement and validity; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
658	Sharpe, "Comparison of the Flow Properties of Aqueous Suspension Corticosteroid Nasal Sprays Under Differing Sample Conditions"	NAQ0954971-78	FRE 402/403/802/805	Response to FRE 402: Document is relevant issues of validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
661	SILS - Scientific Information & Library Services - Bridgewater	NAQ0639353 - NAQ0639360	FRE 402/403	Response to FRE 402: Document is relevant issues of validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
662	Berger, et al., Triamcinolone acetone aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis	NAQ0522324 - NAQ0522331	FRE 402/403/802/80 5	Response to FRE 402: Document is relevant issues of validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
663	Lipworth, et al., Safety of Inhaled and Intranasal Corticosteroids	NAQ0830228 - NAQ0830250	FRE 402/403/802/80 5	Response to FRE 402: Document is relevant issues of infringement, validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
664	Meltzer, et al., Development of questionnaires to measure patient preferences for intranasal corticosteroids in patient with allergic rhinitis	NAQ0510059 - NAQ0510069	FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
666	Fishken Abstract, P206	NAQ0957644	FRE 402/403/802/80 5	Response to FRE 402: Document is relevant issues of validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
667	Meltzer, et al., A Preference Evaluation Study Comparing the Sensory Attributes of Mometasone Furoate and Fluticasone Propionate Nasal Sprays by Patients with Allergic Rhinitis	NAQ0957728 - NAQ0957735	FRE 402/403/802/805	Response to FRE 402: Document is relevant issues of validity, and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
679	Order Re: Discovery Teleconference		FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
680	Order Denying Request of Returned Documents from the 7/5 amd 7/23/07 Teleconferences		FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
693	Complaint and Associated Papers		Duplicative	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
694	Schedule 1.2		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
695	Schedule 1.3		FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
696	Schedule 2.1		FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
697	Schedule 2.2		FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
698	Schedule 2.3		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
699	Schedule 2.4		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
700	Schedule 2.5		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
701	Schedule 3.2		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6); Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
702	Schedule 3.3		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
703	Schedule 3.4		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
704	Schedule 3.5		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; ; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
705	Schedule 3.6		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; ; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
706	Schedule 3.7		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; ; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
707	Schedule 3.8		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; ; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
				identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
708	Schedule 3.9		FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
709	Schedule 3.10		FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
710	Schedule 3.11		FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
711	Schedule 3.12		FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
712	Schedule 3.13		FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
713	Schedule 4.2		FRE 402/403/802/90 1/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
714	Schedule 4.3		FRE 402/403/802/901/1003	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; Response to FRE 901/1003: Defendants have not identified a basis for 901/1003 objection; An authenticated and legible copy of the document will be provided.
720	Viscosity Test Method	PERR00000781	FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
721	E-mail regarding Triamcinolone Acetonide Nasacort Nasal Inhaler.	PERR00012039 - PERR00012040	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
737	Paragraph IV Certification Letter for Patent Nos. '573 and '329		FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
738	February 1, 2008 Letter from Maureen Rurka to Jerney Noe regarding Barr expert witnesses		FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
742	Agis email	PERR00004486 - PERR00004487	FRE 402/403/802	Response to FRE 402: Document is relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
				scope of FRE 803(6).
745	Viscosity Test Method	BARR-TAA-012297	FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
746	Viscosity Test Method	PERR00011624 - PERR00011625	FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
747	Viscosity Test Method	PERR00010730 - PERR00010732	FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
754	It Stays Where It's Sprayed (video)	NAQ00118565	FRE 402/403	Response to FRE 402: Document is relevant to issues of infringement, validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
755	Voyage Au Centre Du Nez (video)	NAQ00453737	FRE 402/403	Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
758	1995 PDR		FRE 106	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit.
759	1995 PDR Supplement A		FRE 106	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit.
760	1996 PDR		FRE 106	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit.
762	2001 PDR		FRE 106/402/403	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit; Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
763	2004 PDR		FRE 106/402/403	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit; Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
764	2006 PDR		FRE 106/402/403	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit; Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
765	2003 PDR		FRE 106/402/403	Response to FRE 106: A complete copy of the PDR will be provided for this exhibit; Response to FRE 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
769	Document demonstrating Nasacort AQ competition	NAQ0274824- NAQ0274825	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
770	Document demonstrating Nasacort AQ competition	NAQ0535385- NAQ0535391	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
772	Document demonstrating Nasacort AQ competition	NAQ0623122- NAQ0623156	FRE 802/803	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
774	Document demonstrating Nasacort AQ competition	NAQ0856042- NAQ0856046	FRE 802/803	Response to FRE 802: Document does not fall within scope of FRE 801; alternatively, document falls within the scope of FRE 803(6).
775	Document demonstrating Nasacort AQ competition	NAQ0893075	FRE 802/803	Response to FRE 802: Document does not fall within scope of FRE 801; alternatively, document falls within the scope of FRE 803(6).
776	Document demonstrating Nasacort AQ competition	NAQ0915376- NAQ0916224	FRE 802/803	Response to FRE 802: Document does not fall within scope of FRE 801; alternatively, document falls within the scope of FRE 803(6).
787	Document demonstrating Nasacort AQ market share	NAQ0485877	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
789	Document demonstrating Nasacort AQ market share	NAQ0535387	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
791	Document demonstrating Nasacort AQ market share	NAQ0674608	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
792	Document demonstrating Nasacort AQ market share	NAQ0674728	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
793	Document demonstrating Nasacort AQ market share	NAQ0854871- NAQ0854872	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
794	Document demonstrating Nasacort AQ market share	NAQ0855193- NAQ0855194	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
795	Document demonstrating Nasacort AQ market share	NAQ0855225- NAQ0855227	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
798	Document demonstrating supply interruptions of Nasacort AQ	NAQ0546215- NAQ0546216	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
799	Document demonstrating supply interruptions of Nasacort AQ	NAQ0912234	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
809	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0478641	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
810	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0478643	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
811	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0846873	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
812	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0881608	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
813	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0538770	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
819	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0621885- NAQ0621900	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
822	Document demonstrating promotional expenditures of Nasacort AQ	NAQ0914799	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
823	Document demonstrating detailing efforts of competitors	NAQ0594444- NAQ0594512	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
824	Document demonstrating detailing efforts of competitors	NAQ0667504	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
825	Document demonstrating detailing efforts of competitors	NAQ0674649	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
828	Document demonstrating detailing efforts of competitors	NAQ0882462- NAQ0882463	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
830	Document demonstrating detailing efforts of competitors	NAQ0890771	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
831	Document demonstrating detailing efforts of competitors	NAQ0891275- NAQ0891276	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
832	Document demonstrating detailing efforts of competitors	NAQ0892920	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
834	Document demonstrating detailing efforts of competitors	NAQ0911404	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
837	Document demonstrating level of expenditures on Nasacort AQ	NAQ0274950	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
840	Document demonstrating level of expenditures on Nasacort AQ	NAQ0524437	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
841	Document demonstrating level of expenditures on Nasacort AQ	NAQ0526934- NAQ0526938	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
842	Document demonstrating level of expenditures on Nasacort AQ	NAQ0526972- NAQ0526975	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
843	Document demonstrating level of expenditures on Nasacort AQ	NAQ0527016- NAQ0527020	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
844	Document demonstrating level of expenditures on Nasacort AQ	NAQ0527099- NAQ0527103	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
845	Document demonstrating level of expenditures on Nasacort AQ	NAQ0538750	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
846	Document demonstrating level of expenditures on Nasacort AQ	NAQ0540786- NAQ0540789	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
847	Document demonstrating level of expenditures on Nasacort AQ	NAQ0542361- NAQ0542531	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
849	Document demonstrating level of expenditures on Nasacort AQ	NAQ0546237	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
854	Document demonstrating level of expenditures on Nasacort AQ	NAQ0846879	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
855	Document demonstrating level of expenditures on Nasacort AQ	NAQ0847623	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
856	Document demonstrating level of expenditures on Nasacort AQ	NAQ0848338	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
857	Document demonstrating level of expenditures on Nasacort AQ	NAQ0848350	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
859	Document demonstrating level of expenditures on Nasacort AQ	NAQ0855002	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
860	Document demonstrating level of expenditures on Nasacort AQ	NAQ0855003	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
861	Document demonstrating level of expenditures on Nasacort AQ	NAQ0857749	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801.
862	Document demonstrating level of expenditures on Nasacort AQ	NAQ0861228	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
863	Document demonstrating level of expenditures on Nasacort AQ	NAQ0867292	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
864	Document demonstrating level of expenditures on Nasacort AQ	NAQ0871364	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
865	Document demonstrating level of expenditures on Nasacort AQ	NAQ0871439	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
868	Document demonstrating level of expenditures on Nasacort AQ	NAQ0881608	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
869	Document demonstrating level of expenditures on Nasacort AQ	NAQ0887688- NAQ0887696	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
870	Document demonstrating level of expenditures on Nasacort AQ	NAQ0890200	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
872	Document demonstrating level of expenditures on Nasacort AQ	NAQ0893770	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
873	Document demonstrating level of expenditures on Nasacort AQ	NAQ0894053	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
874	Document demonstrating level of expenditures on Nasacort AQ	NAQ0911812	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
875	Document demonstrating level of expenditures on Nasacort AQ	NAQ0914693- NAQ0914879	FRE 403/802/805	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
916	Document demonstrating that Patient compliance a persistent problem	NAQ0295250	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
922	Document demonstrating that Patient compliance a persistent problem	NAQ0481683	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
923	Document demonstrating that Patient compliance a persistent problem	NAQ0481708	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of 803(6).
930	Document demonstrating that Patient compliance a persistent problem; Meltzer, E.O. <u>An overview of current pharmacotherapy in perennial rhinitis</u> , J. Allergy Clin. Immunol. 95(5):1097, at 1104	NAQ0471234	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
	(1995)			
932	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0273301	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
934	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0273353	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
937	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0474268	FRE 402/403	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable;
939	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0480041	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
940	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0490637- NAQ0490644	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
941	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0493404- NAQ0493417	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
943	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0493892- NAQ0493918	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
944	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0498914- NAQ0498917	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
945	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0506300- NAQ0506319	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
946	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0509204	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
947	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0518617	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
948	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0530479	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
950	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0540365	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
951	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0546983- NAQ0547003	FRE 802/805	Response to FRE 802/805: Document does not fall within the scope of FRE 801.
952	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0559895-60039	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
953	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0594439	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
954	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0649045-70	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
956	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0775865- NAQ0775888	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
957	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0803987- NAQ0803996	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
959	Document demonstrating need in the industry for odorless aqueous spray that resisted clearance, uniform dosing, safe and effective for adults and children.	NAQ0821728- NAQ0821732	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
963	Document demonstrating that other products sought preferred attributes	NAQ0011807- NAQ0011809	Invalid Bates Range	Response to "Invalid Bates Range": Bates Range corrected.
966	Document demonstrating that other products sought preferred attributes	NAQ0480042	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
967	Document demonstrating that other products sought preferred attributes	NAQ0621649	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
969	<b>REDACTED</b>	NAQ0163029- NAQ0163032	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
970	Document demonstrating Tri-Nasal withdrawn from market	NAQ0956075	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
971	Document demonstrating Tri-Nasal had bitter taste	NAQ0955138- NAQ0955166	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6).
972	Document demonstrating Tri-Nasal had problematic side-effect profile	NAQ0308664	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
973	Document demonstrating Tri-Nasal had problematic side-effect profile	NAQ0163007- NAQ0163010	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
974	<b>REDACTED</b>	NAQ0318678	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
975		NAQ0318702	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
976		NAQ0318616	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
977	Document demonstrating Tri-Nasal received approval in 2000	NAQ0457552	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
978	Document demonstrating Tri-Nasal received approval in 2000	NAQ0955565	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
979	Document demonstrating Tri-Nasal received approval in 2000	NAQ0955170- NAQ0955171	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
980	Document demonstrating Tri-Nasal received approval in 2000	NAQ0955491	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)



PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
981	<b>REDACTED</b>	NAQ0274308 - NAQ0274595	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
983		NAQ0547131	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
984		NAQ0517610- NAQ0517613	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
985		NAQ0955146- NAQ0955166	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
986	Document demonstrating that in June 2002, FDA withdrew approval of Tri-Nasal	NAQ0955169	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
987	Document demonstrating that in June 2002, FDA withdrew approval of Tri-Nasal	NAQ0955175 - NAQ0955197	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
989	Document demonstrating Collegium purchased rights to Tri-Nasal	NAQ0645594	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
990	Document demonstrating Accentia has exclusive right to market Tri-Nasal	NAQ0955319- NAQ0955320	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
991	Document demonstrating Accentia has exclusive right to market Tri-Nasal	NAQ0955224	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)
992	Document demonstrating Accentia has exclusive right to market Tri-Nasal	NAQ0955270 - NAQ0955318	FRE 802	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6)

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
1008	Document demonstrating Vancense AQ is no longer on the market	NAQ0955042	FRE 402/403	Response to 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1009	Document demonstrating that Nasalide and Nasarel contained PEG	NAQ0954999- NAQ0955005	FRE 402/403	Response to 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1010	Document demonstrating that Nasalide and Nasarel contained PEG	NAQ0955063- NAQ0955067	FRE 402/403	Response to 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1011	Document demonstrating that Nasalide and Nasarel contained PEG	NAQ0956460- NAQ0956463	FRE 402/403	Response to 402: Document is relevant to issues of validity and secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1012	<b>REDACTED</b>	BARR-TAA000001- BARR-TAA012709	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1013		BARR-TAA013973- BARR-TAA013974	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
1014	<b>REDACTED</b>	BARR-TAA017177- BARR-TAA017178	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1015		BARR-TAA049965- BARR-TAA050554	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1016	<b>REDACTED</b>	BARR-TAA050609- BARR-TAA050610	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1018	<b>REDACTED</b>	BARR-TAA-016032- 016045	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1019	<b>REDACTED</b>	BARR-TAA-022834	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1020	<b>REDACTED</b>	BARR-TAA022534	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1021		BARR-TAA-022535	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
1024	Document demonstrating Perrigo's development chronicled in lab notebooks	PERR00013819- PERR00013956	Invalid Bates Range	Response to "Invalid Bates Range": Bates Range corrected.
1025	Document demonstrating Perrigo's development chronicled in lab notebooks	PERR00013957- PERR00013976	Invalid Bates Range	Response to "Invalid Bates Range": Bates Range corrected.
1026	Document demonstrating that other competitive products copied some of the aspects of the asserted claims	NAQ0525237	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1027	Document demonstrating that other competitive products copied some of the aspects of the asserted claims	NAQ0621649- NAQ0621651	FRE 403	Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1035	Veramyst	NAQ0955043- NAQ0955062	FRE 402/403	Response to 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1040	<b>REDACTED</b>	NAQ0066975- NAQ0066994	FRE 402/403	Response to 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1041		NAQ0067481- NAQ0067529	FRE 402/403	Response to 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1042	<b>REDACTED</b>	NAQ0067672- NAQ0067689	FRE 402/403	Response to 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
1043	<b>REDACTED</b>	NAQ0068061- NAQ0068084	FRE 402/403	Response to 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable.
1046	Schedule 5.1		FRE 402/403/802	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable. Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6);
1047	Schedule 5.2		FRE 402/403/802	Response to FRE 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable. Response to FRE 802: Document does not fall within the scope of FRE 801.
1048	Meltzer, et. al., Preferences of Adult Patients with Allergic Rhinitis for the Sensory Attributes of Fluticasone Furoate Verses Fluticasone Propionate Nasal Sprays: A Randomized, Multicenter, Double-Blind, Single-Dose, Crossover Study	NAQ0957752- NAQ0957760	FRE 802, FRCP 37(c)(1)	Response to FRE 802: Document does not fall within the scope of FRE 801; alternatively, document falls within the scope of FRE 803(6); Response to FRCP 37(c): Document was properly produced pursuant to FRCP 26.
1056	Document demonstrating Nasacort AQ success in 2007	NAQ0957736- NAQ0957737	FRE 402/403/802/901, FRCP 37(c)	Response to 402: Document is relevant to secondary considerations of non-obviousness; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable; Response to FRE 802/805: Document does not fall within the scope of FRE 801; Response to FRE 901: Defendants have not identified a basis for 901 objection; An authenticated and legible copy of the

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
				document will be provided; Response to FRCP 37(c): Document was properly produced pursuant to FRCP 26.
P. DEM O 001	Demonstrative Exhibit – Asserted Claims of the '573 Patent		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case-in-chief and rebuttal; therefore, objection is not applicable
P. DEM O 002	Demonstrative Exhibit – Asserted Claims of the '573 Patent		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 003	Demonstrative Exhibit – Asserted Claims of the '573 Patent		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 004	Demonstrative Exhibit – Asserted Claims of the '329 Patent		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 005	Demonstrative Exhibit – Asserted Claims of the '329 Patent		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 006	Demonstrative Exhibit – Asserted Claims of the '329 Patent		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 007	Demonstrative Exhibit - Market share		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 008	Demonstrative Exhibit - Market share		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 009	Demonstrative Exhibit - Market share		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 010	Demonstrative Exhibit - Market share		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 011	Demonstrative Exhibit - Market share		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 012	Demonstrative Exhibit - Marketing efforts		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 013	Demonstrative Exhibit - Marketing efforts		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 014	Demonstrative Exhibit - Marketing efforts		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 015	Demonstrative Exhibit – Marketing efforts		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 016	Demonstrative Exhibit – Marketing efforts		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 017	Demonstrative Exhibit – Prices		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 018	Demonstrative Exhibit – Prices		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 019	Demonstrative Exhibit – Prices		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 020	Demonstrative Exhibit – Prices		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 021	Demonstrative Exhibit – Prices		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 022	Demonstrative Exhibit – Supply		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 023	Demonstrative Exhibit – Supply		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 024	Demonstrative Exhibit – Supply		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 025	Demonstrative Exhibit – Supply		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 026	Demonstrative Exhibit – Supply		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 027	Demonstrative Exhibit - Sales		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 028	Demonstrative Exhibit - Sales		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 029	Demonstrative Exhibit - Sales		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 030	Demonstrative Exhibit – Sales		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 031	Demonstrative Exhibit – Sales		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 032	Demonstrative Exhibit - MCO		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 033	Demonstrative Exhibit – MCO		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 034	Demonstrative Exhibit - MCO		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 035	Demonstrative Exhibit - MCO		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 036	Demonstrative Exhibit - MCO		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 037	Demonstrative Exhibit – Brookfield Viscometer		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 038	Demonstrative Exhibit – Brookfield Viscometer		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 039	Demonstrative Exhibit – Burrell action wrist shaker		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 040	Demonstrative Exhibit – Viscosities of materials		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 041	Demonstrative Exhibit – Viscosities of materials		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 042	Demonstrative Exhibit – Viscosities of materials		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 043	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 044	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 045	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 046	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 047	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 048	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 049	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
				Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
				Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 050	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 051	Demonstrative Exhibit – Thixotropic materials		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 052	Demonstrative Exhibit – Thixotropic materials		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 053	Demonstrative Exhibit – Thixotropic materials		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 054	Demonstrative Exhibit – Formulations of Nasacort AQ and Barr TAA nasal spray		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 055	Demonstrative Exhibit – Formulations of Nasacort AQ and Barr TAA nasal spray		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 056	Demonstrative Exhibit – Viscosity testing protocols		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 057	Demonstrative Exhibit – Viscosity testing protocols		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 058	Demonstrative Exhibit – Viscosity testing protocols		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 059	Demonstrative Exhibit – Viscosity testing protocols		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 060	Demonstrative Exhibit – Viscosity testing protocols		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 061	Demonstrative – Errors in viscosity testing protocols		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 062	Demonstrative – Errors in viscosity testing protocols		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 063	Demonstrative – Errors in viscosity testing protocols		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 064	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 065	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 066	Demonstrative Exhibit – Comparative viscosities of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 067	Demonstrative Exhibit – Secondary considerations		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 068	Demonstrative Exhibit – Secondary considerations		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 069	Demonstrative Exhibit – Secondary considerations		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 070	Demonstrative Exhibit – Secondary considerations		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 071	Demonstrative Exhibit – Clinical trial phases		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 072	Demonstrative Exhibit – Clinical trial phases		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 073	Demonstrative Exhibit – Clinical trial phases		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 074	Demonstrative Exhibit – Clinical trial phases		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 075	Demonstrative Exhibit – FDA drug approval process		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 076	Demonstrative Exhibit – FDA drug approval process		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 077	Demonstrative Exhibit – Q1/Q2 requirements		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 078	Demonstrative Exhibit – Q1/Q2 requirements		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 079	Demonstrative Exhibit – FDA confidentiality		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 080	Demonstrative Exhibit – FDA confidentiality		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 081	Demonstrative Exhibit – Perrigo formula development		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 082	Demonstrative Exhibit – Perrigo formula development		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 083	Demonstrative Exhibit – Perrigo formula development		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 084	Demonstrative Exhibit – Perrigo formula development		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 085	Demonstrative Exhibit – Nasal anatomy		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 086	Demonstrative Exhibit – Nasal anatomy		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 087	Demonstrative Exhibit – Nasal anatomy		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 088	Demonstrative Exhibit – Nasal anatomy		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 089	Demonstrative Exhibit – Nasal anatomy		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 090	Demonstrative Exhibit – Nasal anatomy		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 091	Demonstrative Exhibit – Experimental Use		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 092	Demonstrative Exhibit – Experimental Use		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 093	Demonstrative Exhibit – Experimental Use		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 094	Demonstrative Exhibit – Experimental Use		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 095	Demonstrative Exhibit – Experimental Use		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 096	Demonstrative Exhibit – Experimental Use		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 097	Demonstrative Exhibit – Phase III clinical trials		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 098	Demonstrative Exhibit – Phase III clinical trials		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 099	Demonstrative Exhibit - Allergies		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 100	Demonstrative Exhibit – Allergies		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 101	Demonstrative Exhibit – Allergies		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 102	Demonstrative Exhibit – Allergies		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 103	Demonstrative Exhibit – Double-blind testing		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 104	Demonstrative Exhibit – Double-blind testing		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 105	Demonstrative Exhibit – Potency of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 106	Demonstrative Exhibit – Potency of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 107	Demonstrative Exhibit – Potency of intranasal sprays		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 108	Demonstrative Exhibit – Intranasal spray market		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 109	Demonstrative Exhibit – Intranasal spray market		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 110	Demonstrative Exhibit – Intranasal spray market		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 111	Demonstrative Exhibit – Immune response		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 112	Demonstrative Exhibit – Immune response		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 113	Demonstrative Exhibit – Primary and secondary responses		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 114	Demonstrative Exhibit – Primary and secondary responses		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 115	Demonstrative Exhibit – Phenylethyl alcohol		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 116	Demonstrative Exhibit – Phenylethyl alcohol odor		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 117	Demonstrative Exhibit – Phenylethyl alcohol odor		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 118	Demonstrative Exhibit – Phenylethyl alcohol odor		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 119	Demonstrative Exhibit – Steroid function		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 120	Demonstrative Exhibit – Steroid function		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 121	Demonstrative Exhibit – Rhinitis Symptoms		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 122	Demonstrative Exhibit – Rhinitis Symptoms		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
P. DEM O 123	Demonstrative Exhibit – Treatment for rhinitis		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 124	Demonstrative Exhibit – Treatment for rhinitis		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 125	Demonstrative Exhibit – Treatment for rhinitis		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 126	Demonstrative Exhibit – Early stage response		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 127	Demonstrative Exhibit – Early stage response		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 128	Demonstrative Exhibit – Late stage response		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 129	Demonstrative Exhibit – Late stage response		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 130	Demonstrative Exhibit – Anti-inflammatory effect of steroids		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 131	Demonstrative Exhibit – Anti-inflammatory effect of steroids		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 132	Demonstrative Exhibit – Nasal mucosa		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 133	Demonstrative Exhibit – Nasal mucosa		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 134	Demonstrative Exhibit – Nasal mucosa		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 135	Demonstrative Exhibit – Nasal mucosa		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 136	Demonstrative Exhibit – Nasal mucosa		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 137	Demonstrative Exhibit – Administration of intranasal spray		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 138	Demonstrative Exhibit – Administration of intranasal spray		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 139	Demonstrative Exhibit – Administration of intranasal spray		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 140	Demonstrative Exhibit – What is PET		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 141	Demonstrative Exhibit – What is PET		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 142	Demonstrative Exhibit – What is PET		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 143	Demonstrative Exhibit – Labeled TAA		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 144	Demonstrative Exhibit – Labeled Fluticasone		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 145	Demonstrative Exhibit – Conducting PET study		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 146	Demonstrative Exhibit – Conducting PET study		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 147	Demonstrative Exhibit – Conducting PET study		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 148	Demonstrative Exhibit – Conducting PET study		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 149	Demonstrative Exhibit – Conducting PET study		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 150	Demonstrative Exhibit – Conducting PET study		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 151	Demonstrative Exhibit – 1996 Regions of Interest		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 152	Demonstrative Exhibit – 1996 Regions of Interest		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 153	Demonstrative Exhibit – 1996 Regions of Interest		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 154	Demonstrative Exhibit – 1996 Regions of Interest		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 155	Demonstrative Exhibit – 1996 Regions of Interest		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 156	Demonstrative Exhibit – 1998 and 2002 Regions of Interest		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 157	Demonstrative Exhibit – 1998 and 2002 Regions of Interest		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 158	Demonstrative Exhibit – 1998 and 2002 Regions of Interest		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 159	Demonstrative Exhibit – Registration of PET scan and MRI		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 160	Demonstrative Exhibit – Registration of PET scan and MRI		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 161	Demonstrative Exhibit – Registration of PET scan and MRI		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 162	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 163	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 164	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 165	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 166	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 167	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 168	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 169	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 170	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 171	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 172	Demonstrative Exhibit – Graphical representation of 1996 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 173	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 174	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 175	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 176	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 177	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 178	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 179	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 180	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 181	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 182	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 183	Demonstrative Exhibit – Graphical representation of 1998 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 184	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 185	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 186	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 187	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 188	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 189	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 190	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 191	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 192	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 193	Demonstrative Exhibit – Graphical representation of 2002 data		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 194	Demonstrative Exhibit – Mucocilliary clearance		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 195	Demonstrative Exhibit – Mucocilliary clearance		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 196	Demonstrative Exhibit – Nasacort AQ versus Flonase		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 197	Demonstrative Exhibit – Nasacort AQ versus Flonase		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

PTX	Description	Bates No.	Defendant's Objections	Plaintiff's Response to Objections
P. DEM O 198	Demonstrative Exhibit – Nasacort AQ versus Flonase		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 199	Demonstrative Exhibit – Nasacort AQ versus Flonase		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 200	Demonstrative Exhibit – Nasacort AQ versus Flonase		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 201	Demonstrative Exhibit – Nasacort AQ versus Flonase		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 202	Demonstrative Exhibit – Nasacort AQ versus Flonase		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 203	Demonstrative Exhibit – Nasacort AQ versus Flonase		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 204	Demonstrative Exhibit – Nasacort AQ versus Flonase		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 205	Demonstrative Exhibit – sanofi-aventis Corporate Structure		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 206	Demonstrative Exhibit – sanofi-aventis Corporate Structure		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 207	Demonstrative Exhibit – Drug development process		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 208	Demonstrative Exhibit – Drug development process		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 209	Demonstrative Exhibit – sanofi-aventis product portfolio		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 210	Demonstrative Exhibit – sanofi-aventis product portfolio		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 211	Demonstrative Exhibit – Innovator companies		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 212	Demonstrative Exhibit – Innovator companies		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case



<b>PTX</b>	<b>Description</b>	<b>Bates No.</b>	<b>Defendant's Objections</b>	<b>Plaintiff's Response to Objections</b>
P. DEM O 213	Demonstrative Exhibit – Development of Nasacort AQ		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 214	Demonstrative Exhibit – Development of Nasacort AQ		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 215	Demonstrative Exhibit – Development of Nasacort AQ		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 216	Demonstrative Exhibit – Development of Nasacort AQ		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case
P. DEM O 217	Demonstrative Exhibit – Development of Nasacort AQ		FRE 402/403/802	Response to FRE 402 and 802: Document intended for demonstrative purposes only; Response to FRE 403: This is a bench trial with a set amount of time allotted to Plaintiff's case

**SCHEDULE C(3)**

**Barr Laboratories' Exhibits to which Plaintiffs Do Not Object**

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX5	2002 P.E.T. Study Final Report	BERRIDGE000007-53	16/213/ Berridge Ex. 14
DX6	1996 P.E.T. Study Final Report	NAQ0486025-52	6
DX10	Settipane, <i>et al.</i> , <i>Triamcinolone Acetonide Aqueous Nasal Spray in Patients with Seasonal Ragweed Allergic Rhinitis: A Placebo-Controlled, Double Blind Study</i> , Clinical Therapeutics 17:252-263 (1995)	BARR-TAA-012838-50	35/53/ 115
DX11	Kobayashi, <i>et al.</i> , <i>Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Patients with Perennial Allergic Rhinitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study</i> , Clinical Therapeutics 17:503-513 (1995).	BARR-TAA-012793-805	39/55/ 116
DX19	Vancenase AQ Pharmaceutical Development Report	SP 01603-87	
DX20	Avicel RC/CL Specifications and Analytical Methods	FMC000216-21	
DX21	Problem Solver and Reference Manual	FMC000271-428	
DX22	Avicel RC-591 – Pharmaceutical Emulsions and Suspensions	FMC000446-63	
DX23	Ronald Tinkler Lab Notebook Issued Dec. 12, 1991	NAQ0070478-599	130/ 206
DX24	TAA Nasal Spray PPIS Volume III	NAQ0010026-219	128
DX25	TAA Chemistry, Manufacturing, and Controls Summary	NAQ0019699-705	Berridge Ex. 7
DX26	FDA Website Beconase AQ	NAQ0957442	
DX27	FDA Website Vancenase AQ	NAQ0957688	
DX28	FDA Website Flonase	NAQ0957443	
DX31	FDA Website Nasacort Nasal Inhaler	NAQ0957496	

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX32	Orgel, <i>et al.</i> , <i>Clinical, rhinomanometric, and cytologic evaluation of seasonal allergic rhinitis treated with beclomethasone dipropionate as aqueous nasal spray or pressurized aerosol</i> , J. Allergy & Clin. Immunology, 77:858-864 (June 1986).	BARR-TAA-050626-34	36
DX33	RPR Memo re Nasacort AQ Rationale	NAQ0277275-76	100/ 117/ 197
DX34	TAA Nasal Spray PPIS Volume I	NAQ0009427-714	123
DX35	Nasacort AQ IND Form FDA 1571	NAQ0244608-5075	56/105
DX36	Nasacort AQ NDA Form FDA 356h	NAQ0135986-6154	34/57/ 110
DX37	<b>REDACTED</b>	NAQ0163126	121
DX42	Avicel Cellulose Gel – General Technology	FMC000429-39	
DX50	Bachert, <i>Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis</i> , Annals of Allergy, Asthma, & Immunology 89:292-97 (2002).	NAQ0488720-25	
DX51	Gerson, <i>et al.</i> , <i>Patient preference and sensory comparisons of nasal spray allergy medications</i> , J. Sensory Studies 14:491-96 (1999).	NAQ0476110-117	
DX52	<b>REDACTED</b>	NAQ0488718-19	
DX53	Clinical Study Report – Patient Preference and Sensory Comparisons of Three Corticosteroids Administered by Nasal Route in Patients with Perennial or Seasonal Allergic Rhinitis: TAA, FP, and BUD	NAQ0515112-208	

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX54	Clinical Study Report – Patient Preference and Sensory Comparisons of Three Corticosteroids Administered by Nasal Route in Patients with Perennial or Seasonal Allergic Rhinitis: TAA, FP, and MF	NAQ0518981-9071	
DX56	Vancenase AQ 1999 Annual Report	SP 00161-241	
DX58	FDA Website Nasacort AQ	NAQ0957444	
DX59	FDA Website Nasalide	<a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails</a>	
DX60	FMC's Excipients For Pharmaceutical Tablets, Capsules and Suspensions	FMC000238-41	
DX63	<b>REDACTED</b>	GLAXA001080-81	
DX66	Berridge, <i>et al.</i> , <i>Biodistribution and Kinetics of Nasal Carbon-11-Triamcinolone Acetonide</i> , J. Nuclear Med. 39:1972-77 (1998).	NAQ0473310-15	8
DX67	1998 P.E.T. Study Underlying Data	NAQ0920082-92	15/ Berridge Ex. 15
DX68	Abstract – Berridge, <i>et al.</i> , <i>Nasal delivery and kinetics of fluticasone propionate using positron tomography (PET)</i> .	NAQ0485918-19	18
DX69	1998 P.E.T. Study IRB Application	NAQ0486011-16	212
DX70	1998 P.E.T. Study Underlying Data	BERRIDGE000055-55.017	
DX71	2002 P.E.T. Study Underlying Data	NAQ0920071-81	15
DX73	2002 P.E.T. Study Underlying Data	NAQ0915185-86	17
DX74	2002 P.E.T. Study Underlying Data	BERRIDGE000056-56.003	
DX75	1996 P.E.T. Study Final Report	NAQ0449411-36	
DX76	<b>REDACTED</b>	BARR-TAA-050570-76	
DX83	Meltzer, <i>et al.</i> , <i>An overview of current pharmacotherapy in perennial rhinitis</i> , J. Allergy Clin. Immunol., 95(5):1097-1107, 1103-04 (1995).	NAQ0471227-37	

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX84	Klossek, <i>et al.</i> , <i>Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long term treatment of perennial allergic rhinitis</i> , <i>Rhinology</i> , 39:17-22 (2001).	NAQ0955007-12	
DX85	Small, <i>et al.</i> , <i>Triamcinolone acetonide nasal spray (T) vs fluticasone propionate aqueous nasal spray (F) in patients with seasonal allergic rhinitis</i> , <i>J. Allergy Clin. Immunol.</i> 97(1):433(1003) (1996).	NAQ0955006	
DX90	Meltzer, <i>et al.</i> , <i>Development of questionnaires to measure patient preference for intranasal corticosteroids in patients with allergic rhinitis</i> , <i>Otolaryngology – Head and Neck Surgery</i> 132(2):197-207 (2005).	NAQ0510059-69	84
DX91	Bachert Response, <i>Patient Preference and Sensory Comparisons of Three Intranasal Corticosteroids for the Treatment of Allergic Rhinitis</i> , <i>Annals of Allergy &amp; Immunol.</i> 90:576-77 (2003).	NAQ0731726-28	
DX99	Nasacort AQ NDA	NAQ0353301-615	
DX100	IMS Data: National Prescription Audit NRx & TRx 1991-2001	BARR-BOGH-000001-2	
DX101	IMS Data: NPA Monthly Rx 2002-2007	BARR-BOGH-000011	
DX102	Total Nasacort Sales, Margin and Product Contribution Data 2000-2007	NAQ0933411	
DX110	Nasacort AQ/Aerosol 1997 Business Plan	NAQ0934745-865	
DX113	Nasacort AQ/Nasacort Aerosol Brand Plan, Allergy Marketing Team, December 1997	NAQ0474534-615	
DX114	Nasacort AQ Advertisement re “Patient-Preferred Nasacort AQ”	NAQ0476424-32	
DX115	NAQ Marketing Research: Year in Review 2003	NAQ0524832-55	
DX116	Nasacort AQ POA Meeting January 2004	NAQ0531822-73	
DX119	DeNovo Final Presentation: IMPACT Message Optimization for Nasacort AQ	NAQ0576859-916	
DX121	Nasacort AQ Advertisement: “You can’t ignore patient preference”	NAQ0250083-88	

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX122	2002 Nasacort AQ Advertisement: "Nasacort AQ is preferred more than 2 to 1 over Flonase and Nasonex:	NAQ0476410-13	
DX125	Nasacort AQ 2005 Mid-Year Tactical Recommendations	NAQ0606970-88	
DX128	US Planning Update: 2006 Tactical Brand Planning Process, 2005 Update, & 2006 Budget	NAQ0720351-76	
DX129	RPRP 1999 Nasacort Performance Update	NAQ0953838-41	
DX130	Nasacort Brand 2000 Business Plan	NAQ0478749-81	
DX131	1999 National Meeting -- Nasacort/Nasacort AQ	NAQ0935351-71	
DX132	Nasacort AQ 2001 DTC Results and Market Analysis	NAQ0594444-514	
DX133	<b>REDACTED</b>	NAQ0123149	122
DX134		NAQ0011861-62	
DX136	Nasacort 1996 Brand Plan	NAQ0480621-953	159
DX137	Brand Forecast -- Nasacort Family Net Sales (2001-2012)	NAQ0940077	
DX138	Nasacort AQ: 2004 Plan Sales Forecast	NAQ0940059-61	
DX139	Nasacort 2001-2005 Brand Plan (July 14, 2000)	NAQ0953667-709	
DX140	2004-2005 Nasacort AQ Brand Plan (May 7, 2003)	NAQ0857669-812	
DX141	Nasacort Family 2006: Situational Analysis	NAQ0912220-306	
DX144	Nasacort AQ IND Protocol Amendment re Berridge 1996 P.E.T. Study	NAQ0217808-54	4/209
DX146	Berridge/Heald Presentation: Biodistribution and Kinetics of Nasal 11-C Triamcinolone Acetonide	NAQ0734944-56	9
DX150	Movie Loops of 2001-2002 Nasacort-Flonase Study	NAQ0486017-24	21
DX154	Alphabetical Listing of RG 5029Y Investigators	NAQ0023882-90	37/54
DX155	RPR Comprehensive Medical Report of Study 309	NAQ0041684-924	38/59
DX157	Confidential Disclosure Agreement between RPR and Kobayashi	NAQ0305357-59	41/61

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b>EX. #</b>	<b>DOCUMENT TITLE/DESCRIPTION</b>	<b>BATES # SOURCE</b>	<b>DEP. EX. #</b>
DX158	RPR Comprehensive Medical Report of Study 305	NAQ0034059-409	42/58
DX159	Memo re RG 5029Y-305 Protocol Approval	NAQ0248227	43
DX160	Monitor's Site Visit Log for Kobayashi Study 305 Site	NAQ0251709	44
DX161	Nasacort AQ Supportable Claims Chart	NAQ0277307-08	49
DX162	Memo re Unblinding of Study 305	NAQ0257628	51
DX163	Case Report Form for RG 5029Y-309	NAQ0056182-243	60
DX164	TAA-AQ Study/Publication Grid (Last update 11/14/00)	NAQ0521302-05	24/67
DX165	Letter to FDA re Nasacort AQ NDA Submission	NAQ0019648-50	96
DX166	Portion of Nasacort AQ NDA	NAQ0019651-52	97
DX167	<b>REDACTED</b>	NAQ0163205-10	101
DX168	<b>REDACTED</b>	NAQ0123140	104
DX169	Letter and Attachments to FDA re Clinical Study 309 (Aug. 9, 1993)	NAQ0320117-225	109
DX171	<b>REDACTED</b>	NAQ0163124	118
DX172		NAQ0123147	119
DX174		NAQ0123161	125
DX176		NAQ0009715-10025	127
DX177	Ronald Tinkler Lab Notebook Issued Oct. 8, 1991	NAQ0016500-660	129
DX178	Triamcinolone Acetonide Aqueous Nasal Spray Formulation Development Report	NAQ0010944-58	131
DX179	Kim Lab Notebook Issued Feb. 23, 1988	NAQ0014511-97	132
DX180	TAA Aqueous Nasal Spray PPIS Volume IV	NAQ0010220-685	135
DX181	<b>REDACTED</b>	NAQ0011855-56	136
DX183	<b>REDACTED</b>	NAQ0123165-66	138
DX184	Anita Quinn Lab Notebook Issued Aug. 23, 1989	NAQ0018943-19070	139



**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX185	Anita Quinn Lab Notebook Issued March 1, 1990	NAQ0015445-580	140
DX186	Anita Quinn Lab Notebook Issued March 13, 1991	NAQ0017136-80	141
DX187	Timothy Lavery Lab Notebook Issued April 5, 1991	NAQ0017803-935	142
DX188	<b>REDACTED</b>	NAQ0013762-63	
DX190	Nasacort AQ: Rheological Evaluation (S. Kim).	NAQ0011044	147
DX191	Letter to FDA providing additional info re thixotropic properties of Nasacort AQ (Dec. 29, 1998)	NAQ0396270-81	148
DX192	<b>REDACTED</b>	NAQ0011376-77	149
DX193		NAQ0012518-19	150
DX194	Email string re Nasacort AQ preservative system	NAQ0011787-88	151
DX195	Amendment to Nasacort AQ Annual Report (July 22, 2003)	NAQ0173954-66	152
DX196		NAQ0064728-31	153
DX197	<b>REDACTED</b>	NAQ0064358-75	154
DX198		NAQ0064724-26	155
DX199	<b>REDACTED</b>	NAQ0064754-73	156
DX200		NAQ0064470-99	157
DX201	Barr Labs. Inc.'s Notice of Deposition of Plaintiffs Pursuant to FRCP 30(b)(6)		1
DX202	<b>REDACTED</b>	NAQ0140126-28	10
DX203	1995 Letter from Berridge to Heald re P.E.T. Study of TAA	NAQ0311828-29	12
DX204	<b>REDACTED</b>	NAQ0140643-50	14

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX205	Letter re P.E.T. Studies' Internal Identification Numbers	NAQ0272955	23
DX211	Clinical Study Report of "A Multicenter, Randomized, Parallel Group Study of the Efficacy, Safety, Health Care Utilization and Health Related Quality of Life with Two Corticosteroid Aqueous Nasal Sprays in the Treatment of Patients with Seasonal Allergic Rhinitis"	NAQ0738791-878	68
DX212	RPR Comprehensive Medical Report of Study 405 (NAQ vs. Beconase AQ)	NAQ0818745-94	69
DX213	<b>REDACTED</b>	NAQ0813609-33	70
DX215	Final Study Report for Study 704 (Nasacort AQ vs. Vancenase AQ)	NAQ0737505-55	72
DX216	Final Draft Clinical Trials Results Database Proposal for Rhinocort Aqua vs. Nasacort AQ Study	NAQ0736701-05	73
DX217	Clinical Study Report for Nasacort AQ and Rhinocort Aqua Study	NAQ0769828-903	74
DX218	<b>REDACTED</b>	NAQ0504795-97	75
DX219	Final Study Report for Study 706 (Nasacort AQ vs. Nasonex)	NAQ0520578-621	76
DX220	<b>REDACTED</b>	NAQ0488718-42	77
DX221	Clinical Study Report for TAA AQ vs. FP vs. MF AQ Study	NAQ0518981-9071	78
DX222	Clinical Study Report for TAA AQ vs. FP vs. BUD Study	NAQ0515112-208	79
DX223	Final Draft Clinical Trials Results Database Proposal for Nasacort AQ vs. Flonase vs. Nasonex Study (resulting in Stokes publication)	NAQ0736685-89	80
DX224	Final Study Report for Nasacort AQ vs. Flonase vs. Nasonex Study (Volume I)	NAQ0458379-460	81
DX225	Final Study Report for Nasacort AQ vs. Flonase vs. Nasonex Study (Volume II)		
DX226	Final Draft Clinical Trials Results Database Proposal for Meltzer Development of Questionnaires Study		

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX229	Memo re TAA AQ Nasal Spray Stability Study (Mar. 24, 1992)	NAQ0163269	102
DX230	<b>REDACTED</b>	NAQ0140892-901	103
DX231	Memo re Nasacort AQ Study Summaries – FDA Format (July 27, 1993)	NAQ0175031	106
DX232	<b>REDACTED</b>	NAQ0140925-29	107
DX233		NAQ0123157-60	202
DX234		NAQ0123162-64	203
DX235		NAQ0015929-16048	204
DX236	Timothy Lavery Lab Notebook Issued June 21, 1991	NAQ0016259-392	205
DX237	Preliminary Report for P.E.T. Study 5029-130	NAQ0210932-35	210
DX240	Plon Letter to FDA re Nasacort AQ Protocol Amendments (Studies Nos. 304 & 305)	NAQ0319690-91	30
DX241	Clinical Study Medication Shipping Form	NAQ0129062	31
DX242	Memo re Nasacort Project Team Activity Report – June 6, 1995	NAQ0246328-31	33
DX243	Simpson Monitoring Report for Kobayashi Site	NAQ0251704-05	45
DX245	Koepke, <i>et al.</i> , <i>Long-Term Safety and Efficacy of Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Perennial Allergic Rhinitis</i> , Allergy & Asthma Proc. 18(1):33-37 (1997).	NAQ0252570-75	52
DX248	Nasacort AQ Ad – “Patients prefer once-daily Nasacort AQ Nasal Spray”	NAQ0340750-52	173
DX249	Nasacort AQ NDA Correspondence	NAQ0409867-950	174
DX251	RPR’s 1999 Allergy Situation Analysis	NAQ0478542-748	180
DX252	Nasacort AQ Sales and P&L Data	NAQ0933408-20	182
DX253	<b>REDACTED</b>	NAQ0681928-29	183
DX254	2006 Nasacort Call Plan	NAQ0907509-23	185

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b>EX. #</b>	<b>DOCUMENT TITLE/DESCRIPTION</b>	<b>BATES # SOURCE</b>	<b>DEP. EX. #</b>
DX255	Presentation re "Nasacort First" Initiative	NAQ0307345-88	186
DX256	Nasacort AQ Situation Analysis (Feb. 28, 2006)	NAQ0908419-515	187
DX257	<b>REDACTED</b>	NAQ0673546-4054	190
DX258	Becker Presentation – "Nasacort Double Play" (April 21, 1997)	NAQ0275722-39	192
DX259	<b>REDACTED</b>	NAQ0672057-59	199
DX260		NAQ0672666-68	200
DX262	Plaintiffs' First Notice of Deposition of Perrigo Israel Pharmaceuticals Ltd. Pursuant to Fed. R. Civ. P. 30(b)(6)		PDX 1
DX263	Barr ANDA TAA Nasal Spray – Chemistry, Manufacturing and Controls	BARR-TAA-000226-31	PDX 50/ Berridge Ex. 6
DX264	FDA Draft Guidance: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action (April 2003)	BARR-TAA-017829-65	PDX 64
DX265	Expert Report of Marc S. Berridge (Jan. 7, 2008)		Berridge Ex. 1
DX266	Rebuttal Expert Report of Marc S. Berridge (Jan. 31, 2008)		Berridge Ex. 2
DX267	Package Insert for Proposed Barr Product	BARR-TAA-000045-62	Berridge Ex. 5
DX268	Nasacort AQ Package Insert		Berridge Ex. 8
DX269	Final P.E.T. Report for RG 5029Y Pet Study: Regional Biodistribution and Kinetics of Inhaled C-labeled Triamcinolone Acetonide	NAQ0277365-93	Berridge Ex. 9
DX270	Mygind, <i>et al.</i> , <i>Applied anatomy of the airways.</i>	NAQ0957700-15	Berridge Ex. 11
DX271	Donald F. Proctor, <i>Nasal Mucocilliary Function in Humans.</i>	NAQ0957716-27	Berridge Ex. 12

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX272	Opening Expert Report of Robert Y. Lochhead (Jan. 7, 2008)		Berridge Ex. 16
DX273	<b>(Withdrawn)</b>		
DX274	<b>(Withdrawn)</b>		
DX275	<b>(Withdrawn)</b>		
DX276	Declaration of GlaxoSmithKline (06/27/07)		
DX277	Declaration of GlaxoSmithKline (07/05/07)		
DX278	Declaration of FMC Corporation (07/03/07)		
DX279	Declaration of Schering Corporation and Schering-Plough Corporation (07/03/07)		
DX280	Plaintiffs' Third Supplemental Response to Barr Laboratories, Inc.'s First Set of Request for Admissions (Nos. 1-70) (02/07/08)		
DX281	Plaintiffs' Second Supplemental Response to Barr Laboratories, Inc.'s First Set of Requests for Admissions (Nos. 1-70) (06/29/07)		
DX282	Plaintiffs' Responses to Barr Laboratories, Inc.'s First Set of Request for Admissions (Nos. 1-70) (05/18/07)		
DX283	Plaintiffs' Fourth Supplemental Response to Interrogatory Nos. 1-3 of Barr Laboratories Inc.'s Interrogatories (01/25/08)		
DX284	Plaintiffs' Third Supplemental Response to Interrogatory Nos. 7 and 13 of Barr Laboratories, Inc.'s Interrogatories (11/09/07)		
DX285	Plaintiffs' Second Supplemental Response to Interrogatory Nos. 2, 3, 6, 7, and 13 of Barr Laboratories, Inc.'s Interrogatories (08/07/07)		
DX286	Plaintiffs' Supplemental Response to Interrogatory Nos. 9 and 10 of Barr Laboratories, Inc.'s First Set of Interrogatories (03/09/07)		

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX287	Plaintiffs' Response to Barr Laboratories, Inc.'s Second Set of Interrogatories (01/03/07)		
DX288	Plaintiffs' Supplemental Response to Interrogatory Nos. 2, 5, 6, and 7 of Barr Laboratories, Inc.'s First Set of Interrogatories (12/29/06)		
DX289	Plaintiffs' Response to Barr Laboratories, Inc.'s First Set of Interrogatories (09/01/06)		
DX290	Joint Claim Construction Chart		
DX291	Order Construing the Terms of U.S. Patent Nos. 5,976,573 and 6,143,329 (12/06/07)		
DX292	Joint Appendix of Intrinsic and Extrinsic evidence Relied Upon in Claim Construction Briefing (10/01/07)		
DX294	Plaintiffs' Answering Claim Construction Brief (10/01/07)		
DX296	Plaintiffs' Opening Brief on Claim Construction (09/10/07)		
DX297	60 Fed. Reg. 13014 (March 9, 1995)		
DX312	Expert Report of Gregory Bell		
DX313	Opening Expert Report of Marc Berridge		
DX314	Rebuttal Expert Report of Marc Berridge		
DX315	Opening Expert Report of Michael Kaliner		
DX316	Rebuttal Expert Report of Michael Kaliner		
DX317	Opening Expert Report of Robert Lochhead		
DX318	Rebuttal Expert Report of Robert Lochhead		
DX319	Opening Expert Report of Eli Meltzer		
DX320	Rebuttal Expert Report of Eli Meltzer		
DX321	Opening Expert Report of Robert Prud'homme		
DX322	Rebuttal Expert Report of Robert Prud'homme		
DX323	1999 FDA Draft Guidance	NAQ0069122-62	

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS DO NOT OBJECT**

<b><u>EX. #</u></b>	<b><u>DOCUMENT TITLE/DESCRIPTION</u></b>	<b><u>BATES # SOURCE</u></b>	<b><u>DEP. EX. #</u></b>
DX329	Email string re Nasacort AQ AED Clinical Study	NAQ0487664-67	164
DX332	Meltzer, <i>Triamcinolone Acetonide and Fluticasone Propionate Aqueous Nasal Sprays Significantly Improve Nasal Airflow in Patients with Seasonal Allergic Rhinitis</i> , Allergy and Asthma Proc. 25:53-58 (2004).	NAQ0957655-60	
DX335	Total Nasacort Sales, Marketing, and Product Contribution	NAQ0485885	
DX336	Nasacort P & L	NAQ0957685	
DX342	1998 U.S. Budget Presentation	NAQ0938749-804	
DX343	Major Tactical Program Overview 1997	NAQ0477038-74	
DX344	2006-2008 Nasacort AQ Brand Plan	NAQ0871959-65	
DX345	Allergy Brand Plan 1998	NAQ0474723-70	
DX347	Nasacort/Nasacort AQ Sales	NAQ0954289-300	
DX349	1998 Nasacort/Nasacort AQ Marketing Strategies	NAQ0934866-92	
DX350	Total Nasacort Income Statement	NAQ0722815-36	
DX351	RPR Product Sales	NAQ0937495-99	
DX354	FDA Website Beconase	<a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails</a>	
DX355	FDA Website Vancenase	<a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails</a>	

**SCHEDULE C(4)**

**Barr Laboratories' Exhibits to which Plaintiffs Object**



## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX1	D.L. Daniels, et al., <i>The Frontal Sinus Drainage Pathway and Related Structures</i> , Am. J. of Neuroradiology (2003). Declaration of Brandon Simpson	BARR-MACKAY-000132-140		FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX2		BARR-TAA-012851-55	48/112	FRE 105	<ul style="list-style-type: none"> <li>• PTX 196</li> </ul>
DX3	U.S. Patent No. 6,143,329 File History Patent Application No. 09/315454	BARR-TAA-012856-955	88	FRE 105, FRE 106, FRE 1002	<ul style="list-style-type: none"> <li>• Certified copy at PTX 4</li> </ul>
DX4	U.S. Patent No. 5,976,573 File History Patent Application No. 08/678465	BARR-TAA-012956-3156	87	FRE 105, FRE 106, FRE 1002	<ul style="list-style-type: none"> <li>• Certified copy at PTX 2</li> </ul>
DX7	U.S. Patent No. 5,976,573	BARR-TAA-012806-16	2/46/ 85/114/ Berridge Ex. 3	FRE 105	<ul style="list-style-type: none"> <li>• Certified copy at PTX 1</li> </ul>
DX8	U.S. Patent No. 6,143,329	BARR-TAA-012817-28	3/47/ 86/113/ Berridge Ex. 4	FRE 105	<ul style="list-style-type: none"> <li>• Certified copy at PTX 3</li> </ul>
DX9	Pennington, et al., <i>The influence of solution viscosity on nasal spray deposition and clearance</i> , Int. J. Pharm. 43:221-224 (1988).	BARR-TAA-050620-25		FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 485</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX12	PCT Application No. WO 94/05330	BARR-TAA-012727-47		FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 482</li> </ul>
DX13	PCT Application No. WO 92/14473	BARR-TAA-012717-26		FRE 106, FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 480</li> </ul>
DX14	1995 Physicians' Desk Reference pp. 477-78, 2291-92, 2480-81 & 1996 Physicians' Desk Reference pp. 1098-1100	BARR-TAA-012829-37	93	FRE 106, FRE 802, FRE 901, FRE 1003	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 477</li> </ul>
DX15	1995 Physicians' Desk Reference pp. 1971-73	BARR-TAA-050657-60		FRE 106, FRE 802, FRE 1003	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 477</li> </ul>
DX16	1995 Physicians' Desk Reference Supp. A1-A3	BARR-TAA-049953-56	92	FRE 106, FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 477</li> </ul>
DX17	1995 Physicians' Desk Reference pp. 1010-11	BARR-TAA-050678-81		FRE 106, FRE 802, FRE 901, FRE 1003	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• Witness testimony will authenticate under 901(b)(1)</li> <li>• PTX 477</li> </ul>
DX18	Beconase AQ NDA Excerpt	GLAXA001078-79		FRE 106	<ul style="list-style-type: none"> <li>• PTX 453/455/1001</li> </ul>
DX29	Viscosity: Nasacort AQ vs. Vancenase vs. Beconase	NAQ0163347-49	133/ 134	FRE 802, FRE 901, FRE 1006	<ul style="list-style-type: none"> <li>• Admissible under FRE 801, 803, 804, 807</li> <li>• Authentication Testimony: Alcom Dep. Tr. at 280:8-11, 280:13-281:6, 281:23-282:2.</li> <li>• PTX 272</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX30	1998 P.E.T. Study Poster	NAQ0486010, NAQ0933407	211/ Berridge Ex. 13	FRE 1003, FRE 1002	<ul style="list-style-type: none"> <li>• PTX 349</li> <li>• Parties Agree to use PTX 349, which is a more legible copy.</li> </ul>
DX38	Moren, et al., <i>Dosage Forms and Formulations for Drug Administration to the Respiratory Tract</i> , Drug Devel. Ind. Pharm., 13(4&5):695-728 (1987).	BARR-TAA-050714-49		FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX39	U.S. Patent No. 4,936,492	BARR-TAA-050750-60		FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX40	U.S. Patent No. 3,463,093	BARR-TAA-050761-64		FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX41	Merck Index	BARR-TAA-050684-691		FRE 106, FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX43	PCT Application No. WO 92/04365	BARR-TAA-012748-68		FRE 106, FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 481</li> </ul>
DX44	Handbook of Pharmaceutical Excipients	BARR-TAA-012773-92	124	FRE 106, FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 262</li> </ul>
DX45	Richards, et al., <i>Electron microscope study of effect of benzalkonium chloride and edetate disodium on cell envelope of Pseudomonas aeruginosa</i> , J. Pharm. Sci. 65:76-80 (1976).	NAQ0114537-41		FRE 802, FRE 1003	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 487</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX46	1994 Physicians' Desk Reference for Nonprescription Drugs (pp.686-87; 553-54; 611; 645)	BARR-TAA-050661- 67		FRE 106, FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX47	1995 Physicians' Desk Reference for Nonprescription Drugs (pp. 797-98; 805; 645- 548; 734; 765)	BARR-TAA-050668- 77		FRE 106, FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX48	<b>REDACTED</b>	NAQ00270065-66	108/ 146	FRE 402, FRE 805	<ul style="list-style-type: none"> <li>• Relevant to anticipation.</li> <li>• Admissible under FRE 801(d)(2), 801, 803, 804, 807</li> </ul>
DX49	Sheth Comment to Bachert Article	NAQ00623839		FRE 802, FRE 702, FRE 901	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> <li>• PTX 668</li> </ul>
DX55	<b>REDACTED</b>	NAQ0172655		FRE 402	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness</li> </ul>
DX57	Drettner, B., <i>The paranasal sinuses</i> , The Nose: Upper Airway Physiology and the Atmospheric Environment, ch. 6, pp. 144-162 (Proctor, D. & Anderson, I.B. eds. 1982).	BARR-TAA-050785- 804		FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 739</li> </ul>
DX60	FMC's Excipients For Pharmaceutical Tablets, Capsules and Suspensions	FMC000238-41		FRE 105, FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX61	U.S. Patent No. 6,375,984	NAQ0013387-96	144	FRE 402	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX62	Remington's Pharmaceutical Sciences (16th ed. 1980) at 1235	BARR-TAA-050765-67		FRE 106, FRE 402, FRE 802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX64	U.S. Patent No. 4,767,612	BARR-TAA-012769-72	94	FRE 402	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> </ul>
DX65	<b>REDACTED</b>	NAQ0195504-08	5	FRE 402	<ul style="list-style-type: none"> <li>• Relevant to non-enablement and non-infringement.</li> </ul>
DX72	Letter and Attachments re TV ad for Nasacort AQ, including 2002 P.E.T. Study Final Report as an attachment	NAQ0372468-613	16	FRE 1003	
DX77	Klingenberg Laboratory Notes	BARR-KLING-000001-12		FRE 802	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> </ul>
DX78	Bousquet, et al., <i>Allergic Rhinitis and Its Impact on Asthma</i> , J. Allergy Clin. Immunol. 108(5 Suppl.):S147-334 (2001).	NAQ0498709-913		FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX79	Dykewicz, et al., <i>Diagnosis and Management of Rhinitis: Complete Guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology</i> , Annals of Allergy, Asthma & Immunology, 81:478-518 (1998).	NAQ0480155-95		FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX80	Lund, et al., <i>International consensus report on the diagnosis and management of rhinitis</i> , Allergy 49(Suppl. 19):5-34 (1994).	BARR-MACKAY-000027-58		FRE 802, FRE 805, FRCP 37(c)(1)	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX81	Goodman and Gilman's <i>The Pharmacological Basis of Therapeutics</i> , 1431-62 (8th ed., Gilman, et al., eds. 1990).	BARR-MACKAY-000175-206		FRE 802, FRE 805, FRCP 37(c)(1)	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX82	Hanania, et al., <i>Adverse Effects of Inhaled Corticosteroids</i> , Am. J. Med. 98:196-208 (1995).	BARR-MACKAY-000012-26		FRE 802, FRE 805, FRCP 37(c)(1)	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX86	LaForce, et al., <i>Fluticasone Propionate: An Effective Alternative Treatment for Seasonal Allergic Rhinitis in Adults and Adolescents</i> , J. Family Practice 29(1):12-13 (1994).	BARR-MACKAY-000239-48		FRE 802, FRE 805	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX87	Colquitt, et al., <i>Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use</i> , British J. Dermatology 152(1):130-41 (2005).	BARR-MACKAY-000223-35		FRE 802, FRE 805	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX88	Becker, et al., <i>Strategies for enhancing patient compliance</i> , J. Community Health 6:113-135 (1980).	NAQ0472725-47		FRE 802, FRE 805, FRE 1003	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 922</li> </ul>
DX89	Rowe-Jones, et al., <i>Functional endoscopic sinus surgery: 5 year follow up and results of a prospective, randomized, stratified, double-blind, placebo controlled study of postoperative fluticasone propionate aqueous nasal spray</i> , Rhinology 43(1):2-10 (2005).	BARR-MACKAY-000141-49		FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX92	Saengpanich, et al., <i>Fluticasone Nasal Spray and the Combination of Loratadine and Montelukast in Seasonal Allergic rhinitis</i> , Arch Otolaryngol Head Neck Surg. 129:557-562 (2003).	BARR-MACKAY-000249-56		FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX93	Data and Web-based T-Test Calculator	BARR-SIEGEL-000001-5		FRE 106, FRE 702; FRE 701; FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX94	Joseph A. DiMasi, et al., <i>The price of innovation: new estimates of drug development costs</i> , J. Health Econ. 22:151-158 (2003).	BARR-BOGH-000021-55		FRE 402, FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>



## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX95	Jim Gilbert, et al., <i>Rebuilding Big Pharma's Business Model</i> , In Vivo 21(10) (2003).	BARR-BOGH-000056-75		FRE 402, FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX96	American Academy of Allergy, Asthma and Immunology	BARR-BOGH-000084-86		FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX97	American College of Allergy, Asthma & Immunology	BARR-BOGH-000076-81		FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX98	Letter to Doctors re Voluntary Production Withdrawal of Nasacort Nasal Inhaler	NAQ0250206	169	FRE 105, FRE 402, FRE 805	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 307</li> </ul>
DX103	R. Scott Fellers (Senior Analyst, Marketing Therapeutics), <i>Allergy – Intranasal Steroid Situation Analysis 2001</i> .	NAQ0540374-584		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX104	Nasacort AQ Brand Plan 2004-2008	NAQ0478123-89		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801(d)(2), 803(6)</li> </ul>
DX105	Nasacort AQ 2003 Situation Analysis	NAQ0542979-3060; NAQ0524866-947		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> <li>• PTX 400</li> </ul>



## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX106	Nasacort AQ 2004 Situation Analysis	NAQ0847259-430		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX107	Nasacort 2003 INS Situation Analysis: Business Information & Planning	NAQ0480313-620		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> </ul>
				FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX108	Nasacort 1995 Budget	NAQ0939701-20		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX109	"Nasacort First" Initiative (July-December 1995)	NAQ0309001-22		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX111	Nasacort AQ NDA Correspondence File	NAQ0353616-4010		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX112	Nasacort AQ Brand Plan 2003-2007	NAQ0733415-534		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX117	Commercial Overview of INS Market, National Allergist Advisory Board, August 18, 2002	NAQ0942103-116		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX118	Nasacort AQ/Aerosol 2001-2005 Brand Plan	NAQ0739578-645	196	FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> <li>• PTX 334</li> </ul>
DX120	<b>REDACTED</b>	NAQ0622695	194	FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX123	Nasacort AQ Representative/Associate Training 2003	NAQ0529972-30057		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX124	Nasacort AQ Opportunity Analysis Presentation, J. Tretter, July 9, 1990	NAQ0277257-70		FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• NAQ0277258-70 cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX126	Nasacort Brand Marketing Strategies	NAQ00479058-95		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX127	Nasacort HFA Launch and Marketing Overview, March 3, 2005	NAQ0722268-402		FRE 105, FRE 402, FRE 805	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• Admissible under 702, 703, 801, 803, 804, 807</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX135	Nasacort and Nasacort AQ Combined P&L	NAQ0318740	177	FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX142	Nasacort Aerosol: Composition of Medicinal Product	NAQ0062702-80		FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness</li> </ul>
DX143	Jenkins, J., M.D., Testimony on Chlorofluorocarbons (CFCs) in Metered-Dose Inhalers (MDIs) before the House Committee on Commerce, Subcommittee on Health and the Environment (May 6, 1998).	www.fda.gov/ola/1998/cleanai3.htm		FRE 402, FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX145	<b>REDACTED</b>	NAQ0521683-84	7/63	FRE 402	<ul style="list-style-type: none"> <li>• Relevant to anticipation, non-enablement and non-infringement.</li> </ul>
DX147	<b>REDACTED</b>	NAQ0275644-45	13	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• PTX 163</li> </ul>
DX148	Berridge Presentation: "How Can Equivalence of Inhaled Drugs Be Demonstrated?"	NAQ0485949-83	19	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to anticipation, obviousness, non-enablement, and non-infringement</li> <li>• PTX 169</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX149	Berridge Presentation: "How Can Equivalence of Inhaled Drugs Be Demonstrated?"	NAQ0485920-48	20	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation, obviousness, and non-enablement, and non-infringement</li> <li>PTX 170</li> </ul>
DX151	<b>REDACTED</b>	NAQ0521327-29	22/62	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation, obviousness, non-enablement, and non-infringement</li> </ul>
DX152	<b>REDACTED</b>	NAQ0813726-27	28	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation, obviousness, non-enablement, and non-infringement</li> </ul>
DX153	<b>REDACTED</b>	NAQ0185425	32	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation.</li> <li>PTX 182</li> </ul>
DX156	Letter to patients encouraging them to participate in Nasacort AQ studies	NAQ0282344-45	40	FRE 901	<ul style="list-style-type: none"> <li>Authenticated by Simpson Dep. Tr. at 191:23-192:1, 192:11-20</li> <li>PTX 190</li> </ul>
DX170	<b>REDACTED</b>	NAQ0140136-41	111	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation and obviousness.</li> <li>PTX 253</li> </ul>
DX173	Beconase AQ Package Insert	NAQ0163125	120	FRE 802	<ul style="list-style-type: none"> <li>Admissible under 801, 803, 804, 807</li> </ul>
DX175	Abstract: Lavery, <i>et al.</i> , <i>Evaluation of Two Types of Avicel for Development of TAA Aqueous Nasal Spray Formulation.</i>	NAQ0163285	126	FRE 901	<ul style="list-style-type: none"> <li>Authenticated at Lavery Dep. Tr. 90:7, 12-13, 18-20</li> <li>PTX 264</li> </ul>
DX182	Memo re Patient Instructions for Use for Nasacort AQ	NAQ0277225-26	137	FRE 105, FRE 402, FRE 1003	<ul style="list-style-type: none"> <li>Relevant to anticipation and obviousness.</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX189	Email re Thixotropy	NAQ0011223	145	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation and obviousness.</li> <li>PTX 283</li> </ul>
DX206	Nasacort Nasal Inhaler IND			FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation, obviousness, non-enablement, and non-infringement.</li> </ul>
DX207	1994 Annual Report for Nasacort Nasal Inhaler submitted to FDA on Aug. 2, 1994	NAQ0214013-52	25	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation, obviousness, non-enablement, and non-infringement.</li> </ul>
DX208	Research Study Proposal for P.E.T. Study of Nasacort HFA	NAQ0210925-35	26	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation, obviousness, non-enablement, and non-infringement.</li> </ul>
DX209		NAQ0488949-65	27	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation and obviousness.</li> </ul>
	<b>REDACTED</b>	NAQ0524177-188	64	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation, obviousness, non-enablement, and non-infringement.</li> </ul>
DX210		NAQ0813726-27	65	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation and obviousness.</li> <li>Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> </ul>
DX214	Medical Summary of Study 605 (Nasacort Nasal Inhaler vs. Beconase AQ)	NAQ0244108-92	71	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation and obviousness.</li> </ul>
DX227	Letter to FDA re Study 501 comparing Nasacort Nasal Inhaler to Beconase AQ	NAQ0121538	98	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation and obviousness.</li> </ul>
DX228	Protocol for Study 501	NAQ0121546-94	99	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation and obviousness.</li> </ul>
DX238	List of Patents Related to Nasacort	NAQ0486141-43	95	FRE 402	<ul style="list-style-type: none"> <li>Relevant to anticipation and obviousness.</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX239	Brandon Simpson CV	NAQ0121160-64	29	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to anticipation.</li> <li>• PTX 179</li> </ul>
DX244	Nasacort AQ Supportable Claims	NAQ0277288-306	50	FRE 701, FRE 902	<ul style="list-style-type: none"> <li>• Authenticated by Simpson Dep. Tr. at 277:24-278:3</li> <li>• Cited in Plaintiffs' Third Supplemental Response to Interrogatory 13.</li> <li>• PTX 198</li> </ul>
DX246	"Dear Pharmacist" letter re CFC ban and Nasacort Nasal Inhaler	NAQ0250093	165	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• PTX 303</li> </ul>
DX247	Email – "Switch your patients to Nasacort AQ"	NAQ0250089-90	168	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• PTX 306</li> </ul>
DX250	Nasacort HFA 2006 Brand Tactical Plan	NAQ0485677-704	178	FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• PTX 316</li> </ul>
DX261	Berridge Presentation re "A P.E.T. Study to Probe Formulation Equivalency"	NAQ0846077-00000001-52	214	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to anticipation, obviousness, non-enablement, and non-infringement</li> <li>• PTX 352</li> </ul>
DX293	Barr Laboratories, Inc.'s Answering Claim Construction Brief (10/01/07)			FRE 105, FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• FRE 801, 803, 804, 807</li> <li>• PTX 733</li> </ul>
DX295	Barr Laboratories, Inc.'s Opening Claim Construction Brief (09/10/07)			FRE 105, FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• FRE 801, 803, 804, 807</li> <li>• PTX 735</li> </ul>
DX298	Opening Expert Report of Harry Boghigian			FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> </ul>
DX299	Opening Expert Report of Maureen Donovan			FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> <li>• PTX 416</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX300	Second Expert Report of Maureen Donovan			FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> </ul>
DX301	Opening Expert Report of Daniel Klingenberg			FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703</li> <li>• PTX 502</li> </ul>
DX302	Responsive Expert Report of Daniel Klingenberg			FRE 802, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> </ul>
DX303	Opening Expert Report of Ian MacKay			FRE 802, FRCP 26(a)(2)(B)	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> </ul>
DX304	Responsive Expert Report of Ian MacKay			FRE 802, FRCP 26(a)(2)(B)	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> </ul>
DX305	Reply Expert Report of James Morrison			FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> </ul>
DX306	Expert Report of Thomas Needham			FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> <li>• PTX 417 &amp; 501</li> </ul>
DX307	Opening Expert Report of Barry Siegel			FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> </ul>
DX308	Responsive Expert Report of Barry Siegel			FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> </ul>
DX309	Reply Expert Report of Barry Siegel			FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> </ul>



## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX310	Supplemental Expert Report of Barry Siegel			FRE 802, FRCP 26(a)(2)(B)	<ul style="list-style-type: none"> <li>• Admissible under FRE 105, 702, 703, 801, 803, 804, 807</li> </ul>
DX311	Expert Report of Donald O. Beers			FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801(d)(2), 801, 803, 804, 807</li> <li>• PTX 512</li> </ul>
DX324	"Attention Pharmacist" flyer re CFC ban and Nasacort Nasal Inhaler	NAQ0250111	166	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness.</li> </ul>
DX325	"Dear Physician" letter re transitioning from Nasacort Nasal Inhaler to Nasacort AQ due to CFC ban	NAQ0298348	167	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness.</li> </ul>
DX326	Flyer with Nasacort AQ Rebate Coupon and info re Nasacort Nasal Inhaler discontinuation	NAQ0250127-28	170	FRE 105, FRE 402, FRE 805	<ul style="list-style-type: none"> <li>• Relevant to obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX327	Letter to Patients re Nasacort Nasal Inhaler discontinuation	NAQ0250129	171	FRE 105, FRE 402	<ul style="list-style-type: none"> <li>• Relevant to obviousness.</li> </ul>
DX328	Flyer encouraging switch from Nasacort Nasal Inhaler to Nasacort AQ	NAQ0298247-48	172	FRE 105, FRE 402, FRE 805	<ul style="list-style-type: none"> <li>• Relevant to obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX329	Email string re Nasacort AQ AED Clinical Study	NAQ0487664-67	164	FRE 105, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 302</li> </ul>



## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
	Yawn, <i>Comparison of Once-Daily Intranasal Corticosteroids for the Treatment of Allergic Rhinitis: Are They All the Same?</i> , January 25, 2006	NAQ0957054-64		FRE 802, FRE 805	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX330	Bernstein, <i>Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis</i> , Clin. Exp. Allergy 34:952-57 (2004).	BARR-MACKAY-000217-222		FRE 802	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX331				FRE 105, FRE 402	<ul style="list-style-type: none"> <li>Relevant to obviousness.</li> <li>PTX 715</li> </ul>
DX333	Nasacort AQ Financial Impact	NAQ0277256		FRE 105, FRE 805	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>PTX 577</li> </ul>
DX334	"Welcome to Nasacort Training" Presentation	NAQ0529914-71		FRE 802	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX337	IMS Data	BARR-BOGH-000003-8		FRE 802	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX338	IMS Data	BARR-BOGH-000009-10		FRE 802	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX339	IMS Data	BARR-BOGH-000012-14		FRE 802	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX340	IMS Data	BARR-BOGH-000015-20		FRE 802	<ul style="list-style-type: none"> <li>Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

<u>EX. #</u>	<u>DOCUMENT TITLE/DESCRIPTION</u>	<u>BATES # SOURCE</u>	<u>DEP. EX. #</u>	<u>OBJECTIONS</u>	<u>RESPONSES TO OBJECTIONS</u>
DX341	Nasacort Forecast Assumptions Table	NAQ0935398-99		FRE 105, FRE 402, FRE 805	<ul style="list-style-type: none"> <li>• Relevant to obviousness</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX346	Nasacort Brand Marketing Strategies	NAQ0934602-39		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX348	2004 Proposed Sales Forecast	NAQ0524583-89	191	FRE 105, FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> <li>• PTX 329</li> </ul>
DX352	RPRP Allergy, Children's Health & CNS	NAQ0934642-744		FRE 805	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
DX353	Mygind, <i>Glucocorticosteroids and rhinitis</i> , Allergy 48: 476- 490 (1993).	BARR-TAA-013220- 013235		FRE 802	<ul style="list-style-type: none"> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT**

<b><u>EX. #</u></b>	<b><u>DEMONSTRATIVE EXHIBITS<sup>1</sup></u></b>	<b><u>OBJECTIONS</u></b>	<b><u>RESPONSES TO OBJECTIONS</u></b>
Demonstrative Exhibit 1	Patent Claims/Prior Art Composition Chart – Opening Expert Report of Thomas E. Needham, Ph.D. at p. 20	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 2	Patent Claims/Prior Art Composition Chart – Opening Expert Report of Thomas E. Needham, Ph.D. at pp. 28-29	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 3	Figures 1-6 – Opening Expert Report of Dr. Ian S. MacKay at pp. i-vi	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 4	Graph “1998 Results: Average of Volunteers” – Opening Expert Report of Dr. Barry A. Siegel at pp. 17 & 21	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 5	Graph “2002 Results: Average of Volunteers” – Opening Expert Report of Dr. Barry A. Siegel at p. 21	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 6	Figures – Opening Expert Report of Maureen D. Donovan, Ph.D. at pp. 7-8	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 7	Graph “Total Prescriptions 1996-2007” – Opening Expert Report of Harry C. Boghigian at p. 13	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>

<sup>1</sup> Per the parties' agreement, additional demonstrative exhibits may be added to this list.

## BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT

Demonstrative Exhibit 8	Graph "Nasacort Franchise Percent Market Share 1991-2007" - Opening Expert Report of Harry C. Boghigian at p. 15	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 9	Chart - Opening Expert Report of Harry C. Boghigian at p. 25 ¶ 94	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 10	Chart - Opening Expert Report of Harry C. Boghigian at p. 29 ¶ 106	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 11	Chart - Opening Expert Report of Harry C. Boghigian at p. 34 ¶ 124	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 12	Tables 1-3 - Opening Expert Report of Harry C. Boghigian	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 13	Tables A-M - Opening Expert Report of Harry C. Boghigian	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 14	Charts A-E - Opening Expert Report of Harry C. Boghigian	FRE 402/403/802	<ul style="list-style-type: none"> <li>• Relevant to anticipation and obviousness.</li> <li>• Admissible under FRE 702, 703, 801, 803, 804, 807</li> </ul>
Demonstrative Exhibit 15	Demonstrative Exhibit - Nasal Anatomy	FRE 402/403/802	
Demonstrative Exhibit 16	Demonstrative Exhibit - Nasal Anatomy	FRE 402/403/802	

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT**

Demonstrative Exhibit 17	Demonstrative Exhibit -- Nasal Anatomy	FRE 402/403/802	
Demonstrative Exhibit 18	Demonstrative Exhibit -- Nasal Anatomy	FRE 402/403/802	
Demonstrative Exhibit 19	Demonstrative Exhibit -- Nasal Anatomy	FRE 402/403/802	
Demonstrative Exhibit 20	Demonstrative Exhibit -- Nasal Anatomy	FRE 402/403/802	
Demonstrative Exhibit 21	Demonstrative Exhibit -- Nasal Anatomy	FRE 402/403/802	
Demonstrative Exhibit 22	Demonstrative Exhibit -- Nasal Anatomy	FRE 402/403/802	
Demonstrative Exhibit 23	Demonstrative Exhibit - Formulations	FRE 402/403/802	
Demonstrative Exhibit 24	Demonstrative Exhibit - Formulations	FRE 402/403/802	
Demonstrative Exhibit 25	Demonstrative Exhibit - Formulations	FRE 402/403/802	
Demonstrative Exhibit 26	Demonstrative Exhibit - Formulations	FRE 402/403/802	
Demonstrative Exhibit 27	Demonstrative Exhibit - Formulations	FRE 402/403/802	
Demonstrative Exhibit 28	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	
Demonstrative Exhibit 29	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	
Demonstrative Exhibit 30	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	
Demonstrative Exhibit 31	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	
Demonstrative Exhibit 32	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT**

Demonstrative Exhibit 33	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	
Demonstrative Exhibit 34	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	
Demonstrative Exhibit 35	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	
Demonstrative Exhibit 36	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	
Demonstrative Exhibit 37	Demonstrative Exhibit -- Prior Art Products	FRE 402/403/802	
Demonstrative Exhibit 38	Demonstrative Exhibit -- PET Studies	FRE 402/403/802	
Demonstrative Exhibit 39	Demonstrative Exhibit -- PET Studies	FRE 402/403/802	
Demonstrative Exhibit 40	Demonstrative Exhibit -- PET Studies	FRE 402/403/802	
Demonstrative Exhibit 41	Demonstrative Exhibit -- PET Studies	FRE 402/403/802	
Demonstrative Exhibit 42	Demonstrative Exhibit -- PET Studies	FRE 402/403/802	
Demonstrative Exhibit 43	Demonstrative Exhibit -- PET Studies	FRE 402/403/802	
Demonstrative Exhibit 44	Demonstrative Exhibit -- PET Studies	FRE 402/403/802	
Demonstrative Exhibit 45	Demonstrative Exhibit -- PET Studies	FRE 402/403/802	
Demonstrative Exhibit 46	Demonstrative Exhibit -- Clinical Trials	FRE 402/403/802	
Demonstrative Exhibit 47	Demonstrative Exhibit -- Clinical Trials	FRE 402/403/802	
Demonstrative Exhibit 48	Demonstrative Exhibit -- Clinical Trials	FRE 402/403/802	

**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT**

Demonstrative Exhibit 49	Demonstrative Exhibit – Clinical Trials	FRE 402/403/802	
Demonstrative Exhibit 50	Demonstrative Exhibit – Clinical Trials	FRE 402/403/802	
Demonstrative Exhibit 51	Demonstrative Exhibit - Viscosity	FRE 402/403/802	
Demonstrative Exhibit 52	Demonstrative Exhibit - Viscosity	FRE 402/403/802	
Demonstrative Exhibit 53	Demonstrative Exhibit - Viscosity	FRE 402/403/802	
Demonstrative Exhibit 54	Demonstrative Exhibit - Viscosity	FRE 402/403/802	
Demonstrative Exhibit 55	Demonstrative Exhibit - Viscosity	FRE 402/403/802	
Demonstrative Exhibit 56	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	
Demonstrative Exhibit 57	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	
Demonstrative Exhibit 58	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	
Demonstrative Exhibit 59	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	
Demonstrative Exhibit 60	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	
Demonstrative Exhibit 61	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	
Demonstrative Exhibit 62	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	
Demonstrative Exhibit 63	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	
Demonstrative Exhibit 64	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	



**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT**

Demonstrative Exhibit 65	Demonstrative Exhibit – Patent Claims	FRE 402/403/802	
Demonstrative Exhibit 66	Demonstrative Exhibit – Nasacort AQ Formulation	FRE 402/403/802	
Demonstrative Exhibit 67	Demonstrative Exhibit – Nasacort AQ Formulation	FRE 402/403/802	
Demonstrative Exhibit 68	Demonstrative Exhibit – Nasacort AQ Formulation	FRE 402/403/802	
Demonstrative Exhibit 69	Demonstrative Exhibit – Nasacort AQ Formulation	FRE 402/403/802	
Demonstrative Exhibit 70	Demonstrative Exhibit – Nasacort AQ Formulation	FRE 402/403/802	
Demonstrative Exhibit 71	Demonstrative Exhibit – Market Share	FRE 402/403/802	
Demonstrative Exhibit 72	Demonstrative Exhibit – Market Share	FRE 402/403/802	
Demonstrative Exhibit 73	Demonstrative Exhibit – Prescriptions	FRE 402/403/802	
Demonstrative Exhibit 74	Demonstrative Exhibit – Prescriptions	FRE 402/403/802	
Demonstrative Exhibit 75	Demonstrative Exhibit – Sales	FRE 402/403/802	
Demonstrative Exhibit 76	Demonstrative Exhibit – Sales	FRE 402/403/802	
Demonstrative Exhibit 77	Demonstrative Exhibit – Promotion	FRE 402/403/802	
Demonstrative Exhibit 78	Demonstrative Exhibit – Promotion	FRE 402/403/802	
Demonstrative Exhibit 79	Demonstrative Exhibit – Forecasts	FRE 402/403/802	
Demonstrative Exhibit 80	Demonstrative Exhibit – Forecasts	FRE 402/403/802	



**BARR LABORATORIES' EXHIBITS TO WHICH PLAINTIFFS OBJECT**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

AVENTIS PHARMACEUTICALS INC. and	)	
SANOFI-AVENTIS US LLC,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 06-286-GMS
	)	
BARR LABORATORIES, INC.,	)	
	)	
Defendant.	)	

**APPENDIX E**

**NAMES AND ADDRESSES OF WITNESSES  
WHO PLAINTIFFS' INTEND TO HAVE TESTIFY AT TRIAL**

NAME	ADDRESS	WILL CALL	MAY CALL
Salah Ahmed (via deposition)	Perrigo Industries, Israel		X
David Ailinger (via deposition)	14 Spruce Lane West Nyack, New York		X
Donald O. Beers (live)	Arnold & Porter LLP 555 Twelfth Street, N. W. Washington, D.C.	X	
Gregory K. Bell (live)	1 Apple Hill Lane Lynnfield, Massachusetts	X	

Marc S. Berridge (live)	13500 Chenal Parkway, No. 1302, Little Rock, Arkansas	X	
Charles Deliberti (via deposition)	350 Park Street Montclair, New Jersey		X
George Georges (live)	7 Winterberry Court White House Station, New Jersey		X
Natalie Grabarnick (via deposition)	Perrigo Industries, Israel		X
Michael A. Kaliner (live)	11002 Veirs Mill Road, Suite 414 Wheaton, Maryland	X	
Sharon Kochan (via deposition)	Perrigo Industries, Israel		X
Robert Y. Lochhead (live)	159 Pompano Drive Hattiesburg, Mississippi	X	
Eli O. Meltzer (live)	9610 Granite Ridge Drive, Suite B San Diego, California	X	
Christopher Mengler (via deposition)	29 Center Drive Douglas Manor, New York		X
Robert K. Prud'homme (live)	Princeton University A-301 E-Quad Princeton, New Jersey	X	
Yoav Reychav (via deposition)	Perrigo Industries, Israel		X
Brandon Simpson (live)	627 Scroggy Road Oxford, Pennsylvania	X	
Nicholas Tantillo (via deposition)	41 Hunt Avenue Pearl River, New York.		X
Christine Zak (live)	43 Grove Way Clinton, Connecticut		X
Amira Zeevi (via deposition)	Perrigo Industries, Israel		X

deposition)			
-------------	--	--	--

**APPENDIX F****Barr Laboratories' Witness List**

<b>WILL CALL</b>		
<b>Witness</b>	<b>Address</b>	<b>Form of Testimony</b>
Dr. Gregory Alcorn	2056 Welsh Valley Road Valley Forge, PA	Live or by deposition
Dr. Marc Berridge	13500 Chenal Parkway, #1302 Little Rock, AR	Live or by deposition
Harry Boghigian	7 Tudor Place Randolph, NJ	Live
Dr. Maureen Donovan	115 South Grand Avenue Iowa City, IA	Live
Dr. George Georges	7 Winterberry Court Whitehouse Station, NJ	Live or by deposition
Dr. Donald Heald	Pharmaceutical Research & Development (Johnson & Johnson)	Live or by deposition
Dr. Soo-Il Kim	18 McPherson Drive Flemington, NJ	Live or by deposition
Dr. Daniel Klingenberg	1415 Engineering Drive Madison, WI	Live
Timothy Lavery	1357 Mark Drive Lansdale, PA	Live or by deposition
Dr. Ian MacKay	55 Harley Street London W1G 8QR England	Live
James Morrison	5166 Durham Road West Columbia, MD	Live
Dr. Thomas Needham	175 Pine Hill Road Wakefield, RI	Live
Dr. Barry Siegel	510 South Kingshighway Boulevard St. Louis, MO	Live
Brandon Simpson	627 Scroggy Road Oxford, PA	Live or by deposition
Christine Zak	43 Grove Way Clinton, CT 06413	Live or by deposition
<b>MAY CALL</b>		
<b>Witness</b>	<b>Address</b>	<b>Form of Testimony</b>
Ross Oehler	4171 Creek Road Collegeville, PA	Live or by deposition
Judy Plon	Aventis Pharmaceuticals	Live or by deposition
Nicholas Tantillo	41 Hunt Avenue Pearl River, New York.	Live or by deposition
Dr. Amira Zeevi	5 Uchmanat Omer, Israel	Live or by deposition

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

AVENTIS PHARMACEUTICALS INC. and	)	
SANOFI-AVENTIS US LLC,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 06-286-GMS
	)	
BARR LABORATORIES, INC.,	)	
	)	
Defendant.	)	

**APPENDIX G**

**QUALIFICATIONS OF PLAINTIFFS' EXPERT WITNESSES**

**Dr. Gregory K. Bell**

Dr. Bell is an Executive Vice President and Head of Strategy and Business Consulting for CRA International, Inc. He is responsible for the business consulting platform. For the past fifteen years, he has directed the Life Sciences practice at CRA. In this capacity, he has led many projects concerning the economics of business strategy in the pharmaceutical industry. Dr. Bell is also a principal member of the firm's Finance, Intellectual Property, and Transfer Pricing practices. Prior to joining CRA, Dr. Bell acted as a management consultant for Alliance Consulting Group in Boston, Massachusetts, and was an Associate in Corporate Finance at Wood Gundy in Vancouver, Canada. Dr. Bell earned a Ph.D. in Business Economics from Harvard University, a Master's of Business Administration from Harvard's Graduate School of Business Administration, and a B.A. in Finance and Accounting from Simon Fraser University. He has been a lecturer at Harvard University, as well as a Visiting Assistant Professor in the Economics Department at Northeastern University. Dr. Bell has authored a number of

publications on topics including pharmaceutical pricing strategies and other economic issues in the pharmaceutical industry.

**Dr. Marc S. Berridge**

Dr. Berridge is the President of 3D Imaging Drug Design and Development and a Professor in the Department of Radiology at the University of Arkansas for Medical Sciences. Dr. Berridge was the director of the radiochemistry and cyclotron facility at Case Western/University Hospitals of Cleveland, and then the Associate Director of PET (Positron Emission Tomography). In addition to being a tenured professor of Radiology at Case Western Reserve University Previously, Dr. Berridge was also the founder and president of 3D Imaging, LLC, and Cyclo-Tech, LLC which were companies directed to creating labeled molecules for nuclear imaging studies and performing those studies. He has used imaging studies as a drug design and development tool, and pioneered studies that involve radiolabeling of active ingredients of inhaled drugs. Prior to working at Case Western Reserve, Dr. Berridge was a Research Scientist, then Assistant Professor at the University of Texas Health Science Center, where he performed research studies including radiolabeling chemistry, cyclotron targetry, organic chemistry, and animal and human subject research with PET scanning. He performed post-doctoral research at the Nuclear Research Center in Saclay, France to develop radiolabeled tracers for use in PET studies in human subjects. Dr. Berridge earned his Ph.D. in Chemistry from Washington University in St. Louis, Missouri. He also earned a Masters Degree in Chemistry at Washington University, after earning his B.S. in Chemistry at Carnegie Mellon University.

**Mr. Donald O. Beers**

Mr. Beers is a partner in the law firm of Arnold & Porter LLP in Washington, D.C., where he specializes in food and drug law. Prior to joining Arnold & Porter, Mr. Beers served as Associate Chief Counsel for Drugs, and Associate Chief Counsel for Enforcement at the Food and Drug Administration. He is the author of a well-known treatise, Generic and Innovator Drugs: A Guide to FDA Approval Requirements. Mr. Beers has been an adjunct professor at the University of Pennsylvania School of Law, teaching food, drug, and medical device law. He is a frequent speaker on issues relating to the drug approval process. Before working at the FDA, Mr. Beers was a law clerk for the Honorable Milton Pollack of the U.S. District Court of the Southern District of New York. Mr. Beers earned his J.D. at Columbia Law School, after graduating with a B.A. from Dartmouth College.

**Dr. Michael A. Kaliner**

Dr. Kaliner is a physician board-certified in internal medicine and allergy and immunology. He is the Medical Director at the Institute for Asthma and Allergy in Wheaton and Chevy Chase, Maryland. Dr. Kaliner has also served as the President of the World Allergy Organization, and as the President of the American Academy of Allergy, Asthma, and Immunology. For fifteen years prior to entering private practice, Dr. Kaliner served as the head of the Allergic Diseases Section of the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health, and the training program director for allergy and immunology at NIAID. Dr. Kaliner also served in the U.S. Air Force and the United States Public Health Service as an allergist. He was the chairman of the American Board of Allergy and Immunology, the entity that board-certifies physicians in allergy and immunology. He is



the founding editor of Current Allergy and Asthma Reports, and has been the editor of numerous journals and books, including Current Review of Rhinitis and Current Review of Allergic Disease. Dr. Kaliner has published over 500 research articles dealing with allergy and asthma. Dr. Kaliner earned his M.D. at the University of Maryland School of Medicine and a B.S. in Zoology at the University of Maryland.

**Dr. Robert Y. Lochhead**

Dr. Lochhead is a professor of polymer science and Director of the School of Polymers and High Performance Materials at the University of Southern Mississippi. Dr. Lochhead regularly teaches short courses directed to industrial practitioners on the function of polymers in formulations and on the physical principles of formulations. He is also the Director of the Institute for Formulations Science at USM. Dr. Lochhead also currently serves on the Committee for Scientific Affairs of the Society of Cosmetic Chemists. For eleven years, Dr. Lochhead was employed at BF Goodrich Company in positions ranging from Research Associate to Manager of Hydraulic Polymers Research, where his research focused on rheology-modifying polymers. For the nine years prior to his working at BF Goodrich, Dr. Lochhead worked at Unilever Research as a Scientist/Manager in the areas of innovative polymers and colloid and surface science. He has served as the President of the Society of Cosmetic Chemists, and is the current Vice President-Elect. He has also served as the President of the Association of Formulation Scientists. Dr. Lochhead has been awarded the Maison G. deNavarre medal, which is the highest award in the Arts and Sciences of Cosmetics. Dr. Lochhead has published over 200 articles on polymers and surfactants, and is the named inventor on 18 patents. Dr. Lochhead earned his Ph.D. in Molecular Rheology and Dielectric Relaxation of Polymer Solutions from

the Department of Pure and Applied Chemistry at the University of Strathclyde, Scotland, and a B.Sc. with Honors in Pure Chemistry from the University of Strathclyde.

**Dr. Eli O. Meltzer**

Dr. Meltzer is a physician board-certified in allergy and immunology, pediatric allergy, and pediatrics. For over three decades, Dr. Meltzer has practiced medicine at the Allergy and Asthma Medical Group and Research Center, specializing in the treatment of allergies and asthma, and providing care for adults and children with respiratory diseases. He has participated in over 500 clinical research trials related to allergy and asthma and authored about 500 papers related to allergy and asthma. Dr. Meltzer is a Clinical Professor in the Department of Pediatrics, Division of Immunology and Allergy, at the University of California, San Diego. He has served in the past as the Chief of the Division of Allergy and Immunology at the San Diego Children's Hospital and Health Center. He has also served as a member of the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee. Dr. Meltzer also served in the U.S. Navy as a Lieutenant Commander. Dr. Meltzer earned his M.D. from Jefferson Medical College after earning a B.A. in Psychology from the University of Pennsylvania.

**Dr. Robert K. Prud'homme**

Dr. Prud'homme is a Professor of Chemical Engineering and the Director of the Program in Engineering Biology at Princeton University. He has served on the executive committees of the American Institute of Chemical Engineers (Materials Science Division), and the U.S. Society of Rheology, for which he is currently the President. Dr. Prud'homme has also served as the chair of the Technical Advisory Board for Material Science Research for Dow Chemical

Company, and was on the Board of Directors of Rheometric Scientific Inc., the leading manufacturer of rheological instruments. Dr. Prud'homme is also currently serving as the Director of Princeton-University of Minnesota-Iowa State NSF Nanoscience Institute on nanoparticle formation. Dr. Prud'homme has been a consultant to major pharmaceutical companies, including FMC, DuPont, American Cyanamid, Hercules, Merck, Abbot Laboratories, and BASF. Dr. Prud'homme received his B.S.E. in Chemical Engineering from Stanford University. He earned a Ph.D. in Chemical Engineering from the University of Wisconsin, Madison. After graduating from Stanford, Dr. Prud'homme served as an officer in the U.S. Army, and was awarded an Army Commendation Medal and a Bronze Star. After being discharged as a Captain, Dr. Prud'homme studied at Harvard University in a Graduate Special Studies Program in Environmental Science and Public Policy.

## **APPENDIX H**

### **Qualifications of Barr Laboratories' Experts**

#### **I. Mr. Harry Boghigian**

Mr. Harry Boghigian is a pharmaceutical executive with over thirty-five years of domestic and international experience in the commercialization and marketing of pharmaceutical products. He co-founded PBN PHARMA LLC, a Chicago-based research and development healthcare company, in 2003. The company owns twelve patents and is focused on the development, licensing and commercialization of ethical and over-the-counter products. In 2001, Mr. Boghigian founded Pharma Consultants LLC, a New Jersey-based consulting firm serving small to medium sized healthcare companies and advertising agencies in all areas of pharmaceutical sales and marketing.

Mr. Boghigian's career in the pharmaceutical industry began with Hoffman-La Roche, one of the top ten global pharmaceutical research and development companies, in 1971. During his career with Hoffman-La Roche, Mr. Boghigian held numerous positions of increasing responsibility in the U.S. and internationally, including Vice President of Business Operations, Vice President of U.S. Marketing, Global Business Director and Senior Vice President and General Manager of the Canadian division of Hoffman-La Roche. His responsibilities included business development, market research, marketing, brand management, sales, sales management, strategic planning, portfolio management and product commercialization. He was involved with over forty products in various stages of development and commercialization. His experience includes management of a number of successful co-promotion arrangements including Zantac, the first co-promotion arrangement in the history of the pharmaceutical industry. As a result of that arrangement, Zantac became one of the world's most widely prescribed products for the treatment of ulcers and reflux disease.

Mr. Boghigian has a Bachelor of Science Degree from the University of New Hampshire Whittemore School of Business and has attended a number of Executive Business Programs at several of Europe's leading business schools, such as INSEAD Institute of Business Administration in Fontainebleu Cedex, France and IMD Business School in Lausanne, Switzerland.

Mr. Boghigian will testify regarding whether Plaintiffs' commercial product, Nasacort AQ, has been commercially successful.

#### **II. Dr. Maureen Donovan**

Dr. Maureen Donovan is an Associate Professor in the Division of Pharmaceutics at the University of Iowa College of Pharmacy. She has over 18 years of experience working and consulting in the field of pharmaceutics, including pharmaceutical research and development. She has actively taught drug delivery, pharmaceutical preformulation and compounding and has directed research programs focused on drug absorption, nasal

drug delivery, and alternative routes of drug delivery and delivery systems. This experience includes working extensively in the development of nasal formulations.

Dr. Donovan received her B.S. in Pharmacy from the University of Minnesota College of Pharmacy in 1983 and her Ph.D. in Pharmaceutics from the University of Michigan in 1989.

Dr. Donovan's professional experience includes working as a Staff Pharmacist for Clark Professional Pharmacy from 1986 to 1989 and as a Visiting Scholar for SmithKline Beecham Pharmaceuticals in 1991. From 1989 to 1996, Dr. Donovan was an Assistant Professor in the Division of Pharmaceutics of the University of Iowa College of Pharmacy. She became an Associate Professor in 1996.

Dr. Donovan has published numerous articles, book chapters and abstracts in the area of pharmaceutics, drug absorption, drug delivery, and materials characterization. She belongs to several professional societies for pharmaceutical science and technology, including the American Association of Pharmaceutical Scientists and the Controlled Release Society.

Dr. Donovan will be testifying on the level of ordinary skill in the art, as well as the non-enablement and non-infringement of the asserted patent claims.

### **III. Dr. Daniel Klingenberg**

Dr. Daniel Klingenberg is a professor in the Department of Chemical and Biological Engineering and an Associate Chairman of the Rheology Research Center Executive Committee at the University of Wisconsin. He has been a Professor of Chemical and Biological Engineering since 1991 and an Associate Chairman since 1996.

Dr. Klingenberg received his B.S. in Chemical Engineering from the University of Illinois in 1989 and a Ph.D. in Chemical Engineering from the University of Illinois in 1991. He completed a Postdoctoral Fellowship at the University of British Columbia.

Dr. Klingenberg has over 16 years of experience in the area of rheology and 20 years of experience with viscosity testing, including measuring the viscosity and other rheological properties of electrorheological fluids, magnetorheological fluids, and various fiber suspensions. He has published numerous articles in the area of rheology, including publications in the Journal of Rheology dating back to 1993 and has reviewed articles for numerous scientific journals that publish papers in rheology, including the Journal of Rheology, Rheological Acta, Physics of Fluids, Journal of Colloid and Interface Science, and Journal of Fluid Mechanics. He has been a member of several professional societies, including the Society of Rheology, and is currently a Member-at-large on the Executive Committee of the Society of Rheology.

Dr. Klingenberg will testify regarding viscosity testing methods, as well as the rheological characteristics and results of viscosity testing conducted on various compositions relevant to this case.

#### **IV. Dr. Ian Mackay**

Dr. Ian Mackay is a physician registered as a specialist in otorhinolaryngology with the General Medical Council of the United Kingdom. Dr. Mackay received his Bachelor of Medicine and Bachelor of Surgery London qualifications from the Royal Free Hospital (University of London) in 1968. He underwent postgraduate training at the Royal National Throat Nose and Ear Hospital and Charring Hospital London, obtaining an FRCS (Fellow of the Royal College of Surgeons England) in 1974 and Certificate of Completion of Higher Surgical Training in 1976.

Dr. Mackay has specialized in rhinology for over thirty years and established the Nose Clinic at the Royal Brompton Hospital (National Heart and Chest Hospital) in London. He was formerly the head of the Ear, Nose and Throat department at Charring Cross Hospital, the president of the British Association of Otolaryngologist, the president of the Section of Laryngology and Rhinology of the Royal Society of Medicine. He was a founding member of the British Allergy Association. He was a visiting professor at the Mayo Clinic (Rochester) in 1996. He was awarded the British Medical Association Walter Jobson Horne Prize “in recognition of work which has advanced the science and practice of laryngology and otology” in 2001. He has lectured regularly on rhinology and otorhinolaryngology in the United Kingdom and abroad since 1978.

Dr. Mackay was a contributor to the guidelines evolving from the International Conference on Sinus Disease: Terminology, Staging and Therapy held in Princeton, New Jersey, in 1993, sponsored by the American Rhinological Society and the International Rhinological Society. He was a contributor to the World Health Organization (WHO) Initiative: Allergic Rhinitis and Its Impact on Asthma (ARIA). He was also the editor of the 5<sup>th</sup> and 6<sup>th</sup> editions of the Rhinology Volume of Scott-Brown’s Otolaryngology (the standard ENT text book in the UK). He has authored chapters in numerous books relating to allergic and non-allergic rhinitis and published close to one hundred articles on a variety of otorhinolaryngological topics including nasal mucociliary clearance in patients with rhinitis, sinusitis, perennial and seasonal allergic rhinitis, and endoscopic sinus surgery.

Dr. Mackay will testify regarding nasal anatomy, causes and treatment of allergic rhinitis, safety and efficacy of nasal sprays, compliance of patients on nasal sprays, whether there was a long-felt need for the claimed invention, and whether the claimed invention exhibits unexpected results in potency and the treatment of eye symptoms.

#### **V. Mr. James Morrison**

Mr. James Morrison has extensive experience in and is an expert on new drugs, generic drugs, abbreviated new drug applications (“ANDAs”) and bioequivalence. He is thoroughly familiar with the regulations governing approval of new generic drugs and the processes and criteria that the FDA uses to evaluate them. His expertise is based primarily on his training and experience at the FDA while he was Special Assistant to the Director, Bureau of Drugs (the predecessor organization to the Center for Drug Evaluation and Research) (1976-1982); Director of Regulatory Affairs (1982-1983);

Deputy Director, Office of Drug Standards (1983-1990); acting Director, Division of Generic Drugs (1980); and Ombudsman for the FDA's Center for Drug Evaluation and Research ("CDER") (1995-2003).

During the time that Mr. Morrison held these positions at the FDA, he fulfilled many different job responsibilities. He chaired the policy committee that prepared the preface for the FDA's List of Approved Drugs with Therapeutic Equivalence Evaluations (the "Orange Book"), made policy decisions about its content and format, and coordinated the initial publication of the Orange Book in 1979. He oversaw the generic drug review process, including performing tertiary reviews and signing approval letters. He actively participated in the rewrite of the new drug regulations that are currently in effect pertaining to New Drug Applications ("NDAs") and ANDAs. He was the FDA's representative to the Department of Health and Human Services' Maximum Allowable Cost Program ("MAC") from 1977-1981. As Deputy Director of the Office of Drug Standards, Mr. Morrison was responsible for management and policy oversight of the Divisions of Generic Drugs and Bioequivalence. He served as the FDA's principle subject matter liaison with congressional committees during the drafting of the 1984 Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Amendments), chaired the FDA committee that drafted the implementing regulations and was the principal person in the FDA responsible for the policy and subject matter on its implementation. As CDER Ombudsman, he negotiated disputes between ANDA applicants and generic drug and bioequivalence reviewers regarding the implementation of the FDA's procedures and policies.

Mr. Morrison will testify regarding FDA approval of generic products, including generic nasal sprays, in response to Plaintiffs' allegations of copying.

## **VI. Dr. Thomas Needham**

Dr. Thomas Needham is a Professor in the Department of Biopharmaceutical Sciences, the Director of the Drug Delivery Research & Development Laboratory, and the Director of the Good Manufacturing Practice ("GMP") Program at the University of Rhode Island College of Pharmacy. He is an expert in pharmaceuticals and has over 37 years of experience in pharmaceutical research and development including preformulation studies, formulation and product development, process development, production support, preclinical studies, and project management. Dr. Needham has had experience formulating nasal sprays since the early 1980s, including consulting with a European company in approximately 1992 to formulate a generic beclomethasone suspension delivered by a nasal spray pump.

Dr. Needham received a B.S. in Pharmacy in 1965, a M.S. in Pharmaceutics in 1967 and a Ph.D. in Pharmaceutics in 1970 from the University of Rhode Island. From 1970 to 1971 he was a faculty member at the University of Georgia.

From 1979 to 1987, Dr. Needham was affiliated with Baxter Travenol Laboratories in various capacities, including Associate Director of Pharmaceutical Development, Direct of Special Projects and Drug Delivery, and Director of New Product



Development. His responsibilities at Baxter Travenol included direction of product development activities from initiation through final product, including scale-up, manufacturing, and quality control support. From 1987 to 1989, Dr. Needham was the Section Head for Pharmaceutical Development at G.D. Searle, where he was responsible for the technical and administrative activities of the Preformulation, Drug Delivery, and Product Line Extension Groups. In 1989, he became a Professor in the Department of Pharmaceutics and Director of the Drug Delivery Laboratory at the University of Rhode Island and in 1992 he became the Chair of the Department of Pharmaceutics (subsequently known as the Department of Applied Pharmaceutical Sciences, and the Department of Biopharmaceutical Sciences). He was Chair of the Department until 2002. In 2004, Dr. Needham became the Director of the Good Manufacturing Practice ("GMP") Program.

Dr. Needham has published numerous articles, book chapters and abstracts in the area of pharmaceutical science, including co-authoring "An Evaluation of Nasal Spray Deposition and Clearance in Healthy Human Volunteers using Gamma Scintigraphy," published in Drug Delivery Tech. in 2005, which reported his examination of the deposition and clearance of nasal drug vehicles of varying viscosities and formulations. Dr. Needham belongs to several professional societies for pharmaceutical science and technology, including the American Association of Pharmaceutical Scientists, the American Pharmaceutical Association, and the Controlled Release Society.

Dr. Needham will be called to testify regarding the obviousness of the patents in suit, including the scope and content of the prior art, the disclosures of the prior art in relation to the asserted patent claims and the ultimate conclusion that the asserted patent claims would have been obvious to a person of ordinary skill in the art at the relevant time.

## **VII. Dr. Barry Siegel**

Dr. Barry Siegel is a Professor of Radiology and Medicine and the Director of the Division of Nuclear Medicine at the Mallinckrodt Institute of Radiology at the Washington University School of Medicine. Dr. Siegel has more than 37 years of experience working and consulting in the fields of nuclear medicine and radiology.

Dr. Siegel received his A.B. in 1966 from Washington University and his M.D. in 1969 from Washington University School of Medicine. Since 1973, Dr. Siegel has been a member of the Radiology faculty at Washington University School of Medicine, becoming a professor in 1979. Since 1980, Dr. Siegel has been jointly appointed to the faculty of the Department of Medicine at Washington University School of Medicine, becoming a professor in 1983. Since 1973, he has been the Director of the Division of Nuclear Medicine at the Mallinckrodt Institute of Radiology at Washington University School of Medicine. He has also been a staff radiologist at Barnes Hospital (now Barnes-Jewish Hospital) in St. Louis, Missouri since 1973 and has been Nuclear Radiologist-in-Chief since 1986. He holds medical staff appointments in Radiology at St. Louis Children's Hospital and at Barnes-Jewish West County Hospital, both in St. Louis, Missouri.



Dr. Siegel has approximately 30 years of clinical and research experience in the specific area of positron emission tomography (“PET”) imaging, including conducting numerous single-institution clinical trials examining the utility of PET, performed at Washington University School of Medicine, as well as developing and directing multi-center clinical trials conducted by the National Cancer Institute cooperative groups. He has published numerous articles, book chapters and abstracts in the area of radiology and nuclear medicine and began writing about PET imaging in 1977.

Dr. Siegel belongs to several professional societies for radiology and nuclear medicine, including the Academy of Molecular Imaging (AMI), American College of Nuclear Physicians, American College of Radiology (ACR), Association of University Radiologists, Radiological Society of North America, and the Society of Nuclear Medicine. Dr. Siegel has held a variety of leadership positions related to PET in these organizations and has served as a member of several advisory panels and committees, including membership on the U.S. Food and Drug Administration Radioactive Pharmaceuticals Advisory Committee (1974-1977 and 1981-1985, chair 1982-1985), the U.S. Nuclear Regulatory Commission Advisory Committee on the Use of Isotopes (chair 1990-1996), and the Advisory Panel on Radiopharmaceuticals of the U.S. Pharmacopoeia (1975-present, chair 2000-2005). He was on the PET Scanning Assessment Working Group of the American Society of Clinical Oncology (2003-2006) and is co-chair of the National Oncologic PET Registry Working Group (2005-present).

Dr. Siegel is currently Associate Editor of the Journal of Nuclear Medicine, Senior Editor of Molecular Imaging and Biology, Assistant Editor for PET/CT of the American Journal of Roentgenology, and on the Editorial Boards of the Journal of Computer Assisted Tomography and the European Journal of Nuclear Medicine. He previously served on the Advisory Editorial Board and then as an Associate Editor and as a Consultant to the Editor of Radiology (1976-1999).

Dr. Siegel will testify regarding positron emission studies Aventis conducted on nasal sprays, including Nasacort AQ and a prior art product, Flonase.

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

AVENTIS PHARMACEUTICALS INC. and	)	
SANOFI-AVENTIS US LLC,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 06-286-GMS
	)	
BARR LABORATORIES, INC.,	)	
	)	
Defendant.	)	

**APPENDIX I**

**DEPOSITIONS TO BE READ INTO THE RECORD  
ON BEHALF OF PLAINTIFFS**

**SALAH AHMED - July 26, 2007 Deposition**

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
6:11	6:13			
14:8	14:18			
21:17	21:25			
22:2	22:19			
23:2	23:9			
23:11	23:22			
30:15	30:24			
31:14	31:25			
32:2	32:6			
108:11	108:13			
108:16	108:19			
109:2	109:12			
109:16	109:20			
109:23	109:23			
136:10	136:14			
136:17	136:23	137:4-5, 8-16, 20		
137:25	137:25			
138:2	138:5			
138:8	138:8			
138:19	138:25			
139:2	139:4			
139:7	139:13			
145:19	145:25			
146:2	146:3			
146:7	146:11			
146:16	146:21			
146:25	146:25			
147:2	147:7	148:15-18, 23-25; 149:2		
152:24	152:25			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
153:2	153:2			
153:5	153:14			
161:15	161:25			
162:2	162:10			
162:14	162:19			
162:22	162:25			
164:4	164:13			
164:16	164:25			
165:2	165:2			
165:7	165:8			
165:12	165:12			
167:14	167:18			
167:21	167:25			
168:2	168:2			
168:5	168:10			
168:13	168:22			
169:2	169:4	169:5-6, 12-16		
173:4	173:6			
173:9	173:25			
174:19	175:25			
175:2	175:14			
175:17	175:19	176:20-25; 177:2-6, 9-21		
177:22	177:24			
178:3	178:9			
178:17	178:25			
179:2	179:24			
180:5	180:23			

**SALAH AHMED - October 4, 2007 Deposition**

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
230:12	230:24			
232:7	232:15			
233:18	233:21			
233:24	233:25			
134:2	234:7			
234:11	234:18			
234:23	234:25			
235:2	235:14			
235:18	235:20			
242:24	242:25			
243:2	243:7			
244:14	244:14			
244:16	244:17			
244:20	244:25			
245:2	245:3			
245:8	245:12	245:6-7	FRCP 32(a)(6) FRE 611(b)	
247:10	247:14			
247:17	247:22			
251:8	251:10			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
251:15	251:19			
259:20	259:25	257:21-25, 258: 2-25		
260:2	260:4			
260:8	260:8	261: 16-18, 21-25; 262: 2-9; 263:4-21		262:10-14
264:8	264:15			
265:3	265:4			
265:7	265:20			
265:24	265:25	266:2-13		
266:18	266:21			
266:24	266:25			
267:2	267:24	267:25 - 268:11, 13-24		
268:25	268:25			
269:2	269:23			
270:5	270:15			
271:4	271:9			
271:14	271:16			
272:7	272:24			
273:3	273:9			
273:23	273:25			
274:2	274:2			
274:5	274:5	274:17-19, 23-25; 275:2-12, 15-19, 22-24		275:25, 276:2-4, 276:6-8, 276:11-14, 276:17-18

**DAVID AILINGER**

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
7:19	7:25			
8:2	8:6			
10:4	10:10			
10:25	10:25			
11:2	11:14			
11:25	11:25			
12:2	12:17			
13:17	13:21			
14:3	14:7			
14:14	14:25			
15:2	15:9			
15:17	15:23			
17:12	17:13			
17:15	17:15			
17:21	17:24			
19:21	19:25			
20:2	20:4			
20:7	20:15			
20:17	20:21			
21:11	21:14			
21:16	21:19			
22:14	22:22			
23:2	23:5			
23:11	23:17			
23:21	23:25			
24:2	24:10			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
24:13	24:16			
25:4	25:10			
25:17	25:25			
26:2	26:6			
26:9	26:25			
27:2	27:2			
27:5	27:8			
27:10	27:25			
28:2	28:4			
28:11	28:15	28:16, 20-21	FRE 402, FRE 602  28:17 to 28:19 (Objection, calls for speculation, beyond the scope of the 30(b)(6).)	
28:22	28:25			
29:2	29:2			
29:4	29:8			
29:10	29:19			
30:11	30:19			
30:22	31:3			
31:2	31:3			
31:6	31:18	31:19, 23-25, 32:2		
32:3	32:6			
32:9	32:25			
33:2	33:2			
33:5	33:5			
39:6	39:8			
39:11	39:11			
40:21	40:24			
41:4	41:5			
41:12	41:15			
41:18	41:24			
42:4	42:7			
42:11	42:13			
42:17	42:21			
42:24	42:25			
43:2	43:2			
43:5	43:5			
60:3	60:7			
60:11	60:21			
60:24	61:3			
61:13	61:25			
62:2	62:2			
64:9	64:13			
64:16	64:21			
64:25	64:25			
65:2	65:4			
65:7	65:10			
65:12	65:13			
65:15	65:15			
66:16	66:17			
66:20	66:21			
66:23	66:25			
67:2	67:6			
67:11	67:15			
67:23	67:24			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
68:3	68:4			
68:7	68:8			
68:24	68:25			
69:2	69:13			
69:16	69:22			
69:25	69:25			
70:2	70:2			
71:23	71:25			
72:2	72:18			
73:11	73:22			
74:22	74:25			
72:5	75:2			
75:5	75:6	75:7, 9	<p>FRE 602</p> <p>75:3 to 75:4 (Objection, beyond the scope of the 30(b)(6).)</p> <p>75:8 to 75:8 (Objection, beyond the scope of the 30(b)(6).)</p>	
75:10	75:13			
75:15	75:18			
83:2	83:4			
83:8	83:16			
84:6	84:7			
84:19	84:25			
85:3	85:9			
85:12	85:18			
86:2	86:13			
88:2	88:4			
88:7	88:14			
89:13	89:23			
90:4	90:7			
90:10	90:18			
91:7	91:9			
91:13	91:22			
92:2	92:3			
92:19	92:25			
93:2	93:3			
93:7	93:19			
94:2	94:9			
94:12	94:15			
94:17	94:24			
95:3	95:4			
96:6	96:11			
96:14	96:25			
97:2	97:2			
97:5	97:11			
97:14	97:18			
97:21	97:22			
99:10	99:12			
99:16	99:25			
100:2	100:10			
100:18	100:21			
101:4	101:10			
101:15	101:25			
102:2	102:2			

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
102:7	102:16			
102:23	102:25			
102:24	103:2			
103:2	103:2			
103:6	103:19			
104:13	104:15			
104:21	104:23			
105:2	105:10			
105:16	105:23			
106:2	106:7			
108:15	108:21			
112:15	112:17			
112:21	112:25			
113:2	113:3			
113:6	113:7			
113:9	113:10			
113:12	113:12			
113:14	113:21			
114:11	114:12			
114:15	114:17			
114:19	114:21			
114:24	114:25			
115:2	115:3			
115:7	115:16			
115:20	115:21			
115:23	115:25			
121:22	121:25			
122:2	122:2			
122:12	122:13			
122:16	122:17			
122:19	122:20			
122:23	122:25			
123:2	123:2			
124:2	124:3			
124:5	124:9			
124:12	124:15			
124:17	124:17			
124:23	125:25			
125:2	125:2			
125:4	125:5			
125:7	125:11			
125:14	125:14			
125:16	125:17			
125:20	125:20			
126:18	126:22			
126:25	126:25			

**NATALIE GRABARNICK – June 15, 2007 Deposition**

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
18:17	18:22	12:15-25; 13:2-6, 13-17; 13:19-14:5		10:13 to 12:13

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
19:3	19:7			
19:10	19:11			
21:17	22:12			
22:16	22:18			
25:12	25:19			
35:24	36:5			
36:10	36:10			
36:19	36:21			
37:2	37:2			
37:8	37:19			
37:21	38:6			
38:24	39:8			
39:10	39:22			
39:25	40:3			
40:6	40:7			
40:10	40:13			
40:16	40:18			
40:22	40:23			
41:1	41:8			
41:10	41:14			
41:19	41:23			
42:1	42:5			
43:20	43:22			
43:24	44:7			
44:10	44:12			
44:15	44:17			
45:16	45:18			
45:21	45:23			
46:1	46:4			
48:13	49:11			
49:21	50:3			
50:6	50:9			
50:12	50:25			
51:3	51:12			
51:15	51:20			
52:2	53:7			
53:11	54:11			
56:10	56:16			
57:2	57:6			
57:9	57:13			
57:16	57:17			
57:20	57:22			
57:25	57:25			
59:1	59:2			
59:6	59:10			
59:23	59:24			
60:3	60:16			
62:2	62:3			
62:6	62:18			
63:11	64:5			
64:9	64:10			
64:13	64:24			
65:2	65:8			
71:6	71:17			
71:19	72:9			



<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
72:13	72:16			
72:19	72:20			
73:2	73:6			
73:11	73:12			
73:14	73:21			
73:24	73:25			
75:3	75:10			
75:20	76:3			
76:13	76:20			
77:3	77:14			
77:21	78:2			
78:7	80:9			
80:22	81:16			
83:3	84:15			
85:19	85:21			
85:24	86:2			
86:5	87:7			
87:23	88:6			
88:9	88:10			
90:4	90:20			
91:22	92:11			
92:14	93:19			
93:23	94:2			
94:9	94:24			
95:1	95:20			
96:23	96:24			
97:2	97:4			
97:11	97:13			
97:23	98:2			
98:6	98:16			
101:21	101:23			
102:1	102:13			
102:18	103:2			
103:16	104:5			
104:10	104:13			
105:22	106:4			
106:6	106:6			
106:13	106:24	107:3		
107:4	107:13			
107:22	108:14			
112:8	112:15			
112:23	113:6			
113:15	113:18			
113:20	114:4			
114:11	114:17			
115:13	116:8			
116:12	117:9			
117:14	118:18			
118:20	118:20			
118:23	118:24			
119:12	119:13			
119:16	121:6			
122:2	122:18			
122:21	122:25			
123:15	123:16			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
123:21	123:25			
124:3	124:4			
124:18	124:20			
124:22	124:24			
125:13	125:22			
125:24	126:9			
126:11	127:5			
127:17	127:19			
127:24	128:5			
128:14	131:11			
131:13	131:20			
131:22	133:3			
133:6	133:18			

**SHARON KOCHAN**

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
5:8	5:12			
8:5	8:20			
10:15	11:23			
24:9	24:10			
24:12	24:13	24:14-15		24:16-20, 24:22-24, 25:1
25:2	25:3			
25:5	25:15			
25:17	25:19			
25:21	26:7			
27:22	27:24			
28:2	28:5			
28:8	28:8			
31:15	31:16			
31:19	31:19			
34:21	35:1			
35:5	35:7			
35:9	35:16			
35:19	35:22			
37:10	37:12			
37:15	37:17			
37:21	37:22			
37:25	38:4			
38:10	38:16			
38:18	38:24			
39:2	39:6	39:9; 39:11		39:8
39:8	39:8	41:10-20	FRCP 32(a)(6)	41:22-25, 42:7-9, 42:12-14, 42:17-24, 43:2
41:5	41:9			
41:22	41:25			
55:9	55:14			
55:17	55:18			
55:20	56:12			
56:15	57:18			
57:21	57:22			
62:15	62:16			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
62:19	62:19			
64:18	64:21			
64:24	65:8	65:9-10, 19-21; 66:3-4, 7-12		65:22 to 65:23 66:1-66:2
67:25	68:3			
68:6	68:9			
68:12	68:15			
68:20	68:21	68:22-23, 25; 69:1, 11-13, 16-18	FRCP 32(a)(6)	
69:2	69:5			
69:8	69:11			
100:22	101:14	101:15-102:4		
102:5	102:17			
102:20	102:24			
103:2	103:3			
103:6	103:7			
103:12	103:13	103:14-21		
106:4	106:14			
108:8	109:4			
158:18	159:1			
159:6	159:24			
160:4	160:5			
160:8	160:10			
160:13	160:18			
160:21	161:1			
167:18	168:3			
168:6	168:9			
168:12	168:15			
168:18	168:18			
173:10	173:16	173:17-23; 174:1-10		
174:20	175:8			
175:11	175:14	175:15, 18-20; 178:10-15, 18-19		178:24-25, 179:1-4, 179:8-10, 179:13-15, 179:18-20, 179:23

**CHRISTOPHER MENGLER – July 31, 2007 Deposition**

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
6:17	6:20			
22:4	22:14			
40:19	40:24			
42:17	42:23			
43:16	43:25			
45:11	45:23			
66:3	66:6			
66:9	66:10	66:11-12, 16-17		
67:22	67:25			
68:10	68:17			
74:12	74:16			
74:19	74:25			
75:2	75:13			
75:17	75:21			
79:14	79:16			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
79:20	79:25			
80:13	80:17			
80:25	80:25			
81:2	81:14	82:5-9, 11-16, 20-22		
84:19	84:23			
84:25	84:25			
85:2	85:4	85:5-6, 9-13		
85:17	85:20			
85:23	85:25			
86:2	86:4	85:5-12		86:13 to 86:14 86:16 to 86:25 87:2 to 87:4 87:7 to 87:7
92:20	92:23			
92:25	92:25			
93:2	93:7			
93:10	93:10			
93:18	93:21			
93:24	93:25			
94:2	94:3			
94:17	94:21			
94:23	94:25			
95:2	95:11			
95:22	95:25			
96:2	96:2			
96:24	96:25			
97:2	97:11			
97:21	97:24			
109:21	109:25			
110:2	110:4			
110:10	110:13			
112:3	112:4			
112:6	112:13			
112:16	112:24			
113:3	113:5			
115:4	115:23			
124:4	124:6			
124:10	124:14			
126:2	126:19			
127:12	127:17			
127:20	127:25			
128:4	128:15	128:16-20, 24-25; 129:2-13		
129:14	129:16			
129:20	129:25			
130:6	130:14			
137:23	137:25			
138:4	138:13			
138:16	138:25			
139:4	139:11			
139:25	139:25			
140:2	140:7			
141:10	141:25			
142:8	142:12			
142:18	142:18			

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
148:3	148:20			
151:24	151:25			
152:2	152:6			
152:10	152:12			
154:20	154:25			
155:2	155:11			
155:14	155:17	155:18-20, 23-25; 156:2-5		
156:6	156:15			
156:19	156:23			
157:3	157:7			
157:10	157:16			
157:20	157:25			
158:2	158:2			
158:6	158:14			
158:18	158:25			
159:2	159:4			
160:12	160:25			
161:2	161:9	161:10-12, 14-23		161:25 to 161:25 162:2 to 162:5 162:8 to 162:13
162:16	162:17			
162:20	162:25			
163:2	163:2			
163:4	163:4			
163:15	163:18			
163:22	163:25			
164:2	164:25			
165:2	165:19			
166:16	166:19			
167:3	167:8			
167:20	167:25			
168:2	168:8			
168:11	168:11			
168:24	168:25			
169:2	169:2			
169:15	169:25			
170:2	170:15			
170:17	170:17			
171:18	171:20			
171:23	171:25			
172:2	172:2			
172:22	172:25			
173:2	173:4			
173:7	173:8			
173:12	173:22			
174:11	174:16			
174:19	174:25			
175:20	175:25			
176:2	176:3			
177:6	177:15			
177:19	177:19			
179:11	179:13			
179:16	179:23			
180:2	180:3			

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
181:7	181:8			
181:13	181:18			
181:23	181:25			
182:2	182:22			
182:25	182:25			
183:2	183:3			
183:6	183:8			
183:12	183:18			
183:21	183:25			
184:2	184:10			
184:13	184:25			
185:2	185:2			
185:6	185:12			
185:25	185:25			
186:2	186:13			
186:17	186:21			
187:3	187:11			
187:17	187:21			
188:2	188:13			
189:18	189:20			
189:22	189:25			
190:2	190:5			
190:8	190:16			
190:19	190:22			
191:3	191:10			
191:13	191:18			
191:21	191:22			

**YOAV REYCHAV – June 18, 2007 Deposition**

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
5:13	5:16			
5:23	6:1			
6:5	6:9			
8:20	9:15			
9:23	10:16			
12:21	13:10			
16:12	16:19			
17:7	18:10			
18:22	19:1			
19:7	19:14			
22:1	22:2			
22:6	22:7			
22:13	22:18			
24:3	24:5			
24:10	24:14			
24:16	24:19			
27:23	27:24			
28:1	29:6			
30:13	30:14			
30:17	30:20			
30:23	30:24			

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
31:1	31:2			
31:4	31:6			
31:8	31:8			
31:18	31:19			
31:22	31:25			
32:3	32:7			
32:10	32:12			
33:12	33:15			
33:18	33:19			
33:21	33:24			
34:23	34:24			
35:2	35:5			
36:4	36:9			
36:15	36:17			
36:19	36:19			
37:24	38:1			
38:7	38:8			
44:5	44:9			
44:18	44:25			
45:21	47:13			
47:17	48:9			
49:8	49:13			
49:15	49:21			
54:24	55:6			
55:10	55:21			
56:6	56:12			
56:25	57:3			
57:6	57:8			
58:21	59:1			
59:4	59:8			
59:11	59:13			
59:21	59:22			
59:25	60:4			
63:11	63:16			
63:19	64:5			
64:22	65:8			
67:5	67:15			
67:17	67:19			
67:23	68:3			
68:25	68:25			
69:3	69:7			
70:17	70:20			
73:12	73:21			
74:3	74:7			
75:1	75:6			
75:9	75:17			
76:4	76:5			
76:8	76:14			
76:17	76:22			
76:25	77:7			
77:10	77:13			
78:13	79:2			
81:13	82:9			
83:8	83:9			
83:12	83:23			

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
87:14	88:6			
88:9	88:12			
88:15	88:17			
88:20	88:23			
89:1	89:2			
93:10	93:11			
93:14	94:11			
94:14	94:22			
94:25	95:5			
95:10	95:12			
95:20	96:4			
96:8	96:10			
96:13	96:13			
97:12	97:16			
97:19	98:8			
98:12	98:17			
100:19	100:22			
101:11	102:18			
102:21	103:14			
107:1	107:14			
108:24	109:3			
109:6	109:6			
109:11	110:1			
110:4	110:4			
112:18	113:1			
113:4	113:5			
113:7	113:7			
113:10	113:13			
113:15	113:20			
114:8	114:9			
114:12	114:12			
115:17	116:12			
116:15	116:15			
118:23	119:15			
119:20	119:20			
119:22	120:6			
121:21	121:23			
122:10	123:2			
123:24	124:2			
124:13	124:18			
124:21	125:18			
126:10	126:15			
127:1	127:13			
129:4	129:7			
129:10	129:14			
129:17	129:21			
129:24	130:1			
137:13	137:19			
139:6	139:7			
139:10	139:17			
139:23	140:11			
140:14	140:15			
140:24	141:4			
141:7	141:12	141:13-14, 17-19, 22-24; 142:2-3	FRE 602	



Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
			141:15 to 141:16 (Objection, beyond the scope of the 30(b)(6), lack of foundation.)  141:20 to 141:21 (Objection, beyond the scope of the 30(b)(6), calls for speculation.)  141:25 to 142:1 (Objection, beyond the scope of the 30(b)(6), calls for speculation.)	
152:1	152:5			
152:10	152:15			
152:17	152:20			
152:22	153:2			
153:13	153:19			
155:4	155:9			
155:12	155:17			
155:20	155:25			
156:3	156:14			
158:18	159:5			
159:8	159:12			
159:15	159:16			
160:7	160:12			
160:20	160:22			
160:25	161:5			
161:8	161:12			
161:15	161:16			
163:20	163:21			
163:24	165:1			
165:4	165:7			
164:10	164:11			
165: 24	166:9			
166:15	166:22			
167:25	168:2			
168:6	168:8			

**NICHOLAS TANTILLO – July 27, 2007 Deposition**

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
7:18	7:22	19:23-21:7		
8:2	8:5			
11:21	11:24			
12:12	12:25			
13:2	13:15			
14:24	14:25			
15:2	15:16			
21:22	21:25			
22:2	22:2			
22:5	22:7			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
22:9	22:15			
22:25	22:25			
23:2	23:2			
23:4	23:6			
23:8	23:10			
23:13	23:20			
23:23	23:25			
24:4	24:5			
24:8	24:10			
46:5	46:25			
47:2	47:25			
48:2	48:9			
48:12	48:17			
48:20	48:21			
48:24	48:25			
49:2	49:2			
49:6	49:7			
50:8	50:19			
50:22	50:25			
51:2	51:3			
51:7	51:13			
51:15	51:16			
51:19	51:25			
52:4	52:5			
52:7	52:14			
52:17	52:21			
52:24	52:25			
53:2	53:8			
53:12	53:14			
53:18	53:20			
53:24	53:25			
54:2	54:21			
55:2	55:7			
56:16	56:18			
56:21	56:24			
57:3	57:3			
57:21	57:25			
58:2	58:3			
58:7	58:11			
58:14	58:18	59:13-15, 20-25; 60:2-15, 20-25	FRCP 32(a)(6)	
61:2	61:3			
61:8	61:11			
61:16	61:19			
66:2	66:22			
67:2	67:5			
67:8	67:11			
67:14	67:16			
67:22	67:25			
68:2	68:8			
68:11	68:25			
69:2	69:5			
69:14	69:18			
69:24	69:25			
70:2	70:10			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
70:16	70:21	70:22, 25; 71:2-7		
71:8	71:10			
71:14	71:19			
71:25	71:25			
72:2	72:3			
72:8	72:13			
72:19	72:19			
96:23	96:25			
98:2	98:8	101:11-13, 16-17, 21-22	FRCP 32(a)(6) FRE 611(b)	
123:12	123:13			
123:17	123:18			
123:22	123:25			
124:5	124:7			
124:11	124:12			
124:14	124:17			
124:21	124:21			
127:21	127:25			
128:2	128:11			
128:15	128:15			

**AMIRA ZEEVI – June 20, 2007 Deposition**

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
6:12	7:10			
7:12	7:13			
12:15	14:9			
14:16	15:13			
16:14	17:8			
17:10	17:11	17:12		
18:8	18:10			
18:13	18:19			
18:22	18:22	22:12-16; 23:5-7; 24:23-25:16; 25:18-26:23	FRE 611(b)	
30:4	30:5			
30:8	30:10			
30:12	30:20	32:1-23	FRCP 32(a)(6) FRE 611(b)	
33:20	33:22			
33:24	34:22			
48:3	48:13			
48:18	48:19			
49:4	49:9			
49:23	50:10			
61:12	61:16			
61:18	61:21			
61:23	61:24			
62:3	62:4			
62:6	62:7			
62:14	63:4			
63:7	63:19			
63:22	63:25			

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
64:3	64:22			
64:25	65:8			
65:11	65:21			
65:25	66:17			
66:20	67:2			
67:5	67:13			
67:15	67:23			
67:25	68:5			
68:7	68:11			
68:14	70:3			
70:9	70:11			
71:3	71:13			
71:16	71:24			
72:1	72:10	72:11-13, 16-20; 72:23-24	FRE 402	
78:25	79:24			
80:1	80:6			
80:17	80:18			
80:20	81:5			
81:7	81:25			
89:4	89:6			
89:8	89:12			
97:6	97:15			
98:15	98:20			
98:23	99:5			
99:14	100:3			
100:6	100:16			
143:1	143:7			
143:11	143:20			
143:23	143:24			
144:1	144:7			
146:13	147:2			
147:5	147:12			
147:14	147:15			
147:17	147:19			
147:21	148:6			
151:15	151:16			
151:19	151:22			
151:25	151:25			
153:5	153:22			
154:4	154:22			

**CHARLES DILIBERTI – July 27, 2007 Deposition**

Designation Start	Designation End	Defendant's Counter-Designations	Plaintiff's Objections to Defendants Counter-Designations	Plaintiffs' Counter-Counter Designations
6:16	6:20	15:22-25; 16:2-25; 17:2-10		
6:24	6:25			
7:2	7:3			
11:24	11:25			
12:2	12:25			
13:2	13:22			

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
18:6	18:7			
18:10	18:14			
18:17	18:21			
19:16	19:17			
19:20	19:23			
20:2	20:9			
20:12	20:16			
20:19	20:21			
23:20	23:24			
24:3	24:8			
24:14	24:17			
24:20	24:25			
25:2	25:18			
26:11	26:25			
27:2	27:5			
27:8	27:11			
27:14	27:19	27:20-21; 27:25; 28:2-6, 10-14	FRE 701	
28:15	28:17			
28:20	28:25			
29:2	29:9			
29:12	29:25			
30:4	30:25			
31:9	31:16			
33:14	33:25			
34:2	34:3			
34:8	34:10			
34:17	34:25			
35:4	35:5			
35:8	35:25			
36:2	36:25			
37:2	37:14			
37:17	37:22			
37:24	37:25			
38:4	38:7			
38:11	38:23			
39:2	39:2			
39:25	39:25			
40:2	40:3			
40:11	40:21			
40:24:	40:25			
41:2	41:19			
42:8	42:10			
42:13	42:19			
42:22	42:25			
43:2	43:18			
43:21	43:25			
44:2	44:7			
44:10	44:17			
45:2	45:4			
46:8	46:25			
47:5	47:11			
53:24	53:25			
54:2	54:2			
54:5	54:7			

<b>Designation Start</b>	<b>Designation End</b>	<b>Defendant's Counter-Designations</b>	<b>Plaintiff's Objections to Defendants Counter-Designations</b>	<b>Plaintiffs' Counter-Counter Designations</b>
54:10	54:14			
54:16	54:17			
54:19	54:25			
55:5	55:12			
55:15	55:21			
55:24	55:25			
56:2	56:6			
56:9	56:16			
56:19	56:22			

**APPENDIX J****Barr Laboratories' Deposition Designations****GREGORY ALCORN**

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
8:20 to 8:22				
9:2 to 9:4				
9:16 to 9:21				
10:3 to 12:2				
12:18 to 12:21				
13:4 to 13:17				
13:24 to 14:5				
14:10 to 14:11				
14:20 to 14:23				
16:2 to 16:17				
17:9 to 17:14				
17:23 to 18:6				
18:19 to 19:2				
19:5 to 19:18				
20:2 to 20:21				
21:2 to 21:7				
22:3 to 22:7				
22:9 to 22:23				
23:6 to 23:8				
23:11 to 24:5				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
24:9 to 24:12				
24:14 to 26:17				
27:6 to 27:9				
27:17 to 28:2				
28:21 to 29:7		28:21 to 29:10	FRE 105, FRE 802	
29:11 to 29:13		29:11 to 29:16	FRE 105, FRE 802	
31:19 to 32:22				
33:21 to 34:14				
34:22 to 35:1				
35:5 to 35:12				
35:17 to 36:12				
36:20 to 37:16				
39:5 to 39:8				
39:19 to 39:23				
40:6 to 40:14		42:1 to 43:12	FRE 105, FRE 802	
46:5 to 46:7	46:8 to 46:9 (Objection to the form of the question: vague.)			
46:16 to 46:16		46:10 to 46:16		
46:18 to 46:24				
47:4 to 47:12				
48:3 to 48:7				
48:23 to 49:7		48:23 to 50:14	FRE 105, FRE 802	



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
			49:11-50:14 Beyond the Scope of the Designation	
50:15 to 50:20				
50:24 to 51:4		50:24 to 51:4;  51:9 to 52:5;  53:16 to 54:15	FRE 105, FRE 802	
52:6 to 52:13	FRE 602	52:6 to 52:19	FRE 105, FRE 802	
52:20 to 53:15				
54:16 to 55:4	FRE 602	54:16 to 55:10	FRE 105, FRE 802	
55:11 to 55:14		55:11 to 55:21	FRE 105, FRE 802  55:15-19 Nonresponsive	
55:22 to 56:8		55:22 to 56:14	FRE 105, FRE 802  56:9-14 Beyond the Scope of the Designation	
57:17 to 58:3				
60:13 to 61:22	FRE 602	61:23 to 62:5;	FRE 105, FRE 802	
62:6 to 62:11	FRE 602	62:13 to 64:10	FRE 105, FRE 802	62:12

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
64:11 to 65:10				
66:10 to 66:16				
66:24 to 67:24				
68:9 to 68:11				
68:14 to 68:17	FRE 106, FRE 802	68:14 to 69:7	FRE 105, FRE 802  68:21-69:7 Nonresponsive and Beyond the Scope of the Designation	
69:9 to 69:14				
70:5 to 71:7	FRE 602, FRE 802	71:8 to 71:9	FRE 105, FRE 802	
Withdrawn	FRE 602	72:5 to 72:5	FRE 105, FRE 802  Beyond the Scope of the Designation.	
72:6 to 73:23	73:24 to 74:1 (Objection to the form of the question: vague)  FRE 802			
74:9 to 74:19	FRE 602			
75:6 to 76:11	FRE 602			
76:16 to 77:6				
77:10 to 78:1	FRE 402	77:10 to 78:16	FRE 105, FRE 802	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
			78:2-5, 7-13 Nonresponsive	
78:17 to 78:17	FRE 402	78:17 to 79:10;  80:16 to 81:2	FRE 105, FRE 802  78:23-79:2 Nonresponsive	
81:3 to 81:10				
81:12 to 82:23				
83:3 to 83:19	FRE 802, FRE 602	83:20 to 84:2	FRE 105, FRE 802	
84:3 to 84:7	FRE 802, FRE 602			
84:12 to 86:18	FRE 602, FRE 802	86:19 to 87:5	FRE 105, FRE 802  86:21-22 Nonresponsive	
87:6 to 87:18				
87:20 to 88:16				
88:20 to 89:8	FRE 802			
89:10 to 89:12		89:13 to 89:16	FRE 105, FRE 802	
89:17 to 90:19	FRE 602	90:21 to 91:6	FRE 105, FRE 802	
91:7 to 92:10	FRE 602, FRE 802			
92:12 to 93:5				
93:19 to 93:22				
93:24 to 94:3				
94:12 to 94:17				
94:19 to 95:17	FRE 602, FRE 802			
95:22 to 96:1	96:2 to 96:3 (Objection to the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	form of the question: asked and answered.)  FRE 602			
96:20 to 97:7	FRE 602	97:9 to 97:18	FRE 105, FRE 802  Beyond the Scope of the Designation	
97:19 to 98:3				
98:12 to 99:1	FRE 602			
99:4 to 99:5		99:6 to 99:7	FRE 105, FRE 802	
99:9 to 100:5				
100:14 to 100:17				
101:7 to 101:14				
102:8 to 103:17	FRE 802, FRE 602			
103:22 to 104:20	FRE 602	104:21 to 106:8	FRE 105, FRE 802  Beyond the Scope of the Designation	
106:9 to 106:19	FRE 602			
107:1 to 109:21	FRE 802	109:24 to 110:9	FRE 105, FRE 802  Beyond the Scope of the Designation	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
111:4 to 111:6				
111:8 to 111:21	FRE 802	111:22 to 111:23	FRE 105, FRE 802	
111:24 to 112:22	FRE 802			
113:12 to 113:21				
113:23 to 115:2	FRE 602	115:1 to 115:4	FRE 105, FRE 802	115:5 to 115:8
115:9 to 115:14				
116:5 to 116:14				
116:20 to 118:13	FRE 802, FRE 602	118:14 to 118:17	FRE 105, FRE 802	
118:18 to 119:3	FRE 602, FRE 802			
120:7 to 120:16				
120:21 to 121:3	FRE 106, FRE 802	120:21 to 121:3;  121:4 to 121:22;  109:24 to 110:9	FRE 105, FRE 802	
122:2 to 122:8	FRE 802			
124:18 to 125:2	FRE 802	125:3 to 125:21  126:9 to 126:17	FRE 105, FRE 802	
125:22 to 126:3				
126:6 to 126:8				
127:9 to 127:12		128:11 to 128:23	FRE 105, FRE 802	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
			Beyond the Scope of the Designation	
128:24 to 129:8				
129:10 to 129:19				
129:23 to 130:16				
130:19 to 131:24				
132:13 to 132:23				
133:2 to 133:3		133:4 to 133:6	FRE 105, FRE 802  Beyond the Scope of the Designation	
133:7 to 133:21		134:2 to 134:4	FRE 105, FRE 802  Beyond the Scope of the Designation	
134:5 to 134:8				
134:10 to 134:12				
134:14 to 134:18				
134:20 to 134:21				
134:23 to 135:4				
135:6 to 135:8				
135:10 to 135:11				
135:15 to 135:21		135:12 to 135:16	FRE 105, FRE 802	
135:23 to 135:24				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
136:4 to 136:5		136:6 to 136:11  136:12 to 137:4	FRE 105, FRE 802  136:12-137:4 Beyond the Scope of the Designation	
137:8 to 137:12				
137:14 to 138:14	FRE 802			
138:22 to 139:2				
139:8 to 139:13	139:14 to 139:15 (Objection to the form of the question: vague.)			
139:16 to 139:19				
139:21 to 140:9				
140:19 to 141:3				
141:6 to 141:8				
141:12 to 141:24	142:1 to 142:2 (Objection to the form of the question: vague.)			
142:4 to 142:6				
142:8 to 143:20	FRE 602			
144:11 to 144:19				
145:22 to 146:5	FRE 602			
147:3 to 147:19				
147:21 to 148:10	FRE 602			
148:16 to 149:6	FRE 602			
149:12 to 150:20	FRE 802			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
150:24 to 151:10	FRE 802, FRE 701			
151:15 to 152:12	FRE 602, FRE 701,	152:13 to 153:13	FRE 105, FRE 802  Nonresponsive and Beyond the Scope of the Designation	
153:18 to 154:9	FRE 602	154:12 to 155:2	FRE 105, FRE 802  Beyond the Scope of the Designation	155:3 to 155:8
159:1 to 159:14	FRE 802			
159:18 to 159:21				
159:23 to 160:3	FRE 602	159:23 to 160:10	FRE 105, FRE 802	
160:11 to 161:12	FRE 602	161:13 to 161:14	FRE 105, FRE 802	
161:15 to 161:18	FRE 602			
165:16 to 166:19	FRE 802			
167:4 to 167:23				
168:4 to 168:16	FRE 602	168:17 to 169:3	FRE 105, FRE 802	
169:4 to 170:2	170:3 to 170:6 (Objection to the form of the question: This is outside the scope of topic 2, as far as to 30(b)(6) in the PET studies.)  FRE 602			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
170:10 to 170:15				
171:2 to 171:3	171:4 to 171:5 (Same objection.) FRE 602			
171:8 to 171:9				
171:11 to 172:7	172:8 to 172:9 (Objection. Calls for speculation.)  FRE 602, FRE 701			
172:10 to 172:13	FRE 602, FRE 701			
172:21 to 173:17	FRE 602	168:17 to 169:3	FRE 105, FRE 802  Beyond the Scope of the Designation	
173:21 to 173:22	FRE 602	173:23 to 174:7	FRE 105, FRE 802	
175:2 to 175:24	FRE 802			
176:2 to 177:19	FRE 602, FRE 802			
178:2 to 179:6	FRE 602, FRE 802			
179:11 to 179:13				
179:16 to 179:22				
180:1 to 181:4	FRE 802	181:3 to 181:5	FRE 105, FRE 802  181:5 Beyond the Scope of	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
			the Designation	
184:14 to 184:15				
184:20 to 184:21				
184:23 to 186:10	FRE 602, FRE 802			
188:20 to 189:21	FRE 602	189:22 to 190:10	FRE 105, FRE 802	
191:23 to 194:17	FRE 602			
195:4 to 195:16				
195:18 to 196:15	FRE 602			
196:19 to 197:3	197:4 to 197:5 (Objection to the form of the question: Outside of the scope of the topic.)  FRE 602			
197:6 to 197:7	FRE 602			
197:9 to 197:13	197:14 to 197:16 (Objection to the form of the question: calls for speculation. Outside the scope.)  FRE 602			
197:17 to 197:20				
199:1 to 199:3	FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	199:4 to 199:5 (Objection to the form of the question: outside the scope.)			
199:9 to 199:10	FRE 602			
199:12 to 200:2	FRE 602			
200:17 to 200:18	200:19 to 200:20 (Objection to the form of the question: outside the scope  200:8 to 200:9 (Objection to the form of the question: outside the scope.)  FRE 602			
200:23 to 200:23	FRE 602			
201:1 to 201:2	201:3 to 201:4 (Objection to the form of the question: outside the scope.)  FRE 602			
201:7 to 201:7	FRE 602			
201:9 to 201:10	201:11 to 201:12 (Objection to the form of the question: outside the scope.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602			
201:15 to 201:15	FRE 602			
202:16 to 202:17				
202:20 to 203:4	FRE 802			
203:14 to 203:16		203:5 to 203:13	FRE 105, FRE 802	
203:21 to 204:6	FRE 802			
205:7 to 205:11		205:12 to 205:15	FRE 105, FRE 802  Beyond the Scope of the Designation	
205:20 to 205:21				
206:9 to 206:18		206:19 to 206:23	FRE 105, FRE 802	
207:13 to 207:16				
207:19 to 208:24	FRE 802	209:1 to 209:8	FRE 105, FRE 802	
210:3 to 210:4				
210:11 to 210:20		210:21 to 211:6	FRE 105, FRE 802	
211:7 to 211:11				
211:18 to 212:1	FRE 802			
212:23 to 213:3		212:2 to 212:22	FRE 105, FRE 802	
213:10 to 213:15				
213:18 to 213:24				
214:21 to 214:22		214:2 to 214:20;	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
		214:21 to 214:24		
215:1 to 215:19				
215:22 to 216:1				
217:24 to 218:8				
218:10 to 219:2		218:22 to 219:4	FRE 105, FRE 802	
219:6 to 219:10				
219:14 to 220:2				
220:5 to 220:16				
222:12 to 223:1	FRE 602			
223:5 to 223:19				
226:3 to 226:3				
226:9 to 226:12				
228:4 to 228:13	FRE 802			
228:21 to 229:7	FRE 802			
229:20 to 230:14	FRE 802			
231:7 to 232:15	FRE 802			
232:17 to 233:4	FRE 802			
233:19 to 233:24				
234:3 to 234:9		234:10 to 234:19	FRE 105, FRE 802  Beyond the Scope of the Designation  234:14-5 Nonresponsive	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
			234:19 Nonresponsive	
234:20 to 235:2	FRE 602			
237:2 to 237:4				
237:12 to 237:15				
237:18 to 238:14	FRE 802			
238:21 to 239:3				
239:13 to 239:18		239:19 to 239:23	FRE 105, FRE 802	239:24 to 240:9
240:20 to 241:2				
241:9 to 241:17				
241:22 to 242:17	FRE 602	244:18 to 244:24	FRE 105, FRE 802  Beyond the Scope of the Designation	
243:2 to 243:4		243:6 to 243:17	FRE 105, FRE 802	
243:18 to 244:5				
244:14 to 244:17				
245:21 to 245:21				
246:3 to 246:4				
246:6 to 246:15				
246:18 to 247:18				
257:9 to 257:10				
257:13 to 258:10	258:12 to 258:13 (Objection to the form of the question: asked and answered.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602			
258:14 to 258:15	FRE 602			
260:12 to 261:14	FRE 802, FRE 602			
261:17 to 262:1	FRE 602, FRE 802			
262:8 to 262:13				
262:20 to 263:4				
263:18 to 263:23				
264:7 to 264:9				
264:11 to 264:12				
264:15 to 264:15				
264:17 to 264:21	FRE 802	265:13 to 265:17	FRE 105, FRE 802  Beyond the Scope of the Designation	
265:18 to 265:20				
265:23 to 266:11				
266:19 to 266:21		266:22 to 267:4	FRE 105, FRE 802	
268:9 to 268:16		268:18 to 268:20	FRE 105, FRE 802  Beyond the Scope of the Designation	
268:21 to 268:23		268:24 to 269:19	FRE 105, FRE 802	
269:20 to 270:12				
270:22 to 271:6		271:7 to 271:10	FRE 105, FRE 802	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
271:11 to 272:13	FRE 802	272:13 to 272:17	FRE 105, FRE 802  272:14-17 Nonresponsive and Beyond the Scope of the Designation	
271:15 to 272:9				
272:18 to 273:2	273:3 to 273:4 (Objection to the form of the question: asked and answered.)			
273:5 to 273:10	FRE 602			
273:12 to 273:23				
274:1 to 274:2				
274:6 to 274:8				
274:10 to 275:1	FRE 602			
275:10 to 275:16				
278:9 to 279:19	FRE 602, FRE 802	275:17 to 276:18	FRE 105, FRE 802  Beyond the Scope of the Designation	
279:21 to 279:22				
279:24 to 279:24				
280:2 to 280:3				
280:5 to 280:6				
280:8 to 280:11				
280:13 to 281:6	FRE 802	281:7 to 281:22	FRE 105, FRE 802	



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
281:23 to 282:2				
282:14 to 282:15				
282:17 to 282:18				
282:20 to 283:4		283:5 to 284:5;  284:9 to 284:10;  284:16 to 285:7	FRE 105, FRE 802	285:14 to 285:19
285:8 to 285:13				
296:8 to 296:9				
296:16 to 296:16				
296:20 to 297:9	FRE 602			
298:1 to 298:20	FRE 602, FRE 802			
299:7 to 300:12	FRE 602			
301:3 to 301:4				
301:6 to 301:7		301:9 to 301:11	FRE 105, FRE 802  Beyond the Scope of the Designation	
301:12 to 302:22	FRE 602, FRE 802			
303:11 to 303:22				
303:24 to 304:1				
304:3 to 304:4	304:9 to 304:13 (This document appears to be outside the scope of topic	304:6 to 304:8	FRE 105, FRE 802  Beyond the Scope of the	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	number 2, and questions related to it will be outside the scope.)  FRE 602, FRE 701		Designation	
304:20 to 305:10	304:9 to 304:13 (This document appears to be outside the scope of topic number 2, and questions related to it will be outside the scope.)  FRE 602			
305:12 to 305:22	304:9 to 304:13 (This document appears to be outside the scope of topic number 2, and questions related to it will be outside the scope.)			
305:24 to 306:1				
306:3 to 306:4				
306:6 to 306:10				
306:14 to 306:17				
308:16 to 308:17				
308:19 to 308:20				
308:22 to 308:24		309:2 to 309:4	FRE 105, FRE 802	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
			Beyond the Scope of the Designation	
309:5 to 310:8				
310:10 to 310:23	FRE 602			
312:2 to 313:1				
313:18 to 314:7				
314:9 to 314:10				
314:12 to 314:13		314:15 to 314:17	FRE 105, FRE 802  Beyond the Scope of the Designation	
314:18 to 315:9				
315:12 to 316:4	FRE 802			
316:11 to 316:21	FRE 802	316:22 to 317:5	FRE 105, FRE 802	317:6 to 317:10
317:11 to 317:11				
317:14 to 318:7	FRE 602, FRE 802			
318:9 to 318:10				
319:9 to 319:10				
319:12 to 319:13				
319:15 to 319:17		319:20 to 319:22	FRE 105, FRE 802  Beyond the Scope of the Designation	
319:23 to 320:1				
320:7 to 320:23	FRE 602			
321:8 to 321:17				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
322:2 to 322:16	FRE 602			
322:18 to 322:22	FRE 802			
322:24 to 322:24				
323:3 to 324:3	FRE 802			
324:5 to 324:7				
324:20 to 324:22	FRE 802			
324:24 to 325:7	FRE 802			
325:10 to 325:16	FRE 802			
325:18 to 325:19				
325:21 to 325:23		326:1 to 326:3	FRE 105, FRE 802  Beyond the Scope of the Designation	
326:4 to 326:12				
326:15 to 327:5	FRE 602, FRE 802	327:6 to 327:8	FRE 105, FRE 802	
327:13 to 327:13				
327:16 to 327:16				
327:24 to 328:12	FRE 802	328:13 to 328:23	FRE 105, FRE 802	
331:16 to 331:17				
331:19 to 331:20				
331:22 to 331:23		332:1 to 332:4	FRE 105, FRE 802  Beyond the Scope of the Designation	
332:5 to 332:13				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
332:21 to 333:17				
334:1 to 334:16				
334:20 to 334:23				
335:13 to 336:3				
336:8 to 338:1	FRE 802	338:2 to 338:17	FRE 105, FRE 802	
338:18 to 339:5	FRE 602, FRE 802			
339:19 to 340:1				
340:7 to 340:17	FRE 602			
346:10 to 346:11				
346:15 to 347:1				
347:3 to 347:14				
347:17 to 347:19	347:20 to 347:21 (Objection to the form of the question: vague.)  FRE 602			
347:22 to 347:23	FRE 602			
348:1 to 348:5				
348:21 to 349:2	349:3 to 349:5 (Objection to the form of the question: outside the scope of topic number 2, and you can answer in your)  FRE 602			
349:7 to 349:8		349:10 to 349:23	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS

**MARC S. BERRIDGE – 8/3/07**

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
6:4 to 7:7				
20:6 to 20:13				
20:16 to 20:19	20:20 to 20:21 (Objection to the form of the question: vague, calls for a legal conclusion)			
21:1 to 21:5	21:6 to 21:6 (Objection to the form of the question: vague)  FRE 602; FRE 802			
21:7 to 21:8	FRE 602; FRE 802			
21:10 to 21:16	21:17 to 21:17 Objection to the form of the question: compound)			
21:18 to 21:19				
21:25 to 22:4				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
23:5 to 23:25				
24:2 to 24:15				
26:14 to 26:15	FRE 402			
26:17 to 26:18	FRE 402			
26:23 to 27:2	FRE 402			
27:12 to 27:14	27:15 to 27:1 (Objection to the form of the question: calls for speculation.)  FRE 402			
27:16 to 27:16	FRE 402			
27:21 to 27:22	FRE 402			
28:5 to 28:16	FRE 402			
28:19 to 29:1	29:2 to 29:2 (Objection to the form of the question: compound)			
29:3 to 29:3				
29:5 to 29:18		29:19 to 29:24		
30:1 to 30:15				
30:24 to 31:6	31:7 to 31:8 (Objection to the form of the question: calls for speculation, asked and answered)  FRE 602	30:16 to 30:22		

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
31:9 to 31:10	FRE 602			
31:12 to 31:15	FRE 602	31:16 to 32:2 32:12 to 32:20	FRE 105, FRE 602, FRE 802	
33:7 to 33:17				
33:21 to 33:24				
34:6 to 34:10				
35:2 to 35:8				
35:16 to 35:17				
35:22 to 36:11	36:12 to 36:12 (Objection to the form of the question: vague)			
36:13 to 36:14		36:16 to 36:18		
38:17 to 38:25		37:12 to 37:18	FRE 105, FRE 802	
40:6 to 40:16				
40:19 to 40:21	40:22 to 40:23 (Objection to the form of the question: vague. The document speaks for itself)			
40:24 to 41:3				
41:5 to 41:7	41:8 to 41:8 (Objection to the form of the question: vague.)			
41:9 to 41:10				
41:12 to 41:14	41:15 to 41:1			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: vague.)			
41:17 to 41:17				
41:21 to 41:23				
41:24-42:1				
42:3-42:11	FRE 602, FRE 802			
42:12 to 43:4				
43:8 to 43:10	43:11 to 43:12 (Objection to the form of the question: calls for speculation, calls for expert testimony.)  FRE 702			
43:13 to 43:15				
43:17 to 43:18	43:19 to 43:20 (Objection to the form of the question: calls for speculation, calls for expert testimony.)  FRE 702			
43:22 to 43:22	43:23 to 43:23 (Objection to the form of the question: calls for speculation, calls for expert testimony.)  FRE 702			
43:24 to 44:2				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
44:15 to 45:13		46:15 to 48:7 49:10 to 49:17	FRE 105, FRE 802 Beyond the Scope of the Designation	
49:21 to 49:21				
50:19 to 50:23	50:24 to 50:24 (Objection to the form of the question: vague.)			
50:25 to 50:25				
51:2 to 51:3				
51:13 to 51:16	51:17 to 51:17 (Objection to the form of the question: vague.)			
51:18 to 51:19				
51:21 to 52:7		52:9 to 52:23		
53:24 to 54:4		54:5 to 54:6		
54:8 to 55:2	55:3 to 55:3 (Objection to the form of the question: vague.)			
55:4 to 55:4				
55:6 to 55:19				
56:4 to 56:11	56:12 to 56:12 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: vague.)			
56:13 to 56:15				
56:17 to 57:8				
57:10 to 58:5				
58:8 to 58:21	58:22 to 58:22 (Objection to the form of the question: calls for speculation.)			
58:23 to 58:23				
60:6 to 60:7				
60:10 to 60:14	60:19 to 60:19 (Objection to the form of the question: vague.)	60:15 to 60:18		
60:23 to 61:13				
61:21 to 62:4				
62:6 to 62:12	FRE 106	62:13 to 62:23		
62:24 to 63:1				
63:3 to 63:7				
63:11 to 63:14				
63:17 to 63:18				
63:22 to 64:3		64:4 to 64:9		
64:10 to 64:17				
67:7 to 67:15		66:18 to 66:25	FRE 105, FRE 802, Beyond the Scope of the Designation	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
67:23 to 68:1				
68:7 to 68:8				
70:24 to 71:4	71:5 to 71:6 (Objection to the form of the question: calls for speculation, calls for expert testimony.)			
71:7 to 71:7				
71:9 to 71:14	71:15 to 71:16 (Objection to the form of the question: vague, calls for speculation.)			
71:17 to 71:18				
74:23 to 75:16	FRE 701			
76:4 to 76:4	76:5 to 76:5 (Objection to the form of the question: calls for speculation.)	75:21 to 76:3		
76:6 to 76:7				
76:9 to 76:10				
76:25 to 77:9	77:10 to 77:10 (Objection to the form of the question: vague.)			
77:11 to 77:13				
78:6 to 78:11		77:15 to 77:24	FRE 105, FRE 802, Beyond the Scope of the Designation	
78:18 to 79:5		79:6 to 79:15	FRE 105, FRE 802	
79:16 to 80:21	80:22 to 80:23			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: calls for expert testimony.)			
80:24 to 80:25				
81:7 to 81:9	FRE 602; FRE 702			
81:14 to 81:23	81:24 to 81:25 (Objection to the form of the question: calls for speculation, calls for expert testimony, incomplete hypothetical.)  FRE 602; FRE 702			
82:1 to 82:7				
83:4 to 83:15		83:16 to 84:2		
84:3 to 85:4		85:5 to 85:20		
85:21 to 85:24				
86:1 to 86:19	86:20 to 86:20 (Objection to the form of the question: calls for speculation.)  FRE 602			
86:21 to 86:22				
86:24 to 87:3	FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
87:19 to 87:22				
88:3 to 88:14	88:15 to 88:15 (Objection to the form of the question: calls for speculation.)			
88:16 to 88:18				
89:12 to 89:16	FRE 402			
89:19 to 90:9	90:10 to 90:10 (Objection to the form of the question: vague.)			
90:11 to 90:12				
90:14 to 90:18	90:19 to 90:19 (Objection to the form of the question: vague.)			
90:20 to 90:21				
90:23 to 91:1				
93:7 to 93:9				
93:11 to 93:24	93:25 to 93:25 (Objection to the form of the question: vague.)			
94:1 to 94:3				
94:14 to 94:21				
95:2 to 95:3	95:4 to 95:4 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: vague.)			
95:5 to 95:5				
95:7 to 95:8				
96:10 to 96:19	96:20 to 96:21 (Objection to the form of the question: vague and compound)			
96:22 to 96:23				
96:25 to 97:3				
97:21 to 97:23				
98:3 to 98:4	98:5 to 98:5 (Objection to the form of the question: vague.)			
98:6 to 98:6				
98:8 to 98:17	98:18 to 98:19 (Objection to the form of the question: compound and vague.)			
98:20 to 98:21				
99:6 to 99:13				
99:21 to 99:23				
101:22 to 101:23				
101:25 to 102:14				
103:10 to 103:18				
103:20 to 104:11				
104:13 to 104:18		104:19 to 104:24		

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
104:25 to 105:17	105:18 to 105:19 (Objection to the form of the question: vague; calls for speculation, calls for expert testimony.)			
105:20 to 106:2				
106:4 to 106:9	106:10 to 106:10 (Objection to the form of the question: vague.)			
106:11 to 106:15				
106:17 to 106:22				
107:5 to 107:15		107:16 to 107:21	FRE 105, FRE 802	
108:2 to 108:10		107:23 to 108:1		
109:25 to 110:1	110:2 to 110:2 (Objection to the form of the question: vague.)	109:6 to 109:24		
110:4 to 110:4	110:5 to 110:6 (Objection to the form of the question: vague, calls for speculation, calls for expert			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	testimony.)			
110:7 to 110:8		112:10 to 113:19	FRE 105, FRE 802, Beyond the Scope of the Designation	
113:21 to 113:22	113:23 to 113:23 (Objection to the form of the question: vague.)			
113:25 to 113:25	114:1 to 114:1 (Objection to the form of the question: vague.)			
114:2 to 114:3				
114:5 to 114:18		114:19 to 114:22		
114:24 to 115:13	115:14 to 115:14 (Objection to the form of the question: vague.)			
115:15 to 115:15				
116:24 to 117:6	117:7 to 117:7 (Objection to the form of the question: vague.)			
117:8 to 117:15				
118:9 to 118:20				
118:25 to 119:8				
119:15 to 119:16		119:10 to 119:11		
119:18 to 119:18				
121:12 to 121:24				
122:12 to 122:14	122:15 to 122:15 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: vague.)			
123:11 to 123:13				
123:19 to 123:22	123:23 to 123:24 (Objection to the form of the question: vague; compound.)			
123:25 to 124:3				
124:5 to 124:6	124:7 to 124:7 (Objection to the form of the question: vague.)			
124:8 to 124:8				
124:10 to 124:16				
125:21 to 125:25				
126:2 to 126:18	126:19 to 126:19 (Objection to the form of the question: vague.)			
126:20 to 126:24	FRE 602			
127:1 to 127:2				
128:24 to 129:7				
129:18 to 129:20		129:22 to 129:22; 129:24 to 130:2	FRE 105, FRE 802	
130:3 to 130:8				
132:9 to 132:24		132:25 to 133:21	FRE 105, FRE 802, Beyond the Scope of the Designation	
133:25 to 134:4		134:16 to 134:24		

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
134:25 to 136:9				
138:22 to 139:1				
139:5 to 140:12	140:13 to 140:13 (Objection to the form of the question: vague.)			
140:14 to 140:15				
140:17 to 140:25				
141:1 to 141:11	141:12 to 141:12 (Objection to the form of the question: vague.)			
141:14 to 141:16	141:17 to 141:18 (Objection to the form of the question: lack of foundation, calls for speculation.)			
141:19 to 141:21				
141:23 to 141:24	141:25 to 142:1 (Objection to the form of the question: lack of foundation, calls for speculation.)			
142:2 to 142:2				
142:4 to 142:5	142:6 to 142:6 (Objection to the form of the question: lack of foundation.)			
142:7 to 142:7				
142:9 to 142:11	142:12 to 142:12 (Objection to the form of the question: calls for speculation.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
142:13 to 142:14				
142:16 to 143:4	143:5 to 143:5 (Objection to the form of the question: vague.)			
143:6 to 143:8				
143:10 to 143:18	143:19 to 143:19 (Objection to the form of the question: vague.)			
143:20 to 143:21				
143:23 to 144:2	144:3 to 144:3 (Objection to the form of the question)			
144:5 to 144:8	144:9 to 144:10 (Objection to the form of the question: calls for speculation, calls for expert testimony.)			
144:11 to 144:12				
144:14 to 144:16		144:17 to 144:19		
144:20 to 144:25	145:1 to 145:1 (Objection to the form of the question: vague.)			
145:2 to 145:4		145:6 to 145:16		
145:18 to 145:25	146:1 to 146:2 (Objection to the form of the question: vague; compound,			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	calls for speculation.)			
146:3 to 146:5				
146:7 to 146:9				
146:25 to 147:25	148:1 to 148:1 (Objection to the form of the question: vague.)			
148:3 to 148:3	148:4 to 148:4 (Objection to the form of the question: compound)			
148:5 to 148:9		148:10 to 148:13		
150:3 to 150:8		148:21 to 150:2		
150:21 to 151:19		151:24 to 152:3 152:14 to 152:24 153:1 to 153:4	FRE 105, FRE 802, Beyond the Scope of the Designation	
153:13 to 153:20		153:21 to 153:24 154:4 to 154:4	FRE 105, FRE 802, Beyond the Scope of the Designation	
154:10 to 154:21		154:22 to 154:24		
156:16 to 156:21				
157:6 to 157:14				
157:25 to 158:1	158:2 to 158:2 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: vague.)			
158:3 to 158:4		158:6 to 158:9	FRE 105, FRE 802, Beyond the Scope of the Designation	
158:11 to 158:14	158:15 to 158:15 (Objection to the form of the question: vague.)			
158:16 to 158:18				
158:20 to 159:11	159:12 to 159:13 (Objection to the form of the question: vague; calls for speculation.)			
159:14 to 159:14				
159:16 to 160:10	160:11 to 160:11 (Objection to the form of the question: asked and answered.)			
160:12 to 160:15		160:17 to 160:22	FRE 105, FRE 802, Beyond the Scope of the Designation	
160:24 to 161:18		161:19 to 162:19	FRE 105, FRE 602, FRE 802, Beyond the Scope of the Designation	
163:2 to 163:19	FRE 701			
164:21 to 165:5				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
165:7 to 165:11	FRE 402	165:12 to 165:16 165:24 to 165:25	FRE 105, FRE 802, Beyond the Scope of the Designation	
166:1 to 166:11	FRE 402			
166:20 to 166:20	166:21 to 166:22 (Objection to the form of the question: calls for expert testimony.)			
166:23 to 166:24				
167:1 to 167:1	167:2 to 167:3 (Objection to the form of the question: calls for expert testimony; calls for speculation)			
167:4 to 167:4				
167:6 to 167:10	167:11 to 167:12 (calls for speculation; expert testimony.)			
167:13 to 167:15				
167:17 to 167:19	167:20 to 167:21 (Objection to the form of the question: vague; compound)			
167:22 to 168:1				
168:3 to 169:3		169:4 to 169:10	FRE 105, FRE 602, FRE 802, Beyond the Scope of the Designation	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
169:12 to 169:24		169:25 to 170:2		
170:3 to 172:8	172:9 to 172:10 (Objection to the form of the question: asked and answered; calls for speculation; expert testimony.)			
172:11 to 172:12				
173:20 to 173:25	174:1 to 174:2 (Objection to the form of the question: calls for speculation; incomplete hypothetical; calls for expert testimony.)	172:14 to 173:18		
174:3 to 174:3				
174:11 to 174:13	174:14 to 174:15 (Objection to the form of the question: calls for speculation and expert testimony.)			
174:16 to 174:17				
174:19 to 174:20	174:21 to 174:22 (Objection to the form of the question: calls for speculation; expert testimony.)			
174:23 to 174:24				
175:1 to 175:1	175:2 to 175:2 (Objection to the form of the			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: asked and answered.)			
175:3 to 175:5				
175:7 to 175:18	175:19 to 175:19 (Objection to the form of the question: vague.)			
175:20 to 175:20				
175:22 to 176:8		176:10 to 176:11		
176:12 to 176:16				
177:17 to 177:19		177:20 to 177:25	FRE 105, FRE 802, Beyond the Scope of the Designation (177:22-25)	
178:5 to 178:8	178:9 to 178:9 (Objection to the form of the question: vague.)			
178:10 to 178:11				
178:13 to 178:19				
178:24 to 178:24	178:25 to 178:25 (Objection to the form of the question: vague.)			
179:1 to 179:17	179:18 to 179:19 (Objection to the form of the question: lack of foundation, calls for speculation.)			
179:20 to 179:21		179:23 to 180:5	FRE 105, FRE 602, FRE 802, Beyond the Scope of the Designation	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
180:13 to 180:19	180:20 to 180:21 (Objection to the form of the question: lack of foundation; calls for speculation.)			
180:22 to 180:24				
181:1 to 181:6	181:7 to 181:7 (Objection to the form of the question: calls for speculation.)			
181:8 to 181:8				
181:10 to 181:16		181:25 to 182:3		
182:5 to 182:6				
183:2 to 183:4				

**MARC S. BERRIDGE – 2/21/08**

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
4:10 to 4:14				
4:18 to 5:10				
5:18 to 5:23				
6:2 to 6:5				
6:14 to 6:14				
6:17 to 7:9				
7:12 to 8:8	8:9 to 8:9 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: vague.)			
8:11 to 8:14	8:15 to 8:15 (Objection to the form of the question: vague.)			
8:18 to 8:19		8:17 to 8:17		
8:21 to 8:22	8:23 to 8:23 (Objection to the form of the question: vague.)			
9:1 to 9:9				
11:10 to 11:17		11:18 to 11:20	FRE 105, FRE 802	
11:21 to 12:2				
12:4 to 12:5	12:6 to 12:6 (Objection to the form of the question: vague.)			
12:8 to 12:8				
12:10 to 12:19		12:20 to 13:14	FRE 105, FRE 802	
13:20 to 13:22	13:23 to 13:23 (Objection to the form of the question: compound.)			
14:5 to 14:17		14:20 to 15:6	FRE 105, FRE 802	
15:7 to 15:8	15:9 to 15:9 (Objection to the form of the question: vague.)			
15:11 to 15:11				
15:13 to 15:14	15:15 to 15:15 (Objection to the form of the question:			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	vague.)			
15:17 to 15:17				
15:19 to 16:12				
18:3 to 18:4				
18:8 to 18:17	18:18 to 18:18 (Objection to the form of the question: vague.)	18:5 to 18:7		
19:4 to 19:9	19:10 to 19:10 (Objection to the form of the question: vague.)	19:1 to 19:3		
19:12 to 19:12				
19:14 to 19:15				
26:4 to 26:5				
26:7 to 26:10				
26:13 to 26:17				
27:17 to 28:4				
28:12 to 28:19		28:20 to 28:23	FRE 105, FRE 802	
29:15 to 30:4				
30:14 to 30:18				
30:22 to 31:2		31:3 to 31:8	FRE 105, FRE 802	
31:9 to 31:23		31:24 to 32:15		
32:17 to 32:20				
37:24 to 38:6		34:17 to 37:23	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
38:19 to 39:1				
39:3 to 39:4				
39:6 to 39:7				
39:15 to 40:9				
42:4 to 42:12				
42:14 to 43:10				
43:16 to 43:17				
43:19 to 44:6		44:7 to 44:11	FRE 105, FRE 802	
44:16 to 44:19	44:20 to 44:20 (Objection to the form of the question: vague.)			
44:22 to 45:13		45:14 to 45:18		
45:19 to 46:7				
46:21 to 46:22	46:18 to 46:19 (Objection to the form of the question: vague; lack of foundation.)	46:12 to 46:19	FRE 105, FRE 802	
46:24 to 47:11		47:12 to 47:18 48:20 to 48:23 49:7 to 49:8 49:10 to 49:12 49:17 to 50:4	FRE 105, FRE 802 Non-Responsive	
53:15 to 53:18		51:14 to 51:16 52:2 to 52:8 52:10 to 52:13	FRE 105, FRE 802 Non-Responsive	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
		52:21 to 53:5 ***** 106:23 to 108:7		
59:20 to 59:23	59:24 to 60:2 (Objection to the form of the question: asked and answered; incomplete hypothetical; vague and lack of foundation.)			
60:9 to 60:13		60:7 to 60:8	FRE 105, FRE 802	
60:21 to 60:23	60:24 to 61:1 (Objection to the form of the question: vague; compound.)			
61:3 to 61:7		61:8 to 61:16		
61:18 to 61:24	62:2 to 62:3 (mischaracterizes the witness's testimony. Asked and answered)	62:1 to 62:1		
62:5 to 62:5				
62:7 to 62:8	62:12 to 62:13 (Objection to the form of the question: asked and answered. Objection to the form of the question: vague; lack of foundation)			
62:15 to 62:16		62:17 to 62:17 62:19 to 62:24	FRE 105, FRE 802, (62:19	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
		63:13 to 63:23	to 62:24, 63:13 to 63:23) Beyond the Scope of the Designation	
64:1 to 64:2	64:3 to 64:3 (Objection to the form of the question: vague.)			
64:5 to 64:6				
64:8 to 64:9	64:10 to 64:11 (Objection to the form of the question: vague; lack of foundation; asked and answered.)			
64:14 to 64:16		64:13 to 64:13		
64:18 to 64:19				
67:18 to 67:23	67:24 to 67:24 (Objection to the form of the question: vague.)			
68:2 to 68:3				
68:5 to 68:5	68:6 to 68:6 (Objection to the form of the question: vague.)			
68:8 to 68:8				
68:10 to 68:19	68:20 to 68:21 (Objection, vague; lack of foundation.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
68:23 to 69:1				
73:1 to 73:3				
73:10 to 73:14		73:15 to 73:16		
73:18 to 74:1	74:2 to 74:4 (Objection to the form of the question: lack of foundation; vague; mischaracterizes the witness's testimony.)			
74:6 to 74:21				
79:7 to 79:15		79:16 to 79:22	FRE 105, FRE 802	
80:9 to 80:22	79:18 to 79:22 (Objection to the form of the question: Are you asking with respect to this 1996 study, which we've already deposed Dr. Berridge on, or are you asking him about in relation to his expert report, which is what this deposition is about?)	80:8 to 80:8		
81:7 to 81:16	81:17 to 81:17 (Objection to the form of the question: vague.)			
81:19 to 81:21		81:23 to 82:6	FRE 105, FRE 802, Beyond the Scope of the Designation	
83:16 to 83:18		83:13 to 83:15		



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
83:21 to 84:11		84:12 to 84:20		
85:9 to 85:9	85:10 to 85:10 (Objection to the form of the question: vague.)			
85:12 to 85:16				
85:18 to 85:19	85:20 to 85:20 (Objection to the form of the question: vague.)  FREFRE 602			
85:22 to 85:24				
86:2 to 86:7	86:8 to 86:8 (Objection to the form of the question: vague.)			
86:10 to 86:12				
86:14 to 87:1		87:2 to 87:4		
87:5 to 87:9				
87:16 to 88:4				
88:15 to 88:22		89:4 to 89:6	FRE 105, FRE 802, Beyond the Scope of the Designation	
89:10 to 89:13				
91:9 to 92:2	92:3 to 92:3 (Objection to the form of the question: vague.)			
92:5 to 92:7				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
93:18 to 94:3				
94:9 to 94:10	94:11 to 94:13 (Objection to the form of the question: asked and answered. Also covered during Dr. Berridge's previous deposition as a fact witness on this same study)			
94:15 to 94:18				
94:20 to 94:22				
96:3 to 96:7				
96:14 to 96:14				
96:16 to 97:14		97:15 to 98:2		
100:12 to 100:15	100:16 to 100:18 (Objection to the form of the question: calls for speculation. Incomplete hypothetical. Beyond the scope of the expert report.)  FREFRE 602; FREFRE 802	98:3 to 98:7 98:17 to 98:19 98:22 to 99:17	FRE 105, FRE 802, (98:17 to 98:19, 98:22 to 99:17) Beyond the Scope of the Designation	
100:20 to 101:1	101:2 to 101:4 (Objection to the form of the question: calls for speculation. Incomplete hypothetical. Beyond the scope of the expert			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	report)  FREFRE 602; FREFRE 802			
101:6 to 101:9		101:10 to 101:13		
101:19 to 101:24		102:1 to 102:7	FRE 105, FRE 802, Beyond the Scope of the Designation	
104:15 to 104:23		102:8 to 104:14	FRE 105, FRE 802, Beyond the Scope of the Designation	
105:1 to 105:13				
108:21 to 109:6				
110:19 to 110:22	110:23 to 110:23 (Objection to the form of the question: vague.)			
111:1 to 111:1				
111:3 to 111:18				
112:14 to 112:14	112:15 to 112:15 (Objection to the form of the question: vague.)			
112:17 to 112:17				
112:19 to 112:22				
113:2 to 113:2				
113:4 to 113:7				
113:9 to 113:9				
113:12 to 113:18				
114:2 to 114:9				
114:12 to 114:17	114:18 to 114:19			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: asked and answered.)			
114:21 to 114:21				
114:23 to 114:24				
115:5 to 115:24	116:1 to 116:2 (Objection to the form of the question: mischaracterizes the document.)			
116:4 to 116:6				
116:8 to 116:13		116:14 to 116:18		
116:19 to 117:5	117:6 to 117:6 (Objection to the form of the question: vague.)			
117:8 to 117:18				
119:17 to 121:9				
121:11 to 121:15	121:16 to 121:16 (Objection to the form of the question: vague.)			
122:3 to 122:8	122:9 to 122:10 (Objection to the form of the question: mischaracterizes the document.)	121:20 to 122:2		
122:12 to 122:12				
122:14 to 122:23		122:24 to 123:16 *****		

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
		125:20 to 126:6	FRE 105, FRE 802	
126:23 to 127:1	127:2 to 127:2 (Objection to the form of the question: argumentative)			
127:7 to 127:13				
128:8 to 128:10				
128:12 to 128:24		129:1 to 129:13	FRE 105, FRE 802, Beyond the Scope of the Designation	
129:15 to 129:20				
134:20 to 134:21	134:22 to 134:22 (Objection to the form of the question)			
134:24 to 135:1				
135:3 to 135:3	135:4 to 135:5 (Objection to the form of the question: mischaracterizes the previous testimony.)			
135:7 to 135:9				
135:11 to 135:13		135:14 to 136:1	FRE 105, FRE 802, Beyond the Scope of the Designation	
137:16 to 137:19	137:20 to 137:21 (Objection to the form of the question: calls for speculation.)			
137:23 to 138:2				
138:4 to 138:7		138:8 to 138:9		

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
138:15 to 138:16	138:17 to 138:18 (Objection to the form of the question: calls for speculation.)			
138:20 to 138:21				
138:23 to 138:23	138:24 to 138:24 (Objection to the form of the question: calls for speculation.)			
139:2 to 139:4				
139:6 to 139:15	139:16 to 139:17 (Objection to the form of the question: calls for speculation.)			
139:19 to 139:21				
139:23 to 139:23	139:24 to 139:24 (Objection to the form of the question: vague.)			
140:2 to 140:2				
140:4 to 140:13	140:14 to 140:15 (Objection to the form of the question: mischaracterizes the previous testimony.)			
140:17 to 140:18				
140:20 to 140:23		141:11 to 141:20	FRE 105, FRE 802, Beyond the Scope of the Designation	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
143:15 to 143:18	143:19 to 143:20 (Objection to the form of the question: vague; compound; asked and answered.)	143:5 to 143:12		
143:22 to 143:23				
144:1 to 144:3	144:4 to 144:5 (Objection, vague; asked and answered; compound.)			
144:7 to 144:15				
144:17 to 144:20	144:21 to 144:22 (Objection to the form of the question: asked and answered; vague.)			
144:24 to 145:4		145:17 to 146:5		145:6-12
146:7 to 146:8	146:9 to 146:9 (Objection to the form of the question: asked and answered.)			
146:11 to 146:12				
146:18 to 147:3		146:17 to 146:17 147:4 to 147:14 147:20 to 148:3	FRE 105, FRE 802	
148:4 to 148:8	148:9 to 148:9 (Objection to the form of the question: vague.)			
148:11 to 148:13				
148:15 to 148:22	148:23 to 148:23			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: vague.)			
149:1 to 149:2				
149:4 to 149:11		149:12 to 149:21	FRE 105, FRE 802	
149:23 to 150:14				
151:12 to 151:16		151:17 to 151:24		
152:1 to 152:6		152:7 to 152:13		
152:14 to 152:16				
154:2 to 154:23		153:7 to 154:1		
155:2 to 155:8		155:9 to 155:14		
155:15 to 156:3		156:4 to 156:19	FRE 105, FRE 802, Beyond the Scope of the Designation	
157:8 to 157:8	157:9 to 157:10 (Objection to the form of the question: asked and answered.)			
157:12 to 157:18				
157:24 to 158:5		157:20 to 157:23	FRE 105, FRE 802, Beyond the Scope of the Designation	
158:7 to 159:9				



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
159:19 to 159:20	159:21 to 159:22 (Objection to the form of the question: asked and answered.)			
159:24 to 159:24				
160:2 to 160:12	160:13 to 160:15 (Objection to the form of the question: asked and answered. Just because he isn't giving you the answer you want, does not mean it's an incorrect answer. )			
160:17 to 160:18				
160:20 to 161:10	161:11 to 161:11 (Objection to the form of the question: vague.)  161:15 to 161:15 (Objection to the form of the question: vague.)			
161:17 to 161:20				
161:22 to 161:23	161:24 to 161:24 (Objection to the form of the question: vague.)			
162:2 to 162:3				
162:5 to 162:6	162:7 to 162:7 (Objection to the form of the question: vague.)			
162:9 to 162:21	163:8 to 163:8	162:22 to 163:4		

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: vague.)			
163:6 to 163:7	163:8 to 163:8 (Objection to the form of the question: vague.)			
163:10 to 163:11				
163:13 to 164:4	164:5 to 164:7 (Objection to the form of the question: calls for speculation; outside the scope of the expert testimony.)			
164:9 to 164:11				
164:13 to 165:1		165:2 to 165:3		
165:8 to 165:10	165:11 to 165:12 (mischaracterizes the witness's previous testimony)			
165:14 to 165:16				
166:14-22				
168:9 to 168:11		168:12 to 168:15		
168:16 to 168:17		168:18 to 171:2	FRE 105, FRE 802, Beyond the Scope of the Designation (168:23-171:2)	
171:13 to 171:14	171:15 to 171:15 (Objection to the form of the question: vague.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
171:18 to 171:23		172:1 to 172:13	FRE 105, FRE 802, Nonresponsive	
172:15 to 172:17		172:18 to 172:21	FRE 105, FRE 802	
172:22 to 173:2		173:3 to 173:12	FRE 105, FRE 802	
179:5 to 180:4		175:22 to 176:6 176:13 to 176:19 176:21 to 177:1 177:4 to 177:15 ***** 180:15 to 181:1	FRE 105, FRE 802, (176:13 to 176:19, 176:21 to 177:1, 177:4 to 177:15, 180:15 to 181:1) Beyond the Scope of the Designation	177:16-178:11
181:2 to 181:7				
182:15 to 182:15				
182:21 to 184:1				
184:10 to 184:15	184:16 to 184:17 (Objection to the form of the question: asked and answered.)			
184:19 to 184:24				
185:2 to 185:8	185:9 to 185:10 (Objection to the form of the question: asked and answered.)			
185:17 to 185:18		185:12 to 185:16		

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
185:20 to 185:21				
189:13 to 190:6				
194:7 to 194:14				
195:4 to 195:6				
195:8 to 195:21				
196:12 to 196:23		197:1 to 197:4		197:5-7
197:7 to 197:19				
197:21 to 197:22				
197:24 to 198:17				
198:21 to 198:22		198:23 to 199:4	FRE 105, FRE 802, Beyond the Scope of the Designation	
199:20 to 200:5				
203:9 to 204:3	204:4 to 204:4 (Objection to the form of the question: vague.)	202:21 to 203:8	FRE 105, FRE 802	
209:17 to 209:24		207:23 to 209:16	FRE 105, FRE 802	
210:1-14				
211:11 to 211:12				
212:3 to 212:20		212:21 to 212:23 213:1 to 213:2		
213:3 to 213:12				
213:15 to 215:15	FRE 802	215:16 to 216:19	FRE 105, FRE 802, Beyond the Scope of the Designation	
216:20 to 217:14	217:15 to 217:19 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: vague. Objection to the form of the question: calls for expert testimony outside of the scope of his report. He is not here as a viscosity expert. He is relying upon the report of another expert.)  FRE702			
217:21 to 218:1				
218:20 to 218:22	218:23 to 218:24 (Objection to the form of the question: mischaracterizes the previous testimony.)			
219:2 to 219:17				
220:21 to 222:2				
222:9 to 222:11	222:12 to 222:14 (Objection to the form of the question: he is not here as an FDA expert. Outside the scope of his expert testimony.) FRE702			
222:16 to 222:20	FRE702			
222:22 to 222:24	FRE702			
223:14 to 223:19	FRE702			
223:21 to 223:22	FRE702			
224:1 to 224:8	224:9 to 224:12			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: calls for speculation. He is not an expert on FDA regulations for this product. Clearly outside of the scope of his expert testimony.)  FRE702			
224:14 to 224:14				
224:16 to 224:18				
224:20 to 224:21				
226:9 to 227:3		227:4 to 227:4		
227:5 to 227:8		227:9 to 227:10		
227:11 to 227:23				
228:6 to 228:7				
228:9 to 228:19				
228:24 to 229:4				
231:4 to 231:8	231:9 to 231:10 (Objection to the form of the question: lack of foundation)			
231:12 to 231:12		231:14 to 232:21	FRE 105, FRE 802, Beyond the Scope of the Designation	
238:5 to 238:8	238:9 to 238:10 (Objection to the form of the question: vague. Objection,	234:9 to 236:4	FRE 105, FRE 802, Beyond the Scope of the Designation	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	calls for speculation.)			
238:12 to 238:13				
238:15 to 238:18	238:19 to 238:20 (Objection to the form of the question: calls for speculation.)			
238:22 to 239:3		239:5 to 240:1 240:3 to 240:7 240:16 to 240:21 242:10 to 242:20	FRE 105, FRE 802, Beyond the Scope of the Designation	
255:3 to 255:5		247:24 to 248:1 248:6 to 248:8 248:12 to 248:14 249:1 to 249:2 251:11 to 251:17 251:23 to 252:4 252:15 to 253:13 254:1 to 254:24	FRE 105, FRE 802 (except 248:6-8), Beyond the Scope of the Designation	
255:8 to 255:10		255:11 to 255:14		
255:21 to 256:6				
256:8 to 256:9		256:14 to 256:18	FRE 105, FRE 802, Beyond the Scope of the Designation	
256:19 to 256:20		256:21 to 256:22		
256:23 to 256:24	257:1 to 257:1 (Objection to the form of the question: vague.)			
257:3 to 257:8				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
257:10 to 257:16				
257:18 to 257:19		257:24 to 258:2	FRE 105, FRE 802, Beyond the Scope of the Designation	
258:3 to 258:5		258:6 to 258:21 259:10 to 259:10 259:13 to 259:24 260:3 to 260:5	FRE 105, FRE 802, (259:10 to 259:10, 259:13 to 259:24, 260:3 to 260:5) Beyond the Scope of the Designation	260:6-11

**GEORGE GEORGES**

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
8:25 to 9:2				
9:16 to 10:10				
11:17 to 11:21	FRE 402			
12:2 to 12:12	FRE 402			
14:18 to 14:22	FRE 402	14:23 to 15:14	FRE 105, FRE 802  Beyond the Scope of the Designation	
15:19 to 16:14	FRE 402			
18:8 to 18:12				
20:12 to 20:24	FRE 402			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
21:9 to 21:13	FRE 102, FRE 602	21:14 to 21:18	FRE 105, FRE 802	
21:19 to 23:11	FRE 602			
26:18 to 27:3	27:4 to 27:5 (Objection to the form of the question.)  FRE 402			
27:6 to 27:20	27:21 to 27:22 (Objection to the form of the question: vague.)  FRE 402			
27:23 to 28:1	28:2 to 28:3 (Objection to the form of the question.)  FRE 402, FRE 602, FRE 802			
28:4 to 28:7	28:8 to 28:9 (Objection to the form of the question.)  FRE 402, FRE 602, FRE 802	163:11 to 163:13 163:16 to 163:24 164:2 to 164:2 164:4 to 164:11	FRE 105, FRE 802	
28:10 to 28:15	28:16 to 28:19 (I just want to make sure that you understand that these are not 30(b)(6) questions; that			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	he's answering in his personal capacity.)  FRE 402			
28:22 to 29:1	FRE 402			
30:8 to 30:11	30:12 to 30:14 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602, FRE 802			
30:15 to 30:19	30:20 to 30:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602, FRE 701, FRE 802			
30:23 to 31:3	31:4 to 31:6 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 402, FRE 602, FRE 701, FRE 802			
31:7 to 31:14	31:15 to 31:17 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 402, FRE 602, FRE 802			
31:18 to 31:19	31:20 to 31:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602, FRE 701, FRE 802			
31:23 to 32:16	FRE 402, FRE 602, FRE 701, FRE 802			
32:18 to 32:20	FRE 802			
33:7 to 33:20	FRE 802			
33:22 to 33:23	33:24 to 33:25 (Objection to the form of the question: vague.)  FRE 802			
34:4 to 34:11	FRE 802			
35:15 to 35:17	FRE 402	36:6 to 36:9 37:24 to 38:2 38:20 to 39:3	FRE 105, FRE 802  Beyond the Scope of the Designation	
39:23 to 39:24	FRE 802			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
41:10 to 42:14	42:15 to 42:17 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
42:18 to 43:2	43:3 to 43:5 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602, FRE 802			
43:10 to 43:12	FRE 402, FRE 602, FRE 802			
43:14 to 44:3	44:4 to 44:6 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602, FRE 802			
44:7 to 45:1	FRE 106, FRE 402, FRE 802	45:2 to 45:7	FRE 105, FRE 802	
45:8 to 45:8 45:10 to 45:12	45:13 to 45:15 (Objection to the form of the question: lack of foundation and vague.)  FRE 402, FRE 802			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
45:16 to 45:21	FRE 402, FRE 802	45:22 to 46:7	FRE 105, FRE 802, FRE 602	
47:11 to 47:13	47:14 to 47:16 (Objection to the form of the question. Compound and mischaracterizes the testimony.)  FRE 802			
47:17 to 47:18	FRE 802			
47:21 to 48:9	47:14 to 47:16 (Objection to the form of the question: compound and mischaracterizes the testimony.)  FRE 802			
48:13 to 48:14	FRE 802			
53:16 to 53:16	53:17 to 53:19 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
53:20 to 54:6	FRE 402, FRE 602			
54:11 to 54:14				
54:20 to 54:24	55:1 to 55:3			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: It's beyond the scope of the 30(b)(6) Notice.)  FRE 602			
55:4 to 55:10	55:11 to 55:13 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and lack of foundation.)  FRE 602, FRE 802			
55:14 to 55:19	FRE 602, FRE 802			
56:12 to 56:13	56:14 to 56:17 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and calls for expert testimony.)  FRE 402, FRE 602, FRE 701, FRE 802			
56:18 to 56:21	FRE 402, FRE 602, FRE 701, FRE 802			
59:12 to 59:13	59:14 to 59:16 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402, FRE 602			
59:17 to 59:23	59:24 to 60:2 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 402, FRE 602, FRE 701			
60:3 to 60:3	FRE 402, FRE 602, FRE 701			
60:19 to 60:22	60:23 to 61:1 (Objection to the form of the question. Beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 402, FRE 602, FRE 701			
61:2 to 61:6	FRE 402, FRE 602, FRE 701	61:7 to 61:14 61:19 to 61:20	FRE 105, FRE 802, FRE 602  Beyond the Scope of the Designation	
66:21 to 67:4	67:5 to 67:7 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402, FRE 602			
67:11 to 67:13	FRE 402, FRE 602	70:4 to 70:6 70:11 to 70:17	FRE 105, FRE 802, FRE 602  Beyond the Scope of the Designation	
80:7 to 80:9				
80:15 to 80:20				
81:4 to 81:11	FRE 802			
81:24 to 82:1	82:2 to 82:3 (Objection to the form of the question: vague.)  FRE 802, Form			
82:4 to 82:15	FRE 802			
85:19 to 85:21	FRE 802	82:16 to 82:17 82:20 to 83:6 83:11 to 85:18	FRE 105, FRE 802	
86:23 to 87:1	87:2 to 87:4 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.) FRE 602, FRE 802			
87:5 to 87:6	FRE 602, FRE 802			
88:12 to 88:14	FRE 602, FRE 802			
89:5 to 89:7	89:8 to 89:10			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
89:11 to 89:18	FRE 402, FRE 602, FRE 802			
90:1 to 90:11	FRE 402, FRE 802	90:12 to 90:24	FRE 105, FRE 802	
91:5 to 91:8	91:9 to 91:11 (Objection to the form of the question: lack of foundation. Beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
91:12 to 91:14	FRE 402, FRE 602			
98:1 to 98:11	FRE 602, FRE 802	87:20 to 88:3 88:7 to 88:14	FRE 105, FRE 802	
98:14 to 98:17	FRE 402, FRE 802			
98:22 to 99:13 99:15 to 99:15	99:16 to 99:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 802			
99:19 to 99:24	99:25 to 100:2 (objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602			
100:3 to 100:12	100:13 to 100:15 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602			
100:16 to 100:24	100:25 to 101:1 (Objection to the form of the question.)  FRE 402, FRE 602			
101:8 to 101:10	101:11 to 101:12 (Objection to the form of the question: vague.)  FRE 402			
101:13 to 101:18	101:19 to 101:20 (Objection to the form of the question: vague.)  FRE 402			
101:21 to 102:1	102:2 to 102:4 (Objection to the form of the question: beyond the scope of			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	the 30(b)(6) Notice.)  FRE 402, FRE 602			
102:5 to 103:16	103:17 to 103:19 (Objection to the form of the question. Beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 802			
103:20 to 103:20	FRE 402, FRE 602			
107:24 to 108:1				
108:5 to 108:12	FRE 802			
108:20 to 108:23	108:24 to 109:1 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
109:2 to 109:7	109:8 to 109:10 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
109:11 to 110:1	110:2 to 110:4 (Objection to the form of the question. Mischaracterizes the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	testimony.)  FRE 602, FRE 802			
110:5 to 110:6	FRE 802			
112:3 to 112:5	112:6 to 112:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
112:9 to 112:10	FRE 402, FRE 602			
112:23 to 112:24				
113:1 to 113:2				
113:4 to 113:12	113:15 to 113:17 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 402, FRE 602, FRE 802			
113:20 to 113:23	113:24 to 114:1 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 802			
114:2 to 114:5	FRE 402, FRE 602, FRE 802			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
115:25 to 116:4	116:5 to 116:7 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
116:8 to 116:8	FRE 402, FRE 602			
116:19 to 117:5	FRE 402, FRE 602			
117:24 to 119:4	119:5 to 119:6 (Objection to the form of the question.)  FRE 402, FRE 802			
119:7 to 119:12	119:13 to 119:14 (Objection to the form of the question. Calls for speculation.)  FRE 402, FRE 602			
119:15 to 119:20 119:23 to 119:24	119:25 to 120:3 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 402, FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
120:4 to 120:6	FRE 402, FRE 602			
121:14 to 121:16	FRE 402, FRE 602  121:17 to 121:20 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony. Asked and answered.)			
121:21 to 121:23	121:24 to 122:1 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 402, FRE 602			
122:2 to 122:6	122:7 to 122:9 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
122:10 to 122:13	122:14 to 122:16 (Objection to the form of the question. Beyond the scope of the 30(b)(6) Notice.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402, FRE 602			
122:17 to 122:25	123:1 to 123:3 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
123:4 to 123:13	123:14 to 123:16 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
123:17 to 123:20	123:21 to 123:23 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602			
123:24 to 124:2	124:3 to 124:5 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602			
124:6 to 126:8	FRE 402, FRE 602, FRE 802			
128:4 to 128:5				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
128:10 to 129:1	129:2 to 129:4 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
129:5 to 129:10	FRE 602	129:11 to 129:13 129:17 to 129:19		
129:20 to 129:22	129:23 to 129:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
130:1 to 130:5	130:6 to 130:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
130:9 to 130:13	FRE 802			
130:17 to 131:24	FRE 802			
133:2 to 133:5	133:6 to 133:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602			
133:9 to 133:13	133:14 to 133:16 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
133:23 to 134:1	134:2 to 134:5 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 402, FRE 602, FRE 802			
134:6 to 134:8	FRE 402, FRE 602			
134:21 to 135:2	FRE 402, FRE 802			
135:4 to 135:5 135:7 to 135:12	FRE 402, FRE 802			
135:14 to 135:15	135:16 to 135:17 (Objection to the form of the question: vague.)  FRE 402			
135:18 to 135:25	136:1 to 136:3 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
136:4 to 136:5	136:6 to 136:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice and vague.)  FRE 402, FRE 602			
136:9 to 136:12	136:13 to 136:15 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
136:16 to 136:19	136:20 to 136:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 802			
136:23 to 137:2	137:3 to 137:5 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 802			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
137:6 to 137:18	137:19 to 137:21 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 402, FRE 602, FRE 802			
137:22 to 137:24	FRE 402, FRE 602			
138:10 to 138:15	FRE 402, FRE 802	158:7 to 160:22	FRE 105, FRE 802  Beyond the Scope of the Designation	
138:17 to 138:19	138:20 to 138:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 802			
138:23 to 139:3	FRE 402, FRE 602, FRE 802			
139:22 to 140:8	140:9 to 140:11 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 802			
140:12 to 140:18	FRE 402, FRE 602			
141:18 to 141:21	141:22 to 141:23			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: compound.)  FRE 402, FRE 802			
141:24 to 142:6	142:7 to 142:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 802			
142:9 to 142:12	FRE 402, FRE 602, FRE 802			
142:14 to 142:15	FRE 402, FRE 602, FRE 802			
142:17 to 142:18	FRE 402, FRE 602, FRE 802			
143:15 to 143:23	143:24 to 144:1 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 802			
144:2 to 145:11	145:12 to 145:14 (Objection to the form of the question: mischaracterizes the document.)  FRE 402, FRE 602, FRE 802			
145:15 to 145:19	FRE 402, FRE 602, FRE 802			
145:23 to 146:1	146:2 to 146:3			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: mischaracterizes the document.  FRE 802			
146:4 to 146:10	146:11 to 146:12 (Objection to the form of the question: mischaracterizes the document.)  FRE 802			
146:13 to 147:5	147:6 to 147:7 ((Objection to the form of the question: mischaracterizes the document.)  FRE 802			
147:8 to 148:3	FRE 402, FRE 802			
148:11 to 148:14	148:15 to 148:16 (Objection to the form of the question: mischaracterizes the testimony.)  FRE 802			
148:17 to 148:23	148:24 to 148:25 (Objection to the form of the question: mischaracterizes the testimony.)	149:1 to 149:3		

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	106, FRE 802			
150:22 to 150:24	150:25 to 150:25 (Objection to the form of the question: vague.)			
151:1 to 151:9	151:10 to 151:11 (Objection to the form of the question: vague.)  151:13 to 151:14 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602,			
151:12 to 151:12 151:15 to 153:7	153:8 to 153:10 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
153:11 to 153:11	FRE 602			
153:16 to 153:17	153:18 to 153:20 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)	153:12 to 153:17		

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602			
153:21 to 153:21 153:23 to 154:8	154:9 to 154:11 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802	154:12 to 154:12		
154:20 to 154:20				
155:1 to 155:14	155:15 to 155:17 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
155:18 to 155:19	FRE 602			
165:18 to 166:1	FRE 402	164:21 to 165:17		
166:11 to 167:19	FRE 402, FRE 602			
168:2 to 168:2 168:4 to 168:7	FRE 402, FRE 602			
168:9 to 168:10				
168:14 to 168:18	FRE 602			
168:21 to 170:8	FRE 402, FRE 602, FRE 802			
170:13 to 170:15	FRE 402			
170:18 to 171:11	FRE 402, FRE 602,			
171:17 to 171:24	FRE 402, FRE 602			
172:8 to 173:10	FRE 402, FRE 602, FRE 802	174:23 to 174:25	FRE 105, FRE 802	177:4-7

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
		175:3 to 175:6 <hr/> 176:4 to 176:8 176:11 to 176:19 176:22 to 177:3	Beyond the Scope of the Designation	
178:3 to 178:4				
178:9 to 178:19	FRE 402			
178:22 to 179:5	FRE 402			
179:8 to 180:2	180:3 to 180:4 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 802			
180:5 to 180:15	FRE 602, FRE 802			
180:18 to 181:2	181:3 to 181:4 (Objection to the form of the question: lack of foundation.)  FRE 402, FRE 802			
181:5 to 182:8	182:9 to 182:10 (Objection to the form of the question: calls for speculation.)  FRE 402, FRE 602			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
182:11 to 182:13	FRE 602	182:14 to 182:15 182:18 to 183:1	FRE 105, FRE 802	
183:2 to 183:19	FRE 402, FRE 802			
184:6 to 184:9	184:10 to 184:11 (Objection to the form of the question: calls for expert testimony.)  FRE 602, FRE 701			
184:12 to 184:16	FRE 602, FRE 701			
184:25 to 184:25				
185:5 to 185:23	FRE 402, FRE 802			
187:20 to 188:23	188:24 to 188:25 (Objection to the form of the question: calls for speculation.)  FRE 402, FRE 602, FRE 802			
189:1 to 189:6	FRE 402, FRE 602			
189:23 to 189:24				
190:3 to 191:1	191:2 to 191:3 (Objection to the form of the question: lack of foundation.)  FRE 402, FRE 602, FRE 802			
191:4 to 191:10	191:11 to 191:12 (Objection to the form of the	191:13 to 191:19	FRE 105, FRE 802 Nonresponsive	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: calls for speculation.)  FRE 402, FRE 602			
191:20 to 192:3	FRE 402, FRE 602			
196:21 to 196:22		197:3 to 197:7	FRE 105, FRE 802 Beyond the Scope of the Designation	
206:15 to 206:19	206:20 to 206:21 (Objection to the form of the question: lack of foundation.)  FRE 402, FRE 602	201:14 to 202:7  202:14 to 205:19  205:20 to 206:22	FRE 105, FRE 802  Beyond the Scope of the Designation	
206:22 to 207:4	FRE 402, FRE 602			
207:10 to 208:5	208:6 to 208:7 (Objection for the form of the question: lack of foundation.)  FRE 602, FRE 802			
208:8 to 209:14	209:15 to 209:16 (Objection to the form of the question: misstates the testimony.)  FRE 602, FRE 802			
209:17 to 209:22	209:23 to 209:24 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: calls for expert testimony.)  FRE 602, FRE 701			
209:25 to 210:1	FRE 602, FRE 701			
213:7 to 213:7				
213:13 to 214:2	FRE 602, FRE 802  214:3 to 214:4 (Objection to the form of the question: lack of foundation and vague.)			
214:5 to 214:7	214:8 to 214:9 (Objection to the form of the question: lack of foundation.)  FRE 602			
214:10 to 214:22	214:23 to 214:24 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 802			
214:25 to 216:8	FRE 602, FRE 802			
217:2 to 217:3				
217:10 to 217:15				
217:19 to 218:7	FRE 602, FRE 802			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
218:9 to 219:6	219:7 to 219:9 (Objection to the form of the question: lack of foundation and calls for expert testimony.)  FRE 602, FRE 701, FRE 802			
219:10 to 219:22	219:23 to 219:24 (Objection to the form of the question: lack of foundation. Calls for expert testimony.)  FRE 602, FRE 701			
219:25 to 220:15	FRE 602, FRE 701			
220:22 to 221:6	221:7 to 221:8 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 802			
221:9 to 221:20	221:21 to 221:22 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 802			
221:23 to 222:10	FRE 602, FRE 802			
222:14 to 224:5	224:6 to 224:7 (Objection to the form of the question: lack of foundation.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	Calls for expert testimony.)  FRE 602, FRE 701, FRE 802			
224:8 to 224:14	FRE 602, FRE 701			
224:16 to 224:19	224:20 to 224:21 (Objection to the form of the question: lack of foundation. Calls for expert testimony.)  FRE 602, FRE 701			
224:22 to 224:22	FRE 602, FRE 701			
225:4 to 225:12	FRE 802, FRE 701			
225:15 to 225:16	225:17 to 225:18 (Objection to the form of the question: lack of foundation.)  FRE 602			
225:19 to 226:16	FRE 602, FRE 802			
227:7 to 227:10	227:11 to 227:12 (Objection to the form of the question: lack of foundation.)  FRE 602			
227:13 to 227:13	FRE 602	227:14 to 227:18	FRE 105, FRE 802	
227:22 to 228:23	228:24 to 228:25 (Objection to the form of the question: lack of foundation.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602, FRE 802			
229:1 to 229:2	FRE 602			
229:4 to 229:6	FRE 602			
229:15 to 229:21	229:22 to 229:23 (Objection to the form of the question: lack of foundation.)  FRE 602			
229:24 to 230:4	230:5 to 230:6 (Objection to the form of the question: lack of foundation.)  FRE 602			
230:7 to 230:9				
230:11 to 230:14	230:15 to 230:16 (Objection to the form of the question: lack of foundation.)  FRE 602			
230:17 to 230:23	230:24 to 230:25 (Objection to the form of the question: lack of foundation.)  FRE 602			
231:1 to 231:1	FRE 602			
231:16 to 233:22	233:23 to 233:25			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: calls for expert testimony.)  FRE 602, FRE 701, FRE 802			
234:1 to 234:2	FRE 602, FRE 701	234:1 to 234:6	FRE 105, FRE 802	
234:7 to 234:12	FRE 802	234:11 to 234:16	FRE 105, FRE 802	
234:24 to 235:11	235:12 to 235:13 (Objection to the form of the question: lack of foundation.)  FRE 106, FRE 602, FRE 802			
235:14 to 235:17 235:19 to 235:20	FRE 602			
236:5 to 236:6	236:7 to 236:8 (Objection to the form of the question: lack of foundation. Compound.)  FRE 402, FRE 602			
236:9 to 236:14	236:15 to 236:16 (Objection to the form of the question: lack of foundation.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402, FRE 602			
236:17 to 236:20	FRE 402, FRE 602			
236:22 to 237:1	FRE 402, FRE 602			
237:5 to 237:12	FRE 802			
237:14 to 238:6	FRE 802			
238:10 to 239:1	239:2 to 239:3 (Objection to the form of the question: lack of foundation.)  FRE 802			
239:4 to 240:2	FRE 802			
240:18 to 240:24	240:25 to 241:1 (Objection to the form of the question: lack of foundation.)  FRE 602			
241:2 to 242:6	FRE 402, FRE 602			
242:11 to 243:21	FRE 602, FRE 802			
244:4 to 244:7	244:10 to 244:11 (I was going to object as misrepresenting the document.)  FRE 602, FRE 802			
244:12 to 244:12	FRE 602, FRE 802			
245:16 to 245:18	245:19 to 245:20 (Objection to the form of the question: lack of foundation.)	245:2 to 245:5 245:8 to 245:13	FRE 105, FRE 802	



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602			
245:21 to 246:1	246:2 to 246:3 (Objection to the form of the question: lack of foundation.)  FRE 602			
246:9 to 246:15	FRE 602			
246:20 to 247:16	FRE 602, FRE 802			
247:24 to 248:1	248:2 to 248:3 (Objection to the form of the question: lack of foundation.)  FRE 602			
248:4 to 248:5	248:6 to 248:7 (Objection to the form of the question: calls for speculation.)  FRE 602			
248:8 to 248:12	FRE 602			
248:18 to 249:9	249:10 to 249:11 (Objection to the form of the question: lack of foundation.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602, FRE 802			
249:12 to 250:5	250:6 to 250:7 (Objection to the form of the question: calls for speculation.)  FRE 602			
250:8 to 250:18	250:19 to 250:20 (Objection to the form of the question: lack of foundation and vague.)  FRE 602, FRE 802			
250:21 to 251:15	251:16 to 251:17 (Objection to the form of the question: asked and answered.)  FRE 602, FRE 802			
251:18 to 252:19	FRE 602, FRE 802			
252:24 to 253:1 253:3 to 253:4	253:5 to 253:6 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 802			
253:7 to 253:12	253:13 to 253:14 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: lack of foundation. Calls for expert testimony.)  FRE 602, FRE 701, FRE 802			
253:15 to 254:4	FRE 602, FRE 701			
254:12 to 254:13	254:14 to 254:15 (Objection to the form of the question: lack of foundation. Calls for expert testimony.)  FRE 602, FRE 701			
254:16 to 254:24	254:25 to 255:1 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 701			
255:2 to 255:6	255:7 to 255:8 (Objection to the form of the question: lack of foundation.)  FRE 602			
255:9 to 255:9	FRE 602			
255:22 to 255:23				
256:4 to 256:7				
256:14 to 256:23	256:24 to 256:25 (Objection. Lack of foundation.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	106, FRE 602, FRE 802, FRE 701, Form			
257:1 to 257:10	FRE 602, FRE 802			
258:9 to 259:5	259:6 to 259:7 (Objection to the form of the question: Lack of foundation.)  FRE 602, FRE 802			
259:8 to 259:16	FRE 602, FRE 802			
259:23 to 260:10	260:11 to 260:12 (Objection to the form of the question: lack of foundation.)  FRE 402, FRE 602, FRE 802			
260:13 to 260:18	260:19 to 260:21 (Objection to the form of the question: lack of foundation. Calls for speculation. Calls for expert testimony.)  FRE 402, FRE 602, FRE 701			
260:22 to 261:6	FRE 402, FRE 602, FRE 701			
261:10 to 261:10				
261:17 to 261:25	262:1 to 262:3 (Objection to the form of the question: calls for speculation;			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	calls for expert testimony.)  FRE 402, FRE 602, FRE 701			
262:4 to 262:16	262:17 to 262:19 (Objection to the form of the question: calls for speculation. Misrepresents the testimony. Calls for expert opinion.)  FRE 402, FRE 602, FRE 701, FRE 802			
262:20 to 262:21	FRE 602, FRE 701			
263:8 to 263:11	263:12 to 263:14 (Objection to the form of the question: calls for speculation. Calls for expert testimony.)  FRE 106, FRE 602, FRE 701			
263:15 to 264:15	264:16 to 264:17 (Objection to the form of the question: calls for speculation; calls for expert testimony.)  FRE 602, FRE 701, FRE 802			
264:18 to 266:11	266:12 to 266:13 (Objection to the form of the question: lack of foundation.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602, FRE 701, FRE 802			
266:14 to 266:16	266:17 to 266:18 (Objection to the form of the question: lack of foundation; calls for expert testimony.)  FRE 602, FRE 701			
266:19 to 266:20	FRE 602, FRE 701			
266:24 to 267:1				
267:8 to 268:18	FRE 602, FRE 802			
268:20 to 268:21				
268:25 to 269:16	269:17 to 269:18 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 802			
269:19 to 270:11	270:12 to 270:13 (Objection to the form of the question: lack of foundation.)  FRE 602			
270:14 to 270:19	FRE 602,			
270:25 to 271:12	271:13 to 271:13 (Objection to the form of the question: vague.)  FRE 602, FRE 802			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
271:14 to 273:17	273:18 to 273:19 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 701, FRE 802			
273:20 to 273:22	273:23 to 273:24 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 701			
273:25 to 274:3	274:4 to 274:5 (Objection to the form of the question: lack of foundation. Calls for expert testimony.)  FRE 602, FRE 701			
274:6 to 274:19	274:20 to 274:21 (Objection to the form of the question: lack of foundation. Mischaracterizes the --)  FRE 602, FRE 701			
274:22 to 275:18	275:19 to 275:20 (Objection to the form of the question: lack of foundation. Calls for expert testimony.)  FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
275:21 to 276:1	276:2 to 276:3 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 701			
276:4 to 276:15	276:16 to 276:17 (Objection to the form of the question: lack of foundation.)  FRE 602			
276:19 to 276:20 276:23 to 277:7	276:21 to 276:22 (Objection to the form of the question: lack of foundation.)  277:8 to 277:9 (Objection to the form of the question: lack of foundation.)  FRE 602			
277:10 to 277:18	FRE 602			
278:19 to 278:24	278:25 to 279:1 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 701	278:9 to 278:18	FRE 105, FRE 802	
279:2 to 279:8	279:9 to 279:9 (Objection to the form of the question.)			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE 701			
279:10 to 279:18	FRE 602, FRE 701			

**DONALD HEALD**

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
8:19-8:24				
9:3-10:6				
16:2-16:8		14:4-14:18 15:6-15:11 16:2-16:8	FRE 105, FRE 802	
16:9-16:15	FRE 402			
16:16-17:19		16:16-18:12	FRE 105, FRE 802	
17:21-18:12		16:16-18:12	FRE 105, FRE 802	
18:13-19:7	FRE 402			
19:8-20:1		19:8-20:1	FRE 105, FRE 802	
20:1-20:7	20:8-20:9 (Objection to the form of the question: vague).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402			
20:10-21:14		20:10-21:14	FRE 105, FRE 802	
21:16-21:19	21:20-21:21 (Objection to the form of the question: compound).	21:16-21:19	FRE 105, FRE 802	
21:22-21:22		21:22-21:22	FRE 105, FRE 802	
21:24-22:2		21:24-22:2	FRE 105, FRE 802	
22:3-22:7	22:8-22:9 (Objection to the form of the question: vague; compound).  FRE 402			
22:10-22:16		22:10-22:16 22:18-22:20	FRE 105, FRE 802	
22:22-23:8				
26:2-26:3				
26:10-26:13				
26:14-27:14		26:14-27:14	FRE 105, FRE 802	
27:15-27:21				
28:16-28:22				
29:12-29:24				
31:16-31:17				
32:1-32:2				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
32:4-32:16				
32:20-32:21				
32:22-33:1		32:22-33:1	FRE 105, FRE 802	
33:14-34:1		33:14-34:1	FRE 105, FRE 802	
34:3-34:16	34:17-34:18 (Objection to the form of the question: vague).	34:3-34:16	FRE 105, FRE 802	
34:19-35:4		34:19-35:4	FRE 105, FRE 802	
35:6-35:8	35:9-35:10 (Objection to the form of the question: vague).  FRE 402			
35:11-35:18				
35:22-35:24	36:1-36:2 (Objection to the form of the question: vague).  FRE 402	35:20-35:21	FRE 105, FRE 802	
36:3-36:8		36:3-36:8	FRE 105, FRE 802	
37:1-37:2	37:3-37:4 (Objection to the form of the	36:10-36:15 37:1-37:2	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: vague).		(36:10-15) Beyond the Scope of the Designation	
37:5-37:9		37:5-37:9	FRE 105, FRE 802	
37:11-37:20				
37:20-37:24		37:20-37:24	FRE 105, FRE 802	
37:25-38:6				
38:17-38:18				
38:24-39:2				
39:14-39:19				
40:7-40:22	40:23-40:24 (Objection to the form of the question: vague).			
41:3-41:4				
41:10-41:16				
42:24-43:2	43:3-43:4 (Objection to the form of the question: vague).			
43:5-43:5				
43:7-43:11	43:13-43:14 (Objection to the form of the question: calls for speculation).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602			
43:15-43:16				
44:12-44:23	FRE 602			
45:3-45:10				
45:11-45:24		45:11-45:24	FRE 105, FRE 802	
45:24-46:1	46:2-46:3 (Objection to the form of the question: vague).			
46:4-46:6				
46:9-46:14		46:9-46:14	FRE 105, FRE 802	
47:7-47:8				
47:11-48:16				
48:18-49:2				
49:12-49:19		49:12-49:19	FRE 105, FRE 802	
49:20-50:1				
50:9-50:13				
50:15-50:23				
51:2-51:3				
51:12-51:13				
51:15-51:16	FRE 602			
51:19-52:7	FRE 602			
52:8-52:20		52:8-52:20	FRE 105, FRE 802	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
52:21-54:16	54:17-54:18 (Objection to the form of the question: vague).  FRE 602, FRE 701			
54:19-54:22				
54:24-55:20	FRE 602, FRE 701			
56:2-57:2				
57:4-57:14				
57:15-57:22		57:15-57:22	FRE 105, FRE 802	
57:23-58:2	58:4-58:4 (Objection to the form of the question.)  FRE 602			
58:5-58:8				
58:10-59:16	FRE 701			
59:17-59:20	59:22-59:23 (Objection to the form of the question: vague).	59:17-59:20	FRE 105, FRE 802	
59:24-60:12		59:24-60:12	FRE 105, FRE 802	
60:14-60:17	60:18-60:19 (Objection to the form of the question: vague).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE 701			
60:20-60:22				
60:24-61:2	FRE 602			
61:3-61:5	61:7-61:7 (Objection to the form of the question: vague).	61:3-61:5	FRE 105, FRE 802	
61:9-61:16		61:9-61:16	FRE 105, FRE 802	
61:17-63:15	FRE 602, FRE 701			
63:18-64:2	FRE 701			
64:4-64:5	64:6-64:7 (Objection to the form of the question: vague).  FRE 701			
64:8-64:18	FRE 701			
64:20-65:3	65:4-65:5 (Objection to the form of the question: vague).			
65:6-65:15				
65:17-65:22				
67:5-67:13		67:5-67:13	FRE 105, FRE 802	
67:13-68:16	68:17-68:18 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: compound).  FRE 602, FRE 701			
68:19-68:20				
68:23-70:3	FRE 701			
70:12-71:3				
71:18-73:7				
73:23-74:13	74:14-74:15 (Objection to the form of the question: vague).  FRE 602, FRE 701			
74:16-75:4				
75:6-75:10	75:11-75:12 (Objection to the form of the question: vague).  FRE 602, FRE 701			
75:13-75:20				
75:22-76:2	76:3-76:4 (Objection to the form of the question: vague).			
76:5-76:7				
76:9-76:23	76:24-77:1 (Objection to the form of the question: Vague. THE			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	WITNESS: I don't know).  FRE 602, FRE 701			
77:2-77:2				
77:4-77:6				
77:8-77:9	FRE 602, FRE 701			
77:14-77:19				
77:21-78:12	FRE 602, FRE 701			
78:14-78:14				
78:16-78:16				
78:18-78:21	78:22-78:23 (Objection to the form of the question: vague).			
78:24-79:1				
79:4-79:23	80:1-80:2 (Objection to the form of the question: vague. Lack of foundation). FRE 602, FRE 701			
80:3-80:4				
80:6-80:11	FRE 602, FRE 701			
80:13-80:24				
81:4-81:7	81:8-81:10 (Objection to the form of the question: vague; lack of foundation).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE 701			
81:19-81:23				
82:3-82:4	82:5-82:6 (Objection to the form of the question: vague).  FRE 701			
82:7-82:12				
82:14-82:19	82:20-82:21 (Objection to the form of the question: compound).  FRE 701			
82:22-83:2				
83:4-83:11	FRE 701			
83:15-83:21	83:22-83:23 (Objection to the form of the question: vague).  FRE 701			
83:24-83:24				
84:2-84:15	FRE 701			
84:19-85:13	FRE 701			
85:15-86:9	FRE 701			
86:19-88:8	FRE 602, FRE 701			
89:7-91:13	FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
91:15-91:16				
91:19-91:23				
92:1-92:17				
92:23-93:5	93:7-93:8 (Objection to the form of the question: vague).  FRE 701			
93:9-93:14				
93:16-95:3	95:4-95:5 (Objection to the form of the question: vague).  FRE 701			
95:6-95:9				
95:11-96:2				
96:4-96:16				
96:20-97:5	97:6-97:13  (Objection to the form of the question: Calls for a legal conclusion. He's not here to testify as a prosecuting attorney (sic) or -- You can -- you can answer it on an individual basis, if you know, but this isn't within the scope			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	of the 30(b)(6) topic.  98:13-98:15 (Objection to the form of the question: It calls for a legal conclusion).  FRE 701			
98:16-98:17				
98:19-98:20	98:21-98:22 (Objection to the form of the question: calls for a legal conclusion).  FRE 701			
98:23-98:24				
99:2-99:3	99:4-99:5 (Objection. Calls for a legal conclusion).  FRE 602, FRE 701			
99:6-99:8				
99:10-99:13	99:14-99:15 (Objection to the form of the question: calls for a legal conclusion).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE 701			
99:16-100:1				
100:10-100:18				
100:23-100:24				
101:1-101:9				
101:11-101:15				
101:17-101:24	<p>102:1-102:5 (Objection to the form of the question: Calls for a legal conclusion. Outside of the scope of the -- which he's been -- of which he's presented as a corporate witness).</p> <p>FRE 602, FRE 701</p>			
102:6-102:11				
102:13-102:22	<p>102:23-103:1 (Objection: calls for a legal conclusion. Outside the scope. THE WITNESS: It's similar).</p> <p>FRE 602, FRE 701</p>			
103:2-103:5				
103:8-103:9	<p>103:10-103:11 (Objection. Calls for a legal conclusion).</p>			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
103:12-103:13				
103:15-103:16				
103:19-104:4	104:5-104:9 (Objection. Calls for a legal conclusion. Outside the scope of which this witness is being offered as a corporate witness).  FRE 602, FRE 701			
104:10-104:11				
104:13-104:19	104:21-104:21 (Objection).			
104:22-104:24	105:1-105:3 (Objection. Calls for a legal conclusion. Outside the scope).			
105:4-105:5				
105:7-105:16	105:17-105:19 (Objection to the form of the question: Calls for a legal conclusion. Outside the scope).  FRE 602, FRE 701			
105:20-105:21				
105:23-105:24				
106:3-106:11	106:12-106:14			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: Calls for a legal conclusion. Outside the scope).  FRE 602, FRE 701			
106:15-106:16				
106:19-107:3	107:4-107:6 (Objection to the form of the question: Calls for a legal conclusion. Outside the scope).  FRE 602, FRE 701			
107:7-107:8				
107:10-107:18	107:19-107:21 (Objection to the form of the question: Calls for a legal conclusion. Outside the scope).  FRE 602, FRE 701			
107:22-107:23				
108:2-108:3				
108:10-109:16	109:17-109:18 (Objection. Vague).  FRE 602			
109:19-109:19				
109:21-110:2	110:4-110:6			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: Mischaracterizes his previous testimony).			
110:7-110:12				
110:14-111:6	FRE 602			
111:8-112:19				
112:21-112:22				
113:7-113:14	FRE 602, FRE 701			
113:16-113:16				
114:1-114:4	114:5-114:6 (Objection to the form of the question: Vague).  FRE 602, FRE 701			
114:7-114:8				
114:10-114:11				
114:13-114:18	114:19-114:20 (Objection. Vague).  FRE 602, FRE 701			
114:21-114:21				
114:23-115:10	115:11-115:13 (Objection to the form of the question: Mischaracterizes his testimony. Objection. Vague).			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE 701			
115:14-115:17				
115:19-115:20	115:21-115:22 (Objection. Vague).  FRE 602			
115:23-116:2				
116:4-116:10	116:11-116:12 (Objection to the form of the question: Mischaracterizes his testimony).  FRE 602			
116:13-116:19				
117:4-117:19	117:20-117:21 (Objection. Mischaracterizes his testimony).  FRE 602			
117:22-118:7				
118:11-118:14	FRE 402			
120:1-120:6	FRE 402			
120:8-120:17				
120:20-120:21				
120:23-122:4	122:5-122:6 (Objection to the form of the question: vague).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
122:7-122:8				
122:10-122:16	122:17-122:18 (Objection: vague).  FRE 402			
122:19-122:24	123:1-123:2 (Objection to the form of the question: vague).  FRE 402			
123:5-123:6	FRE 402			
123:9-123:14	123:15-123:16 (Objection to the form of the question: vague).  FRE 402, 701			
124:7-124:9	124:10-124:11 (Objection to the form of the question: vague).  FRE 402, 701			
124:12-124:13				
124:15-124:18	124:19-124:20 (Objection to the form of the question: Vague).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402, 701			
124:21-124:21				
124:23-125:7	125:8-125:9 (Objection to the form of the question: vague).  FRE 402, 701			
125:10-125:13				
125:15-125:18	FRE 402, 701			
125:19-125:22	125:23-125:24 (Objection to the form of the question: to the form of the question: vague).	125:19-125:22	FRE 105, FRE 802	
126:1-126:14		126:1-126:14	FRE 105, FRE 802	
126:16-127:5	127:7-127:9 (Objection to the form of the question: Mischaracterizes his testimony and vague).			
127:10-127:13				
127:15-127:17	127:18-127:19 (Objection to the form of the question: vague).			
127:20-127:21				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
127:23-128:9				
129:3-129:6	129:7-129:10 (Objection to the form of the question: Mischaracterizes the previous testimony. Objection. Lack of foundation).	129:3-129:6	FRE 105, FRE 802	
129:11-130:6		129:11-130:6	FRE 105, FRE 802	
130:8-130:18		130:8-130:18	FRE 105, FRE 802	
130:20-131:4		130:20-131:4	FRE 105, FRE 802	
131:5-131:7	131:8-131:9 (Objection: calls for speculation).			
131:10-131:12				
131:14-131:15	131:16-131:17 (Objection to the form of the question: calls for speculation).			
131:18-131:23				
132:1-132:3				
132:10-132:12				
132:15-132:22				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
133:6-133:8				
133:18-134:19				
134:22-135:3	135:4-135:5 (Objection to the form of the question: calls for speculation).  FRE 602, 802, 805			
135:6-135:7				
135:9-135:12	135:14-135:15 (Objection to the form of the question: vague. What time frame?).	135:9-135:12	FRE 105, FRE 802	
135:16-135:17		135:16-135:17	FRE 105, FRE 802	
135:19-135:22		135:19-135:22	FRE 105, FRE 802	
136:1-136:11	FRE 602, 802, 805			
138:17-139:2	FRE 602, 802, 805			
139:5-139:12	139:13-139:14 (Objection to the form of the question: calls for speculation).  FRE 602, 802, 805			
139:15-139:17				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
139:19-140:8	140:9-140:10 (Objection to the form of the question: vague).  FRE 402			
140:11-140:15				
140:19-141:17		140:19-141:17	FRE 105, FRE 802	
141:19-141:23	141:24-142:1 (Objection to the form of the question: vague. THE WITNESS: If a method is).			
142:2-142:6				
148:19-149:1				
149:1-149:4		149:1-149:4	FRE 105, FRE 802	
149:5-149:13	FRE 602, 701			
149:15-151:4		149:14-149:14 149:15-151:4	FRE 105, FRE 802	
151:5-151:9	151:10-151:12 (Objection to the form of the question: vague; lack of foundation).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 701			
151:13-152:1				
152:11-154:6				
154:9-154:23	154:24-155:1 (Objection to the form of the question: asked and answered. THE WITNESS: I don't know).  FRE 602			
155:2-155:2				
155:4-155:11				
155:15-156:14				
156:24-157:5				
157:8-157:8				
157:13-157:14				
157:22-158:4				
158:6-159:5	159:6-159:8 (Objection to the form of the question: vague. The first volunteer in the patent?).  FRE 602			
159:9-159:19				
159:22-161:1				
161:2-161:5	161:6-161:7 (Objection to the form of the	161:2-161:5	FRE 105, FRE 802	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: vague).			
161:8-161:19		161:8-161:19	FRE 105, FRE 802	
161:22-163:1	163:2-163:3 (Objection to the form of the question: vague).  FRE 602, 701			
163:4-163:12	FRE 602, 701			
163:14-163:24				
164:2-165:22	FRE 602, 701			
165:24-167:4	FRE 602			
167:6-167:7				
167:9-167:10				
167:12-167:24				
168:2-168:11				
168:12-168:15	168:16-168:17 (Objection to the form of the question: lack of foundation).	168:12-168:15	FRE 105, FRE 802	
169:3-169:17		169:3-169:17	FRE 105, FRE 802	
169:17-169:17				
169:24-170:3		169:18-169:23 169:24-170:3	FRE 105, FRE 802	



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
170:4-173:14	173:15-173:16 (Objection to the form of the question: vague).  FRE 701			
173:17-173:18				
173:20-174:7				
174:9-174:17	174:18-174:19 (Objection to the form of the question: Form).			
174:20-175:1				
175:3-175:8	175:9-175:10 (Objection to the form of the question: vague).			
175:11-175:11				
175:13-176:10	176:11-176:12 (Objection to the form of the question: vague).			
176:13-176:18				
177:5-177:24				
178:2-178:5	178:6-178:8 (Objection to the form of the question: lack of foundation; vague).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 701			
178:9-178:11				
178:13-178:16				
178:17-178:19		178:17-178:19	FRE 105, FRE 802	
178:20-179:3	FRE 602			
179:4-180:14		179:4-180:14	FRE 105, FRE 802	
180:15-180:19				
181:3-182:13	182:14-182:15 (Objection to the form of the question: vague).  FRE 602			
182:16-182:17				
182:19-183:15	FRE 402			
183:16-183:17		183:16-183:17	FRE 105, FRE 802	
183:18-183:18				
183:19-184:17		183:19-184:17	FRE 105, FRE 802	
185:15-186:12				
186:15-189:15	189:16-189:16 (Objection).  FRE 402			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
190:17-190:19				
190:21-192:3				
192:8-192:10	192:11-192:12 (Objection to the form of the question: vague).			
192:13-192:17				
193:2-193:7				
194:13-195:1				
195:4-195:8				
195:15-197:19	197:21-197:21 (Objection).  FRE 402			
197:22-198:3				
198:6-198:8				
198:13-199:4	199:5-199:6 (Objection to the form of the question: vague).			
199:8-199:15				
199:18-200:2				
200:3-200:13	200:14-200:15 (Objection to the form of the question: vague; compound).	200:3-200:13	FRE 105, FRE 802	
200:18-200:23		200:18-200:23	FRE 105, FRE 802	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
200:24-200:25				
201:1-201:10		201:1-201:10	FRE 105, FRE 802	
201:11-201:12				
201:14-201:21				
201:22-202:1		201:22-202:1	FRE 105, FRE 802	
202:2-202:6	202:7-202:8 (Objection to the form of the question: vague).			
202:9-202:12				
202:14-203:19	FRE 602			
204:9-204:10				
204:16-204:21				
205:8-209:10	FRE 402			
209:18-209:21				
209:24-210:7	FRE 402			
210:8-210:22		210:8-210:22	FRE 105, FRE 802	
210:23-211:24	212:1-212:2 (Objection to the form of the question: vague).			
212:3-212:3				
212:14-212:16				
212:23-213:2				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
213:4-213:14	FRE 602			
213:19-213:20	213:21-213:24 (Objection to the form of the question: lack of foundation. You haven't established yet that he's seen this document).			
214:4-214:5				
214:8-214:11				
214:13-214:16				
215:6-215:17				
216:19-216:23				
217:9-218:13				
219:24-220:3	220:4-220:7 (Objection: first, no foundation. You didn't establish that he's seen the document before).			
220:9-221:1	221:2-221:3 (Objection to the form of the question: vague).  FRE 602			
221:4-221:6				
221:9-221:10	221:11-221:12 (Objection to the form of the question: speculation).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
221:13-221:13				
221:15-221:18	221:19-221:24 (Objection: lack of foundation. We already established earlier that he had not seen this data prior to this deposition. It calls for speculation).			
222:7-222:14	222:15-222:16 (Objection to the form of the question: calls for speculation).  FRE 602			
222:17-222:19				
222:21-222:23	222:24-223:2 (Objection: calls for speculation. He hasn't seen the document before. THE WITNESS: Hmm. I'm not).  FRE 602			
223:3-223:8				
223:14-223:15				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
238:16-238:19	238:20-238:21 (Objection to the form of the question: asked and answered).  FRE 602			
238:22-238:22				
239:1-239:4				
239:6-239:7				
239:9-239:11	239:12-239:13 (Objection to the form of the question: vague).			
239:14-239:16				
239:18-240:7	240:9-240:10 (Objection to the form of the question: vague).			
240:11-240:18				
240:21-241:18	241:19-241:20 (Objection to the form of the question: vague).  FRE 602			
241:21-241:21				
241:23-242:6	FRE 602, 701			
242:9-242:9				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
242:12-242:18				
243:23-244:3				
244:6-244:22	FRE 701			
246:4-246:14	246:15-246:17 (Objection to the form of the question: vague; lack of foundation).  FRE 701			
246:18-247:1				
247:3-248:12	FRE 701			
249:11-249:15	248:20-249:5 (Objection. This is a little beyond the -- the PET testing itself, it's more about the mechanics of the spray bottle. So, I mean, he can testify to the best of his knowledge as an individual, but it's really beyond the scope of the two topics he is designated under the 30(b)(6).  FRE 701	248:16-248:19	FRE 105, FRE 802	
249:23-250:10				
251:19-251:19				
251:20-252:3		251:20-252:3	FRE 105, FRE 802	



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
252:3-252:3	252:4-252:5 (Objection to the form of the question: vague).			
252:6-252:23		252:6-252:23	FRE 105, FRE 802	
252:24-253:6		253:8-253:11	FRE 105, FRE 802	
253:12-253:17	FRE 602, FRE 701			
253:22-253:24				
254:2-254:3	254:5-254:8 (Objection to the form of the question: vague. You can answer as an individual, to the best of your knowledge).  FRE 602, FRE 701			
254:9-254:13				
254:15-254:19		254:15-254:19	FRE 105, FRE 802	
254:22-255:22		254:22-255:22	FRE 105, FRE 802	
255:24-256:14		255:24-256:14	FRE 105, FRE 802	
256:16-256:17	256:18-256:19 (Objection to the form of the question: vague).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
256:20-256:21				
256:23-257:4	257:5-257:6 (Objection to the form of the question: vague).			
257:7-257:7				
257:16-258:1	258:2-258:3 (Objection to the form of the question: vague).			
258:4-258:5				
258:8-258:10				
258:14-259:9	259:13-259:13 (Objection to the form of the question: vague).			
259:14-259:15				
259:17-259:22				
260:3-260:7				
261:21-262:12		263:21-263:23 264:11-264:21	FRE 105, FRE 802 Beyond the Scope of the Designation	
265:21-265:23				
266:1-266:15	266:16-266:17 (Objection to the form of the question: vague).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
266:18-266:20				
266:22-266:24				
267:8-267:11		267:12-267:14	FRE 105, FRE 802 (267:8-267:11)	
267:15-267:16				
267:16-267:16	267:17-267:17 (Objection).	267:16-267:16	FRE 105, FRE 802	
267:18-267:19	267:20-267:21 (Objection to the form of the question: compound).			
267:22-267:23				
268:1-268:6				
268:8-268:9				
268:11-268:12				
268:15-269:7	269:8-269:9 (Objection to the form of the question: vague).			
269:10-269:13				
269:15-270:5	270:6-270:7 (Objection. Vague). FRE 602			
270:8-270:10				
270:22-271:3	271:4-271:10			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: Vague. The witness mentioned earlier that it looked like there were several tests. So could you break it down as to which portion of the presentation you're referring to?).  FRE 602			
271:13-271:24	272:1-272:2 (Objection to the form of the question: vague).  FRE 602			
272:3-272:5	272:6-272:7 (Objection to the form of the question: vague).			
272:8-272:15				
272:18-275:9				
278:3-278:19	FRE 602, FRE701			
278:21-278:24				
279:4-281:23	FRE 602, FRE701			
283:12-283:13				
283:15-283:24	284:1-284:2 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: vague). FRE701			
284:3-284:22				
284:24-285:3				
285:8-285:22	FRE 602, FRE701			
286:1-286:7	FRE 602, FRE701			
286:8-286:21		286:8-286:21	FRE 105, FRE 802	
286:22-288:3	288:4-288:5 (Objection to the form of the question: vague). FRE 602, FRE 701			
288:6-288:20				
289:5-289:13	FRE 602			
289:17-290:1	FRE 602			
291:4-292:18	FRE 602			
292:18-293:1	293:2-293:4 (Objection to the form of the question: vague; calls for speculation).	292:18-293:1	FRE 105, FRE 802	
293:5-293:14		293:5-293:14	FRE 105, FRE 802	
293:16-293:20	293:21-293:23 (Objection to the form of the question: vague; Calls for speculation).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE701			
293:24-294:17				
294:19-294:23	294:24-295:1 (Objection: calls for speculation. THE WITNESS: I think from).  FRE 602, FRE701			
295:2-295:18				
295:20-296:11	FRE701			
296:21-297:1				
297:4-297:15	297:16-297:17 (Objection: vague).			
297:18-297:19				
297:21-299:3	299:4-299:5 (Objection: vague).			
299:6-299:10				
299:12-300:6				
301:17-301:23				
302:2-303:6	303:7-303:8 (Objection: vague).  FRE 402			
303:9-303:21				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
303:23-305:2	FRE 602			
305:9-305:24	FRE 602			
306:3-306:15	306:16-306:17 (Objection to the form of the question: calls for speculation).  FRE 602			
306:23-307:4				
307:7-307:13	307:14-307:15 (Objection to the form of the question: calls for speculation).  FRE 602			
307:23-308:1				
308:4-308:17				
308:19-309:8	FRE 602			
309:11-310:15	310:16-310:17 (Objection to the form of the question: vague).  FRE 402			
310:18-310:19				
310:22-310:23	310:24-311:1 (Objection: vague. Outside the scope. THE WITNESS: I -- I believe).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402			
311:2-311:3				
311:5-312:2	312:3-312:4 (Objection to the form of the question: calls for speculation).  FRE 402			
312:5-312:6				
312:9-312:10				
313:1-313:11	FRE 402			
313:18-313:22	FRE 402			
314:1-314:4	FRE 402			
314:6-315:3	315:4-315:5 (Objection to the form of the question: vague). FRE 402			
315:6-315:6	FRE 402			
315:8-316:11	FRE 402			
316:19-316:23	FRE 402			
317:2-317:9	FRE 402			
317:13-317:16	FRE 402			
317:18-318:8	FRE 402			
318:11-318:22	318:23-318:24 (Objection to the form of the question: foundation).			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402			
319:1-319:8	FRE 402			
319:10-319:18	319:19-319:21 (Objection: vague; lack of foundation).  FRE 402			
319:23-320:3	FRE 402			
320:5-320:22	320:23-320:24 (Objection to the form of the question: calls for speculation).  FRE 402			
321:1-321:6	FRE 402			
321:8-321:17	321:19-321:21 (Objection to the form of the question: outside the scope of his 30(b)(6) testimony.);  322:6-322:10 (Deposition and clearance testing, in general, is not included within topic number 6. If you're asking specifically about PET testing, that's fine).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	322:6-322:10 (Deposition and clearance testing, in general, is not included within topic number 6. If you're asking specifically about PET testing, that's fine.)  FRE 402, FRE 602			
322:23-323:1	FRE 402			
323:8-323:21	323:22-323:23 (Objection to the form of the question: calls for speculation).			
323:24-324:2	FRE 402			
324:4-324:5	324:6-324:7 (Objection to the form of the question: calls for speculation).  FRE 402			
324:8-324:8	FRE 402			
324:10-324:11	324:12-324:13 (Objection to the form of the question: calls for speculation).  FRE 402			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
324:14-324:14	FRE 402			
324:16-324:17	324:18-324:19 (Objection to the form of the question: calls for speculation).  FRE 402			
324:20-324:20	FRE 402			
324:22-325:3	FRE 402			
325:4-325:8	325:9-325:10 (Objection: calls for speculation).	325:4-325:8	FRE 105, FRE 802	
325:11-325:13				
325:15-325:24		325:15-325:24	FRE 105, FRE 802	
325:25-326:14				
326:15-326:17	326:18-326:19 (Objection to the form of the question: mischaracterizes the testimony).	326:15-326:17	FRE 105, FRE 802	
326:20-327:8		326:20-327:8	FRE 105, FRE 802	
327:10-327:12	327:14-327:1 (Objection to the form of the question: calls for speculation).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402, FRE 602			
327:16-327:17	FRE 402, FRE 602			
327:19-327:20	327:21-327:22 (Objection to the form of the question: calls for speculation).  FRE 402, FRE 602			
327:23-327:23	FRE 402, FRE 602			
328:7-328:11				
328:14-329:9	FRE 602			
329:11-329:20	329:21-329:22 (Objection to the form of the question: calls for speculation).  FRE 602			
330:7-330:8				
330:10-330:16				
330:18-331:7	331:8-331:9 (Objection to the form of the question: vague).  FRE 602			
331:10-331:10				
332:4-332:8	332:9-332:10 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: calls for speculation).  FRE 602			
332:11-332:11				
332:13-335:18	FRE 402			

**SOO IL KIM**

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
8:3-8:5				
8:9-8:14				
8:19-9:17	Objection to the designation to the extent it includes the question at 9:15 to 9:17 without inclusion at the deponents answer. The designation for 9:15 to 9:17 should be withdrawn.			
9:19-10:1				
13:3-14:6				
14:15-14:17	FRE 402			
15:3-15:24				
16:3-16:9				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
16:18-16:22				
17:1-17:5				
17:13-17:16				
18:2-18:5				
19:6-19:10				
19:15-20:22	FRE 402			
22:4-22:5	Objection to the designation to the extent it includes the question at 22:4 to 22:5 without inclusion at the deponents answer. The designation for 22:4 to 22:5 should be withdrawn.			
22:9-22:21	Objection to the designation to the extent it includes the question at 22:4 to 22:5 without inclusion at the deponents answer. The designation for 22:9 to 22:12 should be withdrawn.			
22:23-23:7				
23:16-24:9	FRE 402			
25:17-25:19	FRE 402			
26:2-26:4				
26:9-26:13	26:17-26:18 (Objections. Calls for speculation.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	Objection to the designation to the extent that it excludes the clarification at the question included at 26:5 to 26:8.			
26:19-26:21	26:22-26:23 (Objection. Calls for speculation).  FRE 402			
27:3-27:8	27:9-27:10 (Objection. Lack of foundation. Calls for expert testimony).  FRE 402, FRE 701			
27:11-27:13	FRE 402, FRE 701			
27:17-27:19	FRE 402, FRE 701			
27:20-25				
28:6-28:16				
30:12-30:17	FRE 402, FRE 602, FRE 701			
31:11-31:15	FRE 402, FRE 602, FRE 701			
31:20-31:25	Objection to the designation to the extent it includes the question at 31:25 without inclusion at the deponents			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	answer. The designation for to 31:25 should be withdrawn.			
32:1				
32:2-32:11	FRE 701			
32:14-32:24	32:25-33:1 (Objection. Mischaracterizes the testimony).  FRE 402, FRE 701			
33:2-33:12	FRE 402, FRE 701			
33:15-33:18	33:19-33:20 (Objection to the form of the question).  33:22-33:24 (Calls for speculation. Let me finish my objections as well. It calls for expert testimony.)			
34:1-34:1	FRE 402, FRE 701			
37:5-37:8				
37:15-37:23	37:24-37:24 (Objection. Vague).  Objection to the designation to the extent it includes the question at 37:22 without			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	inclusion at the deponents answer. The designation for 37: 22 should be withdrawn.  FRE 701			
38:2-38:3	38:4-38:4 (Objection. Vague).			
38:11-38:14	38:15-38:15 (Objection. Vague).  FRE 701			
38:16-38:19	38:20-38:20 (Objection. Vague).  FRE 701			
38:21-38:23	FRE 701			
39:1-39:2	FRE 602, FRE 701			
39:9-39:13	FRE 701			
39:17-39:23	39:24-39:24 (Objection. Vague).  FRE 602, FRE 701			
39:25-40:3	40:4-40:4 (Objection. Vague).  FRE 701			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
40:5-40:6	FRE 701			
42:4-42:4				
42:7-42:13	42:14-42:15 (Objection to the form of the question. Vague).  FRE 402, FRE 602, FRE 701			
42:16-42:19	FRE 402, FRE 602, FRE 701			
42:24-43:8	FRE 402, FRE 602, FRE 701			
43:18-43:19				
44:2-44:3				
45:25-46:3	FRE 602, FRE 701			
46:7-46:24	FRE 602, FRE 701			
47:19-48:4	FRE 602, FRE 701			
49:13-49:15	49:16-49:18 (Objection to the form of the question. Calls for expert testimony. Lack of foundation).  FRE 402, FRE 602, FRE 701			
49:19-49:22	49:23-49:25 (Objection to the form of the question. Calls for expert testimony. Lack of foundation).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402, FRE 602, FRE 701			
50:1-50:1				
51:21-51:25	<p>52:1-52:3 (Objection. Argumentative. Calls for expert testimony. Lack of foundation).</p> <p>Objection to the designation to the extent it includes the question at 51:21 to 51:25 without inclusion at the deponents answer. The designation for 51:21 to 51:25 should be withdrawn.</p> <p>FRE 402, FRE 602, FRE 701</p>			
52:10-52:14				
52:23-53:7	<p>53:8-53:9 (Objection. Calls for expert testimony).</p> <p>FRE 602, FRE 701</p>			
53:10-53:12	FRE 602, FRE 701			
54:9-54:12	<p>54:13-54:15 (Objection. Incomplete hypothetical. Calls for expert</p>			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	testimony. Calls for speculation).  FRE 602, FRE 701			
54:16-54:22	54:22-54:22 (Same objections).  FRE 602, FRE 701			
54:22-55:1	55:1-55:1 (Same objections).  FRE 602, FRE 701			
55:1-55:19	55:19-55:20 (Objection. Lack of foundation. Vague).  FRE 602, FRE 701			
55:21-56:2	56:2-56:2 (Objection. Vague).  FRE 602, FRE 701			
56:2-56:6	56:6-56:6 (Objection. Vague).  FRE 602, FRE 701			
56:6-56:12	FRE 602, FRE 701			
56:12-56:18	FRE 602, FRE 701	56:12-56:18	FRE 105, FRE 802	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
56:19-56:19	56:19-56:20 (Objection. Calls for expert testimony. Vague).			
56:21-56:21	FRE 602, FRE 701			
56:21-56:25		56:21-56:25	FRE 105, FRE 802	
56:26-57:6	57:6-57:7 (Objection. Lack of foundation. Vague).  FRE 602, FRE 701			
57:8-57:10	57:10-57:10 (Same objections).			
57:10-57:16	57:16-57:16 (Objection. Vague).  FRE 602, FRE 701			
57:16-57:22	57:22-57:23 (Objection. Calls for expert testimony).  FRE 602, FRE 701			
57:24-58:9	58:9-58:10 (Objection. Calls for expert			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	testimony. Vague).  FRE 602, FRE 701			
58:11-58:15	58:15-58:16 (Objection. Lack of foundation. Vague).  FRE 402, FRE 602, FRE 701			
58:16-58:24	58:24-58:25 (Objection. Lack of foundation. Mischaracterizes the testimony).			
58:25-59:21	FRE 402, FRE 602, FRE 701			
60:4-60:6	60:7-60:8 (Objection. Calls for speculation).  FRE 402, FRE 602, FRE 701			
60:9-60:10	FRE 602, FRE 701			
61:11-61:12	61:13-61:14 (Objection. Calls for expert testimony).			
61:15-61:22	61:23-61:24 (Objection. Calls for expert testimony. Vague).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602, FRE 701			
61:25-62:5	FRE 602, FRE 701			
62:21-62:23	62:24-62:25 (Objection. Calls for expert testimony?).			
63:1-63:1	FRE 602, FRE 701			
63:3-63:3	63:4-63:5 (Objection. Calls for expert testimony).			
63:6-63:10	63:11-63:13 (Objection. Mischaracterizes the testimony. Calls for expert testimony).			
63:14-63:14	FRE 602, FRE 701			
63:16-63:18	63:19-63:20 (Objection. Calls for expert testimony).			
63:21-63:25	64:1-64:2 (Objection. Calls for expert testimony).			
	FRE 402, FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
64:3-64:6	64:7-64:8 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
64:9-64:11	64:12-64:13 (Objection. Vague. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
64:14-64:18	64:19-64:20 (Objection. Vague. Lack of foundation).  FRE 402, FRE 602, FRE 701			
64:21-65:3	65:4-65:4 (Objection. Vague).  FRE 402, FRE 602, FRE 701			
65:5-65:14	FRE 402, FRE 602, FRE 701			
65:17-66:11	FRE 602, FRE 805			
66:15-66:18				
67:24-68:6	68:7-68:8 (Objection. Calls for expert testimony).			
68:9-68:12	68:13-68:14			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection. Calls for expert testimony. Lack of foundation).  FRE 402, FRE 602, FRE 701, FRE 805			
68:15-68:18	68:19-68:20 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
68:21-69:5	FRE 402, FRE 602, FRE 701, FRE 805			
69:9-69:23	69:24-69:25 (Objection. Calls for expert testimony, and vague).  FRE 402, FRE 602, FRE 701, FRE 805			
70:1-70:7	70:8-70:8 (Objection. Vague).  FRE 402, FRE 602, FRE 701, FRE 805			
70:9-70:12	70:13-70:13 (Objection. Vague).  FRE 402, FRE 602, FRE 701,			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 805			
70:14-70:16	70:17-70:18 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701, FRE 805			
70:19-70:22	70:23-70:24 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
70:25-71:1	FRE 402, FRE 602, FRE 701			
71:8-71:9				
71:11-71:17	71:18-71:19 (Object to the form of the question. Vague).  FRE 402, FRE 701			
71:20-71:21	FRE 402, FRE 602, FRE 701			
73:1-73:5	73:6-73:8 (Objection to the form of the question. Calls for expert testimony).			
73:9-73:11	73:12-73:13 (Objection. Lack of			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	foundation).  FRE 602, FRE 701			
73:14-73:18	73:19-73:20 (Objection. Lack of foundation).  FRE 602, FRE 701			
73:21-74:1	74:2-74:3 (Objection. Lack of foundation).  FRE 402, FRE 602, FRE 701			
74:4-74:7	74:8-74:9 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
74:10-74:14	74:15-74:16 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
74:17-74:22	74:23-74:24 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
74:25-74:25	FRE 402, FRE 602, FRE 701			
75:13-75:15	75:16-75:17 (Objection. Calls for expert testimony).			
75:18-75:21	75:22-75:23 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
75:24-76:1	76:2-76:3 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
76:4-76:5	76:6-76:7 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
76:8-76:16	FRE 402, FRE 602, FRE 701			
76:24-77:3	77:4-77:5 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
77:6-77:10	77:11-77:12			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection. Lack of foundation).  FRE 602, FRE 701			
77:13-77:16	77:17-77:18 (Objection. Lack of foundation).  FRE 402, FRE 602, FRE 701			
77:19-77:21	77:22-77:23 (Objection. Lack of foundation. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
77:24-77:24	FRE 402, FRE 602, FRE 701			
78:15-78:22				
78:25-79:1	FRE 402, FRE 602			
79:5-79:12	79:13-79:14 (Objection. Lack of foundation).  FRE 402, FRE 602			
79:15-79:16	FRE 402, FRE 602			
80:7-80:8	80:9-80:10 (Objection. Lack of foundation).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
80:11-80:13	80:14-80:15 (Objection. Lack of foundation).  FRE 402, FRE 602			
80:16-80:19	80:20-80:21 (Objection. Lack of foundation). FRE 402, FRE 602			
80:22-80:23	80:24-80:25 (Objection. Lack of foundation).  FRE 402, FRE 602			
81:1-81:6	FRE 402, FRE 602, FRE 701			
81:10-81:15	81:16-81:17 (Objection. Lack of foundation).			
81:18-81:20	81:21-81:22 (Objection. Lack of foundation).  FRE 402, FRE 602, FRE 701			
81:23-81:24	FRE 402, FRE 602, FRE 701			
82:14-82:18	82:19-82:20			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection. Calls for expert testimony).			
82:21-83:9	83:10-83:11 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
83:12-83:22	83:23-83:24 (Objection. Calls for speculation).  FRE 402, FRE 602, FRE 701			
83:25-84:5	84:6-84:7 (Objection. Lack of foundation).  FRE 402, FRE 602, FRE 701			
84:8-84:11	84:12-84:13 (Objection. Lack of foundation).  FRE 402, FRE 602, FRE 701			
84:14-84:22	84:23-84:24 (Objection. Calls for expert testimony. Lack of foundation).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402, FRE 602, FRE 701			
84:25-85:1	FRE 402, FRE 602, FRE 701			
85:8-85:10	85:11-85:12 (Objection. Calls for expert testimony).			
85:13-86:1	86:2-86:3 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701, FRE 805			
86:4-86:4	FRE 402, FRE 602, FRE 701, FRE 805			
86:7-86:13	FRE 402, FRE 602, FRE 805			
87:12-87:17				
87:23-87:25	88:1-88:2 (Objection. Lack of foundation).			
88:3-88:3				
88:7-88:9	88:10-88:10 (Objection. Vague).			
88:11-88:18	FRE 602, FRE 701			
88:24-89:1	89:2-89:3 (Objection. Asked and			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	answered).			
89:4-89:6	89:7-89:8 (Objection. Calls for speculation. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
89:9-89:16	FRE 402, FRE 602, FRE 701			
89:25-90:4	90:5-90:6 (Objection. Lack of foundation).  FRE 602, FRE 701			
90:7-90:8	FRE 602, FRE 701			
90:11-90:16	FRE 602, FRE 701			
90:25-91:2				
91:4-91:6				
91:9-91:11	FRE 602, FRE 701			
91:21-92:7	92:8-92:9 (Objection. Lack of foundation).  FRE 602			
92:17-93:9	93:10-93:11 (Objection. Calls for expert testimony).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402, FRE 602, FRE 701			
93:12-93:20	FRE 402, FRE 602, FRE 701			
94:13-94:15	94:16-94:17 (Objection. Calls for expert testimony).			
94:18-94:25	94:25-95:1 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
95:2-95:11	95:11-95:12 (Objection. Calls for expert testimony. Lack of foundation).  FRE 402, FRE 602, FRE 701			
95:13-96:1	96:1-96:2 (Objection. Lack of foundation. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
96:3-96:18	96:18-96:19 (Objection. Calls for speculation).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402, FRE 602, FRE 701			
96:20-97:21	97:21-97:22 (Objection calls for expert testimony).  FRE 402, FRE 602, FRE 701			
97:23-97:25	97:25-98:1 (Objection. Calls for expert testimony).			
98:2-98:5	98:5-98:6 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
98:7-98:12	98:12-98:13 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
98:14-98:24	98:24-98:25 (Objection. Lack of foundation).  Objection to the designation to the extent it includes the question at 98:22 to 98:23 without inclusion at the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	deponents answer. The designation for 98:22 to 98:23 should be withdrawn.			
99:5-99:15	99:16-99:17 (Objection. Lack of foundation. Vague).  FRE 602			
99:18-99:24	FRE 602			
100:1-100:6	100:7-100:8 (Objection. Lack of foundation).			
100:9-100:11	FRE 602, FRE 701			
100:13-101:4	FRE 602, FRE 701			
101:9-101:21	101:23-101:23 (Objection. Vague).  Objection to the designation to the extent it includes the question at 101:17 to 101:21 without inclusion at the deponents answer. The designation for 101:17 to 101:21 should be withdrawn.			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
101:25-102:13	102:14-102:15 (Objection. Lack of foundation. Mischaracterizes the testimony).  FRE 402, FRE 602, FRE 701			
102:16-103:3	103:4-103:4 (Objection).  FRE 402, FRE 602, FRE 701			
103:5-103:7	103:8-103:9 (Objection. Lack of foundation. Mischaracterizes the testimony).			
103:10-103:12	FRE 402, FRE 602, FRE 701	103:13-103:25	FRE 105, FRE 802	
104:1-104:6	104:7-104:8 (Objection. Lack of foundation).  FRE 402, FRE 602			
104:9-104:16	FRE 402, FRE 602			
104:22-104:23	104:24-104:24 (Objection. Vague).			
104:25-105:4	105:5-105:5			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection. Vague).  FRE 602, FRE 701			
105:6-105:8	FRE 602, FRE 701			
105:12-105:18	FRE 402, FRE 602, FRE 701			
105:24-106:3	FRE 602, FRE 701			
106:8-106:17	106:18-106:19 (Objection. Lack of foundation).  FRE 602, FRE 701			
106:20-107:5	107:6-107:6 (Objection. Vague).  FRE 402, FRE 602, FRE 701, FRE 805			
107:7-107:10	107:11-107:12 (Objection. Calls for speculation).  FRE 402, FRE 602, FRE 701			
107:13-107:21	FRE 402, FRE 602, FRE 701, FRE 805			
108:10-108:21	FRE 602, FRE 701			
109:9-109:13	109:14-109:15 (Objection. Calls for a legal conclusion).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 701			
109:16-109:17	109:18-109:19 (Objection calls for a legal conclusion).			
109:20-109:20	FRE 701			
110:3-110:4	110:5-110:6 (Objection. Calls for a legal conclusion).			
110:7-110:8	FRE 402, FRE 602, FRE 701			
111:17-111:19	111:20-111:22 (Objection. Calls for a legal conclusion. Calls for expert testimony).			
111:23-112:2	112:3-112:5 (Objection. Calls for a legal conclusion. Calls for expert testimony and vague).  FRE 402, FRE 602, FRE 701			
112:6-112:13	112:14-112:17 (Objection to the form of the question. Calls for expert testimony. Calls for legal conclusion. Vague).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402, FRE 602, FRE 701			
112:18-112:20	112:21-112:23 (Objection. Calls for a legal conclusion. Calls for expert testimony. Vague).  FRE 402, FRE 602, FRE 701			
112:24-113:1	113:2-113:4 (Objection. Calls for a legal conclusion. Calls for expert testimony. Vague).  FRE 402, FRE 602, FRE 701			
113:5-113:6	113:7-113:10 (Objection to the form of the question. Calls for a legal conclusion. Calls for expert testimony. Vague).  FRE 402, FRE 602, FRE 701			
113:11-113:12	113:13-113:16 (Objection to the form of the question. Calls for expert testimony. Calls for legal conclusion. Vague).  FRE 402, FRE 602, FRE 701			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
113:17-113:18	113:19-113:22 (Objection to the form of the question. Calls for a legal conclusion. Calls for expert testimony. Vague).  FRE 402, FRE 602, FRE 701			
113:23-113:24	113:25-114:3 (Objection to the form of the question. Calls for a legal conclusion. Calls for expert testimony. Vague).  FRE 402, FRE 602, FRE 701			
114:4-114:18	114:19-114:22 (Objection to the form of the question. Calls for legal conclusion. Calls for expert testimony. Vague).  FRE 402, FRE 602, FRE 701			
114:23-115:4	115:5-115:6 (Objection. Calls for -- calls for expert testimony).  FRE 402, FRE 602, FRE 701			
115:7-115:12	115:13-115:14 (Objection. Calls for expert			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	testimony).  FRE 402, FRE 602, FRE 701			
115:15-115:19				
115:21-116:4	116:5-116:7 (Objection. Calls for expert testimony. Incomplete hypothetical).  Objection to the designation to the extent it includes the question at 116:2 to 116:4 without inclusion at the deponents answer. The designation for 116:2 to 116:4 should be withdrawn.  FRE 402, FRE 602, FRE 701			
116:8-116:8	FRE 402, FRE 602, FRE 701			
116:16-116:19	116:20-116:21 (Objection. Vague. Calls for expert testimony).			
116:22-116:25	117:1-117:2 (Objection. Vague. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
117:3-117:5	117:6-117:7 (Objection. Calls for speculation. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
117:8-117:8	FRE 402, FRE 602, FRE 701			
117:16-117:17	117:20-117:22 (Objection. Calls for expert testimony. Incomplete hypothetical).			
117:23-118:3	FRE 602, FRE 701			
118:6-118:7	118:8-118:9 (Objection. Lack of foundation. Vague).			
118:10-118:14	118:15-118:16 (Objection. Lack of foundation. Vague).  FRE 602, FRE 701			
118:17-118:17				
118:21-118:23	118:24-118:24 (Objection. Vague).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602, FRE 701			
118:25-119:1	FRE 602, FRE 701			
119:4-119:8				
119:10-119:14	119:15-119:16 (Objection. Calls for speculation).  FRE 602, FRE 701			
119:20-120:1	120:2-120:3 (Objection. Calls for speculation).  FRE 602, FRE 701			
120:4-120:4	FRE 402, FRE 602, FRE 701			
121:1-121:6	121:7-121:7 (Objection. Vague).			
121:8-121:22	121:23-121:23 (Objection. Vague).  FRE 402, FRE 602, FRE 701			
121:24-122:1	122:2-122:2 (Objection. Vague).  FRE 402, FRE 602			
122:3-122:6	122:7-122:7 (Objection. Vague).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602			
122:8-122:9	FRE 402, FRE 602, FRE 701			
123:8-123:13	123:14-123:15 (Objection. Calls for expert testimony).			
123:16-123:21	123:22-123:23 (Objection. Calls for expert testimony). FRE 602, FRE 701			
123:24-124:3	124:4-124:5 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
124:6-124:9	124:10-124:10 (Objection. Vague).  FRE 602, FRE 701			
124:11-124:11	FRE 602, FRE 701			
124:16-124:20	124:21-124:22 (Objection. Calls for expert testimony. Lack of foundation).			
124:23-124:23	FRE 402, FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
126:11-126:12	126:13-126:15 (Objection. Calls for expert testimony. Vague. Incomplete hypothetical).			
126:16-126:18	126:19-126:21 (Objection. Vague. Incomplete hypothetical. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
126:22-126:24	126:25-127:2 (Objection. Vague. Incomplete hypothetical. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
127:3-127:6	FRE 402, FRE 602, FRE 701			
127:8-127:10				
127:25-128:9	FRE 701			
134:13-134:15	FRE 602, FRE 701			
135:22-136:4	136:5-136:6 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
136:7-136:17	136:18-136:19			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection. Calls for expert testimony. Lack of foundation).  FRE 402, FRE 602, FRE 701			
136:20-136:20	FRE 402, FRE 602, FRE 701			
142:10-142:11				
142:15-142:23	FRE 402, FRE 602, FRE 701			
143:14-143:18	143:19-143:20 (Objection. The question calls for expert testimony).			
143:24-143:25	FRE 402, FRE 602, FRE 701			
144:14-144:20	FRE 402, FRE 602, FRE 701			
145:2-145:5	145:6-145:7 (Objection. Calls for expert testimony).			
145:10-145:12	145:13-145:14 (Objection. Lack of foundation. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
145:15-145:22	145:23-145:24 (Objection. Calls for expert			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	testimony).  FRE 402, FRE 602, FRE 701			
145:25-146:4	146:5-146:6 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
146:7-146:9	146:10-146:12 (Objection of the lack of foundation. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
146:13-147:2	FRE 602, FRE 701			
147:8-147:11	FRE 402, FRE 602			
147:14-148:1	Objection to the designation to the extent it includes the question at 147:24 to 148:1 without inclusion at the deponents answer. The designation for 147:24 to 148:1 should be withdrawn.  FRE 402, FRE 602, FRE 701			
148:16-148:16	148:17-148:18 (Objection. Calls for expert			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	testimony).			
148:19-148:20	FRE 402, FRE 602, FRE 701			
149:23-150:1	150:2-150:3 (Objection. Lack of foundation. Argumentative).  Objection to the designation to the extent it includes the question at 149:23 to 150:1 without inclusion at the deponents answer. The designation for 149:23 to 150:1 should be withdrawn.			
150:6-150:14				
150:17-150:19	150:20-150:21 (Objection. Calls for expert testimony).			
150:22-151:5	FRE 402, FRE 602, FRE 701			
151:8-151:15	FRE 402, FRE 602, FRE 701			
152:19-152:21	152:22-152:23 (Objection. Calls for expert testimony).			
152:24-152:24	FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
153:9-153:11				
153:15-153:22	153:23-153:24 (Objection. Asked and answered).  FRE 701			
153:25-154:3	154:4-154:5 (Objection. Asked and answered).  FRE 602, FRE 701			
154:6-154:10	154:11-154:12 (Objection. Calls for expert testimony).  FRE 602, FRE 701			
154:13-154:18	FRE 602, FRE 701			
154:22-155:1	155:2-155:3 (Objection. Calls for expert testimony).			
155:4-155:4	FRE 602, FRE 701			
157:12-157:13	157:14-157:15 (Objection. Calls for expert testimony).			
157:16-157:20	157:21-157:22 (Objection. Calls for expert			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	testimony).  FRE 602, FRE 701			
157:23-158:2	FRE 602, FRE 701			
159:2-159:20	159:21-159:22 (Objection. Calls for expert testimony).  FRE 602, FRE 701			
159:23-159:23	FRE 602, FRE 701			
163:4-163:13	163:14-163:15 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
163:16-163:19	FRE 402, FRE 602, FRE 701			
163:24-164:1	164:2-164:3 (Objection. Calls for expert testimony).			
164:4-164:7	164:8-164:9 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
164:10-164:16	FRE 602, FRE 701			
165:3-165:4	165:5-165:6			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection. Calls for expert testimony).			
165:7-165:8	FRE 602			
167:2-167:9	FRE 602			
167:12-167:14	FRE 602			
167:18-167:21	167:22-167:23 (Objection. Lack of foundation).  FRE 602			
167:25-168:3	FRE 602			
169:7-169:12	169:13-169:14 (Objection. Lack of foundation).			
169:15-169:22	FRE 402, FRE 602			
170:5-170:7	FRE 402, FRE 602			
171:19-172:3	FRE 402, FRE 602, FRE 701			
173:22-174:4				
175:2-175:10				
175:13-176:15	FRE 602, FRE 701			
176:17-176:18	176:19-176:20 (Objection. Compound).			
176:21-176:25	FRE 602, FRE 701			
177:9-177:16	FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
178:3-178:21	178:22-178:23 (Objection. Calls for expert testimony. Lack of foundation).  FRE 402, FRE 602, FRE 701			
178:24-178:25	FRE 602, FRE 701			
179:4-179:10	FRE 602, FRE 701			
179:17-180:1				
182:8-182:19	182:20-182:21 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
182:22-183:13	183:14-183:15 (Objection. Asked and answered).  FRE 402, FRE 602, FRE 701			
183:16-183:18	183:19-183:20 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
183:21-184:1	Objection to the designation to the extent it includes the question at 183:23 without			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	inclusion at the deponents answer. The designation for 183:23 should be withdrawn.  FRE 602, FRE 701			
184:19-185:12	FRE 602, FRE 701			
185:24-186:4	186:5-186:6 (Objection. Calls for expert testimony).  FRE 602, FRE 701			
186:7-186:17	186:18-186:19 (Objection. Calls for expert testimony).  FRE 602, FRE 701			
186:20-187:1	FRE 402, FRE 602, FRE 701			
188:9-188:10				
188:13-189:5	189:6-189:7 (Objection. Lack of foundation).  FRE 602, FRE 701			
189:8-189:16	FRE 602, FRE 701			
189:24-190:14	FRE 602, FRE 701			
191:11-191:12				
191:17-191:21	FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
191:23-191:25	FRE 602, FRE 701			
192:16-192:18	192:19-192:21 (Objection. Incomplete hypothetical. Calls for expert testimony).			
192:22-192:24	FRE 402, FRE 602, FRE 701			
193:3-193:5	193:6-193:8 (Objection. Mischaracterizes the testimony. Calls for speculation).  Objection to the designation to the extent it includes the question at 193: 3 to 193:5 without inclusion at the deponents answer. The designation for 193: 3 to 193:5 should be withdrawn.			
193:9-193:13	FRE 602, FRE 701			
195:7-195:12	FRE 602			
195:19-195:23	FRE 602			
196:1-196:8	FRE 602			
196:12-196:13				
197:6-197:15	197:16-197:17 (Objection. Lack of foundation).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602			
197:18-197:18	FRE 602			
198:22-198:23	198:24-198:25 (Objection. Lack of foundation).			
199:1-199:2	FRE 402, FRE602			
199:14-199:16	199:17-199:18 (Objection. Mischaracterizes the testimony).			
199:19-200:1	200:2-200:3 (Objection. Lack of foundation).  FRE 402, FRE 602, FRE 701			
200:7-200:8	FRE 402, FRE 602, FRE 701			
200:13-200:20	FRE 402, FRE 602, FRE 701			
204:22-205:13	205:14-205:14 (Objection. Vague).  FRE 602			
205:15-205:16	FRE 602, FRE 701			
205:25-206:3	FRE 602, FRE 701			
207:20-208:5	208:6-208:7 (Objection. Calls for expert testimony. Calls for			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	speculation).			
208:8-208:9	FRE 602, FRE 701			
208:15-208:18	FRE 402, FRE 602, FRE 701			
214:1-214:2	214:3 to 214:3 (Objection. Vague.)  FRE 402, FRE 602			
214:4-214:10	214:11 to 214:11 (Objection. Vague.)  FRE 402, FRE 602			
214:12-215:6	215:7 to 215:7 (Objection. Vague.)  FRE 402, FRE 602			
215:8-215:10	215:11 to 215:11 (Objection. Vague.)  FRE 402, FRE 602			
215:12-215:14	215:15 to 215:15 (Objection. Vague.)  FRE 402, FRE 602			
215:16-215:16	FRE 402, FRE 602			
216:5-216:7				
216:14-216:22	FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
217:16-217:17	217:18-217:19 (Objection. Asked and answered).			
217:20-217:21	FRE 402, FRE 602, FRE 701			
217:24-218:2	FRE 602, FRE 701			
221:2-221:6	221:7-221:8 (Objection. Lack of foundation).			
221:9-221:10				
221:15-221:18	221:19-221:19 (Objection. Vague).			
221:20-221:23	221:24-221:25 (Objection. Calls for speculation).  FRE 602, FRE 701			
222:1-222:5	222:6-222:7 (Objection. Calls for speculation. Lack of foundation).  FRE 602, FRE 701			
222:8-222:11	FRE 602			
223:2-223:12	FRE 602			
223:21-223:25	FRE 602, FRE 701			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
224:4-224:17	224:19-224:20 (Objection. Lack of foundation. Calls for expert testimony). 224:25-225:1 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
225:2-225:16	FRE 402, FRE 602, FRE 701			
225:20-225:25	FRE 402, FRE 602, FRE 701			
227:11-227:13	227:14-227:15 (Objection. Asked and answered).			
227:16-227:19	FRE 402, FRE 602, FRE 701			
228:6-228:8	228:9-228:10 (Objection. Asked and answered).			
228:11-228:11	FRE 402, FRE 602, FRE 701			
228:16-228:17	228:18-228:19 (Objection. Lack of foundation).  FRE 402, FRE 602, FRE 701			
228:20-229:8	FRE 402, FRE 602, FRE 701			
231:14-231:15				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
231:19-232:14				
232:17-232:23	232:24-232:25 (Objection. Compound).  FRE 402, FRE 602			
233:1-233:7	FRE 402, FRE 602			
233:12-233:13				
233:16-234:8	FRE 402, FRE 602			
234:20-234:24	FRE 402, FRE 602, FRE 701			
235:13-235:13				
236:12-237:2	FRE 602, FRE 701			
238:12-238:15	238:16-238:17 (Objection. Calls for speculation. Calls for expert testimony).			
238:18-238:20	238:21-238:22 (Objection. Calls for speculation. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
239:7-239:11	FRE 402, FRE 602, FRE 701			
239:23-239:24	239:25-240:1 (Objection. Lack of foundation).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
240:2-240:7	FRE 602, FRE 701			
241:12-241:13				
241:17-241:18				
241:24-242:18	FRE 602, FRE 701			
243:4-243:6	243:7-243:7 (Objection. Vague).			
243:8-243:13	FRE 402, FRE 602, FRE 701			
243:16-243:19	FRE 402, FRE 602, FRE 701			
243:22-244:5	244:6-244:7 (Objection. Calls for a legal conclusion).  FRE 602, FRE 701			
244:8-244:10	FRE 402, FRE 602, FRE 701			
244:15-245:8	245:13-245:14 (Objection. Calls for a legal conclusion).  FRE 602, FRE 701			
245:16-245:25	FRE 602, FRE 701			
246:3-246:6	246:7-246:8 (Objection. Lack of foundation).  FRE 602, FRE 701			
246:12-247:4	247:5-247:6			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	<p>(Objection. Calls for speculation).</p> <p>Objection to the designation to the extent it includes the question at 247:2 to 247:3 without inclusion at the deponents answer. The designation for 247:2 to 247:3 should be withdrawn.</p> <p>FRE 602, FRE 701</p>			
247:8-247:9	<p>247:10-247:11</p> <p>(Objection. Calls for speculation).</p>			
247:12-247:12	FRE 602, FRE 701			
248:12-248:20	<p>248:21-248:22</p> <p>(Objection. Calls for expert testimony).</p> <p>FRE 602, FRE 701</p>			
248:23-248:25	FRE 602, FRE 701			
251:12-251:21				
251:25-252:7	<p>252:8-252:9</p> <p>(Objection. Calls for expert testimony).</p>			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE 701			
252:10-252:13	FRE 602, FRE 701			
253:19-254:1				
255:18-255:23				
256:2-256:5	FRE 602, FRE 701			
257:1-257:2	257:3-257:5 (Objection. Calls for expert testimony. Incomplete hypothetical).			
257:6-257:8	257:9-257:10 (Objection. Calls for expert testimony).  FRE 402, FRE 602, FRE 701			
257:11-257:12	FRE 602, FRE 701			
257:15-257:15	257:16-257:18 (Objection. Incomplete hypothetical. Calls for expert testimony).  FRE 602, FRE 701			
257:19-257:22	FRE 602, FRE 701			
258:10-258:11	258:12-258:14 (Objection. Calls for expert			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	testimony. Incomplete hypothetical).			
258:15-258:16	258:17-258:17 (Same objections).			
258:18-258:19	FRE 602, FRE 701			
258:22-258:23	258:24-258:25 (Objection. Calls for expert testimony).			
259:1-259:2	259:3-259:4 (Objection. Calls for expert testimony).			
	FRE 602, FRE 701			
259:5-259:5	FRE 602, FRE 701			
259:16-259:19				
262:3-262:4	262:5-262:6 (Objection. Calls for speculation. Lack of foundation).			
	FRE 402, FRE 602, FRE 701			
262:7-262:7				



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602, FRE 701			
263:22-264:2				
264:6-264:11	264:12-264:13 (Objection. Calls for speculation).  FRE 602			
264:14-264:15	FRE 602, FRE 701			
265:10-265:19	FRE 602, FRE 701			
267:10-267:11				
267:16-267:17				
267:21-268:2	FRE 402			
268:5-268:6	FRE 402			
268:9-268:13	FRE 402			
268:16-268:17				
269:24-270:2	FRE 602			
270:4-270:5				
270:22-271:2	271:3-271:4 (Objection. Vague. Calls for speculation).  FRE 602			
271:5-271:5	FRE 602, FRE 701			
271:10-271:14	FRE 402			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
271:21-271:22				
272:1-272:10	FRE 402, FRE 602, FRE 701			
277:8-277:9	277:10-277:11 (Objection. Calls for expert testimony).			
277:12-277:12	FRE 602, FRE 701			
278:6-278:10	FRE 602, FRE 701			

**TIMOTHY LAVERTY**

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
7:22-8:1				
8:10-9:8				
11:22-11:24		9:9-10:10 10:13-10:22 10:23-11:15		

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
12:5-12:12		12:1-12:4 12:5-12:12 12:13-12:14		
12:15-13:10		12:15-13:10 13:16-15:5	FRE 105, FRE 802	
15:6-15:14		15:6-15:14	FRE 105, FRE 802	
15:22-16:1				
16:11-16:12		16:11-16:12	FRE 105, FRE 802	
16:15-16:24		16:15-16:24 17:1-17:13 19:4-19:11	FRE 105, FRE 802	
19:12-19:14				
19:21-20:9				
20:14-20:17				
21:1-21:3	Objection to the designation to the extent it includes the question at 21:1-2 without inclusion of the deponents answer. The designation for 21:1-2 should be withdrawn.			
21:15-21:24				
22:6-22:11	FRE 402			
32:24-33:21	FRE 402, FRE 602	33:22-34:5 34:7-34:10	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
34:21-35:4	FRE 402			
35:7-35:16	FRE 402			
35:18-35:19	FRE 402			
36:16-37:9	FRE 402, FRE 602			
39:4-39:10	39:11-39:13 (Objection, mischaracterizes the witness' testimony). FRE402			
39:14-39:21	FRE 602, FRE 402			
47:16-47:19	47:20-47:22 (Objection, vague. Lack of foundation). FRE402, FRE701			
48:8-49:1				
49:5-49:19	FRE 402, FRE 602, FRE 701			
51:10-51:13	Objection to the designation to the extent it includes the question at 51:10-12 without inclusion of the deponents answer. The designation for 51:10-12 should be withdrawn. FRE402, FRE701	51:10-51:17	FRE 105, FRE 802	
51:23-51:24	52:1-52:2 (Objection, vague).			
52:6-52:8	FRE402, FRE602			
53:21-53:23	53:24-54:1 (Objection, vague).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
54:2-54:24	FRE 402, FRE 602			
56:5-57:4	FRE 401, FRE 602			
57:9-59:20	FRE 402, FRE 602			
60:10-60:13	60:15-60:17 (Objection, calls for speculation. Objection, lack of foundation). Objection to the designation to the extent it includes the question at 60:10-13 without inclusion of the deponents answer. The designation for 60:10-13 should be withdrawn. FRE 402, FRE 602, FRE 701	60:10-19	FRE 105, FRE 802	
60:22-62:17	FRE 402, FRE 602, FRE 701			
64:10-64:24	65:1-65:4 (Objection, vague. Calls for speculation. Lack of foundation).			
65:5-65:22	FRE 402, FRE 602, FRE 701			
66:1-66:4	FRE 701			
66:13-66:15				
67:10-67:14	67:15-67:18 (Objection, vague. Calls for speculation. Lack of foundation).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
67:19-67:21	FRE 402, FRE 602, FRE 701			
68:6-68:9				
70:15-70:17	70:19-70:20 (Objection, calls for expert testimony). FRE602, 711			
70:21-70:22	Objection to the designation to the extent it includes the question at 70:21-22 without inclusion of the deponents answer. The designation for 70:21-22 should be withdrawn.			
71:2-71:21	FRE 402, FRE 602, FRE 701			
75:20-76:6	FRE 701			
79:1-79:4		79:1-79:10 79:20-80:4	FRE 105, FRE 802 (79:1-4) Non-Responsive	
80:7-80:10				
80:12-81:8	Objection to the designation to the extent that it excludes the clarification of the question included at 79:5-10 and 79:20- 80:11. FRE 602, FRE 701			
81:10-81:14	81:15-81:16 (Objection, vague).  FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
81:18-81:22	FRE 701			
83:9-84:6	84:7-84:8 (Objection, vague). FRE 602, FRE 701			
84:9-84:13	84:15-84:16 (Objection, vague). FRE 602, FRE 701			
84:17-85:1	FRE 701			
90:3-90:4				
90:7-90:7				
90:12-90:13	Objection to the designation to the extent it includes the question at 90:12-13 without inclusion of the deponents answer. The designation for 90:12-13 should be withdrawn.			
90:18-90:20	FRE 602, FRE 701			
91:19-92:9	92:10-92:12 (Objection, calls for speculation. Lack of foundation). FRE 402, FRE 701			
92:13-92:15	FRE 402, FRE 602, FRE 701			
93:1-93:2				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
93:4-93:11	<p>93:12-93:15 (Objection, vague. Calls for speculation. Lack of foundation).</p> <p>Objection to the designation to the extent it includes the question at 93:4-11 without inclusion of the deponents answer. The designation for 93:4-11 should be withdrawn.</p>			
93:16-93:20	FRE 402, FRE 602, FRE 701			
93:22-93:24	FRE 402, FRE 602, FRE 701			
94:19-94:21				
94:23-95:2	<p>95:3-95:5 (Objection, lack of foundation. Calls for speculation).</p>			
95:6-95:8	FRE 602, FRE 701			
98:15-99:2	<p>99:3-99:4 (Objection, lack of foundation).</p> <p>99:6-99:7 (Calls for expert testimony).</p> <p>FRE 602, FRE 701</p>			
99:8-99:9				



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
99:12-99:14	99:15-99:16 (Objection, calls for expert testimony). FRE 701			
99:17-99:18	FRE 602, FRE 701			
99:21-100:4	100:5-100:8 (Objection, vague. Lack of foundation. Calls for speculation).  Objection to the designation to the extent it includes the question at 99:21-100:4 without inclusion of the deponents answer. The designation for 99:21-100:4 should be withdrawn.  FRE 602, FRE 701			
100:11-100:13	FRE 402, FRE 602, FRE 701			
100:15-100:16	100:17-100:21 (Objection, Calls for expert testimony.)			
100:22-101:1	FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
101:3-101:10	101:11-101:13 (Objection. Calls for expert testimony. Calls for speculation). FRE 602, FRE 701			
101:23-102:2	FRE 602, FRE 701			
102:6-102:7	102:9-102:11 (Objection, calls for speculation. Calls for expert testimony). FRE 602, FRE 701			
102:12-102:13				
102:20-102:23	102:24-103:2 (Objection, lack of foundation. Calls for speculation).			
103:3-103:14	103:15-103:16 (Objection, vague).			
104:10-105:3	FRE 602, FRE 701			
105:10-105:16				
106:5-106:7	FRE 402			
106:18-106:19	106:20-106:21 (Objection, vague). FRE402			
106:22-106:24	FRE 402, FRE 602			
107:2-107:4	107:5-107:6 (Objection vague).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
107:7-107:8	FRE 402, FRE 602, FRE 701			
107:10-107:18	FRE 602, FRE 701			
109:7-109:18	109:19-109:21 (Objection, incomplete hypothetical. Calls for speculation).			
109:22-110:1	FRE 602, FRE 701			
110:2-110:6	110:7 to 110:10 (Objection, lack of foundation. Calls for expert testimony. Calls for speculation.)			
110:11-110:15	FRE 106, FRE 602, FRE 701	110:16 to 110:19		
111:1-111:2				
111:5-111:18				
111:22-112:12	FRE 402, FRE 602			
112:19-113:1	FRE 602, FRE 701			
114:16-114:19				
115:3-115:13	FRE 602			
115:20-115:21	115:22-115:23 (Objection, lack of foundation).			
116:17-117:2	FRE 402, FRE 602, FRE 701			
122:19-122:22	122:23-122:24 (Objection, vague). FRE 602			
123:8-123:10	FRE 402, FRE 602			
123:18-124:1				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
124:3-124:3				
124:12-124:13	124:14-124:15 (Objection, lack of foundation).			
124:16-124:22	FRE 602			
126:2-126:3				
126:6-126:17				
127:2-127:17	FRE 701			
129:18-129:23	FRE 602, FRE 701			
134:21-136:2	FRE 701			
136:13-136:21				
141:9-141:15				
141:18-141:22				
141:24-142:4	FRE 602, FRE 701			
144:16-144:18	Objection to the designation to the extent it includes the question at 144:16-18 without inclusion of the deponents answer. The designation for 144:16-18 should be withdrawn.	144:21-144:24		
145:2-145:2	FRE 602	144:16-145:2	FRE 105, FRE 802	
148:5-148:7	148:8-148:9 (Objection. Calls for speculation).			
148:10-148:14	FRE 602, FRE 701			
148:16-148:23	FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
149:1-149:5	FRE 602, FRE 701			
149:14-150:2	150:3-150:4 (Objection, vague. Lack of foundation).			
150:8-150:9	FRE 602, FRE 701			
150:11-150:16	FRE 602, FRE 701			
153:2-153:6				
153:14-153:17	153:18-153:19 (Objection, vague).			
153:20-153:24	FRE 602, FRE 701			
154:3-154:18	FRE 602, FRE 701			
160:19-160:22				
161:11-162:7	FRE 701			
162:10-162:12				
162:15-163:8	163:9-163:13 (Objection, vague). FRE 701			
163:14-163:16	FRE 602, FRE 701			
164:17-164:20	164:21-164:22 (Objection, vague).			
164:23-165:1	FRE 602, FRE 701			
165:3-165:6	FRE 602, FRE 701			
165:10-165:12	165:14-165:15 (Objection, vague).	165:17-165:19		
165:20-165:24	FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
166:2-166:6	166:7-166:8 (Objection, vague. Calls for speculation).			
166:9-166:10	FRE 602, FRE 701			
167:2-167:4	167:5-167:6 (Objection, vague).			
167:7-167:10	FRE 701			
167:13-167:14				
168:1-168:2	168:3-168:4 (Objection, vague).			
168:5-168:7	FRE 602, FRE 701			
168:9-168:14	FRE 602, FRE 701			
168:19-169:3	FRE 602, FRE 701			
170:20-170:24	FRE 602, FRE 701			
172:2-172:5	FRE 602, FRE 701			
172:7-172:14	172:15-172:17 (Objection, lack of foundation. Calls for speculation).			
172:18-172:24	FRE 602, FRE 701			
174:16-174:17				
174:19-175:7	FRE 602			
175:18-176:6	FRE 602			
181:3-181:10	FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
184:12-184:15	184:17-184:19 (Objection, calls for speculation. Calls for expert testimony). FRE602, FRE701			
184:23-185:1	Objection to the designation to the extent it includes the question at 184:23-185:1 without inclusion of the deponents answer. The designation for 184:23-185:1 should be withdrawn.			
193:12-193:22				
194:4-194:6	194:7-194:8 (Objection, vague).			
194:9-194:11	FRE 602			
194:13-194:20	FRE 602, FRE 701			
195:1-195:6	FRE 602, FRE 701			
199:14-199:15	199:16-199:17 (Objection, vague).	199:14-199:23		
199:21-199:23		199:14-199:23		
200:1-200:6	FRE 602, FRE 701			
200:10-200:16	FRE 602, FRE 701			
200:18-200:19	200:20-200:21 (Objection, vague).			
200:22-200:24	FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
204:22-205:5	205:6-205:7 (Objection, calls for speculation). FRE 602			
205:8-205:9	FRE 602, FRE 701			
205:11-205:17	FRE 602, FRE 701			
206:8-206:17	FRE 602, FRE 701			
206:20-206:23				
207:7-207:10	FRE 602			
207:12-207:18	FRE 602			
208:18-208:20				
208:23-208:24	FRE 602			
209:3-209:9	FRE 602			
209:11-209:12	FRE 602			
210:7-210:10	FRE 602			
210:12-210:17	FRE 602			
210:19-210:22	FRE 602			
210:24-211:12	FRE 602			
211:15-211:22	FRE 602			
211:24-212:2	212:3-212:4 (Objection, vague). FRE 602			
212:5-212:10	FRE 602			
212:13-212:19	FRE 602			
213:21-214:3	214:4-214:5 (Objection, calls for speculation).			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
214:7-214:9	FRE 602			
216:15-216:15				
217:4-217:11	FRE 602			
217:13-217:15	Objection to the designation to the extent it includes the question at 217:13-15 without inclusion of the deponents answer. The designation for 217:13-15 should be withdrawn.	217:13-217:21	FRE 105, FRE 802	
217:17-217:17	Objection to the designation to the extent it includes the question at 217:17-17 without inclusion of the deponents answer. The designation for 217:17-17 should be withdrawn.	217:13-217:21	FRE 105, FRE 802	
217:19-217:20	Objection to the designation to the extent it includes the question at 217:19-20 without inclusion of the deponents answer. The designation for 217:19-20 should be withdrawn.	217:13-217:21		
217:22-217:24	218:1-218:2 (Objection, calls for speculation).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
218:3-218:7	FRE 602			
218:9-218:10	218:11-218:13 (Objection, calls for expert testimony. Calls for speculation).			
218:14-218:24	FRE 602, FRE 701	218:9-219:5	FRE 105, FRE 802	
219:7-219:10				
220:22-220:24				
221:3-221:11	FRE 602			
221:21-222:8	FRE 602			
223:20-223:20				
223:24-224:5	FRE 602			
225:3-225:4				
225:6-225:8	FRE 602			
225:14-225:16	FRE 602			
227:3-227:6	227:7-227:8 (Objection, calls for speculation). FRE 602			
228:9-228:12	228:13-228:14 (Objection, calls for speculation).			
228:15-228:16	FRE 602			
228:21-229:2	229:3-229:4 (Objection, calls for speculation). FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
229:5-229:6	FRE 602			
229:10-229:11	229:12-229:13 (Objection, calls for speculation).			
229:14-229:18	FRE 602, FRE 701	229:5-230:1	FRE 105, FRE 802	
230:20-231:2	231:3-231:4 (Objection, calls for speculation). FRE602			
231:5-231:10	231:11-231:12 (Objection, calls for speculation). FRE 602			
231:13-231:19	FRE 602			
231:21-231:23				
232:1-232:4	FRE 602			
241:3-241:10	241:11-241:12 (Objection, compound). FRE 602			
241:13-241:15	FRE 602			
241:20-241:20				
242:3-242:10	FRE 602	242:7-242:17	FRE 105, FRE 802	
242:15-242:16	FRE 602	242:7-242:17	FRE 105, FRE 802	
242:18-242:22	FRE 602			
243:7-243:10	FRE 602, FRE 701			
245:10-245:10				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
245:15-245:17	245:18-245:19 (Objection, compound. Calls for speculation).			
245:20-246:3				
248:5-248:8	248:9-248:10 (Objection, calls for speculation).			
248:13-248:16	FRE 602	248:5-248:16	FRE 105, FRE 802	
248:18-248:20				
269:9-269:21	FRE 402, FRE 602			
270:7-270:7				
270:11-270:17	270:18-270:19 (Objection, vague). FRE 602			
270:20-270:22	FRE 602			
271:1-271:9	FRE 602, FRE 701			
274:7-275:3	FRE 602			
275:18-276:4	FRE 602			
276:10-276:10	FRE 602			
287:14-287:18	FRE 602			
287:20-287:24	FRE 602			
291:7-291:7				
291:9-291:14	FRE 602			
292:23-293:18	293:19-293:20 (Objection, vague). FRE 602			
293:21-293:23	FRE 602, FRE 701			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
294:1-294:21	FRE 602			
295:1-295:5	FRE 602, FRE 701			
295:9-295:14	295:15-295:16 (Objection, vague).			
295:17-295:23	FRE 602			
302:15-302:16				
302:21-302:21				
303:12-304:4	FRE 602			
320:1-320:15	320:16-320:17 (Objection, vague). FRE 602			
320:18-320:22	FRE 602			
320:24-321:9	FRE 602, FRE 701			
321:13-322:3	FRE 602			
322:9-322:10	FRE 602			
322:12-322:12	FRE 602			
322:17-323:13	FRE 602			
334:14-334:18				
336:10-336:12				
336:15-336:17	336:18-336:19 (Objection, calls for speculation).			
336:20-337:4	FRE 602			
337:6-337:8				
337:10-337:14				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
338:10-338:13	338:14-338:16 (Objection, vague. Calls for speculation).			
338:17-338:18	FRE 602			
338:20-339:2	FRE 602			
339:7-339:9	FRE 602			
341:22-342:1	342:2-342:3 (Objection, calls for speculation).			
342:4-342:8	FRE 602			
342:14-342:16	FRE 602			
343:1-343:6	FRE 602			
346:6-346:7				
346:10-346:16	FRE 602			
348:9-348:12	348:13-348:14 (Objection, calls for speculation).			
349:1-349:6	FRE 602	349:8-349:9		
349:11-349:13	349:14-349:15 (Objection, calls for speculation).			
349:16-349:17	FRE 602			
349:19-349:24	350:1-350:2 (Objection. Calls for speculation). FRE 602			
350:3-350:5	FRE 602			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
350:8-350:10	FRE 602			
351:19-351:19				
351:22-352:12	FRE 602			
352:14-352:20	FRE 602			
354:14-354:15	354:16-354:17 (Objection, vague. Calls for speculation).			
354:18-354:24	FRE 602			
355:2-355:4	FRE 602			
355:15-355:15				
355:18-356:3	FRE 602			
357:2-357:4	357:5-357:6 (Objection, calls for speculation).	357:2-358:4	FRE 105, FRE 802	
357:24-358:3				
361:17-361:18				
361:20-361:21				
362:1-362:2	FRE 602			
362:4-362:8	FRE 602			
363:1-363:2	FRE 602	362:16-363:6	FRE 105, FRE 802	
363:7-363:10	FRE 602			
363:17-363:17	FRE 602			
365:14-365:16				
365:18-365:21	365:22-365:24 (Objection, lack of foundation. Calls for speculation). FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
366:1-366:8	FRE 602			
366:10-366:14	FRE 602			
368:6-368:6				
368:11-368:19	368:20-368:21 (Objection, calls for speculation). FRE 602			
368:22-368:23	FRE 602			
370:23-370:23				
371:2-371:6	FRE 602			
372:12-372:14				
372:16-373:2	FRE 602	372:16-373:3	FRE 105, FRE 802	
373:4-373:5	373:6-373:8 (Objection, calls for speculation. Calls for expert testimony).			
373:12-373:18	FRE 602, FRE 701	373:4-373:18	FRE 105, FRE 802 (373:12- 18)	
373:20-373:22	FRE 602			
373:24-374:1	FRE 602			
374:20-375:1	375:2-375:3 (Objection, calls for speculation).			
375:7-375:18	FRE 602, FRE 701	374:20-375:18		
380:5-380:5				
380:8-380:18	FRE 602			
380:20-380:23	FRE 602			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
381:11-381:13				
381:19-382:10	FRE 602			
382:14-382:17				
383:19-383:20	FRE 602			
383:23-384:2				
384:7-384:8				
384:13-384:14	FRE 602	384:7-384:16	FRE 105, FRE 802	
384:16-385:8	FRE 402, FRE 602			

**ROSS OEHLER**

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
7:15 to 7:17				
12:7 to 12:11				
14:20 to 16:3				
16:7 to 16:13				
21:19 to 21:23				
24:6 to 24:22				
25:1 to 25:14				
28:1 to 28:5				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
28:11 to 29:2	29:3 to 29:4 (Objection to the form of the question: vague; calls for a legal opinion.)  FRE 701			
29:5 to 29:16	FRE 701			
30:3 to 30:8	30:9 to 30:10 (Objection to the form of the question: vague; calls for a legal opinion.)  FRE 701			
30:11 to 30:14	FRE 701			
41:8 to 41:9				
41:15 to 41:21				
41:23 to 42:5				
42:10 to 42:12	42:13 to 42:14 (Objection to the form of the question: vague; calls for a legal opinion.)  FRE 701			
42:15 to 42:21	42:22 to 42:23 (Objection to the form of the question: calls for a legal opinion.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 701			
42:24 to 43:6	FRE 701			
45:18 to 45:21	45:22 to 46:4 (Objection to the form of the question: calls for a legal opinion. Beyond the scope of the 30(b)(6).  FRE 602, FRE 701			
46:5 to 46:19	46:20 to 46:20 (Objection to the form of the question: calls for a legal opinion. Beyond the scope of the 30(b)(6).  FRE 602, FRE 701			
46:21 to 47:9	47:10 to 47:16 (Objection to the form of the question: calls for a legal opinion. Beyond the scope of the 30(b)(6). You can answer in your individual capacity to the extent that you have any personal knowledge.)  FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
47:17 to 47:24	48:1 to 48:1 (Objection to the form of the question: calls for a legal opinion. Beyond the scope of the 30(b)(6). You can answer in your individual capacity to the extent that you have any personal knowledge.)  FRE 602, FRE 701			
48:2 to 48:10	FRE 602			
48:13 to 48:20	48:21 to 48:23 (Objection to the form of the question: calls for a legal opinion. Beyond the scope of the 30(b)(6).  FRE 701			
48:24 to 49:5				
50:15 to 50:16				
50:21 to 50:23	FRE 602, FRE 701			
51:1 to 51:3	51:18 to 52:2 Objection beyond the scope of the 30(b)(6).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602, FRE 701			
51:6 to 51:10	FRE 602, FRE 701			
54:20 to 54:24	51:18 to 52:2  55:1 to 55:4 (Objection to the form of the question: beyond the scope of the 30(b)(6).  FRE 602, FRE 701			
55:5 to 55:20	55:22 to 56:2 (Objection to the form of the question: calls for a legal opinion. Beyond the scope of the 30(b)(6).  FRE 602, FRE 701			
56:4 to 56:10				
60:24 to 61:4				
61:10 to 61:12	61:5 to 61:9 (Objection to the designation to the extent that excludes the clarification of the question.)  FRE 602, FRE 701			
61:16 to 62:3	FRE 602, FRE 701			
62:21 to 63:3	63:4 to 63:4			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: vague.)  FRE 602, FRE 701			
63:5 to 63:7	FRE 602, FRE 701			
76:22 to 77:10	77:12 to 77:16 (Objection to the form of the question: vague; beyond the scope of the 30(b)(6).  FRE 602, FRE 701			
77:17 to 77:24	78:1 to 78:1 (Objection to the form of the question: vague; beyond the scope of the 30(b)(6).  FRE 602, FRE 701			
78:2 to 78:2	FRE 602, FRE 701			
81:16 to 81:17	FRE 602, FRE 701			
81:21 to 81:22				
82:2 to 82:3	82:4 to 82:8 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
82:9 to 82:14	82:15 to 82:22			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: vague. Beyond the scope of 30(b)(6).  FRE 602			
82:23 to 83:5	FRE 602, FRE 701			
83:9 to 83:10	83:11 to 83:15 (Objection to the form of the question: beyond the scope of 30(b)(6).			
83:16 to 83:22	83:23 to 84:6 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
84:7 to 84:12	84:13 to 84:13 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602; FRE 701			
84:14 to 84:17	FRE 701			
84:21 to 84:21				
85:3 to 85:4	85:5 to 85:8 (Objection to the form of the question: beyond the scope of			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	30(b)(6).  FRE 602, FRE 701			
85:9 to 85:15	85:16 to 85:24 (Objection to the form of the question: beyond the scope of 30(b)(6). Calls for a legal opinion.  FRE 602, FRE 701			
86:1 to 86:6	FRE 602			
86:9 to 86:10	86:11 to 86:18 (Objection to the form of the question: vague. Beyond the scope of 30(b)(6).  FRE 602			
86:19 to 86:23	FRE 602 FRE 701			
87:3 to 87:4	87:5 to 87:9 (Objection to the form of the question: beyond the scope of 30(b)(6). Calls for a legal opinion.			
87:10 to 87:13	FRE 602, FRE 701			
88:16 to 88:17				
88:21 to 88:23	89:5 to 89:8 (Objection to the form of the			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
89:10 to 89:19	89:20 to 90:2 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602; FRE 701			
90:3 to 90:8	90:9 to 90:9 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
90:14 to 90:18	FRE 602, FRE 701			
90:22 to 90:23	90:24 to 91:3 (Objection to the form of the question: beyond the scope of 30(b)(6). You can answer in your individual capacity.)			
91:4 to 91:6	FRE 602, FRE 701			
92:10 to 92:13	92:14 to 92:20 (Objection to the form of the question: beyond the scope of			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	30(b)(6).			
92:21 to 93:1	FRE 602, FRE 701			
93:5 to 93:6	93:7 to 93:10 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602; FRE 701			
93:12 to 93:18	93:19 to 94:1 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
94:2 to 94:6	FRE 602, FRE 701			
94:10 to 94:11	94:12 to 94:15 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
94:17 to 94:22	94:23 to 95:4 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
95:5 to 95:9	FRE 602, FRE 701			
95:12 to 95:14	95:15 to 95:19 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
95:21 to 96:1	FRE 602, FRE 701			
105:7 to 105:8				
105:12 to 105:13	105:14 to 105:18 (Objection to the form of the question: beyond the scope of 30(b)(6).			
105:19 to 105:24	106:1 to 106:8 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
106:9 to 106:14	106:15 to 106:1 (Objection to the form of the question: vague.)  FRE 602, FRE 701			
106:17 to 106:18	106:19 to 106:22 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: beyond the scope of 30(b)(6).			
106:23 to 107:5	107:6 to 107:12 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602			
107:13 to 107:17	107:18 to 107:19 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602			
107:20 to 107:24	108:1 to 108:5 (Objection to the form of the question: vague. Beyond the scope of 30(b)(6).  FRE 602, FRE 701			
108:6 to 108:11	108:12 to 108:18 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602			
108:19 to 108:23	108:24 to 108:24 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: beyond the scope of 30(b)(6).  FRE 602			
109:1 to 109:6	109:7 to 109:14 (Objection to the form of the question: beyond the scope of 30(b)(6). Lack of foundation. Beyond the scope of 30(b)(6).  FRE 602, FRE 701			
109:22 to 110:4	110:5 to 110:13 (Objection to the form of the question: mischaracterizes his prior testimony. Vague. Beyond the scope of 30(b)(6).  FRE 602			
111:10 to 111:17	111:18 to 111:24 (Objection to the form of the question: vague. Beyond the scope of 30(b)(6).  FRE 602, FRE 701			
112:1 to 112:6	112:7 to 112:15 (Objection to the form of the question: mischaracterizes his			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	prior testimony; vague. Beyond the scope of 30(b)(6).  FRE 602, FRE 701			
112:16 to 112:22	112:23 to 112:23 (Objection to the form of the question: mischaracterizes his prior testimony; vague. Beyond the scope of 30(b)(6).  FRE 602, FRE 701			
113:4 to 113:6	FRE 602, FRE 701			
114:8 to 114:10	114:11 to 114:12 (Objection to the form of the question: mischaracterizes his prior testimony; vague. Beyond the scope of 30(b)(6).  113:12 to 113:20 (Objection to the form of the question: mischaracterizes his prior testimony. Beyond the scope of 30(b)(6).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE 701			
114:13 to 114:18	114:19 to 114:2 (Objection to the form of the question: mischaracterizes his prior testimony. Asked and answered. Beyond the scope of 30(b)(6).  FRE 602, FRE 701			
114:22 to 114:23	FRE 602, FRE 701	114:24 to 115:11		
115:12 to 115:13				
115:18 to 115:23	115:24 to 116:4 (Objection to the form of the question: beyond the scope of 30(b)(6).			
116:6 to 116:23	116:24 to 117:3 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
117:4 to 117:8	117:9 to 117:15 (Objection to the form of the question: vague. Beyond the scope of 30(b)(6).			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE 701			
117:17 to 117:19	FRE 602, FRE 701			
118:9 to 118:10				
118:14 to 118:14				
118:18 to 118:19	118:20 to 118:24 (Objection to the form of the question: beyond the scope of 30(b)(6).			
119:1 to 119:3	FRE 602, FRE 701			
119:17 to 119:18				
120:23 to 121:3	121:4 to 121:7 (Objection to the form of the question: mischaracterizes his prior testimony. Beyond the scope of 30(b)(6).)  121:8 to 121:21 (objection to the designation to the extent that excludes the clarification of the question.  FRE 602, FRE 701			
121:23 to 122:3				
122:10 to 122:11	122:12 to 122:16			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: beyond the scope of 30(b)(6).			
122:17 to 122:19	FRE 602, FRE 701			
123:6 to 123:10	FRE 602, FRE 701	122:21 to 122: 22;  122:23 to 123:5  123:6 to 123:10	FRE 105, FRE 802	
123:14 to 123:15				
123:19 to 123:20	123:21 to 123:24 (Objection to the form of the question: beyond the scope of 30(b)(6).			
124:1 to 124:10	124:11 to 124:17 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
124:18 to 124:22	124:23 to 125:4 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
125:5 to 125:9	FRE 602, FRE 701			
125:12 to 125:13	125:14 to 125:18 (Objection to the form of the question: beyond the scope of 30(b)(6).			
126:2 to 126:7	126:8 to 126:14 (Objection to the form of the question: beyond the scope of 30(b)(6). You can answer in your individual capacity to the extent doing so would not cause you to reveal the substance of an attorney/client communication.)  FRE 602, FRE 701			
126:15 to 126:20	126:21 to 126:24 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
127:1 to 127:3	FRE 602, FRE 701			
144:18 to 144:19				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
144:22 to 145:1	145:2 to 145:5 (Objection to the form of the question: beyond the scope of 30(b)(6).			
145:6 to 145:8	FRE 602, FRE 702			
153:16 to 153:16				
153:21 to 154:1	154:2 to 154:6 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
154:8 to 154:14	154:15 to 154:20 (Objection to the form of the question: beyond the scope of 30(b)(6). Calls for a legal opinion. FRE 602, FRE 701			
154:21 to 155:3				
155:5 to 155:7	155:8 to 155:13 (Objection to the form of the question: beyond the scope of 30(b)(6). Calls for a legal opinion. You can answer in your individual capacity based on any personal knowledge.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602, FRE 701			
155:14 to 155:21	FRE 602, FRE 701			
156:1 to 156:2	156:3 to 156:7 (Objection to the form of the question: vague. Beyond the scope of 30(b)(6). Calls for a legal opinion.			
156:8 to 156:21	156:22 to 157:2 (Objection to the form of the question: beyond the scope of 30(b)(6). Calls for a legal opinion.  FRE 602, FRE 701, FRE 402			
157:3 to 157:5				
158:8 to 158:14				
158:19 to 158:24	159:1 to 159:4 (Objection to the form of the question: beyond the scope of 30(b)(6).  FRE 602, FRE 701			
159:5 to 159:9	159:10 to 159:10 (Objection to the form of the question: beyond the scope of 30(b)(6).			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602, FRE 701, FRE 402			
159:11 to 160:1	FRE 602, FRE 701, FRE 402			
160:3 to 160:8	FRE 602, FRE 701, FRE 402			
169:22 to 170:3	170:4 to 170:9 (Objection to the form of the question: vague. Beyond the scope of the 30(b)(6).  FRE 602, FRE 701, FRE 402	170:1 to 170:3;  170:4 to 170:9;  170:10 to 170:19;  170:20 to 171:2  171:3 to 171:4	FRE 105, FRE 802	
170:10 to 170:16	FRE 602, FRE 701, FRE 402			
171:6 to 171:24	172:1 to 172:2 (Objection to the form of the question: vague. Beyond the scope of the 30(b)(6).			
172:3 to 172:9	172:10 to 172:11 (Objection to the form of the question: vague. Beyond the scope of the 30(b)(6).  FRE 602, FRE 805, FRE 701			
172:12 to 172:16	172:17 to 172:21 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	<p>question: beyond the scope of the 30(b)(6). You can answer in your individual capacity based on personal knowledge.)</p> <p>172:23 to 172:24 (Objection to the form of the question: calls for a legal opinion.)</p> <p>FRE 602</p>			
172:22 to 172:22	<p>172:15 to 172:16 (Objection to the designation to the extent that it includes the question without inclusion of the deponents answer. The designation for 172:22 should be withdrawn.</p>	173:1 to 173:16	173:1-173:9 Nonresponsive	
173:10 to 173:17	<p>173:18 to 173:243 (Objection to the form of the question: to the extent the question calls for expert is testimony and/or legal opinion and beyond the scope of the 30(b)(6).</p> <p>FRE 602, FRE 701</p>			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
174:1 to 174:10	174:11 to 174:11 (Objection to the form of the question: to the extent the question calls for expert is testimony and/or legal opinion and beyond the scope of the 30(b)(6).  FRE 602, FRE 701			
174:12 to 174:12	FRE 602, FRE 701			
176:11 to 176:17	176:18 to 177:1 (Objection to the form of the question: vague; objection to the extent the question calls for attorney/client privilege and I will caution the witness that your answer should not reveal the substance of any attorney/client communication.)			
177:9 to 177:14	177:15 to 177:15 (Objection to the form of the question: vague; objection to the extent the question calls for attorney/client privilege and I will caution the witness that your answer should not reveal the substance of any			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	attorney/client communication.)  FRE 602, FRE 701			
177:16 to 177:17	FRE 602, FRE 701			

**JUDY PLON**

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
8:10 to 8:12		8:10 to 8:12	FRE 105, FRE 802	
9:21 to 10:6				
10:11 to 10:17				
10:20 to 11:6				
12:2 to 12:11				
13:18 to 14:10		13:18 to 14:10	FRE 105, FRE 802	
20:5 to 20:14		20:5 to 20:14	FRE 105, FRE 802	
21:1 to 21:4		21:1 to 21:4	FRE 105, FRE 802	
21:9 to 21:16		21:9 to 21:16	FRE 105, FRE 802	
21:19 to 21:21		26:22 to 27:4		
27:18 to 27:23		27:18 to 27:23	FRE 105, FRE 802	
28:13 to 28:17				
28:22 to 29:3				



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
29:7 to 29:9				
31:6 to 31:11		31:6 to 31:11	FRE 105, FRE 802	
31:17 to 31:22				
32:6 to 32:12				
32:18 to 32:19				
32:24 to 34:25		32:24 to 32:9	FRE 105, FRE 802 Invalid Page/Line Range	
33:1 to 33:12				
33:23 to 34:24				
35:7 to 35:14	FRE 402			
36:8 to 36:21	36:22 to 36:23 (Objection to the form of the question: vague)			
37:4 to 37:6				
37:17 to 37:21				
38:8 to 38:18		38:8 to 38:18 38:19 to 38:24 39:2 to 39:6 39:7 to 39:13 39:21 to 40:22	FRE 105, FRE 802  All Except 38:8-38:18 Beyond the Scope of the Designation	
41:16 to 41:19	FRE 402	41:16 to 41:19 41:20 to 41:25 42:20 to 42:24	FRE 105, FRE 802  All Except 41:16-19 Beyond	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
		43:5 to 43:12 44:11 to 45:19	the Scope of the Designation	
52:16 to 52:17		52:16 to 52:17	FRE 105, FRE 802	
52:19 to 53:10				
56:8 to 57:5	57:15 to 57:19 MS. BALDWIN: And for the record, this document doesn't appear to be in the same time frame as the scope of topic number 16, so she can answer in an individual capacity.  FRE 402	56:8 to 57:5 57:15 to 57:19	FRE 105, FRE 802	
58:11 to 58:16				
58:23 to 59:5				
59:9 to 59:9				
60:3 to 60:12				
61:7 to 61:14				
61:23 to 62:7				
62:22 to 63:1				
63:11 to 63:19	63:20 to 63:21 (Objection to the form of the question: mischaracterizes the document.)			
63:25 to 64:8				
64:23 to 65:2				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
65:22 to 65:24	65:25 to 66:1 (Objection to the form of the question: vague)			
66:2 to 66:9	66:10 to 66:11  (Objection to the form of the question: vague.)  FRE 402			
66:23 to 67:2	FRE 402	66:13 to 66:24		
71:4 to 72:2	FRE 602	71:4 to 72:7 72:11 to 72:14 74:15 to 74:16 74:22 to 74:23	FRE 105, FRE 802,  All Except 71:4-72:7 Beyond the Scope of the Designation	
76:17 to 76:20	FRE 602			
77:20 to 77:22				
83:17 to 83:21	FRE 802, FRE 805, FRE 602	81:20 to 81:23 81:25 to 82:6 82:10 to 82:12		
83:24 to 84:3	FRE 802, FRE 805	83:24 to 84:3	FRE 105, FRE 802	
84:7 to 84:17	FRE 802, FRE 805			
85:8 to 85:12	85:13 to 85:16			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: beyond the scope; lack of foundation; calls for speculation.)  FRE 802, FRE 805, FRE 602			
85:17 to 85:23	85:24 to 86:1 (Objection to the form of the question: beyond the scope. Objection; calls for speculation.)  FRE 802, FRE 805, FRE 602	85:17 to 85:20	FRE 105, FRE 802	
86:2 to 86:9	86:10 to 86:11 (Objection to the form of the question: vague; beyond the scope.)  FRE 802, FRE 805			
86:12 to 86:18	FRE 802, FRE 805, FRE 602			
86:21 to 86:21	86:22 to 86:25 (Objection to the form of the question: beyond the scope; lack of foundation; calls for speculation.)			
87:1 to 87:6				

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
88:2 to 88:3	88:4 to 88:5 (Objection to the form of the question: beyond the scope.)  FRE 602, FRE 402			
88:6 to 88:8	FRE 602, FRE 402			
89:4 to 89:5	89:6 to 89:8 (Objection to the form of the question: beyond the scope; calls for speculation.)  FRE 602, FRE 402	88:9 to 88:14 88:18 to 88:21 89:4 to 89:5	FRE 105, FRE 802	
89:10 to 89:12	FRE 602, FRE 402	89:10 to 89:12 89:13 to 89:16 89:21 to 90:2 90:5 to 90:10 90:14 to 90:16 92:15 to 92:19 93:6 to 93:11 93:14 to 93:14	FRE 105, FRE 802  All Except 89:10-12 Beyond the Scope of the Designation	
94:8 to 94:16		94:8 to 94:16	FRE 105, FRE 802	
95:12 to 95:21	95:5 to 95:7 (Objection to the form of the question: standing objection to this exhibit for being beyond the scope.)	95:12 to 95:21 96:25 to 97:20	FRE 105, FRE 802  (96:25-97:20) Beyond the Scope of the Designation	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
98:17 to 98:23	FRE F 602, FRE 402			
99:4 to 99:5	99:6 to 99:7 (Objection to the form of the question: lack of foundation.)  FRE 602, FRE 402			
99:8 to 99:11				
99:24 to 100:5				
109:12 to 109:17	109:18 to 109:22 (Objection to the form of the question: outside the scope for this exhibit.)  FRE 802			
109:24 to 110:5				
112:4 to 112:9				
112:19 to 113:4				
116:3 to 116:8	116:9 to 116:15 (Objection to the form of the question: object as being outside the scope and she's testifying under her individual capacity)  FRE 402, FRE 802	116:6 to 116:8 116:17 to 117:8 119:3 to 119:20	FRE 105, FRE 802	
116:17 to 118:9				
118:17 to 118:20	FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
119:2 to 119:2	FRE 602			
119:4 to 120:1	FRE 805, FRE 602	119:24 to 120:1	FRE 105, FRE 802	
122:11 to 122:20	FRE 802			
123:2 to 123:22		123:2 to 123:22	FRE 105, FRE 802	
125:6 to 125:14	FRE 602	125:6 to 125:14	FRE 105, FRE 802	
125:15				
130:5 to 130:21	130:22 to 130:25 (Objection to the form of the question: beyond the scope of topic 16. You can answer in your personal capacity, if you have knowledge.)  FRE 602, FRE 802, FRE 805	130:5 to 130:21	FRE 105, FRE 802	
131:1 to 131:3	FRE 802, FRE 602	131:1 to 131:11	FRE 105, FRE 802	
132:1 to 132:5	132:6 to 132:7 (Objection to the form of the question: beyond the scope of topic 16.)  FRE 602	131:12 to 131:15 131:19 to 131:25		131:4-11
132:8 to 132:9	FRE 602			
133:25 to 134:9	134:10 to 134:12 (Objection to the form of the question: beyond the scope of topic 16. Objection. Lack of			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	foundation. Calls for speculation.)  FRE 805, FRE 802, FRE 602			
134:21 to 135:2	FRE 602	135:11 to 135:14 135:20 to 136:13 136:14 to 136:17	FRE 105, FRE 802 Beyond the Scope of the Designation	
137:11 to 137:20				
138:4 to 138:15				
140:11 to 141:22	FRE 802			
141:25 to 142:18	FRE 802			
143:21 to 144:3	144:4 to 144:6 (Objection to the form of the question: beyond the scope of topic 16. Calls for speculation.)  FRE 602, FRE 402			
144:8 to 144:14	144:15 to 144:16 (Objection to the form of the question: outside the scope of topic 16.)  FRE 602, FRE 402			
144:17 to 145:6	FRE 602, FRE 802			
145:20 to 145:22	145:23 to 145:25 (Objection to the form of the			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: outside the scope of topic 16. Calls for speculation.)  FRE 602			
146:1 to 146:9				
149:4 to 149:5	149:6 to 149:7 (Objection to the form of the question: beyond the scope of the topic 16)			
149:8 to 149:10				
150:1 to 150:19	FRE 106			
152:2 to 152:6	152:7 to 152:8 (Objection to the form of the question: beyond the scope of exhibit -- of topic 16.)			
152:9 to 152:11				
152:20 to 152:24	152:25 to 153:1 (Objection to the form of the question: beyond the scope of topic 16.)			
153:2 to 153:3				
155:12 to 155:15	155:6 to 155:9 (Objection to the form of the question: beyond the scope of topic 16; asked and answered; calls for speculation.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 602			
155:17 to 155:18				
155:20 to 156:1	156:2 to 156:6 (We'll make a standing objection based upon the date of the document unless the question shows otherwise, this appears to be beyond the scope of topic 16.)  FRE 802	155:20 to 156:1	FRE 105, FRE 802	
156:7 to 156:14	FRE 802	156:7 to 156:14	FRE 105, FRE 802	
156:23 to 157:10	FRE 805	156:23 to 157:10 157:11 to 157:24	FRE 105, FRE 802	
159:21 to 159:22				

**BRANDON SIMPSON**

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
8:14 to 8:16				
20:24 to 21:1				
21:8 to 21:12				
21:17 to 21:24				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
22:11 to 22:15				
22:20 to 22:22				
24:17 to 24:21				
24:23 to 25:4				
39:15 to 40:4				
40:6 to 40:19		36:4 to 38:8 39:15 to 40:4 40:6 to 40:19	FRE 105, FRE 802  36:4-38:8 Beyond the Scope of the Designation	
40:22 to 41:1		40:22 to 41:1	FRE 105, FRE 802	
42:17 to 42:18				
43:8 to 44:6	FRE 402, FRE 602			
44:10 to 44:22	44: 23-24 (Objection to the form of the question: vague); Also object to designation to the extent that it includes the question at 44: 20-22 without inclusion of the deponents answer. The designation for 44: 20-22 should be withdrawn.  FRE 602, FRE 402			
46:2 to 46:10	FRE 402			
46:15 to 47:2				
48:1 to 48:11				
50:9 to 52:9	FRE 402, FRE 602			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
52:12 to 52:22	FRE E 402			
53:1 to 53:6	FRE F 402			
53:9 to 53:14	53:15 to 53:17 (Objection to the form of the question: mischaracterizes witness' testimony)  FRE 402			
53:18 to 55:4	FRE 402, FRE 602			
55:12 to 56:1	FRE 402, FRE 602			
56:19 to 57:14	FRE 402			
57:18 to 57:20				
58:1 to 58:9				
58:12 to 59:15	FRE 402			
60:7 to 61:6				
61:9 to 65:7	FRE 402			
66:3 to 66:9	FRE 602, FRE 402	66:12 to 66:15		
66:16 to 66:20	FRE 402			
66:23 to 67:5	67:5-67:7 (Objection to the form of the question: vague)  Objection to the designation to the extent that excludes the clarification of the question included at 67: 8-12.	67:8-12		

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402, FRE 602			
67:13 to 67:18	FRE 402, FRE 602			
67:21 to 68:6	FRE 402, FRE 602	67:21 to 68:6 68:7 to 68:13 69:2 to 69:5	FRE 105, FRE 802  68:7-68:13, 69:2-5 Beyond the Scope of the Designation	
70:8 to 70:14	FRE 402, FRE 602			
70:17 to 70:20	FRE 402, FRE 602			
71:3 to 71:8	FRE 402			
71:13 to 71:17	FRE 402			
72:16 to 73:12		72:16 to 73:12	FRE 105, FRE 802	
74:2 to 74:4		74:2 to 74:4	FRE 105, FRE 802	
74:7 to 74:17		74:7 to 74:17	FRE 105, FRE 802	
74:20 to 74:23		74:20 to 74:23	FRE 105, FRE 802	
75:1 to 75:23		75:1 to 75:23	FRE 105, FRE 802	
76:16 to 77:4	FRE 602	76:16 to 77:4 77:5 to 77:10	FRE 105, FRE 802	
78:1 to 78:8	77:23-24 Objection to the designation to the extent that it does not include the clarification of the question being answered by the witness,  FRE 602	77:11 to 77:24 78:1 to 78:8	FRE 105, FRE 802	
78:11 to 78:16	78:17 to 78:18 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: vague)  FRE 602			
78:19 to 79:7	FRE 805, FRE 602			
79:10 to 79:17	FRE 602, FRE 402	79:10 to 79:17 79:18 to 79:22	FRE 105, FRE 802	
80:9 to 80:14	80:15 to 80:16 (Objection to the form of the question: asked and answered)  FRE 402			
80:17 to 80:23	FRE 402, FRE 602			
81:1 to 82:3	82:4 to 82:6 (Objections to form of the question: vague, calls for speculation)  FRE 402, FRE 602			
82:7 to 82:10				
82:13 to 82:16	FRE 402			
83:3 to 83:4	FRE 802			
83:10 to 83:17	FRE 802			
84:3 to 85:7	85:8-85:9 (Objection to the form of the question: lack of foundation)  FRE 402, FRE 802, FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
85:10 to 85:13	FRE 402, FRE 602			
85:16 to 85:19	FRE 402, FRE 602			
86:2 to 87:19	87:20-87:23 (Objection to the form of the question: calls for speculation)  FRE 402, FRE 805, FRE 602			
87:24 to 88:6	88:7 to 88:8 (Objection to the form of the question: vague)  FRE 402			
88:9 to 88:13	88:14 to 88:15 (Objection to the form of the question: vague)  FRE 402			
88:16 to 88:21	FRE 402			
91:8 to 92:12	FRE 602			
93:9 to 94:11	FRE 602			
94:15 to 94:16		94:15 to 94:16	FRE 105, FRE 802	
94:22 to 95:13		94:22 to 95:13	FRE 105, FRE 802	
96:4 to 96:7				
96:16 to 97:19	FRE 602	96:16 to 97:19	FRE 105, FRE 802	
98:1 to 98:8	FRE 602			
98:16 to 99:3	FRE 402			
99:14 to 100:9	FRE 602			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
100:21 to 101:21	FRE 805, FRE 602			
103:7 to 103:8				
104:11 to 104:12				
104:18 to 106:1	FRE 602			
106:8 to 106:18	FRE 602			
106:21 to 107:1	107:2 to 107:3 (Objection to the form of the question: vague)  FRE 602			
107:4 to 107:11				
107:14 to 107:21	FRE 602			
108:19 to 109:13	FRE 402, FRE 805			
109:16 to 110:6				
111:9 to 112:11	FRE 602			
112:14 to 113:13				
113:17 to 113:19				
114:1 to 114:11				
115:2 to 117:15				
118:13 to 119:15	119:16 to 119:17 (Objection to the form of the question: asked and answered)  FRE 602, FRE 402			
119:18 to 119:20	FRE 602, FRE 402			
119:23 to 120:9	FRE 602, FRE 402	119:23 to 120:20	FRE 105, FRE 802	



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
120:21 to 121:1		120:21 to 121:1	FRE 105, FRE 802	
121:4 to 121:22		121:4 to 121:22	FRE 105, FRE 802	
122:1 to 122:4		122:1 to 122:4 122:7 to 122:13	FRE 105, FRE 802	
122:14 to 123:8	FRE 602	122:14 to 123:8 123:9 to 123:15	FRE 105, FRE 802	
123:16 to 126:10	FRE 602			
127:5 to 128:6	FRE 402, FRE 602	127:5 to 128:6	FRE 105, FRE 802	
128:14 to 128:21				
129:4 to 130:23		129:4 to 130:23	FRE 105, FRE 802	
131:1 to 131:4		131:1 to 131:4	FRE 105, FRE 802	
131:19 to 133:9	133:10 to 133:11 (Objection to the form of the question: asked and answered)  FRE 602			
133:12 to 133:13				
133:16 to 135:23	FRE 602	133:21 to 135:23	FRE 105, FRE 802	
136:13 to 138:3	FRE 602	136:13 to 136:20	FRE 105, FRE 802	
138:15 to 140:12				
141:19 to 148:23	FRE 602	141:19 to 148:23	FRE 105, FRE 802	
149:3 to 150:2	150:3 to 150:4 (Objection to the form of the question: asked and answered)	149:3 to 150:2	FRE 105, FRE 802	
150:12 to 150:20		150:12 to 150:20	FRE 105, FRE 802	
150:23 to 151:9	151:10 to 151:11 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: vague)			
151:12 to 151:14				
151:17 to 152:7				
152:14 to 152:14				
152:16 to 153:24	FRE 402			
155:1 to 155:2				
155:13 to 160:17				
161:1 to 161:6	161:7 to 161:8 (Objection to the form of the question: compound)			
161:9 to 161:20	161:21 to 161:23 (Objections to form of the question: lack of foundation and vague)	161:14 to 161:20	FRE 105, FRE 802	
161:24 to 163:15	FRE 602	161:24 to 163:15	FRE 105, FRE 802	
163:19 to 164:16	FRE 602, FRE 805			
165:15 to 168:12	FRE 602	165:15 to 167:13	FRE 105, FRE 802	
169:2 to 169:24	Objection to inclusion of 169:18-24. The witness said the he would have to review the document in order to answer the question and the questioning attorney told him not to do so and moved on to the next question. (170: 1-3) Inclusion of 169:18-24 mischaracterizes the transcript			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	and the witness' ability and willingness to answer the question.  FRE 602			
170:15 to 171:10				
171:13 to 171:17				
171:20 to 173:13	173:14 to 173:15 (Objection to the form of the question: vague.)			
173:16 to 173:17				
173:20 to 176:5	FRE 602			
177:24 to 178:7				
178:10 to 178:24		178:14 to 178:24	FRE 105, FRE 802	
179:3 to 179:11				
179:14 to 180:11	180:12 to 180:13 (Objection to the form of the question: mischaracterizes the document)  FRE 805			
180:14 to 182:3	182:4 to 182:5 (Objection to the form of the question: vague)	180:14 to 181:19	FRE 105, FRE 802	
182:6 to 183:24	184:1 to 184:2			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: lack of foundation)  FRE 602			
184:3 to 186:19				
186:24 to 191:17	FRE 602	186:24 to 191:15	FRE 105, FRE 802	
191:23 to 192:23	FRE 602	191:23 to 192:23	FRE 105, FRE 802	
193:2 to 193:3	FRE 602			
193:6 to 193:24	FRE 602			
194:3 to 194:22	194:23 to 194:24 (Objection to the form of the question: lack of foundation)  FRE 402			
195:1 to 195:13	195:14 to 195:15 (Objection to the form of the question: vague)  FRE 602			
195:16 to 197:24	FRE 602			
199:22 to 200:3				
200:14 to 200:19		200:14 to 200:19 202:8 to 203:13 204:6 to 206:8	FRE 105, FRE 802  Objections to the following	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
		206:16 to 206:18	as nonresponsive and beyond the scope of the designation: 202:8 to 203:13 204:6 to 206:8 206:16 to 206:18	
207:4 to 207:17	FRE 402			
208:13 to 208:14				
208:20 to 209:16		208:20 to 209:16	FRE 105, FRE 802	
209:18 to 209:19		209:18 to 209:19	FRE 105, FRE 802	
210:9 to 213:17	FRE 602	210:9 to 212:17	FRE 105, FRE 802	
213:20 to 213:23				
214:1 to 214:8				
214:11 to 214:12				
215:1 to 215:17				
215:19 to 221:23	FRE 805			
222:5 to 223:2				
223:20 to 223:24	224:1 to 224:2 (Objection to the form of the question: calls for speculation)			
224:3 to 225:18	FRE 602			
225:24 to 226:17	FRE 402			
226:21 to 226:24				
227:3 to 227:4				
227:7 to 227:18	227:19 to 227:21 (Objections to form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: vague and mischaracterizes the witnesses previous testimony)  FRE 402			
227:22 to 228:21				
229:3 to 230:11	FRE 402, FRE 602			
230:19 to 231:1				
231:16 to 232:19	FRE 602			
233:18 to 234:3		232:20 to 232:24 233:3 to 233:16	FRE 105, FRE 802	
234:9 to 235:20	FRE 402			
236:5 to 237:6	FRE 402, FRE 602			
237:22 to 239:7	FRE 602			
239:13 to 240:10	FRE 602			
240:15 to 241:14	FRE 602			
241:16 to 241:17				
241:23 to 244:11		241:23 to 244:11	FRE 105, FRE 802	
245:4 to 245:10		245:4 to 245:10 245:19 to 246:20	FRE 105, FRE 802 Beyond the Scope of the Designation.	
246:21 to 248:2				
248:12 to 249:11				
250:10 to 251:13				
252:9 to 252:13		251:14 to 252:19	FRE 105, FRE 802	
253:4 to 254:1	254:2 to 254:5	253:4 to 253:21	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: asked and answered)  Objection to the designation to the extent that it excludes 254:18 to 254:19 which clarifies that the witness is answering as to his personal understanding.			
254:20 to 255:19				
256:16 to 256:17		256:16 to 256:17	FRE 105, FRE 802	
256:19 to 257:17		256:19 to 257:17	FRE 105, FRE 802	
258:9 to 262:6	262:7 to 262:8 (Objection to the form of the question: asked and answered)  FRE 602			
262:9 to 262:15				
263:2 to 264:21	264:22 to 264:23 (Objection to the form of the question: vague)			
264:24 to 266:10	266:11 to 266:12 (Objection to the form of the question: asked and answered)	265:3 to 266:10	FRE 105, FRE 802	
266:13 to 266:17		266:13 to 266:17	FRE 105, FRE 802	
267:3 to 268:23	268:24 to 269:1 (Objection to the form of the	268:11 to 268:23	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: asked and answered)  FRE 602			
269:2 to 269:8	269:9 to 269:10 (Objection to the form of the question: asked and answered)	269:2 to 269:3	FRE 105, FRE 802	
269:11 to 269:18	269:19 to 269:20 (Objection to the form of the question: asked and answered)			
269:21 to 269:23				
270:5 to 272:22	FRE 402, FRE 602			
273:13 to 273:18	273:19 to 273:20 (Objection to the form of the question: vague)  FRE 402, FRE 602			
273:21 to 274:21				
275:10 to 275:14		276:11 to 276:14 276:17 to 276:18 276:20 to 277:1 277:5 to 277:6	FRE 105, FRE 802	
277:8 to 278:7	FRE 402, FRE 602			
278:22 to 279:11	279:12 to 279:13 (Objection to the form of the question: vague)  FRE 402			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
279:14 to 279:24	280:1 to 280:2 (Objection to the form of the question: calls for speculation)  FRE 402, FRE 602			
280:5 to 280:7				
281:2 to 282:1	FRE 402, FRE 602			
282:9 to 282:10				
282:16 to 283:5	FRE 802, FRE 602			
283:7 to 286:20	286:21 to 286:22 (Objection to the form of the question: calls for speculation)  FRE 402			
286:23 to 287:9	287:10 to 287:11 (Objection to the form of the question: calls for speculation)			
287:12 to 293:9	FRE 402, FRE 602			
293:15 to 293:16				
293:22 to 296:2	FRE 402, FRE 602			
300:22 to 302:16	FRE 402, FRE 602			

**CHRISTINE ZAK**

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
-----------------------------	-----------------------------------	--	--	--

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
10:3 to 10:8				
16:22 to 16:25		12:15 to 12:17 14:24 to 15:25 16:22 to 17:3 19:17 to 19:25 20:1 to 20:3 21:13 to 21:14 21:17 to 21:22 22:15 to 22:16 22:19 to 22:19 23:3 to 23:7 27:6 to 27:10 27:14 to 28:1 28:21 to 29:1 29:18 to 29:21 30:13 to 31:3	FRE 105, FRE 802  Beyond the Scope of the Designation	
25:8 to 25:10	FRE 402	25:13 to 25:16	FRE 105, FRE 802	
25:13 to 25:16	25:17 to 25:18 (Objection to the form of the question: compound.)  FRE 402			
25:19 to 26:1	26:2 to 26:3 (Objection to the form of the question: calls for speculation.)			
26:4 to 26:9	26:14 to 26:14			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: vague.)			
26:15 to 26:20	26:21 to 26:22 (Objection to the form of the question: mischaracterizes the testimony.)  Form			
26:23 to 27:1	27:2 to 27:3 (Objection to the form of the question: mischaracterizes the testimony.)			
27:4 to 27:5				
31:4 to 32:8	32:9 to 32:9 (Objection to the form of the question: vague.)			
32:10 to 32:22	32:23 to 32:24 (Objection to the form of the question: calls for expert testimony.)  FRE 402			
32:25 to 33:3	33:4 to 33:5 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: calls for expert testimony.)  FRE 402, FRE 701			
33:6 to 33:15	33:16 to 33:16 (Objection to the form of the question: vague.)			
33:17 to 33:23	FRE 402, FRE 701			
34:6 to 34:19	34:20 to 34:21 (Objection to the form of the question: lack of foundation.)	34:2 to 34:5	FRE 105, FRE 802	
34:22 to 35:7				
35:10 to 36:6	36:7 to 36:8 (Objection to the form of the question: lack of foundation.)  FRE 402			
36:9 to 36:11	36:12 to 36:12 (Objection to the form of the question: vague.)  FRE 402			
36:13 to 38:15	38:16 to 38:17 (Objection to the form of the question: lack of foundation.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402			
38:18 to 38:20	38:21 to 38:21 (Objection to the form of the question: vague.)  FRE 402			
38:22 to 39:4	FRE 402			
39:13 to 40:4	40:5 to 40:6 (Objection to the form of the question: lack of foundation.)  FRE 402			
40:7 to 48:25	41:7 to 41:18  45:25 to 46:3 (Objection to knowing misrepresentation of what Ms. Zak is here to testify to.)  46:20 to 46:23 (Same objection and instruction.)  47:8 to 47:9 (Same objection and instruction.)	40:7 to 48:25	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	<p>47:16 to 47:17 (Same objection and instruction.)</p> <p>47:24 to 47:25 (Same objection and instruction.)</p> <p>48:5 to 48:6 (Same objection and instruction.)</p> <p>48:10 to 48:11 (Same objection and instruction.)</p> <p>48:16 to 48:17 (Same objection and instruction.)</p> <p>48:21 to 48:22 (Same objection and instruction.)</p> <p>FRE 402, FRE 802</p>			
49:1 to 49:3	<p>49:4 to 49:5 (Objection to the form of the question: beyond the scope of</p>			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	the 30(b)(6) Notice.)  FRE 602			
49:8 to 49:11	49:12 to 49:13 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
49:16 to 49:20	49:21 to 49:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
49:25 to 50:2	50:3 to 50:4 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
50:7 to 50:9	FRE 602			
50:17 to 50:18	50:19 to 50:20 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
50:23 to 51:3	FRE 402, FRE 602			
51:24 to 51:25	52:1 to 52:1 (Objection to the form of the question: vague.)			
52:2 to 52:20	52:21 to 52:22 (Objection to the form of the question: mischaracterizes the testimony.)  FRE 602	54:5 to 54:15	FRE 105, FRE 802	
52:23 to 52:25	53:1 to 53:2 (Objection to the form of the question: mischaracterizes the testimony.)			
53:3 to 53:12	53:17 to 53:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague.)			
53:19 to 54:4	None			
54:16 to 54:16	54:17 to 54:19 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402, FRE 701			
54:20 to 54:22	54:23 to 54:25 (Objection. Beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 402, FRE 701			
55:1 to 55:6	55:7 to 55:9 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 402, FRE 701			
55:10 to 55:12	FRE 402, FRE 701			
56:3 to 56:6	56:7 to 56:8 (Objection to the form of the question: calls for expert testimony.)  FRE 402, FRE 701			
56:9 to 58:5	FRE 402, FRE 602, FRE 701, FRE 802			
58:14 to 58:16	58:8 to 58:9 (Objection to the form of the question: beyond the scope of			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	the 30(b)(6) Notice.)  58:17 to 58:18 (Objection to the form of the question: speculation.)  FRE 402, FRE 602			
58:19 to 58:21	FRE 402, FRE 602			
59:1 to 59:2	59:3 to 59:3 (Objection to the form of the question: vague.			
59:4 to 59:25				
60:14 to 61:15		60:4 to 60:7		
62:1 to 63:14		62:20 to 64:7	FRE 105, FRE 802	
64:8 to 64:13		64:8 to 64:13	FRE 105, FRE 802	
65:1 to 65:5	65:6 to 65:7 (Objection to the form of the question: lack of foundation.)  FRE 701			
65:8 to 65:15	FRE 802, FRE 701	66:16 to 66:24	FRE 105, FRE 802	
66:8 to 66:9	66:10 to 66:11 (Objection to the form of the question: beyond the scope of	65:25 to 66:7	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	the 30(b)(6) Notice.)  FRE 602			
66:14 to 66:15	FRE 602			
66:25 to 67:1	67:2 to 67:3 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
67:6 to 67:9	67:10 to 67:13 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. You can answer on your personal knowledge, if you know. And also vague.)  FRE 602			
67:14 to 68:3	FRE 402, FRE 602			
68:6 to 68:10	FRE 402			
68:13 to 68:23	106, FRE 402			
69:10 to 70:3	FRE 402			
70:12 to 70:15	70:16 to 70:17 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402, FRE 602			
70:18 to 70:18	FRE 402, FRE 602			
70:22 to 70:25	71:1 to 71:2 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
71:3 to 71:7	71:8 to 71:9 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, Form			
71:10 to 71:15	FRE 402			
71:22 to 71:25	72:1 to 72:2 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
72:3 to 72:10	72:11 to 72:12 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402, FRE 602			
72:13 to 73:6	73:7 to 73:7 (Objection to the form of the question: vague.)			
73:8 to 73:21	73:22 to 73:23 (Objection to the form of the question)			
73:24 to 74:7	74:8 to 74:8 (Objection to the form of the question: vague.)			
74:9 to 75:1	75:12 to 75:12 (Objection to the form of the question: vague.)	81:10 to 81:19	FRE 105, FRE 802	
75:13 to 76:14	76:15 to 76:16 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)	229:24 to 230:11 230:13 to 235:14	FRE 105, FRE 802	
76:17 to 76:23	76:24 to 77:1 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 701			
77:1 to 77:10	77:11 to 77:12 (Objection to the form of the			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: beyond the scope of the 30(b)(6) Notice.)  FRE 701			
77:13 to 77:14	77:15 to 77:16 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 701			
77:17 to 77:23	77:24 to 77:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 701			
78:1 to 78:7	78:8 to 78:9 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 701			
78:10 to 78:18	78:19 to 78:20 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
78:21 to 78:23	78:24 to 78:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 701			
79:1 to 79:6	79:7 to 79: (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 701			
79:9 to 79:15	79:16 to 79:17 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 701			
79:18 to 80:1	80:2 to 80:3 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 701			
80:4 to 80:4	FRE 602, FRE 701	80:5 to 80:12	FRE 105, FRE 802	
80:13 to 80:16	80:17 to 80:1 (Objection to the form of the question: vague.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 701			
80:19 to 80:22	80:23 to 80:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Mischaracterizes the testimony.)  FRE 602, FRE 701			
81:1 to 81:6	FRE 602			
83:10 to 83:17	83:18 to 83:19 (Objection to the form of the question: calls for expert testimony.)  FRE 106, FRE 701	81:24 to 83:9	FRE 105, FRE 802  Beyond the Scope of the Designation	
83:20 to 84:10	84:11 to 84:12 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602	83:21 to 84:8	FRE 105, FRE 802	
84:13 to 84:22	84:23 to 84:24 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)	84:14 to 84:20	FRE 105, FRE 802	



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402, FRE 602			
84:25 to 85:1	85:2 to 85:3 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
85:4 to 85:11	85:12 to 85:13 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
85:14 to 85:19	85:20 to 85:21 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
85:22 to 86:6				
86:10 to 86:13	86:14 to 86:15 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
86:16 to 86:22	86:23 to 86:24			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
86:25 to 87:1	87:2 to 87:3 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
87:4 to 87:5	87:6 to 87:7 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
87:8 to 87:9	87:10 to 87:11 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
87:12 to 87:18	87:19 to 87:20 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402			
87:21 to 87:23	87:24 to 87:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
88:1 to 88:11	88:12 to 88:14 (Objection to the form of the question: beyond the scope of the 30(b)(6)Notice.)  FRE 402			
88:15 to 88:18	88:19 to 88:20 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
88:21 to 88:22	FRE 402			
89:10 to 89:15	89:16 to 89:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 701, FRE 802			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
89:19 to 89:20	89:21 to 89:23 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 402, FRE 701			
89:24 to 89:25	FRE 402, FRE 701			
90:2 to 90:3	90:4 to 90:6 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 402, FRE 701			
90:7 to 90:11	90:12 to 90:13 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague.)  FRE 402, FRE 701			
90:14 to 90:22	90:23 to 90:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Incomplete hypothetical.)	167:18 to 169:10	FRE 105, FRE 802  Beyond the Scope of the Designation	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602, FRE 701			
91:1 to 91:3	91:4 to 91: (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Incomplete hypothetical.)  FRE 602, FRE 701			
91:5 to 91:8	91:9 to 91:10 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Incomplete hypothetical. Asked and answered.)  FRE 602, FRE 701			
91:11 to 91:23	FRE 602			
92:14 to 92:16	92:17 to 92:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 701	171:24 to 172:8	FRE 105, FRE 802  Beyond the Scope of the Designation	
92:19 to 93:6	93:7 to 93:8 (Objection to the form of the question: beyond the scope of			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 701, 805			
93:9 to 93:9	FRE 402, FRE 602			
93:12 to 93:20	FRE 802			
95:16 to 95:16				
95:24 to 96:5	95:20 to 95:21 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
96:15 to 96:16	96:7 to 96:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  96:17 to 96:17 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
96:18 to 97:8	97:9 to 97:10 (Objection to the form of the question: beyond the scope of			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	the 30(b)(6) Notice.)  FRE 402, FRE 802			
97:11 to 97:12	FRE 802			
97:17 to 97:17	97:18 to 97:20 (Objection to the form of the question: calls for speculation. Beyond the scope of the 30(b)(6) Notice.)  FRE 602			
97:21 to 97:22	97:23 to 97:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 602			
98:1 to 98:1	FRE 602			
98:18 to 98:22	98:23 to 98:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 402, FRE 602			
99:1 to 99:1	FRE 402, FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
99:5 to 99:16	FRE 802			
99:19 to 99:19	99:20 to 99:21 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
99:22 to 99:24	FRE 402			
100:12 to 101:16	101:17 to 101:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802	99:25 to 100:4 100:7 to 100:8	FRE 802	
101:19 to 101:19	101:17 to 101:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
102:4 to 102:7	102:8 to 102:9 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
102:10 to 102:13	102:14 to 102:15			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
102:16 to 102:16	FRE 602			
103:6 to 103:10				
103:13 to 103:17	FRE 701	103:18 to 103:19 104:2 to 104:4	FRE 105, FRE 802	
104:13 to 105:6	105:7 to 105:8 (Objection to the form of the question: the scope of the 30(b)(6) Notice.)  FRE 802	104:13 to 105:6	FRE 105, FRE 802	
105:9 to 105:10				
105:18 to 105:20	105:21 to 105:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
105:23 to 105:24	FRE 602	105:25 to 107:13	FRE 105, FRE 802  Beyond the Scope of the Designation	
107:14 to 107:18	107:19 to 107:19	107:14 to 107:18	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question.)			
107:20 to 108:8	108:9 to 108:10 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
108:11 to 108:14	108:15 to 108:17 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 602	109:9 to 109:19 109:24 to 110:3	FRE 105, FRE 802  Beyond the Scope of the Designation	
108:18 to 108:18	FRE 602			
110:12 to 110:15	110:16 to 110:1 (Objection to the form of the question: vague.)	110:12 to 110:15	FRE 105, FRE 802	
110:17 to 110:20	110:21 to 110:22 (Objection to the form of the question: Calls for expert testimony.)  FRE 701	110:17 to 110:20	FRE 105, FRE 802	
110:23 to 111:4	FRE 701	110:23 to 111:14	FRE 105, FRE 802	
111:15 to 111:20	111:21 to 111:22	111:15 to 111:20	FRE 105, FRE 802	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: mischaracterizes the testimony.)  Form			
111:23 to 112:5		111:23 to 112:5	FRE 105, FRE 802	
113:14 to 114:8				
114:24 to 115:1	115:2 to 115:2 (Objection to the form of the question: vague.)			
115:3 to 115:7	115:8 to 115:9 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
115:10 to 115:18	FRE 602	115:5 to 117:6	FRE 105, FRE 802	117:7-10, 13, 18-21, 24-25
117:7 to 117:10	117:11 to 117:12 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
117:13 to 117:13	FRE 602			
120:14 to 120:16	120:17 to 120:18 (Objection to the form of the	119:16 to 120:1	FRE 105, FRE 802	120:2-3, 6-9

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
120:19 to 120:22	120:23 to 120:24 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
120:25 to 121:2	121:3 to 121:4 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.  FRE 402			
121:5 to 121:6	121:7 to 121:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
121:9 to 121:9	FRE 402, FRE 602			
121:18 to 121:23 122:2 to 122:4	121:24 to 122:1 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. You may answer.)	123:3 to 124:10	FRE 105, FRE 802  Beyond the Scope of the Designation	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 402			
124:18 to 124:23				
124:25 to 125:7	125:8 to 125:9 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602, FRE 701			
125:10 to 125:16	FRE 402, FRE 602			
127:6 to 127:6	FRE 701	127:11 to 127:21	FRE 105, FRE 802 Beyond the Scope of the Designation	
127:22 to 127:24	127:25 to 128: (Objection to the form of the question: mischaracterizes the document. Lack of foundation.)  FRE 802			
128:3 to 128:3	FRE 802			
128:13 to 128:14	128:15 to 128:16 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
128:17 to 128:18	128:19 to 128:20 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
128:21 to 128:25	FRE 402			
131:11 to 131:14	FRE 402			
132:19 to 132:20				
132:22 to 133:5	133:6 to 133:7 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 701			
133:8 to 133:11	133:12 to 133:13 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
133:14 to 133:17	133:18 to 133:19 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice, and vague.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602			
133:20 to 133:21	133:22 to 133:23 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague.)  FRE 602			
133:24 to 134:14	134:15 to 134:16 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
134:17 to 134:19	134:20 to 134:21 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
134:22 to 134:24				
135:1 to 135:9	135:10 to 135:11 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 701,			
135:12 to 135:13	135:14 to 135:15			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
135:16 to 135:19	135:20 to 135:21 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
135:22 to 136:2	FRE 602			
136:18 to 136:20	136:21 to 136:21 (Objection to the form of the question: vague.)  FRE 402			
136:23 to 137:1	137:2 to 137:2 (Objection to the form of the question: vague.)  Objection to the designation of the extent that it excludes the clarification at 136:21 to 136:22.  FRE 402			
137:3 to 137:3	FRE 402			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
137:7 to 137:7	137:8 to 137:9 (Objection to the form of the question: vague. Mischaracterizes the testimony.)  FRE 402			
137:10 to 137:13	137:14 to 137:15 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
137:16 to 137:20 137:23 to 137:23	137:21 to 137:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  137:24 to 137:24 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
137:25 to 138:4	138:5 to 138:6 (Objection to the form of the question: vague. Beyond the scope of the 30(b)(6) Notice.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402, FRE 602			
138:7 to 138:9	138:10 to 138:11 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
138:12 to 138:13	FRE 402			
138:19 to 138:20	138:21 to 138:22 (Objection to the form of the question: vague. Beyond the scope of the 30(b)(6) Notice.)  FRE 402			
138:23 to 139:5	139:6 to 139:6 (Objection to the form of the question: vague.)  Form			
139:7 to 139:8	139:9 to 139:10 (Objection to the form of the question: asked and answered. Vague.)			
139:11 to 139:14	139:15 to 139:16 (Objection to the form of the question: beyond the scope of			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	the 30(b)(6) Notice. Vague.)  FRE 402, Form			
139:17 to 139:23	139:24 to 139:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague.)			
140:1 to 140:10				
141:14 to 141:16	141:17 to 141:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602	141:4 to 141:13	FRE 105, FRE 802  Beyond the Scope of the Designation	
141:19 to 141:21	141:22 to 141:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
141:23 to 141:23	141:24 to 141:24 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
141:25 to 142:6	142:7 to 142:9			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 402, FRE 602			
142:10 to 142:16	142:17 to 142:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
142:19 to 142:21	142:22 to 142:23 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
142:24 to 143:1	143:2 to 143:3 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
143:4 to 143:4	FRE 402			
143:12 to 143:13	143:14 to 143:14 (Objection to the form of the question: vague.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
143:15 to 143:19	143:20 to 143:20 (Objection to the form of the question: vague.)			
143:21 to 143:22				
144:5 to 144:9	144:10 to 144:11 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402	143:23 to 144:2	FRE 105, FRE 802	
144:12 to 144:13	144:14 to 144:15 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
144:16 to 144:20	144:21 to 144:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
144:23 to 145:5 145:7 to 145:7	145:8 to 145:9 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
145:10 to 145:12				
145:14 to 145:24	FRE 701			
146:19 to 146:25	147:1 to 147:2			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	(Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
147:3 to 147:5				
147:7 to 148:4				
148:9 to 148:9	148:10 to 148:11 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  Form			
148:12 to 148:15	None			
148:23 to 148:25	149:1 to 149:2 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
149:4 to 149:5	149:6 to 149:7 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
149:8 to 149:8				
149:19 to 149:25	150:1 to 150:2 (Objection to the form of the question: beyond the scope of			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	the 30(b)(6) Notice.)			
150:3 to 150:4	150:5 to 150:6 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
150:7 to 150:8	150:9 to 150:10 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
150:11 to 150:12	150:13 to 150:13 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
150:14 to 150:14	FRE 602			
153:2 to 153:5	152:17 to 152:19 (Objection to the form of the question: calls for speculation. Beyond the scope of the 30(b)(6) Notice.)  153:6 to 153:6 (Objection to the form of the	150:21 to 151:17 152:1 to 153:1	FRE 105, FRE 802  Beyond the Scope of the Designation	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: calls for speculation. Beyond the scope of the 30(b)(6) Notice.)  FRE 602			
153:7 to 153:12	153:13 to 153:14 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
153:15 to 153:17	153:18 to 153:19 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice Form.)			
153:20 to 153:23	153:24 to 153:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
154:1 to 154:4	154:5 to 154:6 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
154:7 to 154:9	None			
154:17 to 155:8	155:9 to 155:11 (Objection to the form of the			



BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: compound. Beyond the scope of the 30(b)(6) Notice.)  FRE 602			
155:12 to 156:5	156:6 to 156:7 (Objection to the form of the question: lack of foundation.)			
156:8 to 156:18		156:8 to 156:18	FRE 105, FRE 802	
156:21 to 157:5	157:6 to 157:7 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
157:8 to 157:9	157:10 to 157:11 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)	169:11 to 170:1	FRE 105, FRE 802	
157:12 to 157:18	157:19 to 157:21 (Objection to the form of the question: compound. Beyond the scope of the 30(b)(6) Notice.)  Form	157:13 to 157:15	FRE 105, FRE 802	
157:22 to 157:22	Form			
158:19 to 158:23	158:24 to 158:25 (Objection to the form of the	157:23 to 158:7	FRE 105, FRE 802 Beyond the Scope of the	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	question: beyond the scope of the 30(b)(6) Notice.)  FRE 602		Designation	
159:1 to 159:4	159:5 to 159:6 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
159:7 to 159:10	159:11 to 159:12 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
159:13 to 159:18				
159:20 to 159:21	FRE 701	159:22 to 159:24	FRE 105, FRE 802 Beyond the Scope of the Designation	
160:8 to 160:12	160:13 to 160:14 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802	161:7 to 163:15	FRE 105, FRE 802  Beyond the Scope of the Designation	
160:15 to 160:15	FRE 602, Form			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
169:5 to 169:6	169:7 to 169:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
169:9 to 169:10	FRE 602			
173:5 to 173:9	173:10 to 173:11 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
173:12 to 173:17	173:18 to 173:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
173:19 to 173:21	173:22 to 173:22 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
173:23 to 174:4	174:5 to 174:5 (Objection to the form of the question: beyond the scope of			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	the 30(b)(6) Notice.)  FRE 602, FRE 802			
174:6 to 174:6	FRE 602			
175:14 to 176:10	176:11 to 176:12 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague.)  FRE 402			
176:13 to 176:19	176:20 to 176:22 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for expert testimony.)  FRE 402, FRE 602			
176:23 to 176:25	177:1 to 177:2 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague.)  FRE 402			
177:3 to 177:4	177:5 to 177:6 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402			
177:7 to 177:8	177:9 to 177:10 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague.)  FRE 402			
177:11 to 177:15	177:16 to 177:17 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  177:19 to 177:20 Objection to the form of the question: calls for speculation. FRE 402, FRE 602			
177:18 to 177:18 177:21 to 178:12	178:13 to 178:15 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602	181:5 to 181:13 183:21 to 184:2	FRE 105, FRE 802  Beyond the Scope of the Designation	
178:16 to 178:17	FRE 402, FRE 602			
184:21 to 184:25	None			
185:2 to 185:19	FRE 701			
186:7 to 186:9	FRE 802			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
186:16 to 186:24	186:25 to 187:1 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
187:1 to 187:3	187:4 to 187:5 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
187:6 to 187:7	187:8 to 187:8 Objection to the form of the question: vague.)			
187:9 to 187:11	187:12 to 187:13 Objection to the form of the question: the scope of the 30(b)(6) Notice.)  FRE 602			
187:14 to 189:1	FRE 602, FRE 802			
189:15 to 191:2	FRE 802			
191:10 to 191:14	191:15 to 191:16 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	FRE 402, FRE 602			
191:17 to 191:20	191:21 to 191:22 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
191:23 to 191:23	FRE 602			
194:9 to 194:14	194:15 to 194:16 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)	191:24 to 193:7	FRE 105, FRE 802  Beyond the Scope of the Designation	
194:17 to 194:21	194:22 to 194:23 Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
194:24 to 194:25	FRE 602, Form			
195:4 to 195:5	195:6 to 195:7 Objection to the form of the question: vague. Beyond the scope of the 30(b)(6) Notice.)  FRE 602			
195:8 to 195:10	195:11 to 195:11			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	Objection to the form of the question: vague. Beyond the scope of the 30(b)(6) Notice.)  FRE 602			
195:12 to 195:18	195:19 to 195:19 Objection to the form of the question: vague. Beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
195:20 to 196:8	FRE 602, FRE 802			
197:19 to 197:21	197:15 to 197:17 (Objection to the form of the question: compound, vague. Beyond the scope of the 30(b)(6) Notice.)  197:22 to 197:22 (Objection to the form of the question: compound, vague. Beyond the scope of the 30(b)(6) Notice.)  FRE 402	196:9 to 197:11	FRE 105, FRE 802  Beyond the Scope of the Designation	
197:23 to 197:25	FRE 402			
198:18 to 198:20				



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
198:23 to 199:7	199:8 to 199:9 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
199:10 to 200:16	200:17 to 200:18 (Objection to the form of the question: Compound.)  FRE 802			
200:19 to 200:25	201:1 to 201:2 (Objection to the form of the question: Compound.)			
201:3 to 201:6	201:7 to 201:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
201:9 to 201:10		201:18 to 202:2	FRE 105, FRE 802	
204:3 to 204:5				
204:7 to 204:19				
204:25 to 205:2		205:3 to 205:18 206:3 to 206:20	FRE 105, FRE 802  Beyond the Scope of the Designation	
207:3 to 207:7		207:8 to 207:19 207:20 to 208:13 209:18 to 211:7	FRE 105, FRE 802  Beyond the Scope of the	

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
			Designation	
211:8 to 211:14				
212:4 to 212:5	212:6 to 212:7 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague.)  FRE 402, Form	211:20 to 212:3	FRE 105, FRE 802	
212:8 to 212:10	212:11 to 212:12 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
212:13 to 212:23	212:24 to 212:25 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
213:1 to 213:4	213:5 to 213:6 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
213:7 to 213:15	213:16 to 213:17			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	(Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
213:18 to 213:20	213:21 to 213:21 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
213:22 to 214:4	214:5 to 214:6 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, Form			
214:7 to 214:10	214:11 to 214:12 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
214:13 to 214:24	214:25 to 215:1 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
	FRE 602			
215:2 to 215:6	FRE 602			
216:2 to 216:3 216:6 to 216:6	216:4 to 216:5 (Objection to the form of the question: beyond the scope --)  216:7 to 216:8 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
216:9 to 216:9	FRE 602			
216:24 to 216:25	217:1 to 217:3 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Calls for speculation.)  FRE 602			
217:4 to 217:8	217:9 to 217:10 (Objection to the form of the question: vague. Beyond the scope of the 30(b)(6) Notice.)  FRE 602			
217:11 to 217:11	FRE 602			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
217:24 to 218:3				
218:5 to 218:13	218:14 to 218:15 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602			
218:16 to 219:13	219:14 to 219:16 (Objection to the form of the question: mischaracterizes the testimony. Beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
219:17 to 220:5	220:6 to 220:7 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
220:8 to 220:8	FRE 602			
221:8 to 221:10	221:11 to 221:12 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)	221:4 to 221:7	FRE 105, FRE 802	
221:13 to 221:20		221:21 to 222:25	FRE 105, FRE 602, FRE 701, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
			Beyond the Scope of the Designation	
223:1 to 223:6		223:7 to 223:12 223:18 to 223:23 224:5 to 224:23	FRE 105, FRE 802  Beyond the Scope of the Designation	223:13-15, 17
227:21 to 227:22	227:23 to 227:24 (Objection to the form of the question: vague. Beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 701	225:9 to 227:20	FRE 105, FRE 602, FRE 701, FRE 802  Beyond the Scope of the Designation	
227:25 to 228:2	228:3 to 228:4 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 701			
228:5 to 228:9	228:10 to 228:12 (Objection to the form of the question: mischaracterizes the testimony. Beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 701			

<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
228:13 to 228:16	228:17 to 228:18 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 701	228:21 to 229:17	FRE 105, FRE 602, FRE 701, FRE 802  Beyond the Scope of the Designation	
228:19 to 228:20	FRE 602, FRE 701			
241:19 to 243:12	FRE 802, FRE 701			
244:2 to 244:9		244:10 to 246:14	FRE 105, FRE 802  Beyond the Scope of the Designation	
246:15 to 246:17	246:18 to 246:19 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)			
246:20 to 246:21		246:22 to 248:15	FRE 105, FRE 802  Beyond the Scope of the Designation	
253:15 to 253:16				
253:18 to 253:23	FRE 701	253:24 to 254:1	FRE 105, FRE 802  Beyond the Scope of the Designation	
255:19 to 255:21	255:22 to 255:23 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: beyond the scope of the 30(b)(6) Notice.)  FRE 602, FRE 802			
255:24 to 256:1	FRE 602, Form			
257:22 to 257:25	258:1 to 258:2 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
258:3 to 258:3	FRE 402, FRE 602			
258:20 to 258:24	258:25 to 259:2 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402			
259:3 to 259:3	FRE 402			
259:6 to 259:9	FRE 701	259:10 to 259:11	FRE 105, FRE 802  Beyond the Scope of the Designation	
259:12 to 259:18	None			
259:22 to 259:23	259:24 to 259:25 (Objection to the form of the question: compound.			



<b>BARR DESIGNATION</b>	<b>PLAINTIFFS' OBJECTIONS</b>	<b>PLAINTIFFS' COUNTER DESIGNATION</b>	<b>BARR'S OBJECTIONS TO COUNTER DESIGNATIONS</b>	<b>BARR'S COUNTER COUNTER DESIGNATIONS</b>
260:1 to 260:2				
260:17 to 260:19	260:20 to 260:21 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 701			
260:22 to 261:1		261:2 to 262:8	FRE 105, FRE 802	
262:13 to 262:15	262:16 to 262:17 (Objection to the form of the question: Beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
262:18 to 262:20	262:21 to 262:22 (Objection. Beyond the scope of the 30(b)(6) Notice.)  FRE 402, FRE 602			
262:23 to 262:23	FRE 402, FRE 602e			
265:10 to 265:14	265:15 to 265:17 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Vague. Lack of foundation.)	251:8 to 253:14	FRE 105, FRE 802	
265:18 to 265:19		265:20 to 267:7	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
			Beyond the Scope of the Designation	
267:19 to 267:21				
267:23 to 268:7		268:8 to 268:14	FRE 105, FRE 802	
268:15 to 268:16	268:17 to 268:19 (Objection to the form of the question: beyond the scope of the 30(b)(6) Notice. Asked and answered.)  FRE 602			
268:20 to 268:24				
273:3 to 274:18	FRE 802	274:19 to 275:6	FRE 105, FRE 802	
275:7 to 275:10	275:11 to 275:12 (Objection to the form of the question: asked and answered.)  FRE 802			
275:13 to 275:22	275:23 to 275:24 (Objection to the form of the question: asked and answered.)			
275:25 to 276:1		276:2 to 276:8	FRE 105, FRE 802	
276:9 to 277:2	277:3 to 277:5 (Objection to the form of the			

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
	question: beyond the scope of the 30(b)(6) Notice. Compound. Calls for expert testimony.)  FRE 802			
277:6 to 277:7		277:8 to 280:9	FRE 105, FRE 802  Beyond the Scope of the Designation	

**AMIRA ZEEVI**

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
6:12-14				
6:19-25				
15:4-9				
16:14-17:8				
17:10-12				

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
22:12-16	FRE 402, FRE 403			
23:5-7	FRE 402, FRE 403			
24:23-25:16	FRE 402, FRE 403			
25:18-26:7	FRE 402, FRE 403			
26:9-26:23	FRE 402, FRE 403			
32:1-23	FRE 402, FRE 403			
61:15-16				
61:18-19				
62:14				
62:24-63:1		62:19-23	FRE 105, FRE 802	
63:3-4				
63:7-14				
63:23-25				
64:3-13				
64:25-65:8				
65:11				
65:13				
65:25-66:15		66:16-17, 66:20-21, 74:18-21, 74:24	FRE 105, FRE 802  74:18-21, 74:24 Beyond the Scope of the Designation	
67:16-23				
67:25-68:4		68:5, 68:7-11, 68:14	FRE 105, FRE 802	
68:24-69:1				
69:6-69:16				
69:19-23		69:17-18, 69:24-70:3	FRE 105, FRE 802	
71:10-13		71:3-9	FRE 105, FRE 802	

BARR DESIGNATION	PLAINTIFFS' OBJECTIONS	PLAINTIFFS' COUNTER DESIGNATION	BARR'S OBJECTIONS TO COUNTER DESIGNATIONS	BARR'S COUNTER COUNTER DESIGNATIONS
71:16-24				
72:2-13				
72:16-72:20				
72:23-24		72:25-73:5, 73:8-74:2, 74:5-6, 74:8-14, 74:17	FRE 105, FRE 802  73:24-74:2; 74:5-6; 74:8-14; 74:17 Beyond the Scope of the Designation	